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Summary 
 
The threat to public health from antibiotic resistance has increased, with growing 
evidence that antibiotic use is a major driver of resistance. This has led to campaigns 
to reduce prescribing of antibiotics by GPs, particular for respiratory tract infections 
(RTIs). These are among the most common reasons for prescribing antibiotics in 
primary care, in spite of the fact that there is evidence that most RTIs recover at a 
similar rate without antibiotic treatment, rarely resulting in complications if 
untreated. There are concerns, that a ‘blanket’ reduction in prescribing may occur, 
with reductions in prescribing that may benefit patients, leading to an increase in 
complications that can arise from untreated RTIs. The aim of this thesis was to 
explore the relationships between community antibiotic dispensing, complications 
from RTIs and resistance. We showed that decreasing rates of antibiotic dispensing 
in Wales coincided with increases in hospital diagnosed complications such as 
pneumonia and septicaemia from 1996-2006. At a practice level, there was evidence 
of a negative association between dispensing and complications. While a positive 
association was found between lagged dispensing and resistance, no clear pattern 
was found between change in dispensing and resistance for any of the organism/ 
antibiotic combinations examined possibly due to a lack of power. At an individual 
patient level, antibiotics are not justified to reduce the risk of a complication in those 
diagnosed with an acute RTI or sore throat. However, for patients presenting with a 
chest infection, the risk of developing a complication is higher and antibiotics appear 
to reduce the risk of complications; GPs should therefore consider prescribing for 
these patients. Further research is required to examine different lag periods of 
dispensing and their association with resistance and also to identify subgroups of 
patients at high risk of complications to help GPs target their prescribing of 
antibiotics. 
 
viii 
CONTENTS 
Declaration and Statements ...................................................................................... iii 
ACKNOWLEDGEMENTS ....................................................................................... v 
Summary ................................................................................................................... vii 
CONTENTS ............................................................................................................. viii 
List of Tables ............................................................................................................ xiii 
List of Figures ......................................................................................................... xvii 
List of Appendices .................................................................................................... xx 
Glossary of abbreviations ....................................................................................... xxi 
Chapter 1 Background ......................................................................................... 1 
1.1 The discovery of antibiotics and their role in disease management ............. 1 
1.2 The emergence of resistance ........................................................................ 2 
1.3 Mechanisms of resistance ............................................................................. 4 
1.4 Drivers of resistance ..................................................................................... 5 
1.5 Minimising resistance by reducing antibiotic use ........................................ 5 
1.5.1 Antibiotic use in primary care .............................................................. 6 
1.5.2 Reducing antibiotic prescribing in the community .............................. 7 
1.5.3 Evidence of a decrease in antibiotic prescribing ................................. 7 
1.6 Advantages of reducing antibiotic prescribing ............................................. 9 
1.7 Disadvantages of reducing antibiotic prescribing ...................................... 10 
1.8 The relationship between antibiotic use and complications ....................... 12 
1.9 Limitations of the evidence base ................................................................ 13 
1.10 The need to monitor trends ......................................................................... 14 
1.11 Aims and objectives ................................................................................... 15 
1.12 Structure of the thesis ................................................................................. 17 
Chapter 2 Detailed appraisal of the evidence base supporting the rationale 
for the current study ................................................................................................ 18 
2.1 Introduction ................................................................................................ 18 
2.2 Search strategy ........................................................................................... 18 
2.3 Respiratory tract infections ........................................................................ 20 
2.4 Complications arising from RTIs ............................................................... 20 
2.5 The role of antibiotics in RTIs ................................................................... 21 
2.5.1 Evidence from Cochrane systematic reviews ..................................... 21 
2.5.2 Additional evidence ............................................................................ 25 
2.6 Relationship between antibiotic use and complications ............................. 26 
2.6.1 Evidence from Cochrane systematic reviews ..................................... 26 
2.6.2 Ecological level evidence ................................................................... 27 
2.6.3 Individual level evidence .................................................................... 31 
2.6.4 Summary ............................................................................................. 36 
2.7 Relationship between antibiotic use and resistance ................................... 36 
2.7.1 Ecological level evidence ................................................................... 36 
2.7.2 Individual level evidence .................................................................... 37 
2.8 Summary of Chapter 2 ............................................................................... 39 
ix 
Chapter 3 Overview of methods and datasets ................................................. 40 
3.1 Introduction ................................................................................................ 40 
3.2 Ecological studies....................................................................................... 40 
3.2.1 Study population – Wales ................................................................... 40 
3.2.2 Geographical areas ............................................................................ 41 
3.2.3 Identifying general practices.............................................................. 42 
3.2.4 Practice populations and characteristics........................................... 42 
3.2.5 Deprivation Measures ........................................................................ 43 
3.3 Ecological level datasets ............................................................................ 44 
3.3.1 Antibiotic dispensing data .................................................................. 44 
3.4 Individual level datasets ............................................................................. 45 
3.4.1 General Practice Morbidity Database ............................................... 45 
3.4.2 Hospital Episodes Statistics ............................................................... 46 
3.4.3 Antibiotic resistance data ................................................................... 47 
3.4.4 General Practice Research Database ................................................ 48 
3.5 Statistical methods ..................................................................................... 48 
3.6 Ethical approval ......................................................................................... 51 
Chapter 4 Antibiotic dispensing and complications arising from RTIs: a 
study of a sample of Welsh practices ...................................................................... 52 
4.1 Introduction ................................................................................................ 52 
4.2 Methods ...................................................................................................... 52 
4.2.1 Complications arising from respiratory tract infections ................... 52 
4.2.2 Antibiotic dispensing data .................................................................. 52 
4.2.3 General practice populations ............................................................. 53 
4.3 Statistical analysis ...................................................................................... 54 
4.3.1 Patterns of dispensing and complications ......................................... 55 
4.3.2 Changes over time .............................................................................. 55 
4.4 Results ........................................................................................................ 57 
4.4.1 Trends in dispensed antibiotics .......................................................... 57 
4.4.2 Trends in complications arising from RTIs ........................................ 59 
4.4.3 Associations between complications and dispensed antibiotics ........ 61 
4.4.4 Changes in dispensing of total antibiotics and complications ........... 64 
4.5 Discussion .................................................................................................. 66 
4.5.1 Main findings ..................................................................................... 66 
4.5.2 Strengths and weaknesses of the study ............................................... 66 
4.5.3 Comparisons with existing literature ................................................. 68 
4.5.4 Implications of findings for clinical practice and future research .... 69 
4.6 Introduction to All-Wales general practice level analysis ......................... 70 
Chapter 5 Antibiotic dispensing in Wales ........................................................ 71 
5.1 Introduction to antibiotic dispensing data .................................................. 71 
5.2 Methods ...................................................................................................... 71 
5.2.1 Antibiotic dispensing data .................................................................. 71 
5.2.2 Type of antibiotics .............................................................................. 72 
5.2.3 Practice characteristics ..................................................................... 73 
5.2.4 Data quality and exclusions ............................................................... 73 
5.2.5 External validity of the practices ....................................................... 77 
5.2.6 Sub-group analyses ............................................................................ 78 
5.3 Statistical analysis ...................................................................................... 80 
x 
5.3.1 Population and rates .......................................................................... 80 
5.3.2 Multilevel modelling ........................................................................... 81 
5.4 Results ........................................................................................................ 82 
5.4.1 Antibiotic dispensing in Wales: 1996 to 2006 (quarterly data) ......... 82 
5.4.2 Antibiotic dispensing in Wales: 2000 to 2006 (monthly data) ......... 107 
5.4.3 Antibiotic dispensing in Wales for children: 2000 to 2006 .............. 112 
5.4.4 Comparisons in trends between the two datasets: antibiotic 
dispensing for all ages vs. children, 2000 to 2006 ........................................... 116 
5.4.5 Broad- vs. narrow-spectrum antibiotic dispensing .......................... 119 
5.5 Discussion ................................................................................................ 123 
5.5.1 Main findings .................................................................................... 123 
5.5.2 Strengths and weaknesses of the study ............................................. 124 
5.5.3 Comparisons with existing literature ............................................... 125 
5.5.4 Implications of findings for clinical practice and future research ... 128 
5.6 Introduction to Welsh resistance data ...................................................... 130 
Chapter 6 Antibiotic resistance in Wales ....................................................... 131 
6.1 Introduction .............................................................................................. 131 
6.2 Methods .................................................................................................... 131 
6.2.1 Microbiology data ............................................................................ 131 
6.2.2 Allocating practice codes to individual samples .............................. 133 
6.2.3 Data quality within laboratories ...................................................... 134 
6.2.4 Potential bias in resistance data ...................................................... 135 
6.3 Statistical analysis .................................................................................... 138 
6.3.1 Trends in resistance rates ................................................................ 138 
6.3.2 Association between antibiotic dispensing and resistance .............. 141 
6.3.3 Duplicate isolates ............................................................................. 141 
6.3.4 Changes in antibiotic dispensing and resistance ............................. 141 
6.3.5 Sensitivity analyses ........................................................................... 142 
6.4 Results ...................................................................................................... 143 
6.4.1 Microbiology data ............................................................................ 143 
6.4.2 Selective testing at laboratory level ................................................. 145 
6.4.3 Trends in isolate testing and resistance data ................................... 147 
6.4.4 Multilevel modelling of all isolates .................................................. 150 
6.4.5 Multilevel modelling for sputum and ENT samples ......................... 158 
6.4.6 Changes in antibiotic dispensing and resistance ............................. 159 
6.4.7 Sampling data ................................................................................... 169 
6.4.8 Duplicate isolates ............................................................................. 170 
6.5 Discussion ................................................................................................ 173 
6.5.1 Main findings .................................................................................... 173 
6.5.2 Strengths and weaknesses of the study ............................................. 174 
6.5.3 Comparisons with existing literature ............................................... 177 
6.5.4 Implications of findings for clinical practice and future research ... 182 
6.6 Introduction to hospital events for complications in Wales ..................... 183 
Chapter 7 Hospital events for acute RTIs and complications in Wales ...... 184 
7.1 Introduction .............................................................................................. 184 
7.2 Methods .................................................................................................... 185 
7.2.1 Data source - Patient Episode Database for Wales (PEDW) .......... 185 
7.2.2 PEDW records .................................................................................. 185 
7.2.3 Identifying acute RTIs and complications ........................................ 186 
xi 
7.2.4 Linking episodes ............................................................................... 186 
7.2.5 Study population and period ............................................................ 188 
7.2.6 Dataset fields .................................................................................... 188 
7.3 Statistical analysis .................................................................................... 188 
7.3.1 Counting acute RTIs and complications .......................................... 188 
7.3.2 Main analysis ................................................................................... 189 
7.4 Results ...................................................................................................... 192 
7.4.1 All-Wales events of hospital infections for acute RTIs and 
complications arising from RTIs ...................................................................... 192 
7.4.2 Events of hospital infection by type of acute RTI ............................. 197 
7.4.3 Events of hospital infection by type of complication ........................ 204 
7.4.4 Multilevel modelling of hospital events............................................ 221 
7.4.5 Comparison of results from single- and multi-level modelling ........ 229 
7.5 Discussion ................................................................................................ 231 
7.5.1 Main findings ................................................................................... 231 
7.5.2 Strengths and weaknesses of the study ............................................. 232 
7.5.3 Comparisons with existing literature ............................................... 235 
7.5.4 Implications of findings for clinical practice and future research .. 237 
7.6 Introduction to antibiotic dispensing and complications at an All-Wales 
level 237 
Chapter 8 Antibiotic dispensing and complications arising from RTIs: an 
All-Wales study ...................................................................................................... 238 
8.1 Introduction .............................................................................................. 238 
8.2 Methods .................................................................................................... 238 
8.2.1 Linking antibiotic dispensing to hospital events of infections ......... 238 
8.2.2 Linking to antibiotic resistance ........................................................ 238 
8.2.3 General practices ............................................................................. 239 
8.3 Statistical analysis .................................................................................... 239 
8.3.1 Main analysis ................................................................................... 239 
8.3.2 Adjusting for confounders ................................................................ 240 
8.3.3 Comparisons of antibiotics, infections and resistance ..................... 241 
8.3.4 Sensitivity analyses........................................................................... 242 
8.3.5 Changes in antibiotic dispensing and complications ....................... 242 
8.4 Results ...................................................................................................... 243 
8.4.1 The relationship between hospital events for complications arising 
from acute RTIs and antibiotic dispensing at a general practice level ........... 243 
8.4.2 General practice level resistance data ............................................. 251 
8.4.3 The relationship at the Local Health Board level ............................ 253 
8.4.4 The relationship between hospital infections for acute RTIs and 
antibiotic dispensing at a general practice level ............................................. 256 
8.4.5 The relationship between hospital infections for pneumonia and 
antibiotic dispensing at a general practice level ............................................. 258 
8.4.6 Changes in antibiotic dispensing and complications ....................... 260 
8.5 Discussion ................................................................................................ 263 
8.5.1 Main findings ................................................................................... 263 
8.5.2 Strengths and weaknesses of the study ............................................. 264 
8.5.3 Comparisons with existing literature ............................................... 266 
8.5.4 Implications of findings for clinical practice and future research .. 267 
8.6 Introduction to individual level analysis of antibiotic prescribing and 
xii 
complications arising from RTIs .......................................................................... 268 
Chapter 9 Antibiotic prescribing and complications arising from RTIs: 
Individual patient level analysis ............................................................................ 269 
9.1 Introduction to individual level ................................................................ 269 
9.2 Methods .................................................................................................... 269 
9.2.1 General Practice Research Database .............................................. 269 
9.2.2 Study population ............................................................................... 270 
9.2.3 Exposure ........................................................................................... 271 
9.2.4 Clinical outcome of interest ............................................................. 273 
9.2.5 Observation period ........................................................................... 274 
9.3 Statistical analysis .................................................................................... 274 
9.3.1 Patient level characteristics ............................................................. 274 
9.3.2 Predictors of antibiotic prescribing ................................................. 276 
9.3.3 Association between antibiotics and complications ......................... 276 
9.3.4 Numbers needed to treat .................................................................. 277 
9.3.5 Exclusions ......................................................................................... 278 
9.4 Results ...................................................................................................... 279 
9.4.1 RTI cohort ........................................................................................ 279 
9.4.2 Antibiotic prescribing ....................................................................... 281 
9.4.3 Complications diagnosed in primary care ....................................... 286 
9.4.4 Complications diagnosed in primary and secondary care............... 294 
9.4.5 Summary of results ........................................................................... 305 
9.5 Discussion ................................................................................................ 308 
9.5.1 Main findings .................................................................................... 308 
9.5.2 Strengths and weaknesses of the study ............................................. 308 
9.5.3 Comparisons with existing literature ............................................... 312 
9.5.4 Implications of findings for clinical practice and future research ... 314 
9.6 Introduction to Chapter 10 ....................................................................... 315 
Chapter 10 Discussion ........................................................................................ 316 
10.1 Main findings ........................................................................................... 316 
10.1.1 Antibiotic dispensing ........................................................................ 316 
10.1.2 The benefits of reducing antibiotic dispensing ................................. 316 
10.1.3 The risks of reducing antibiotic dispensing ...................................... 317 
10.2 Study strengths and limitations ................................................................ 318 
10.2.1 Strengths - Practice level ................................................................. 318 
10.2.2 Strengths - Individual patient level .................................................. 319 
10.2.3 Limitations - Practice level .............................................................. 320 
10.2.4 Limitations - Individual patient level ............................................... 322 
10.3 Implications of main findings for clinical practice .................................. 323 
10.3.1 Should ecological level data be used to inform clinical decision? .. 323 
10.3.2 Should antibiotics be prescribed to prevent complications? ........... 324 
10.4 Key messages for general practitioners .................................................... 325 
10.5 Implications of main findings for future research .................................... 325 
10.5.1 Study design ...................................................................................... 325 
10.5.2 Blanket reductions in dispensing or in inappropriate dispensing? .. 326 
10.5.3 Identifying those that will benefit from antibiotics ........................... 326 
10.6 Conclusions .............................................................................................. 328 
References ............................................................................................................... 330 
xiii 
Appendices .............................................................................................................. 349 
 
List of Tables 
Table 2.1 Categorisation of included studies from the literature search .................... 19 
Table 2.2 Summary of Cochrane reviews for the efficacy of antibiotics in RTI 
(Comparisons are antibiotics vs. placebo; Risk Ratio (RR)<1 or mean 
difference <0 provide evidence for the efficacy of antibiotics) .................. 23 
Table 2.3 Summary of evidence from studies examining the association between 
antibiotic prescribing in general practice and complications arising from 
of RTIs – ecological level ........................................................................... 29 
Table 2.4 Summary of evidence from studies examining the association between 
antibiotic prescribing in general practice and complications arising from 
of RTIs – individual level ........................................................................... 33 
Table 4.1 Read codes for selected complications arising from RTIs ......................... 53 
Table 4.2 Linear regression models to estimate trends in antibiotic dispensing in 
general practice per 1,000 practice population from 1996 to 2000 ............ 58 
Table 4.3 Primary care diagnoses of complications arising from RTIs in 26 
general practices between 1996 and 2000................................................... 60 
Table 4.4 Multilevel Poisson regression models examining the relationship 
between primary care diagnosed complications and antibiotic dispensing 62 
Table 5.1 Characteristics of included and excluded practices from April 1996 to 
March 2006 ................................................................................................. 78 
Table 5.2 Comparison of parameter estimates (SE) from the single- and two-level 
repeated measures linear model for total antibiotic dispensing rates 
(estimated by RIGLS method) .................................................................... 90 
Table 5.3 Parameter estimates for quarterly antibiotic dispensing rates per 1,000 
pp, by antibiotic group (estimated by MCMC methods) .......................... 101 
Table 5.4 Local Health Board and practice variation for dispensing rates by 
antibiotic group (estimated by MCMC methods) ..................................... 102 
Table 5.5 Univariate associations between total antibiotic dispensing rate per 
1,000 and practice characteristics (estimated by RIGLS methods) .......... 103 
Table 5.6 Multivariate analysis for antibiotic dispensing and practice 
characteristics by antibiotic group (estimated by MCMC methods) 
(parameter estimates β (SE) for significant practice characteristics shown 
only
i
) ......................................................................................................... 106 
Table 5.7 Parameter estimates for quarterly antibiotic dispensing rates per 1,000 
pp, by antibiotic group: 2000 to 2006 (estimated by MCMC methods) ... 110 
Table 5.8 Parameter estimates for quarterly antibiotic dispensing rates for children 
per 1,000 pp, by antibiotic group: 2000 to 2006 (estimated by MCMC 
methods) .................................................................................................... 114 
Table 5.9 Comparison of annual rate of change (per 1,000 pp) between antibiotics 
dispensed for all ages and for children: 2000 to 2006 .............................. 117 
Table 5.10 Local Health Board and practice variation for dispensing rates in 
children by antibiotic groups (estimated by MCMC methods) ................ 118 
Table 6.1 Antibiotics commonly tested for resistance by organism ........................ 133 
Table 6.2 Practice characteristics for included and excluded practices for H. 
xiv 
influenzae isolates ..................................................................................... 143 
Table 6.3 Characteristics of the patients with H. influenzae, S. pneumoniae and S. 
pyogenes infections ................................................................................... 144 
Table 6.4 Summary of testing and resistance incidence (N) and rates (%) by year 
of isolate - submission for all isolates (excluding duplicates and 
selectivity) ................................................................................................. 146 
Table 6.5 Summary of testing and resistance incidence (N) and rates (%) by year 
of isolate - submission for Sputum and ENT samples (excluding 
duplicates and selectivity) ......................................................................... 149 
Table 6.6 Univariate models between amoxicillin resistance and sample 
characteristics in H. influenzae isolates .................................................... 151 
Table 6.7 Univariate models for tetracycline resistance and sample characteristics 
in H. influenzae isolates ............................................................................ 152 
Table 6.8 Univariate models between erythromycin resistance and sample and 
practice characteristics in S. pneumoniae isolates ..................................... 153 
Table 6.9 Univariate models between penicillin resistance and sample 
characteristics in S. pneumoniae isolates .................................................. 154 
Table 6.10 Modelling for antibiotic resistance and lagged dispensing in H. 
influenzae, S. pneumoniae and S. pyogenes isolates for all isolates ......... 157 
Table 6.11 Practice characteristics for included and excluded practices ................. 159 
Table 6.12 Median dispensed antibiotic items (per 1,000 practice population per 
annum) in 1998 and 2005 in 271 Welsh practices .................................... 160 
Table 6.13 Quartiles with 5
th
 and 95
th
 percentiles, for reductions in dispensed 
antibiotic rates (per 1,000 practice population per annum) between 1998 
and 2005 .................................................................................................... 160 
Table 6.14 Changes (%) in resistance to amoxicillin and tetracycline over an 8-
year period, in all H. influenzae isolates, by quartile of reductions in: ..... 162 
Table 6.15 Quartiles with 5
th
 and 95
th
 percentiles for decrease in dispensed 
antibiotics rates (per 1,000 practice population) between 1998 and 2005 163 
Table 6.16 Changes (%) in resistance to erythromycin and penicillin over an 8-
year period, in all S. pneumoniae isolates, by quartile of reductions in: ... 165 
Table 6.17 Quartiles with 5
th
 and 95
th
 percentiles for decrease in dispensed 
antibiotics rates (per 1,000 practice population) between 1998 and 2005 166 
Table 6.18 Changes (%) in resistance to erythromycin over an 8-year period, by 
quartile of reductions in total antibiotic dispensing in S. pyogenes 
isolates ....................................................................................................... 168 
Table 6.19 Resistance rates (%) (N isolates tested) for duplicate and non-duplicate 
isolates ....................................................................................................... 170 
Table 6.20 Multivariate model for duplicates in H. influenzae isolates ................... 171 
Table 7.1 Breakdown of acute RTI and complication episodes within an event ..... 192 
Table 7.2 Annual incidence of events (per 10,000 population) of acute RTIs and 
complications by age group and gender in Wales, 1996-2006 ................. 196 
Table 7.3 Example of two events containing several episodes ................................ 198 
Table 7.4 Hospital events of infections in Wales by diagnosis of acute RTIs 
between 1996 and 2006-all ages
i
 .............................................................. 199 
Table 7.5 Hospital events of infections in Wales by diagnosis of acute RTIs 
between 1996 and 2006-children aged 0-14 years
i
 ................................... 200 
Table 7.6 Hospital events of infections in Wales by complications arising from 
RTIs between 1996 and 2006-all ages
i
 ..................................................... 205 
Table 7.7 Hospital events of infections in Wales by complications arising from 
xv 
RTIs between 1996 and 2006-children aged 0-14 years
i
 .......................... 209 
Table 7.8 Multilevel model for standardised incidence rates (SIRs) for acute RTI 
hospital events-all ages and children ........................................................ 222 
Table 7.9 Multilevel model for standardised incidence rates (SIRs) for hospital 
events for complications-all ages and children ......................................... 226 
Table 7.10 Multilevel model for standardised incidence rates (SIRs) for 
pneumonia hospital events-all ages .......................................................... 227 
Table 7.11 Multilevel model for standardised incidence rates (SIRs) for 
septicaemia hospital events-all ages ......................................................... 228 
Table 7.12 Comparison of estimates for year from the single- and multilevel 
modelling - parameter estimate (confidence interval) .............................. 229 
Table 8.1 Unadjusted multilevel models for hospital events for complications and 
antibiotic dispensing per 1,000 pp: 1996 to 2005 ..................................... 244 
Table 8.2 Unadjusted and adjusted models for hospital events for complications 
and dispensing rate per 1,000 pp by type of antibiotic, 1996 to 2005 
(Parameter estimates (standard error) shown for dispensing rate only).... 248 
Table 8.3 NB models for hospital events for complications and dispensing per 
1,000 pp by type of antibiotic: 1996 to 2005 and 1998 to 2005 
(Parameter estimates (standard error) shown for dispensing rate only).... 250 
Table 8.4 Summary of isolates and resistance per practice (pp) per annum ............ 251 
Table 8.5 NB models for hospital events for complications and dispensing per 
1,000 pp by type of antibiotic at LHB level, 1998 to 2005....................... 255 
Table 8.6 Multivariate model for hospital events for acute RTIs and dispensing 
per 1,000 pp by type of antibiotic, 1996 to 2005  and 1998 to 2005 
(Parameter estimate (standard error) shown for dispensing rate only) ..... 257 
Table 8.7 Multivariate model for hospital events for pneumonia and dispensing 
per 1,000 pp by type of antibiotic, 1996 to 2005 and 1998 to 2005 
(Parameter estimate (standard error) shown for dispensing rate only) ..... 259 
Table 8.8 Median dispensed antibiotic items (per 1,000 practice population) in 
1998 and 2005 in 426 Welsh practices ..................................................... 260 
Table 8.9 Quartiles with 5
th
 and 95
th
 percentiles, for reductions in dispensed 
antibiotic rates (per 1,000 practice population) between 1998 and 2005 . 260 
Table 8.10 Change (mean (sd)) in all complications and pneumonia (per 100,000 
population) over an 8-year period, by quartile of reductions in total 
antibiotic dispensing per 1,000 population ............................................... 262 
Table 9.1 Demographics of patients diagnosed with an RTI in 2005 (N(%) unless 
otherwise specified) .................................................................................. 280 
Table 9.2 Number (%) of diagnoses by index RTI group alongside N (%) of 
antibiotic prescribed (no antibiotic prescribed, same day and subsequent) 
(sorted by % of same day prescribing)...................................................... 281 
Table 9.3 Factors associated with same day antibiotic prescribing (as the index 
RTI) - univariate and multivariate analyses .............................................. 284 
Table 9.4 Complications diagnosed in primary care within 60 days of the RTI ..... 286 
Table 9.5 Risk of complications (diagnosed in primary care) within 60 days of the 
index RTI (per 10,000 patients) ................................................................ 288 
Table 9.6 Factors associated with complications diagnosed in primary care within 
60 days of the index RTI ........................................................................... 289 
Table 9.7 Risk of complications (diagnosed in primary care) within 60 days of the 
index sore throat/chest infection (per 10,000 patients) ............................. 292 
Table 9.8 Demographics of patients diagnosed with an RTI in 2005 (N(%) unless 
xvi 
otherwise specified) – practices linked to HES data and those not linked 295 
Table 9.9 Complications diagnosed in primary and secondary care within 60 days 
of the RTI (N(%) unless otherwise specified) ........................................... 297 
Table 9.10 Median (25
th
 to 75
th
 percentiles) days after index RTI to first diagnosis 
of complication by health care setting ...................................................... 298 
Table 9.11 Risk of complications (diagnosed in primary and/or secondary care) 
within 60 days of the index RTI (per 10,000 patients) ............................. 299 
Table 9.12 Factors associated with complications diagnosed in primary and/or 
secondary care within 60 days of index date for the RTI - univariate and 
multivariate analyses ................................................................................. 301 
Table 9.13 Risk of complications (diagnosed in primary and/or secondary care) 
within 60 days of the index sore throat/chest infection (per 10,000 
patients) ..................................................................................................... 304 
Table 9.14 Complication rates (per 10,000) by index RTI group and antibiotic 
prescribing status ....................................................................................... 307 
Table 9.15 Numbers needed to treat (NNT) with antibiotics to prevent one 
complication by healthcare setting ............................................................ 309 
Table 9.16 Proportion of antibiotics prescribed by type of RTI .............................. 313 
xvii 
List of Figures 
Figure 1.1 Development and discovery of antibiotics over time (Norrby SR et al. 
2005) ............................................................................................................. 3 
Figure 1.2 Trends in Prescribing of Antibacterial Drugs in General Practice in ......... 8 
Figure 1.3 Modelling the relationship between antibiotic use, complications, 
resistance and other factors. ........................................................................ 15 
Figure 3.1 Age/sex distribution of the Welsh population and patients included in 
the GPMD in 1999/2000 ............................................................................. 46 
Figure 4.1 Quarterly trends in dispensing rates of total antibiotics and 
flucloxacillin from 1996 to 2000 for 26 practices contributing data to the 
GPMD ......................................................................................................... 57 
Figure 4.2 Box-whisker plot of pneumonia rates per 100,000 pp in 1996 and 2000 
by practices’ change in dispensing rates of total antibiotics ....................... 65 
Figure 4.3 Box-whisker plot of change (2000-1996) in pneumonia rates per 
100,000 pp by practices’ change in dispensing rates of total antibiotics .... 65 
Figure 5.1 Monthly populations and dispensing from a practice based in a 
university area ............................................................................................. 74 
Figure 5.2 Flow chart of the process of excluding practices dispensing data from 
April 2000 to March 2006 ........................................................................... 75 
Figure 5.3 Flow chart of the linkage of practices from the April 2000 to March 
2006 dataset and practices from the April 1996 to March 2000 dataset ..... 77 
Figure 5.4 Dispensing by antibiotic group as a proportion of total antibiotics .......... 82 
Figure 5.5 Dispensed antibiotic items rates in primary care in Wales per 1,000 
practice population, by study year 1996 to 2005 ........................................ 83 
Figure 5.6 Stacked bar-chart of dispensing rates in primary care in Wales per 
1,000 practice population, by antibiotic group and study year 1996 to 
2005 ............................................................................................................. 83 
Figure 5.7 Annual percentage change in antibiotic items dispensed in primary care 
in Wales per 1,000 practice population by antibiotic group 1996 to 2005 . 84 
Figure 5.8 Number of antibiotic items dispensed per quarter in primary care in 
Wales per 1,000 practice population, by antibiotic group, 1996 to 2005 ... 86 
Figure 5.9 Total antibiotic dispensing per quarter per 1,000 pp, with fitted linear 
and quadratic models .................................................................................. 87 
Figure 5.10 Residual plots (actual antibiotic dispensing rates – predicted rates 
from fitted model) for linear and quadratic models .................................... 87 
Figure 5.11 MLwiN output for two-level repeated measures linear model for total 
antibiotic dispensing rates (estimated by RIGLS method) ......................... 88 
Figure 5.12 Box-whisker plot of total antibiotic dispensing rates in 1996 and 2005 89 
Figure 5.13 Diagnostics for the slope parameter β1 for total antibiotic dispensing 
rates (after 40,000 iterations) ...................................................................... 90 
Figure 5.14 MLwiN output for two-level repeated measures linear model for total . 91 
Figure 5.15 Fitted total antibiotic dispensing rates from the fitted two-level model 
by general practices ..................................................................................... 91 
Figure 5.16 Histogram of the practices slopes from the fitted two-level model for 
total antibiotic dispensing rates ................................................................... 92 
Figure 5.17 Caterpillar plots: practice-level residuals for total antibiotic 
dispensing rates ( 1.96SD) vs. rank .......................................................... 92 
Figure 5.18 Practice-level standardised residuals for total antibiotic dispensing 
rates: slope vs. intercept .............................................................................. 93 
xviii 
Figure 5.19 Actual and fitted total antibiotic dispensing rates over time: ................. 94 
Figure 5.20 MLwiN output for three-level repeated measures linear regression 
model for total antibiotic dispensing rates (estimated by MCMC 
methods) ...................................................................................................... 95 
Figure 5.21 Fitted total antibiotic dispensing rates from the fitted three-level 
model by Local Health Board ..................................................................... 96 
Figure 5.22 Local Health Board-level standardised residual plot for total antibiotic 
dispensing rates: slope vs. intercept ............................................................ 96 
Figure 5.23 Caterpillar plots: Local Health Board-level residuals for total 
antibiotic dispensing rates ( 1.96SD) vs. rank .......................................... 97 
Figure 5.24 MLwiN output for three-level repeated measures quadratic model for 
total antibiotic dispensing rates (estimated by MCMC methods) ............... 98 
Figure 5.25 Fitted total antibiotic dispensing rates from the fitted three-level 
model by Local Health Board ..................................................................... 98 
Figure 5.26 Caterpillar plot: Local Health Board-level residuals for total antibiotic 
dispensing rates ( 1.9SD) vs. rank ............................................................ 99 
Figure 5.27 Caterpillar plots: practice-level residuals of flucloxacillin dispensing 
rates ( 1.96SD) vs. rank ........................................................................... 100 
Figure 5.28 Fitted total antibiotic dispensing rates from the fitted three-level 
model by single/multi-handed status of the practice ................................. 104 
Figure 5.29 Fitted total antibiotic dispensing rates from the fitted three-level 
model by practice deprivation quintile ...................................................... 104 
Figure 5.30 Most commonly dispensed antibiotics in primary care from 2000 to 
2006 by antibiotic type (BNF chemical) ................................................... 107 
Figure 5.31 Monthly trends in antibiotic dispensing rates by antibiotic group: 
April 2000 to March 2006 ......................................................................... 108 
Figure 5.32 Monthly trends for flucloxacillin dispensing rates compared to 
remaining penicillins ................................................................................. 109 
Figure 5.33 Fitted cephalosporin dispensing rates by Local Health Board ............. 111 
Figure 5.34 Most commonly dispensed liquid oral antibiotics in primary care from 
2000 to 2006 by antibiotic group .............................................................. 112 
Figure 5.35 Monthly trends in antibiotic dispensing in children by antibiotic group113 
Figure 5.36 Fitted total antibiotic dispensing rates for children from the fitted 
three-level model by Local Health Board ................................................. 115 
Figure 5.37 Broad- and narrow-spectrum antibiotic dispensing monthly rates over 
time (April 2000 to March 2006) .............................................................. 119 
Figure 5.38. Monthly broad-spectrum antibiotic dispensing per 1,000 practice 
population (April 2000 to March 2006) .................................................... 120 
Figure 5.39 Caterpillar plots: practice-level residuals for broad-spectrum 
dispensing rates ( 1.96SD) vs. rank ........................................................ 121 
Figure 5.40 Fitted monthly broad-spectrum dispensing rates by Local Health 
Board ......................................................................................................... 121 
Figure 5.41 Caterpillar plots: practice-level residuals for narrow-spectrum 
antibiotic dispensing rates ( 1.96SD) vs. rank ........................................ 122 
Figure 5.42 Fitted monthly narrow-spectrum dispensing rates from the fitted 
three-level model by Local Health Board ................................................. 122 
Figure 6.1 Trends in resistance rates by organism (excluding duplicates and 
selectivity) - All isolates ............................................................................ 148 
Figure 6.2 Trends in resistance rates by organism (excluding duplicates and 
selectivity) - Sputum and ENT isolates ..................................................... 148 
xix 
Figure 6.3 Trends in sampling rates for practices submitting H. influenzae isolates 
between 1998 and 2006 (average rate and 95% confidence interval)....... 169 
Figure 7.1 Scenarios of patients’ events and consultant episodes in hospital .......... 187 
Figure 7.2 Annual overall incidence of hospital events (for both acute RTIs and 
complications) (per 10,000 population) in Wales ..................................... 193 
Figure 7.3 Annual incidence of events (per 10,000 population) by acute RTIs and 
complications in Wales ............................................................................. 194 
Figure 7.4 Quarterly incidence of events (per 10,000 population) by acute RTIs 
and complications arising from RTIs in Wales ......................................... 195 
Figure 7.5 Quarterly incidence of acute RTIs events (per 10,000 population) by 
age group, in Wales ................................................................................... 195 
Figure 7.6 Quarterly incidence of complication events (per 10,000 population) by 
age group, in Wales ................................................................................... 197 
Figure 7.7 Annual incidence of events (per 100,000 population) by acute RTI 
type, in Wales ............................................................................................ 201 
Figure 7.8 Annual incidence of unspecified otitis media events (per 100,000 
population) by age group, in Wales .......................................................... 202 
Figure 7.9 Annual incidence of acute pharyngitis and tonsillitis events (per 
100,000 population) in Wales ................................................................... 202 
Figure 7.10 Annual incidence of acute pharyngitis and tonsillitis events (per 
10,000 population) by age group, in Wales .............................................. 203 
Figure 7.11 Hospital admissions for tonsillectomies (European age standardised 
rates (EASRs)) in Wales, 2001 and 2006 ................................................. 204 
Figure 7.12 Annual incidence of pneumonia and COPD events (per 100,000 
population) in Wales ................................................................................. 213 
Figure 7.13 Annual incidence of pneumonia events by type (per 100,000 
population) in Wales ................................................................................. 214 
Figure 7.14 Annual incidence of bacterial pneumonia, not elsewhere classified 
(J15) events by type (per 100,000 population), by age group................... 215 
Figure 7.15 Annual incidence of pneumonia, organism unspecified (J18) events 
by type (per 100,000 population), by age group ....................................... 215 
Figure 7.16 Annual incidence of bronchiectasis, peritonsillar abscess, pleural 
effusion and septicaemia events (per 100,000 population) in Wales ........ 216 
Figure 7.17 Annual incidence of other septicaemia (A41) events (per 100,000 
population) by age group, in Wales .......................................................... 217 
Figure 7.18 Annual incidence of pyothorax, acute epiglottitis, legionnaire’s 
disease and intracranial and intraspinal abscess events (per 100,000 
population), in Wales ................................................................................ 218 
Figure 7.19 Annual incidence of abscess, furuncle and carbuncle of nose and 
acute lymphadenitis of face, head and neck events (per 100,000 children 
population) in children, in Wales .............................................................. 219 
Figure 7.20 Annual incidence of mastoiditis and meningococcal infection events . 220 
Figure 7.21 Histogram of the rate of acute RTIs (per 10,000 practice population) 
practice per annum .................................................................................... 221 
Figure 7.22 Caterpillar plots: LHB-level residuals ( 1.96SD) vs. rank ................. 223 
Figure 7.23 Caterpillar plots: Practice-level residuals ( 1.96SD) vs. rank ............ 224 
Figure 7.24 Histogram of complication rates (per 10,000 practice population) per 
practice per year ........................................................................................ 225 
Figure 7.25 Caterpillar plots: LHB-level residuals ( 1.96SD) vs. rank ................. 227 
Figure 7.26 Comparison of acute RTI and complication event rates (per 10,000 
xx 
population) from all-Wales and ‘Up to Standard’ (UTS) practices .......... 230 
Figure 8.1 MLwiN output for three-level repeated measures NB model for 
hospital events for complications .............................................................. 245 
Figure 8.2 Fitted association between hospital events for complications (predicted 
SIR) and total antibiotic dispensing rate ................................................... 246 
Figure 8.3 Trends in total antibiotic dispensing and complication rates, 1996 to 
2005 ........................................................................................................... 249 
Figure 8.4 Histogram of the number of H. influenzae isolates tested for 
amoxicillin resistance per practice per annum, 1998 to 2005 ................... 251 
Figure 8.5 Histogram of number of hospital events for complications and 
resistance by LHB per annum ................................................................... 253 
Figure 9.1 Relationship between the absolute risk reduction and number needed to 
treat and their confidence intervals (NNTB=number needed to treat 
(benefit); NNTH=number needed to treat (harm)) .................................... 278 
Figure 9.2 Antibiotic prescribing in 60 GPRD practices ......................................... 282 
Figure 9.3 Box plot of the number of days between the index RTI and the first 
complication .............................................................................................. 287 
 
List of Appendices 
Appendix I Literature search terms by databases ..................................................... 349 
Appendix II Antibiotics used in the treatment of respiratory tract infections .......... 355 
Appendix III Liquid oral antibiotic preparations ..................................................... 357 
Appendix IV Broad- and narrow-spectrum classifications ...................................... 365 
Appendix V Modelling for antibiotic resistance and lagged dispensing in H. 
influenzae, S. pneumoniae and S. pyogenes in sputum/ENT isolates. ...... 367 
Appendix VI Changes (%) in resistance to amoxicillin and tetracycline over an 8-
year period, in Sputum and ENT H. influenzae isolates, by quartile of 
reductions in: ............................................................................................. 368 
Appendix VII Changes (%) in resistance to erythromycin and penicillin over an 8-
year period, in Sputum and ENT S. pneumoniae isolates, by quartile of 
reductions in: ............................................................................................. 370 
Appendix VIII Changes (%) in resistance to erythromycin over an 8-year period, 
in Sputum and ENT S. pyogenes isolates, by quartile of reductions in: ... 372 
Appendix IX List of respiratory infections seen in hospital (ICD10 codes) ............ 373 
Appendix X Complications arising from RTIs (ICD10 codes) ................................ 374 
Appendix XI List of respiratory tract infections (Read codes) by type and the 
number of patients identified with each code ........................................... 377 
Appendix XII Complications arising from respiratory tract infections (Read 
codes) ........................................................................................................ 389 
Appendix XIII ICD10 codes for complications ....................................................... 394 
Appendix XIV List of Read codes used to identify co-morbidities ......................... 399 
 
 
 
 
xxi 
Glossary of abbreviations 
  
BNF British National Formulary 
BSP  Broad spectrum penicillin 
CI Confidence interval 
(AE) COPD (Acute Exacerbations of) Chronic obstructive pulmonary disease 
CV Coefficient of variation 
DIC Deviance Information Criterion 
DOH Department of Health 
ENT  Ear, nose and throat 
GP General Practitioner 
GPMD General Practice Morbidity Database 
GPRD General Practice Research Database 
HA  Health Authority 
ICC Intra-class correlation 
ICD10 International Statistical Classification of Diseases and Related 
Health Problems, 10
th
 revision 
IQR Interquartile range 
LHB  Local Health Board 
LRTI Lower respiratory tract infection 
MCMC Markov Chain Monte Carlo 
MIC Minimum Inhibitory Concentration 
NHS National Health Service  
NICE National Institute of Clinical Excellence 
NNT Number needed to treat 
NNTB/NNTH Number needed to treat for benefit / harm 
NPHS  National Public Health Service 
NWIS NHS Wales Informatics Service 
OM Otitis media 
OPCS Office of Population, Censuses and Surveys Classification of 
Surgical Operations and Procedures 
OR Odds ratio 
PEDW  Patient Episode Database for Wales 
PACT  Prescribing Analysis and Cost  
PSU Prescribing Services Unit 
RIGLS Restricted iterative generalized least squares 
RR Relative risk 
RTI  Respiratory tract infection 
SD Standard deviation 
SE Standard error 
SMAC Standing Medical Advisory Committee 
UTS Up-to-standard 
URTI Upper respiratory tract infections 
xxii 
 
 
Chapter 1 
1 
Chapter 1  Background 
The History of Medicine 
 2000 B.C. – Here, eat this root. 
 1000 A.D. – That root is heathen. Here, say this prayer. 
 1850 A.D. – That prayer is superstition. Here, drink this potion. 
 1920 A.D. – That potion is snake oil. Here, swallow this pill. 
 1945 A.D. – That pill is ineffective. Here, take this penicillin. 
 1955 A.D. – Oops...bugs mutated. Here, take this tetracycline. 
 1960-1999 – 39 more "oops”…Here, take this more powerful antibiotic. 
 2000 A.D. – The bugs have won! Here, eat this root. 
Anonymous (World Health Organisation (WHO) infectious 
disease report) 
 
1.1 The discovery of antibiotics and their role in disease 
management   
The development of antibiotics in the 20
th
 century, spurred on by the landmark 
discovery of penicillin by Sir Alexander Fleming in 1928, revolutionised modern 
medicine. Antibiotics have a vital role in treating infectious bacteria and in 
maintaining health and, alongside improvements in the social determinants of health 
such as diet, housing and sanitary water have helped the decline of both morbidity 
and mortality from infectious diseases (Cosby et al. 2007).  
 
General practitioners (GPs) immediately noticed a profound effect of antibiotics on 
outcomes for their patients and were given access to life-saving drugs. Complications 
and deaths from common infections such as pneumonia and acute rheumatic fever, 
which had previously been relatively common, became rarer. A study examining the 
mortality of respiratory illnesses in children in England and Wales between 1968 and 
2000 found that pneumonia deaths fell over all age groups, with the most striking 
decrease of 96% found in post-neonatal infants (from 165 per 100,000 in 1968 to 27 
in 1985 and 6.8 in 2000) (Panickar et al. 2005). The authors concluded that this was 
partly due to improvements in primary and secondary care, and immunisation, but 
mainly to the use of antimicrobial agents. The use of antibiotics has grown 
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substantially over the past 50 years and antibiotic prescribing continued to rise 
steadily throughout the 1980s and early 1990s. For example, between 1980 and 1993 
the overall increase in the number of prescriptions for antibiotics
 
in England was 
45.8% (Davey 1996) while increases were greater for many European countries over 
a similar period (e.g. in West Germany an increase of 78% and France 65%) 
(Taboulet 1990).  
 
1.2 The emergence of resistance 
One drawback to this widespread increase in antibiotic use has been the rise of 
resistance to antibiotics in many bacteria. Antibiotic resistance occurs when bacteria 
lose their susceptibility to the antibiotic, usually to cheap and effective "first-line" 
drugs (WHO fact sheet no. 194). The bacterial infections that contribute most to 
human disease are also those in which emerging microbial resistance is most evident: 
diarrhoeal diseases, respiratory tract infections (RTIs), meningitis, sexually 
transmitted infections, and hospital-acquired infections. Some important examples 
include penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant 
enterococci, methicillin-resistant Staphylococcus aureus, multi-resistant salmonellae, 
and multi-resistant Mycobacterium tuberculosis. The problem is not confined to 
bacterial infections. The development of resistance to drugs commonly used to treat 
protozoal infections such as malaria is of particular concern, as is the emerging 
resistance to anti-retroviral drugs. 
 
Antibiotic resistance is a threat to public health especially for immunocompromised, 
debilitated and elderly patients. Resistance, however, also presents a threat in the 
arena of common infections in primary care (Butler et al. 2006). Resistance can 
increase the length and severity of illness, contribute to the spread of disease, 
increase the use of antibiotic therapy and reconsultations, and finally increase the 
financial costs of treatment and care (National Prescribing Centre, MeReC Briefing 
Issue 21 2003; Alam et al. 2008). The concept of resistance was recognised as early 
as 1945, when, during his Nobel Prize Lecture, Fleming stated  
“It is not difficult to make microbes resistant to penicillin in the laboratory by 
exposing them to concentrations not sufficient to kill them, and the same thing 
has occasionally happened in the body.” (Nobel Prize website).  
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The first documented clinically serious consequence of antibiotic resistance was in 
the early 1950s with a case involving a penicillin-resistant strain of Staphylococcus 
aureus (WHO Bulletin 2001). The immediate response to this was to develop new 
antibiotics able to kill the bacteria and, as an antibiotic became less useful and 
resistance emerged, another antibiotic was generally developed that solved the 
problem. However, by the late 1990s the development of new antibiotics had slowed 
down and new classes of antibiotics have been harder to identify (Figure 1.1). Many 
existing classes of antibiotics, such as beta-lactams and quinolones, are effectively 
‘exhausted’, or near exhaustion, for treating certain infections. No new truly novel 
class of antibiotics for treating gram negative organisms is likely to come to market 
in the short to medium term (Wellcome focus 2005). An additional concern is that 
major pharmaceutical companies are devoting fewer and fewer resources to 
antibiotic discovery because of the high associated costs, low chances of success and 
cautious profit projections (Wise 2004; Norrby et al. 2005). In light of the lack of 
new antibiotics, and increasingly limited options of other therapeutic agents to 
control infections, some experts have forecast a return to pre-antibiotic days (Wise et 
al. 1998). Measures must therefore be taken to either stop or delay the growth of 
resistance. 
 
Figure 1.1 Development and discovery of antibiotics over time (Norrby SR et al. 
2005) 
 
  
 
 
 
 
 
 
 
 
 
 
 Year 
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1.3 Mechanisms of resistance 
Susceptible bacteria can acquire resistance to antibiotics by either genetic mutation 
or by accepting antibiotic resistant genes from other bacteria. This usually occurs 
through one of several biochemical mechanisms: mutation, destruction or 
inactivation, and efflux. Mutation is a change in the DNA that can sometimes cause a 
change in the gene product, which is the target of the antibiotic. Antibiotics can no 
longer bind efficiently (usually leading to cell death) allowing the bacterium with the 
mutated DNA to continue DNA replication. Many bacteria possess genes which 
produce enzymes that chemically degrade or deactivate the antibiotic (destruction), 
rendering them ineffective against the bacterium. Lastly, certain bacteria can often 
become resistant to antibiotics through a mechanism known as efflux. An efflux 
pump is a channel that actively exports antimicrobial and other compounds out of the 
cell. The antibiotic enters the bacterium through a channel, and then is pumped back 
out of the bacterium by the efflux pump preventing the antibiotic from attacking the 
bacteria. 
 
In addition to genetic material being passed down through successive generations, 
genetic material can be transferred between bacteria by several means, most often by 
conjugation, transduction and transformation. During conjugation bacteria coming 
into physical contact with each other are able to share extra-chromosomal genetic 
material.  This may either be in the form of plasmids (circular segments of self-
replicating DNA of varying size) or transposons (short segments of DNA that can 
insert into chromosomes or plasmids). This enables susceptible bacteria to acquire 
resistance to a particular antimicrobial agent. Transduction involves the sharing of 
extra chromosomal DNA passed between bacteria by bacteriophages (viruses that 
infect bacteria).  Transformation involves the take up of exogenous DNA from the 
environment. Conjugation is the predominant mechanism by which bacteria share 
resistance mechanisms.  This ability to share genetic material between different 
species of bacteria is a key part of their evolutionary success, enabling them to 
accumulate a wide genetic armoury which allows them to adapt to environmental 
pressures.  
 
In any large population of bacteria, a few cells will be present that have undergone 
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genetic changes which means that they possess traits that enable them to survive in 
the presence of a noxious substance, such as being able to fend off the action of an 
antibiotic. This indicates that susceptible organisms, those lacking the advantageous 
trait, will be destroyed, leaving the remaining resistant populations behind. With 
long-term antibiotic use in a given environment, the bacterial communities will 
change dramatically, with an increase in the proportion of more resistant organisms. 
This can result in a situation where the next time an antibiotic is needed it may no 
longer be effective to treat what was previously an easily treatable infection.  
 
1.4 Drivers of resistance 
The causes of antibiotic resistance have been categorised into two factors: the spread 
of resistance genes in bacteria (as detailed above) and antibiotic use, and (Levy and 
Marshall 2004). An association has been shown, in both ecological and individual 
studies, between antibiotic prescribing in the community and resistance for a number 
of organism-drug combinations. There is somewhat less evidence for an association 
in secondary care, primarily because it is much harder to measure usage (Goossens et 
al. 2005; Goossens 2009; Berrington 2010). It is not only human antibiotic 
consumption that contributes to resistance levels; veterinary, agricultural and other 
industries may play a role in the growth of antibiotic resistance, as there is concern 
that antimicrobial-resistant bacteria in animals may transfer to humans, in particular 
through food (Inter-Agency Report 2004).  
 
With no completely new class of antibiotic expected on the market in the short term, 
what can be done to at least slow down the progress of increasing resistance? Three 
strategies were suggested by Wise (2007): firstly, attempt to prevent the spread of 
organisms, secondly develop vaccines to restrict pathogens and thirdly reduce 
selective pressure on organisms to become resistant through reducing antibiotic use. 
 
1.5 Minimising resistance by reducing antibiotic use 
In the mid 1990s, before the publication of large scale studies demonstrating the link 
between antibiotic use and resistance, numerous influential bodies raised concerns, 
through reports and strategies, regarding the problem of continuously rising 
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resistance rates (American Society for Microbiology 1994, House of Lords 1998, 
Standing Medical Advisory Committee (SMAC) 1998). These national strategies 
aimed to improve surveillance of resistance and contain resistance through 
promoting more prudent antibiotic prescribing by education of both GPs and 
patients, thus preserving the possibility of effective antibacterial treatment for present 
and future generations. To reduce inappropriate antibiotic prescribing it was 
important to identify where the majority of antibiotic usage occurred, for example in 
which healthcare setting, for which patient populations, and for which infections.  
 
1.5.1 Antibiotic use in primary care 
In the United Kingdom (UK), around half of antibiotic use occurs in humans and half 
in agriculture (Inter Agency Report 2007). Around 80% of human use is in the 
community, attributable to GP prescribing (SMAC 1998). Based on data collected in 
the Fourth General Practices Morbidity Survey (between September 1991 and 
August 1992), it was estimated that 41% of the population consulted to general 
practice each year with an infection; RTIs accounted for half of these (Wilson and 
Bhopal 1998; Fleming et al. 2002). Approximately half of all antibiotic prescriptions 
are for respiratory symptoms (Davey et al. 1996) and more recent figures show that 
RTIs account for more than 50% of all antibiotic prescribing in primary care in the 
UK (Ashworth et al. 2004; Petersen and Hayward 2007). Additionally, studies have 
shown that antibiotic prescribing between RTI groups varies greatly; over 82% of 
those with chest infection are prescribed an antibiotic, over 60% with sore throat, but 
only 44% with upper RTIs (Petersen and Hayward 2007).   
 
RTIs range from the common cold to life-threatening cases of pneumonia. Many 
empirical observational studies and trials have been conducted to investigate the role 
of antibiotics in their treatment, with Cochrane reviews providing the best and most 
accurate summary of the highest quality evidence to date (Sanders et al. 2004; Smith 
et al. 2004; Arroll and Kinealy 2009; Spinks et al. 2006; Ahovuo-Saloranta et al. 
2008). In essence, these reviews conclude that the benefit of antibiotics for the 
average patient is modest or even non-existent. Most of these infections are caused 
by viruses and therefore would not be expected to respond to antibiotics in any case. 
Even bacterial infections can be self-limiting and benefit from antibiotic treatment is 
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often marginal or non-existent. In other words, for most patients these infections will 
resolve without the need for antibiotics, and the risk of complications is low. 
 
1.5.2 Reducing antibiotic prescribing in the community 
Results arising from randomised controlled trials (RCTs), the gold standard of 
evidence, suggest that RTIs are especially appropriate to consider when aiming to 
achieve a reduction in antibiotic prescribing since most of these infections can be 
safely managed without the need of immediate assessment or antibiotic treatment. As 
a result, several initiatives took place and recommendations were produced to 
encourage the appropriate prescribing of antibiotics by GPs for RTIs. In September 
1998, the UK SMAC report recommended the following actions to influence 
antibiotic prescribing in RTIs in the community: no prescribing of antibiotics for 
simple coughs, colds or viral sore throats and limiting prescribing of antibiotics over 
the telephone to exceptional cases (SMAC 1998). Other sources of prescribing 
support and guidance are available to aid GPs with antibiotic prescribing in practice 
(National Institute of Clinical Excellence (NICE) Clinical Guidelines 69 2008, 
Health Protection Agency, Scottish Intercollegiate Guidelines Network) and on-line 
guidance (Clinical Knowledge Summaries).  
 
1.5.3 Evidence of a decrease in antibiotic prescribing 
Antibiotic prescribing in developed countries rose steadily throughout the 1980s and 
early 1990s and reached a peak in several countries between 1992 and 1995 (McCaig 
et al. 1995; Metlay et al. 1998; Frischer et al. 2001; Wrigley et al. 2002). 
Subsequently, and influenced by prescribing guidelines, national reports, and public 
campaigns by the Department of Health (DOH), antibiotic prescribing in primary 
care declined in the UK. 
 
Evidence from numerous sources demonstrates a downward trend in antibiotic 
prescribing up until 2000, with rates levelling out and then increasing slightly again, 
as shown in Figure 1.2 (Frischer et al. 2001; Wrigley et al. 2002; Majeed et al. 2004; 
Sharland et al. 2005; Fleming et al. 2005; Prescribing Review 2006; Schneider-
Lidner et al. 2011). Data from the DOH’s Prescription Cost Analysis for England 
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showed that the number of antibiotic prescriptions
 
dispensed by GPs decreased by 
25% between 1995 and 2000,
 
from 49.4 to 36.9 million prescriptions. A detailed
 
analysis of antibiotic prescribing data from 210 general practices in England and 
Wales showed
 
that the largest reductions in overall antibiotic prescribing rates were
 
seen between 1995 and 1998 and most marked among children (Frischer et al. 2001). 
 
Figure 1.2 Trends in Prescribing of Antibacterial Drugs in General Practice in  
England (Prescribing Review 2009, NHS Prescription Services) 
 
 
ADQ=Average daily quantities 
 
This broad pattern was also true for other countries such as the United States (US), 
Portugal, Spain and Sweden (McCaig et al. 2002; Mölstad et al. 2002), whereas 
countries such as France and Greece experienced an increase in the number of 
antibiotic prescriptions between 1994 and 1997 (Mölstad et al. 2002).  
 
A study specifically examining the impact of the SMAC report on prescribing for 
coughs/colds and sore throats using General Practice Research Database (GPRD) 
data found that, whilst there were significant annual decreases in antibiotic 
prescriptions for sore throat prior to its publication (Jan. 1993 to Sept. 1998), no 
significant annual change occurred thereafter (Smith et al. 2004). Conversely, there 
was a significant annual increase in antibiotic prescriptions for coughs/colds after the 
publication (Oct 1998 to Dec 2001). Similarly, trends in antibiotic dispensing in 
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children (using oral liquid formulations of antibacterials as a proxy) showed a 
decline in prescriptions between 1996 and 2004 although there was evidence of a 
slight increase after 2000 (reduction of 64% between 1996 and 2000 and 55% 
between 1996 and 2005) (Sharland 2007).  
 
The SMAC report of 1998 was regarded as an important landmark but evidence hints 
towards trends in prescribing falling prior to this, with little evidence to suggest a 
major decrease after the report. This suggested that maybe GPs were already aware 
of the need to reduce antibiotic prescribing and of the limited effectiveness of 
antibiotics for many RTIs, and had begun to change their prescribing practice to 
reflect this.  
 
There are other possible explanations of the decline observed in antibiotic 
prescriptions in the community. Fleming et al. (2003) studied 73 practices in 
England and Wales and found a reduction of consultations for RTIs and concluded 
that this was the main contributor or explanation for the widespread decline in 
antibiotic prescribing. This decline in RTI consultations could have either 
represented a true decrease in the incidence of infections or changing thresholds for 
patient consultation behaviour. Indeed, Ashworth et al. (2006) reported that patients 
were not consulting as often for common infections. Reassuringly, even though RTI 
consultations have decreased, the proportion of antibiotics prescribed for RTIs has 
also decreased, suggesting a true change in GP prescribing behaviour (Frischer et al. 
2001; Ashworth et al. 2004; Gulliford et al. 2009). Ashworth et al. (2004) and 
Gulliford M et al. (2009) additionally ascertained that the proportion of antibiotics 
prescribed for upper RTIs (URTIs) declined between 1994 and 2000 whilst antibiotic 
prescribing for lower RTIs (LRTIs) remained static. The largest relative reductions 
of prescribing occurred in patients diagnosed with influenza, upper RTIs, laryngitis 
and sore throats. These findings were also replicated in a study in children from the 
US; additionally they found no significant decline in prescribing for acute otitis 
media (AOM), sinusitis and bronchitis (McCaig et al. 2002). 
  
1.6 Advantages of reducing antibiotic prescribing 
It has been demonstrated that reducing the use of antibiotics is essential to the 
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problem of resistance but reducing antibiotic use is important for many other reasons 
(Butler et al. 1998a). Firstly, there are resource implications; receiving antibiotics 
reinforces patients’ perceptions that antibiotics are needed for common infections, 
encouraging them to consult with similar infections in the future, a cycle known as 
medicalisation. A survey from the US found that previous antibiotic usage had a 
strong relationship with belief in the effectiveness of antibiotics in the treatment of 
URTIs (Mainous III et al. 1997). Another study in England found that 38% of 
patients initially prescribed an antibiotic re-consulted with a sore throat in the future, 
compared with 27% not prescribed an antibiotic (Little et al. 1997).  
 
The financial implications of reducing antibiotic prescribing have also been 
highlighted. In 1994 the Audit Commission estimated that the NHS could save up to 
£425 million a year if general practitioners changed their prescribing habits by 
controlling the volume of prescribing, increasing rates of generic prescribing, and 
using expensive products more appropriately, with £77 million in savings made from 
rational antibiotic prescribing (Audit Commission 1994). More recently, the Audit 
Commission developed a national prescribing savings database from which they 
estimated that in 2002/03, the potential saving for the average primary care trust 
(PCT) in England was £430,000, of which £59,000 was specifically in antibiotic 
prescribing (Audit Commission 2003).  
 
Finally, antibiotics may cause as much illness as they reduce. In children with otitis 
media, antibiotic treatment may cause an increase in adverse effects such as nausea, 
diarrhoea, and rash (Glasziou et al. 2004). In adults with bronchitis, patients reported 
adverse effects such as nausea, vomiting, headaches, skin rash, and vaginitis (Fahey 
et al. 2004). 
 
1.7 Disadvantages of reducing antibiotic prescribing 
Just as there have been positive consequences of the increased use of antibiotics in 
the community during the past 50 years, there may also have been unintended 
consequences of reducing antibiotic usage in the community. Firstly, patients who 
expect or demand antibiotics from their GP, but do not receive them, may be 
dissatisfied with care, and this could potentially damage the doctor-patient 
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relationship. One study reported that patients with LRTIs who did not receive an 
antibiotic
 
that they hoped for were much more likely to express dissatisfaction to 
their doctor (Macfarlane et al. 1997). Doctors are also fully aware of this problem 
and report preserving the doctor-patient relationship as one of the reasons for 
prescribing antibiotics, although not the primary reason (Bradley 1992; Butler et al. 
1998b; Kumar et al. 2003). 
Perhaps more important is the potential for unintended adverse events such as 
complications arising from untreated common infections. One possible explanation 
for the turn-around in antibiotic prescribing is concern amongst GPs that reduced 
levels of antibiotic prescribing have been associated with increases in complications 
from common infections. Fear of medico-legal problems if a patient acquires a 
complication is an important reason why GPs do not reduce antibiotic prescribing 
beyond a certain threshold (Butler et al. 1998b). 
 
This concern is supported by several qualitative interview studies in which clinicians 
are invited to reflect on individual cases. One GP described how, by changing 
practice policy to stop all antibiotic prescribing for sore throats, the practice saw “an 
unprecedented rise in the number of patients with quinsy” (Kumar et al. 2003). After 
returning to prescribing antibiotics for the severest sore throat symptoms, cases of 
quinsy fell. Another GP recollected that on one occasion when antibiotics were 
withheld, the patient subsequently developed streptococcal septicemia. More 
generally, a GP wrote that not using antibiotics in the NHS has “caused an increase 
in LRTI and death” (Searle 2004) and recent NICE guidelines recognised the 
concern of GPs and patients regarding the danger of complications (NICE Clinical 
Guidelines 69 2008). There is also concern that GPs may miss serious illness due to 
early symptoms being identical to those seen in common infections. In a recent 
editorial, Harnden (2007) raised concern regarding missing meningococcal infections 
in feverish young children, as their symptoms are the same as those of self-limiting 
viral infections. 
 
Responsible reductions in antibiotic prescribing should limit inappropriate 
prescribing without denying benefits to those patients who are likely to derive benefit 
from antibiotic treatment (Woodhead et al. 2004). However, concerns have been 
raised by some GPs that some prescribers are aiming to achieve a ‘blanket’ 
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reduction, rather than one targeted at reducing inappropriate prescribing (prescribing 
that does not benefit patients). This ‘blanket’ reduction may then lead to patients who 
need antibiotics, and are likely to gain most benefit from them, not actually receiving 
them, and, as a result, being put at a higher risk of developing a complication 
(Wilkinson 2006). In addition, alongside the development of complications comes 
the accompanying downside of additional costs driven largely by possible hospital 
admissions and inpatient stays. 
 
1.8 The relationship between antibiotic use and complications 
The need for further research into the relationship between complications and 
antibiotic prescribing has been called for by many leading professionals in the field 
(Woodhead et al. 2004; Price et al. 2004a; Goossens et al. 2005). These calls have 
focussed on the merits of using patient-level data to clarify the relations between 
antibiotic use, resistance and clinical outcomes that could be obscured by group-level 
data. The potential problem in using group level data has been demonstrated by 
Donnan and colleagues where, at a practice level, trimethoprim prescribing was not 
related to
 
trimethoprim resistance, but at an individual level a strong
 
association 
existed between the two (Donnan et al. 2004).  
 
A number of studies have already examined the relationship between complications 
and antibiotic prescribing at both an ecological and individual level. These studies 
are described more fully in Chapter 2. In summary, ecological level analyses showed 
evidence of a negative relationship between antibiotic use and certain complications 
(diagnosed in either primary or secondary care). Recent evidence from individual 
patient level studies using data from the UK-based GPRD, examining the protective 
effect of antibiotics in patients with RTIs against the risk of complications, did not 
provide conclusive answers. Most of the studies of individual patient data showed 
there was a higher risk of developing a complication if antibiotics were not 
prescribed for an acute RTI, but the risk of developing a complication was still low, 
with large numbers needed to treat, apart from specific patient sub-groups (quinsy in 
patients with a diagnosis of tonsillitis and pneumonia in the elderly) (Dunn et al. 
2006; Petersen et al. 2007). The research from this thesis hopes to contribute to this 
important debate of the relationship between antibiotic use and complications.  
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1.9 Limitations of the evidence base  
Whilst the ecological level studies have provided useful results at both national and 
international levels, they are limited for several reasons.  
 They have generally not examined the relationship between prescribing and 
complications using antibiotic prescribing data for all commonly used 
antibiotics in primary care over several years. 
 Outcomes were restricted to a narrow set of complications in some of the 
studies. 
 There are many challenges and competing factors in deciding whether to 
prescribe antibiotics or not, and these need to be balanced. For example, as a 
result of reduced prescribing, does the gain to society of possible reduced 
resistance outweigh the risk of developing a complication in any one 
individual? Several studies have shown that GPs see the risk of patients 
developing serious problems outweighing the risk of developing bacterial 
resistance (Wood et al. 2007; Simpson et al. 2007).  
 None of the ecological studies so far have adequately examined confounding 
factors, such as practice and GP characteristics that could alter the 
relationship between antibiotic prescribing and the occurrence of 
complications.  
 These studies used large units of aggregation and may have suffered from the 
‘ecological fallacy’ in which erroneous inferences regarding individuals 
within the same area are made from ecological models based on aggregate 
data. The evidence base of these studies has been questioned for these reasons 
(Woodhead et al. 2005).  
 
Group level studies may be helpful, either by producing convergent data with 
individually linked studies or by raising questions on the validity of conclusions from 
such studies. In fact the effect of antibiotic prescribing on rare complications of acute 
RTIs has already been examined at an individual patient level by several studies 
(Dunn et al. 2006; Petersen et al. 2007; Thompson et al. 2009a; Winchester et al. 
2009, Crocker et al. 2012). Whilst these studies have been very useful, and have 
involved a large study population using the GPRD, they may have failed to capture 
the true incidence of complications in the population. Complications can develop and 
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be managed by a number of different pathways. Firstly, they can be diagnosed and 
treated entirely within primary care by the GP (either in practice or during an out of 
hours (OOH) home visit). Alternatively, they can be diagnosed in general practice 
but then urgently referred to secondary care for treatment (possibly with no record of 
a complication recorded within the GP system). Complications can also be solely 
diagnosed and treated outside of general practice but still within primary care 
services such as in accident and emergency (A&E) or OOH consultations and 
possibly admitted to secondary care as in-patients. 
 
Whilst GPs contributing to the GPRD are asked to record OOH consultations and 
home visits, under-recording is likely. GPs should also be informed of any patient 
hospitalisations, although again this information may be under-recorded in their 
electronic clinical records and there may also be an associated time lag in recording 
the information.  More research is therefore needed to identify, more robustly, 
complications of common infections managed initially in primary care. 
 
Most studies on individual patients have not controlled for important confounders. 
Patients, who are more ill, with co-morbidities or immunosuppression, are more 
likely to be given antibiotics for these reasons and are also more likely to have 
adverse outcomes (Coenen and Goossens 2007). Lastly, whilst these studies are 
useful in showing the protective effect of antibiotics against complications, there is 
no evidence to show that this level of protection has changed over time, during the 
same period when antibiotic prescribing declined.  
 
1.10 The need to monitor trends 
The need to monitor the incidence of antibiotic prescribing, resistance and 
complications has been highlighted (Goossens et al. 2006; Cosby et al. 2007; 
Hayward et al. 2007; Thompson et al. 2009b). This is especially true in countries 
where national campaigns to reduce antibiotics are undertaken, to ensure that any 
changes in antibiotic use are not causing harm. There is a continually changing 
relationship between bacteria, human host and antibiotic as the social determinants of 
disease change, bacteria change and antibiotic prescribing exerts their influence over 
time. Several programmes have been undertaken by The Royal College of General 
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Practitioners, the Prescriptions Pricing Authority’s Prescribing Analysis and Cost 
(PACT) data and the Health Protection Agency (HPA) to examine issues of 
resistance and prescribing but they are based on less than perfect data and 
surveillance (Hayward et al. 2007; Wise R 2007). For outcomes of infections, 
hospital episode statistics (HES) are the best source for monitoring trends since they 
cover the whole population (and therefore incur no bias as would general practice 
based databases), but this monitoring is not carried out routinely in England and 
Wales. Additionally, very few studies have examined time trends in complications 
arising from RTIs at a national level for some of the more rare complications. 
 
1.11 Aims and objectives 
This introduction has identified a possible relationship between antibiotic prescribing 
and risk of resistance and presented some evidence to suggest that antibiotics have a 
protective effect against serious complications arising from acute RTIs. As a result 
the following hypothesis was generated: 
Reduced levels of community antibiotic prescribing are associated with higher 
levels of complications arising from common RTIs. 
 
Figure 1.3 shows the main relationship between antibiotic use and complications and 
other measureable factors that could also impact on complication rates and their 
relationships with one another.  
 
Figure 1.3 Modelling the relationship between antibiotic use, complications, 
resistance and other factors. 
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Therefore, the main focus of this thesis will be on investigating these relationships 
whilst taking the field forward by (a) the use of improved statistical methods; (b) 
controlling for certain confounders that could also affect the relationship, and (c) 
paying additional attention to possible biases found in data sources (such as the 
possible undercounting of complications in individual studies based on GP held data 
alone). This relationship will be investigated by using a number of datasets at both 
the general practice level (using national routinely collected data from Wales) and 
individual level (using a general practice database from the UK). The advantage of 
investigating this relationship at both geographical levels is that a comparison can be 
made of the results, thus exploring the ‘ecological fallacy’.  
 
The objectives of the thesis are as follows: 
  
At a general practice level:  
I. To examine national (Wales) trends in antibiotic dispensing and antibiotic 
resistance data in primary care, and complications of RTIs managed in 
secondary care; 
II. To examine the variation in trends in these data between general practices and 
Local Health Board areas in Wales and determine possible practice and GP 
factors associated with any variation; 
III. To examine the relationship between antibiotic dispensing and resistance in 
primary care and investigate whether reductions in dispensed antibiotics are 
related to changes in antibiotic resistance; 
IV. To examine the relationship between antibiotic dispensing in primary care and 
complications from RTIs in secondary care and investigate whether reductions 
in dispensed antibiotics are related to changes in complications. 
 
At an individual patient level:  
V. To investigate the effect of antibiotics prescribed in primary care on the risk of 
developing a complication arising from an RTI in both primary and secondary 
care using up-to-date data; 
VI. To identify sub-groups of patients benefiting most from antibiotics. 
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1.12 Structure of the thesis 
Chapter 1 provided an overview of the direct issues to be examined in this thesis; the 
underlying evidence is presented more comprehensively in Chapter 2. This will 
examine the role of antibiotics in RTIs and their complications, the relationship 
between antibiotic dispensing and complications, and between dispensing and 
resistance and whether resistance modifies this relationship. Chapter 3 describes the 
datasets that were used in the current general practice and individual level analyses 
as well as providing an overview of the statistical methods used throughout this 
thesis. 
  
Chapter 4 allows an initial exploration (at a general practice level) of the hypothesis 
on the relationship between dispensing and complications for a sample of Welsh 
practices and the feasibility of carrying out further analysis on larger datasets. 
Chapters 5 to 8 examine the trends in dispensing, resistance and complications and 
the relationship between them for the whole of Wales at a practice level. Chapter 9 
examines the relationship at an individual patient level using a general practice 
dataset. Finally Chapter 10 will return to the initial aims and objectives, summarising 
the achievements in the thesis and highlighting strengths and weaknesses, and 
discussing the implications of the results in clinical practice and future research. It 
will also contain the conclusions of the thesis. 
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Chapter 2  Detailed appraisal of the evidence base 
supporting the rationale for the current study 
2.1 Introduction 
The purpose of this chapter is to identify, describe and appraise the evidence that has 
led to the specific hypotheses and objectives outlined in Chapter 1. Firstly respiratory 
tract infections (RTIs) and their complications will be defined. Secondly the 
evidence on the effectiveness of antibiotics in the treatment of RTIs and their 
complications will be reviewed and summarised. The current evidence surrounding 
the relationship between antibiotic prescribing and complications arising from RTIs 
will also be reviewed, as will the relationship between prescribing and resistance.  
 
2.2 Search strategy 
To identify relevant literature, MEDLINE, EMBASE and all Evidence-Based 
Medicine (EBM) Reviews (Cochrane Database of Systematic Reviews (CDSR), 
ACP Journal Club, Database of Abstracts of Reviews of Effects (DARE), and the 
Cochrane Controlled Trial Register (CCTR)) were searched in February 2006 and 
updated in June 2009.  
 
Two comprehensive search strategies were developed to identify all papers relating 
to (a) antibiotic prescribing and resistance and (b) antibiotic prescribing and 
complications arising from infections using the search strategies in Appendix I. 
Inclusion and exclusion criteria were developed to assess abstracts for inclusion in 
the review. Literature that examined prescribing and resistance in hospital settings 
(e.g. Intensive Care Units) and studies examining the effect of antibiotic 
consumption in animals were excluded. 
 
Papers included were categorised from level 1 to 4; level 1 literature was directly 
relevant to the study aims whilst literature falling into levels 2 to 4 contributed to the 
background of the study (Table 2.1). References of selected studies and relevant 
reviews were hand-searched to find additional relevant studies and other studies were 
obtained from expert colleagues. There were no language or publication restrictions. 
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Additionally, Zetoc alerts were created to identify possible relevant literature using 
the terms ‘antibiotic’ and ‘antimicrobial’ and updates were received from selected 
journals known to contain relevant papers (Zetoc, Mimas). 
 
Table 2.1 Categorisation of included studies from the literature search 
 
Level 1 evidence - Associations between prescribing and resistance in 
primary care. 
- Associations between prescribing in primary care and 
complications in primary or secondary care. 
 
Level 2 evidence Factors associated with:  
a. GP prescribing  
b. Antibiotic resistance levels 
c. Patients consulting with an RTI 
d. Patients’ inappropriate use of antibiotics  
i. use without a prescription e.g. hoarding, 
borrowing 
ii. compliance 
 
Level 3 evidence - Prescribing or resistance levels within/between 
countries. 
- Trends in prescribing, complications or serious 
common infections or resistance 
 
Level 4 evidence - Cochrane reviews examining effect of antibiotics on 
RTIs. 
- Letters or studies indicating a need for further research 
into the relationship between complications and 
prescribing.  
- Methodology (e.g. methods for comparing prescribing 
between GPs etc) 
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2.3 Respiratory tract infections 
The respiratory tract is the part of the anatomy that is involved in the process of 
respiration. The passageway through which air travels is traditionally divided into 
two sections: the upper respiratory tract and the lower respiratory tract. The upper 
respiratory tract includes the nose, throat, larynx, and trachea and the lower 
respiratory tract includes bronchi, bronchioles, and alveoli (NHS direct). The 
respiratory tract is a common site for infections and the spectrum of diseases 
affecting it ranges from the common cold to life-threatening cases of pneumonia. 
Infections are also classified according to whether they mainly affect the upper 
(URTIs) or lower respiratory tract (LRTIs). URTIs are most commonly caused by 
viruses, especially rhinovirus, influenza virus, and respiratory syncytial virus 
(Makela et al. 1998; Gwaltney 2002; Wat 2004) and are rarely serious in developed 
countries. Symptoms/diagnoses include the common cold, ear infections (otitis 
media), sore throat/pharyngitis, tonsillitis, and sinusitis. A study from the 
Netherlands found that 53% of all acute URTIs (mainly diagnoses of flu-like illness, 
common cold, acute pharyngitis and tonsillitis) were viral, with rhinovirus as the 
most frequent pathogen found (25% of all URTIs) (Van Gageldonk-Lafeber et al. 
2005). Bacterial infections were found in 18% with group A β-hemolytic 
streptococcus (GABHS) and Staphylococcus aureus most frequently found.  
 
LRTIs are also caused by both viruses and bacteria and include diagnoses of acute 
cough, acute bronchitis and pneumonia. In a study by Holm et al. (2007), pathogens 
were identified in 40% of patients, with bacterial (including Streptococcus 
pneumoniae and Haemophilus influenzae) and viral infections (including rhinovirus 
and influenza A virus) equally common. Streptococcus pneumoniae is the primary 
cause of community-acquired pneumonia (CAP) in the UK (Macfarlane et al. 2001; 
Holm et al. 2007).  
 
2.4 Complications arising from RTIs 
Complications are defined as those that can either develop from an RTI or as a new 
presentation of a more serious illness. Complications that can arise from RTIs 
include mastoiditis (may complicate acute otitis media (AOM)), peritonsillar abscess 
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(quinsy), epiglottitis, rheumatic fever and acute glomerulonephritis (may complicate 
a streptococcus infection in the throat), and empyema and pneumonia (complicate a 
simple lower or upper RTI). Other potential complications of RTIs are brain 
abscesses, meningitis, and periorbital infections. Some complications, such as 
septicaemia or pyelonephritis, can originate in other sites such as in skin and urinary 
tract infections, as well as the respiratory tract.  
 
A complication can arise either from an untreated bacterial infection, a viral infection 
that goes on to become more serious (e.g. viral pneumonia) or develop from a 
secondary bacterial infection, or from a failure of treatment due to the antibiotic 
prescribed (incorrect type, dosage or duration). However, not all bacterial infections 
need antibiotics, depending on the patient’s own ability to fight the infection and the 
virulence of the organism. Some bacterial infections, although self-limiting, might 
recovery more quickly if treated with antibiotics (such as in streptococcal 
pharyngitis). 
 
2.5 The role of antibiotics in RTIs 
RTIs such as the common cold, ear infections (AOM), sinusitis, sore throat, acute 
cough and bronchitis are those most commonly presented to GPs and therefore most 
commonly treated with antibiotics in primary care. In the following sections the 
current evidence for the efficacy of antibiotics for specific RTIs is presented, based 
on recently updated systematic reviews from The Cochrane Library. The results are 
summarised in Table 2.2 and section 2.5.1 below. 
 
2.5.1 Evidence from Cochrane systematic reviews 
In the Cochrane review for common cold and purulent rhinitis (Arroll and Kinealy 
2009), there was no benefit for antibiotics although there was an increase in adverse 
events and therefore routine use was not recommended by the authors. In acute 
maxillary sinusitis (Ahovuo-Saloranta et al. 2008), antibiotics resulted in a lower 
clinical failure rate, defined as lack of cure or improvement at follow-up, than 
placebo at 7 to 15 days after the start of treatment in participants with acute sinusitis. 
However, 80% of patients treated with a placebo also improved within two weeks. 
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The authors concluded that clinicians needed to weigh the moderate benefits of 
antibiotic treatment against the potential for adverse effects at both the individual and 
general population level. 
 
For acute sore throats (Spinks et al. 2006), antibiotics had a beneficial effect on both 
non-suppurative complications (acute rheumatic fever within two months) and 
suppurative complications (acute otitis media within 14 days, and peritonsillar 
abscess (quinsy) within two months). Antibiotics also had a beneficial effect on 
symptom reductions such as sore throat and headache at day 3, and also sore throat at 
one week. The authors concluded that antibiotics give relative benefits (reducing 
complication rates) in the treatment of sore throat but the absolute benefits in terms 
of resolution of symptoms were modest; the average duration of symptoms was only 
reduced by about 16 hours. Protecting against these complications would require 
treating many with antibiotics for one patient to benefit.  
 
For AOM in children (Sanders et al. 2004), antibiotics had no early impact on pain 
reduction and only a modest overall impact on the clinical course of AOM. Children 
given antibiotics did however have increased side effects such as vomiting, diarrhoea 
and rash. Most cases settle spontaneously in a couple of days and again the authors 
concluded that benefits must be weighed against the possible harms. Antibiotics were 
most useful in children under two years of age, with bilateral AOM, and with both 
AOM and discharging ears.  
 
In the Cochrane systematic review for acute bronchitis (Smith et al. 2004), patients 
given antibiotics were less likely to have a cough or a night cough at follow-up, less 
likely not to improve according to the clinician’s global assessment and have an 
abnormal lung examination. Antibiotic-treated patients also had a reduction in days 
feeling ill and in days with limited activity. Antibiotics appeared to have a modest 
beneficial effect in patients and the authors concluded that the magnitude of the 
benefit needed to be weighed up against problems associated with prescribing 
antibiotics such as side effects, medicalisation and resistance.  
 
 
  
Table 2.2 Summary of Cochrane reviews for the efficacy of antibiotics in RTI (Comparisons are antibiotics vs. placebo; Risk Ratio 
(RR)<1 or mean difference <0 provide evidence for the efficacy of antibiotics) 
 
Condition (reference) Outcomes No. of 
studies  
N. of 
participants  
Risk Ratio (RR)  
(95% CI )  
Common cold and acute 
purulent rhinitis (Arroll 
and Kinealy 2009) 
Persisting symptoms 1 to 7 days: 
    In adults 
    In children 
Adverse effects: 
   In adults 
   In children 
Persistent rhinitis (clear) 
Persistent rhinitis (purulent) 
6 
4 
2 
6 
4 
2 
2 
5 
1047 
891 
449 
1495 
1267 
228 
227 
772 
0.95 (0.59 to 1.51) 
0.92 (0.78 to 1.07) 
1.36 (0.59 to 3.15) 
1.80 (1.01 to 3.21) 
2.62 (1.32 to 5.18) 
0.91 (0.51 to 1.63) 
0.58 (0.23 to 1.48) 
0.60 (0.37 to 0.98) 
Acute maxillary sinusitis 
(Ahovuo-Saloranta et al. 
2008)  
Clinical failure defined as lack of cure or 
improvement:  
   7 to 15 days 
   16 to 60 days 
 
 
7 
1 
 
 
631 
169 
 
 
0.66 (0.44 to 0.98) 
0.85 (0.36 to 1.98) 
Acute sore throat  
(Spinks et al. 2006) 
 
 
 
 
 
Symptom reduction (at day 3): 
   Sore throat 
   Headache 
    Fever  
Symptom reduction (at 6-8 days (one week)):          
   Sore throat 
Non-suppurative complications: 
    Acute rheumatic fever (within 2 months) 
    Acute glomerulonephritis (within 1 month) 
Suppurative complications: 
   Acute otitis media (within 14 days) 
   Acute sinusitis (within 14 days) 
   Peritonsillar abscess (quinsy) (within 2 months) 
 
      
 
15 
3 
7 
 
13 
 
16 
10 
 
11 
8 
8 
 
 
3621 
911 
1334 
 
2974 
 
10,101 
5147 
 
3760 
2387 
2433 
 
0.68 (0.59 to 0.79) 
0.44 (0.27 to 0.71) 
0.71 (0.45 to 1.10) 
 
0.49 (0.32 to 0.76) 
 
0.27 (0.12 to 0.60) 
0.22 (0.02 to 2.08) 
 
0.30 (0.15 to 0.58) 
0.48 (0.08 to 2.76) 
0.15 (0.05 to 0.47) 
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Table 2.2 Summary of Cochrane reviews for the efficacy of antibiotics in RTI (Comparisons are antibiotics vs. placebo; Risk Ratio 
(RR)<1 or mean difference <0 provide evidence for the efficacy of antibiotics) 
 
Condition (reference) Outcomes No. of 
studies  
N. of 
participants  
Risk Ratio (RR)  
(95% CI )  
Acute otitis media in 
children 
(Sanders et al. 2004) 
 
 
Pain at 24 hours 
Pain at 2 to 7 days 
Abnormal tympanometry at 1 month 
Abnormal tympanometry at 3 months 
Perforation 
Vomiting, diarrhoea, or rash 
Contralateral otitis (in unilateral cases) 
Late recurrences 
 
5 
10 
4 
3 
2 
5 
3 
6 
1229 
2791 
927 
808 
381 
1401 
579 
2153 
0.90 (0.78 to 1.04) 
0.72 (0.62 to 0.83) 
0.89 (0.75 to 1.07) 
0.97 (0.76 to 1.24) 
0.55 (0.24 to 1.27) 
1.38 (1.09 to 1.76) 
0.47 (0.17 to 1.36) 
0.93 (0.79 to 1.10) 
Acute Bronchitis 
(Smith et al. 2004) 
 
Cough at follow-up (7 to 15 days) 
Night cough at follow-up 
Not improved by physicians’ global assessment at 
follow-up 
Abnormal lung exam at follow-up 
Adverse events  
Productive cough at follow up 
Proportion with activity limitations at follow up 
 
4 
4 
6 
 
5 
10 
7 
5 
275 
538 
891 
 
613 
1509 
713 
478 
0.64 (0.49 to 0.85) 
0.67 (0.54 to 0.83) 
0.61 (0.48 to 0.79) 
 
0.54 (0.41 to 0.70) 
1.15 (0.92 to 1.44) 
0.97 (0.82 to 1.16) 
0.75 (0.46 to 1.22) 
Condition (reference) Outcomes No. of 
studies  
N. of 
participants  
Mean difference 
(95% Confidence 
interval) 
Acute Bronchitis 
(Smith et al. 2004) 
Days feeling ill
 
Days of impaired activities 
Days of cough 
Days of productive cough 
5 
6 
6 
6 
809 
767 
969 
699 
-0.64 (-1.16 to -0.13) 
-0.49 (-0.94 to -0.04) 
-0.44 (-0.95 to 0.07) 
-0.43 (-0.93 to 0.07) 
 
2
3
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2.5.2 Additional evidence 
There is some recent evidence not yet included in Cochrane reviews. A study 
examining the effectiveness of amoxicillin, compared to no antibiotic treatment, in 
adults with acute maxillary sinusitis showed that neither management was effective 
in altering the symptom severity, duration or the natural history of the condition 
(Williamson et al. 2007). Young et al. (2008) carried out a meta-analysis of RCTs 
based on both aggregate and individual patients’ data from adults with clinical signs 
and symptoms of rhinosinusitis. For the aggregate data (based on 11 RCTs), the 
estimated odds ratio (OR) for the overall treatment effect of antibiotics relative to 
placebo was 1.35 (95% CI=1.15 to 1.59), based on having no or mild symptoms in 
the 8-15 days after receiving treatment. Based on the individual data, the OR was 
increased slightly to 1.37 but with wider confidence intervals (95% CI=1.13 to 1.66). 
Fifteen patients would have to be given antibiotics before an additional patient would 
benefit (with no or mild symptoms). The authors concluded that antibiotics were not 
justified for adult patients with rhinosinusitis-like complaints, even if the patient 
reported symptoms for longer than 7–10 days.  
 
Rovers et al. (2006) carried out a meta-analysis of individual data from trials 
examining the effect of antibiotics in preventing an extended course of AOM 
(defined as pain, fever or both at 3-7 days) in children. They found that antibiotics 
were protective in children aged less than two years with bilateral acute otitis media, 
and in those with both acute otitis media and otorrhoea (ear discharge). In these 
groups the NNT was three to four children to prevent an extended course of the 
disease in one child. The authors recommended observation rather than immediate 
antibiotic treatment for most other children with acute otitis media. The meta-
analysis was not adequately powered to determine the protective effect of antibiotics 
for otitis media against the risk of mastoiditis. 
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2.6 Relationship between antibiotic use and complications 
2.6.1 Evidence from Cochrane systematic reviews 
The effect of antibiotics on complications was assessed only in the reviews for sore 
throat and AOM (Table 2.2). In the sore throat systematic review by Spinks et al. 
(2006), several studies found a protective effect of antibiotics against acute 
rheumatic fever (within two months of diagnosis) which reduced the risk of this 
complication to about one quarter of that in the placebo group (risk ratio (RR)=0.27, 
95% CI=0.12 to 0.60). The incidence of quinsy was also reduced in relation to the 
placebo group (RR=0.15, 95% CI=0.05 to 0.47). There is some doubt regarding the 
relevance of these results since the studies that reported incidence of acute rheumatic 
fever were set in the 1950s-60s, a period where the background incidences of 
rheumatic fever and quinsy were much higher in Western society than they are now. 
Studies from the late 20
th
 century had virtually no occurrences of acute rheumatic 
fever in either the antibiotic or placebo group. However, more recent clinical trials 
provided some evidence that targeting penicillin to a subset of patients with higher 
clinical likelihood of group A β-hemolytic streptococcus (GABHS) showed a lower 
development of quinsy when compared to the placebo group but these studies were 
not powered on this outcome (Dagnelie et al. 1996; Zwart et al. 2000). For acute 
glomerulonephritis, out of ten studies reporting acute glomerulonephritis as an 
outcome, only two studies reported any cases, amounting to a total of two individuals 
(both in the placebo group) (Chamovitz et al. 1954; Siegel et al. 1961). The estimate 
of the effect thus has very low precision (RR= 0.22, 95% CI=0.02 to 2.08) and 
concluding that antibiotics are protective from acute glomerulonephritis is not 
possible.  
 
For AOM, only one case of mastoiditis occurred (in the penicillin group when 
compared to the untreated group) in over 2,000 children included in the studies 
summarised in the Cochrane review (Sanders et al. 2004). However one study, 
excluded from the review, found a higher rate of mastoiditis in the untreated group 
(17%, 1.5% and 0% in the placebo, sulphonamide and penicillin groups respectively) 
(Rudberg RD 1954). The overall evidence for the protective effect of antibiotics 
against mastoiditis is limited. 
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2.6.2 Ecological level evidence 
An ecological study is one in which the unit of observation is at an aggregate level 
(population-level), such as a group of people living within a geographically-defined 
area (for example a general practice population), rather than at an individual level. 
One of the main reasons for using ecological models is the relative ease of obtaining 
data at aggregate level.  
 
To date ecological studies have been performed at the general practice (GP), primary 
care trust (PCT), health authority (HA) and country level for a variety of 
complications (Table 2.3). Findings from some of these analyses of routine health 
care databases suggest that the reductions in GP prescribing of antibiotics may be 
associated with increases in rare complications of bacterial infection. For example, 
Little and colleagues examined primary care prescribing of penicillin and hospital 
admissions for complications and acute RTIs at the HA level, for a cross-sectional 
population in England (Little et al. 2002). After adjusting for age, gender, 
deprivation and standardised mortality ratio they found higher levels of primary care 
prescribing of penicillin significantly associated with lower rates of admissions (per 
10,000 HA residents) for both quinsy and mastoiditis. A comparative study across 
several European countries, Canada, Australia and the US was performed to examine 
the incidence rate of acute mastoiditis in children discharged from hospital and 
compare it with antibiotic prescribing rates for AOM, between 1991 and 1998 (Van 
Zuijlen et al. 2001). This study demonstrated that countries practising a restrictive 
use of antibiotics, such as in the Netherlands, had a comparable rate of acute 
mastoiditis to Norway and Denmark, who are higher prescribers. In all other 
countries where prescribing rates were high, incidence rates were low. Lastly a study 
examined aggregate data (at a PCT level) for pneumonia mortality, incidence of 
primary care visit for influenza or influenza-like illness, and their relationship with 
antibiotic prescribing for LRTIs in 12-week winter periods between 1993/4 and 
1999/2000 in England and Wales (Price et al. 2004b). The results from a negative 
binomial regression model show that antibiotic prescribing (per 1,000 population) for 
LRTI had a significant association with excess winter pneumonia mortality even 
after adjusting for influenza incidence. 
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Not all studies demonstrated an association. In the USA, a longitudinal study 
compared the percentage of patients with episodes of acute bronchitis and cough that 
were prescribed an antibiotic and hospitalisations for RTIs (including pneumonia and 
empyema) (Mainous III et al. 2006). Antibiotic prescribing declined up until 2001 
and then increased, and appeared to have a weak negative correlation with 
hospitalizations for all RTIs (Spearman’s correlation coefficient rs=-0.22).  More 
recently a study conducted in Spain at the GP level examined the relationship 
between antibiotic prescribing indicators (e.g. total prescribing defined daily doses) 
and hospital admissions for complications of pneumonia and chronic obstructive 
pulmonary disease (Fernández Urrusuno et al. 2008). A linear regression model 
showed a positive association between hospital admissions and prescription of 
antibiotics.  
 
However, one of the problems with ecological level data is that association at this 
population level may not hold at local levels. For example, Majeed and colleagues 
found that while antibiotic prescribing reducing in England coincided with an 
increase in hospital admissions for RTIs at a national level, at a PCT level a 
moderate positive association held (rs=0.51) (Majeed et al. 2004). They suggested 
that the finding at the national level would benefit from further investigation. 
 
     
  
Table 2.3 Summary of evidence from studies examining the association between antibiotic prescribing in general practice and 
complications arising from of RTIs – ecological level 
 
Reference Study population 
and period 
Study design Antibiotics 
data 
Clinical outcomes Findings 
Van Zuijlen 
et al. 2001 
UK, Netherlands, 
Denmark, Norway, 
Canada, US and 
Australia, 1991-
1998.  
 
Children aged≤14 
years 
Cross-sectional 
comparative 
analysis 
Antibiotic 
prescription 
rates for acute 
otitis media, by 
country 
Incidence rates of 
hospitalisations with  acute 
mastoiditis 
Incidence of acute mastoiditis 
was lower (1.2-2.0 per 
100,000 person-years) in 
countries with high (>96%) 
antibiotic prescribing rates 
and higher (3.5-4.2) in 
countries with lower (31-
76%) antibiotic prescribing 
rates. 
Little et 
al.2002  
82 Health 
Authorities (HAs) 
in England, 1997-
1998 
 
All ages 
 
Cross-sectional 
comparative 
Dispensed 
penicillins, by 
HA  
Hospital admissions for 
acute RTI, complications 
(quinsy, rheumatic fever, 
mastoiditis, pneumonia, 
septicaemia, anaphylaxis) 
and operations related to 
RTIs. 
Higher penicillin use was 
associated with lower rates of 
quinsy (p=0.0035), 
mastoiditis (0.009) and 
tonsillectomy (0.028) but not 
pneumonia. 
 
 
Majeed et al. 
2004 
Primary care trust 
(PCT) level in 
England, 1996-
2002 
 
All ages 
 
Longitudinal Antibiotics 
prescribed 
within PCTs, 
weighted by age 
and sex 
 
 
 
Hospital admissions for 
RTIs 
In England, prescriptions 
decreased over the time 
period whilst hospital 
admissions increased between 
1996 and 1998 before 
declining thereafter. 
However, at a PCT level 
prescribing was positively 
correlated with hospital 
admissions (rs=0.51,p<0.01). 
2
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Table 2.3 Summary of evidence from studies examining the association between antibiotic prescribing in general practice and 
complications arising from of RTIs – ecological level 
 
Reference Study population 
and period 
Study design Antibiotics 
data 
Clinical outcomes Findings 
Price et al. 
2004 
England and 
Wales,  
1993 -2000 
 
All ages 
1993-2000 
Longitudinal  Antibiotics 
prescribed for 
LRTI during 
winter 
Winter pneumonia mortality Antibiotic prescribing had a 
significant association with 
pneumonia mortality after 
controlling for incidence of 
influenza (p<0.001). 
Sharland et 
al. 2005 
England,  
1993-2003 
 
Children aged≤15 
years 
 
Longitudinal Antibiotic 
prescribing and 
dispensing from 
around 130 
practices  
Hospital admissions for 
quinsy, rheumatic fever and 
mastoiditis. 
General practice episodes of 
mastoiditis. 
A 37% decline in antibiotic 
prescribing (and similar in 
dispensing) corresponded 
with a 19% rise in mastoiditis 
and simple mastoidectomy. 
No increase in quinsy or 
rheumatic fever. 
Mainous III 
et al.2006  
USA, 
1996-2003  
 
Adults 18-64years 
old 
Longitudinal Ambulatory 
antibiotic 
prescribing for 
bronchitis and 
cough for a 
representative 
sample of the 
population. 
Hospital admissions for 
lower respiratory tract 
infections from 
approximately 500 
hospitals. 
A weak negative association 
between antibiotic 
prescribing for acute 
bronchitis and cough and 
LRTI hospitalizations  
(rs=-0.22).  
Fernández 
Urrusuno et 
al. 2008 
162 GPs in a 
Primary Health 
Care Area, Spain, 
2004 
 
All Ages 
Cross-sectional 
comparative 
Antibiotic 
prescribing 
indicators 
Hospital admissions due to 
RTIs in 3 hospitals of the 
study area 
Higher prescribing of 
antibiotics was associated 
with a higher number of 
hospital admissions due 
complications arising from 
RTIs (p<0.001).  
2
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2.6.3 Individual level evidence 
At the start of this study, the only published studies examining the effect of 
antibiotics on complications in the area of RTIs at the individual level were those 
included in the aforementioned Cochrane reviews (Sanders et al. (2004), Spinks et 
al. (2006)). Most of the studies included in the Cochrane reviews were not 
adequately powered to determine the protective effect of antibiotics against the risk 
of complications. Since then several studies have been conducted, based on larger 
retrospective cohorts of patients obtained from the UK General Practice Research 
Database (GPRD) (Table 2.4). The GPRD is a large computerised database of 
anonymised longitudinal medical records from primary care with around 3.4 million 
active patients (around 5% of the UK population) from around 450 general practices 
in the United Kingdom (UK) (http://www.gprd.com).  
 
Dunn et al. (2006) investigated the factors associated with cases of quinsy diagnosed 
in primary care; these factors included exposure to antibiotics (on the same day as 
the sore throat diagnosis or within 30 days). In 198,316 episodes of sore throat, they 
found only 192 cases of quinsy; antibiotic exposure had no significant effect on the 
occurrence of quinsy. However, there was some evidence to suggest that antibiotics 
may reduce the risk of quinsy in patients with a diagnosis of tonsillitis (as opposed to 
sore throat) although this was not statistically significant.  
 
Petersen et al. (2007) identified cohorts of patients diagnosed with otitis media, sore 
throat and chest infection/URTI between 1991 and 2001. The aim of the study was to 
compare the risk of complications (mastoiditis, quinsy and pneumonia) in the month 
following otitis media, sore throat and chest infection respectively between patients 
exposed to antibiotics and those not on the day of the consultation, after adjusting for 
age, gender and social deprivation. Whilst the absolute risks of complications were 
low, antibiotics did significantly reduce the risk of complications in all RTI groups. 
However, the numbers needed to treat (NNT) with antibiotics to prevent one 
complication were high (over 4,000 patients). For episodes of chest infection, 
antibiotics reduced the risk of pneumonia across all ages, particularly in the 65 plus 
age group. The numbers of cases of acute rheumatic fever and glomerulonephritis 
following sore throat diagnoses were too low to allow investigation of the protective 
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effect of antibiotics. The authors concluded that, for diagnoses of URTIs, sore throat 
and otitis media, research should focus on interventions to reduce antibiotic 
prescribing even further, whilst for chest infections, clinical algorithms and 
diagnostic technology should be developed to identify those at a higher risk of 
developing pneumonia.   
 
Thompson et al. (2009a) specifically examined the risk of mastoiditis in children 
(aged 3 months to 15 years) within 3 months of otitis media (OM) diagnosis, in those 
who were prescribed an antibiotic and those who were not, between 1996 and 2006. 
In total, from 1,182,272 cases of OM, 288 children developed mastoiditis. The 
prescription of antibiotics for otitis media halved the risk of mastoiditis but the low 
absolute risk of mastoiditis meant the number of OM episodes needing antibiotic 
treatment to prevent one case of mastoiditis (NNT) was very high. When restricted to 
children with mastoiditis requiring surgery, antibiotics were found to have a more 
protective effect. Winchester et al. (2009) conducted a similar study, but examined 
patients with a first diagnosis of an acute LRTI in general practice to identify 
predictors of hospital admissions and death from pneumonia or another LRTI in the 3 
months following the LRTI diagnosis. Those who received an antibiotic prescription 
on the same day as the LRTI diagnosis were less likely to be admitted to hospital 
with pneumonia or other LRTI after adjusting for age, age squared, sex, NHS region 
and practice deprivation. The NNT to prevent one hospital admission was 1,002. In 
age-stratified analyses, same day antibiotic prescribing was associated with a 
significantly reduced risk of admission in patients aged 18-64 years but not in those 
aged 1-17 years or ≥65 years. The association between same day prescribing of 
antibiotics and mortality held for all ages, in the 18-65 and ≥65 age group. 
 
Adding to this pool of evidence, a recent case-control study examined children (aged 
6 months to 16 years) presenting to secondary care with radiographic evidence of 
pneumonia or empyema (cases) from seven hospitals in South Wales (Crocker et al. 
2012). The study found that the 89 cases were less likely than the 166 matched 
controls to have been prescribed an antibiotic at the first GP consultation although 
they were not less likely to have taken antibiotics at any time during the illness prior 
to the date of hospitalisation.
  
 
Table 2.4 Summary of evidence from studies examining the association between antibiotic prescribing in general practice and 
complications arising from of RTIs – individual level 
 
Author Study population 
and period 
Study design Clinical outcomes Findings 
Dunn et al. 
(2006)  
 
Consultations for sore 
throats identified in 
the GPRD,  
1995-1997 
  
All ages 
Retrospective 
case-control  
Case: Quinsy within 30 days 
of sore throat diagnosis 
Control: no quinsy within 30 
days of sore throat 
A total of 606 cases of quinsy but only 192 
following a diagnosis of sore throat. The 
study found that 169/192 (88%) cases and 
167,811/198,124 (84%) controls were 
prescribed antibiotic at the index illness and 
antibiotic exposure had no significant effect 
on the occurrence of quinsy (adjusted 
OR=1.2, 95% CI=0.7 to 2.2). Quinsy 
presenting without warning had identical 
risk factors to those presenting in GPs (Male 
smokers aged 20-39 years). 
Petersen et 
al. (2007) 
 
Consultations for 
chest infection, URTI, 
sore throats and acute 
otitis media identified 
in the GPRD, 
1991-2000 
 
All ages 
Retrospective 
cohort  
Risk of pneumonia, quinsy 
and mastoiditis in the month 
following a diagnosis of 
URTI and chest infection, 
sore throat and otitis media 
respectively. 
Same day antibiotic prescribing significantly 
reduced the risk of complications in all RTI 
groups.  
URTI→Pneumonia, adjusted OR=0.68 
(95% CI=0.58 to 0.79) 
Otitis media→Mastoiditis, 0.56 (0.37 to 
0.86) 
Sore throat→Quinsy, 0.84 (0.73 to 0.97) 
 
However, the NNT with antibiotics to 
prevent one complication were high (over 
4,000 patients). For episodes of chest 
infection, antibiotics reduced the risk of 
pneumonia across all ages, particularly in 
the 65 plus age group (OR=0.35 (95% 
CI=0.33 to 0.38) and NNT=39. 
3
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Table 2.4 Summary of evidence from studies examining the association between antibiotic prescribing in general practice and 
complications arising from of RTIs – individual level 
 
Author Study population 
and period 
Study design Clinical outcomes Findings 
Thompson 
et al. 
(2009a) 
Consultations for 
acute otitis media, 
identified in the 
GPRD, 
1990-2006 
 
Children aged 3 
months to 15 years 
Retrospective 
cohort 
Risk of mastoiditis within 3 
month following a diagnosis 
of otitis media 
An antibiotic prescribed in the same 
consultation as the OM diagnosis 
significantly reduced the risk of developing 
mastoiditis within the following 3 months 
(adjusted OR=0.56, 95% CI=0.44 to 0.71). 
A total of 4,831 episodes of otitis media 
would need to be treated with antibiotics to 
prevent one child from developing 
mastoiditis.  
In sensitivity analyses restricted to children 
with mastoiditis requiring surgery, the 
adjusted OR was 0.39 (95% CI=0.28 to 
0.55).  
Winchester 
et al. 
(2009) 
Consultations for first 
diagnosis of LRTI 
identified in the 
GPRD,  
2004 
 
All ages 
Retrospective 
cohort 
Hospital admission and death 
from pneumonia or another 
LRTI in the 3 months 
following a diagnosis of 
LRTI 
Patients receiving an antibiotic prescription 
on the same day as the LRTI diagnosis were 
less likely to be admitted to hospital 
(adjusted hazard ratio (HR) =0.73, 95% 
CI=0.58 to 0.92, NNT=1,002) or die (0.31, 
0.26 to 0.37, 7,247). 
 
Same day antibiotics also reduced the risk of 
hospital admissions (HR=0.61, 95% 
CI=0.44 to 0.84, NNT= 1,222) and death in 
the 18-64 year olds (0.21, 0.13 to 0.35, 
6,329). The risk of death was reduced in the 
≥65 years of age (0.31, 0.26 to 0.37, 
14,439). 
3
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Table 2.4 Summary of evidence from studies examining the association between antibiotic prescribing in general practice and 
complications arising from of RTIs – individual level 
 
Author Study population 
and period 
Study design Clinical outcomes Findings 
Crocker et 
al. 2012 
Cases and control 
with a GP diagnosis 
of URTI, LRTI or 
cough. 
 
Children aged 6 
month to 16 years  
Case-control Cases: diagnosed with 
pneumonia or empyema and 
previously seen by a GP for 
an index illness (URTI, 
LRTI, cough) 
Controls: matched on age, GP 
and had been seen by a GP 
for a URTI, LRTI or cough  
The study found that 31/89 (35%) cases and 
83/166 (50%) controls were prescribed 
antibiotic at the index illness (unadjusted 
OR=0.53, 95% CI=0.31 to 0.90). No 
confounders were identified with cases. 
 
For prescribing between the index date and 
the hospitalisation date, cases were still less 
likely to have received antibiotics than 
controls (40/89 (45%) vs. 96/166 (58%), 
adjusted OR=0.62, 0.37 to 1.04). 
3
4
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2.6.4 Summary  
The majority of RTIs are self-limiting illnesses for most patients. While antibiotics 
reduce intensity and duration of some symptoms or pain, they generally provide only 
marginal benefit for the otherwise healthy patient with an RTI. Antibiotics are of 
some benefit in protection from complications (with a higher risk of developing a 
complication if antibiotics were not prescribed) for acute RTIs, but as the risk of 
developing a complication is exceedingly low in resource-rich countries, the number 
of patients required to be treated with antibiotics to protect one from a complication 
are large, apart from for specific high-risk patient sub-groups. Therefore, based on 
current evidence, recommendations are that further gains are to be made in reducing 
inappropriate antibiotic prescribing in the community as antibiotics are of little 
benefit for the majority of patients. This reduction of antibiotic prescribing would be 
of benefit as widespread antibiotic prescribing is known to encourage clinic visits for 
subsequent episodes (medicalisation of RTIs), intensify pressure on clinicians to 
prescribe, increase risk of exposure to antibiotics and antibiotic use, and increase 
antibiotic resistance. 
 
2.7 Relationship between antibiotic use and resistance 
Evidence examining the relationship between antibiotic usage and resistance rates is 
mostly derived from urine coliform infections (such as Escherichia coli (E.coli)), 
although recently respiratory pathogens (such as Streptococcus pneumoniae (S. 
pneumoniae) and Haemophilus species) have been examined too. Most studies have 
demonstrated associations between antibiotic usage and resistance though proving 
causality is difficult. 
 
2.7.1 Ecological level evidence  
Until recently the association between antibiotic use and resistance had only been 
examined at a country or general practice level. At country level, studies have mainly 
used data from the European Surveillance of Antimicrobial Consumption (ESAC) 
project that maps out national antibiotic prescribing and resistance rates 
longitudinally across numerous European countries. These studies showed significant 
correlations between antibiotic use and resistance generally, but especially in S. 
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pneumoniae (Goossens et al. 2005; Van de Sande-Bruinsma et al. 2008). Whilst 
significant correlations existed at a country level, there was wide variation in the 
association between different European countries. For example, Sweden and 
Denmark had higher rates of penicillin use than the UK but had lower resistance, 
whilst Finland had lower rates of penicillin use but higher resistance. The authors 
suggest that the variation between countries can be explained by differential selection 
pressure for resistance within countries. Subclasses and different classes of 
antibiotics may select for resistance to both that antibiotic class and sub class and 
also to other antibiotics. 
 
At a general practice level, studies have shown low correlation coefficients and 
hence weak associations, mostly in urine coliforms, whilst others found a strong 
correlation between the use of trimethoprim and amoxicillin and resistance to 
ampicillin and trimethoprim (Steinke et al. 1999; Magee et al. 1999; Howard et al. 
2001; Priest et al. 2001, Hay et al. 2005). A recent study in coliform isolates from 
urine samples has shown that general practices with the greatest reduction in overall 
dispensed antibiotics showed a significant reduction in antibiotic resistance to 
ampicillin and trimethoprim when compared with practices that reduced their 
antibiotic dispensing the least (Butler et al. 2007).  
 
As previously discussed, interpretation of these ecological level analyses should be 
made with caution as conclusions arising from these aggregate data may not 
necessarily apply to individuals within that area. This problem can be overcome by 
use of individual patient data.  
 
2.7.2 Individual level evidence 
In UTIs, Donnan and colleagues demonstrated how results from group level analyses 
could disguise individual level effects by performing a multilevel model analysis at 
both the practice and individual level (Donnan et al. 2004). They compared 
trimethoprim prescribing with resistance to trimethoprim in gram negative bacilli in 
urine samples routinely submitted from GPs and found that when analysed at a 
practice level, using practice rates of resistance and usage, trimethoprim prescribing 
was not related to trimethoprim resistance, but when using individual level data a 
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strong association existed between the two. A key issue in ecological studies is that 
prescribing at a practice level is related to resistance in urine submitted for patients 
within the practice and many of these patients may not themselves have been 
prescribed antibiotics in the recent past. Indeed, many will not have had antibiotics 
recently, and it is the consumption of recent antibiotics by individuals that is the 
greatest risk factor for infection with a resistance compared to a sensitive 
uropathogen. This stresses the problem that can be created by ecological level studies 
and evidence arising from them is much weaker. A similar study, again involving 
urine samples, showed no evidence of a dose-response relationship between exposure 
to any antibiotic prescribed over a 12 month period and resistance to amoxicillin 
and/or trimethoprim (Hay et al. 2005). However, greater levels of resistance were 
found in patients recently (within 2 months of the sample submission) exposed to any 
antibiotic and there was a dose–response relationship to increasing exposure to 
trimethoprim. 
 
Several recent studies have shown that using antibiotics is associated with resistance 
in respiratory pathogens in individuals. A cohort study in children with acute RTIs 
found that the community
 
prescribing of beta-lactam antibiotics at presentation of 
RTI doubled the prevalence of antibiotic resistant Haemophilus isolates in individual
 
children compared to no prescription (Chung et al. 2007). Malhotra-Kumar et al. 
(2007) found that macrolide use was the single most important driver of the 
emergence of macrolide resistance in oral streptococci flora in individual adults. 
Another study by Nasrin et al. (2002) showed an association between beta lactam use 
and
 
the carriage rates of penicillin resistant pneumococci in children aged less than 4 
years. However, in a recent study by Sundqvist et al. (2010), the potential of 
reversing antibiotic resistance by decreasing use of trimethoprim was examined in E. 
coli samples. Whilst trimethoprim prescribing use was greatly reduced (by 85% over 
2 years), resistance rates in E. coli samples were practically unaffected and did not 
follow that trend. The model did show a halt in the rise of trimethoprim resistance 
but only a slow reversibility in resistance rates. This is contradictory to what Butler 
et al. (2007) found at general practice level. This was highlighted in an article by 
Enne (2010) where some studies showed a reduction in resistance in response to 
prescribing reduction, while others did not. The reason for these differences could be 
due to factors not measured, such as the clonality of resistant isolates, co-selection or 
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the fitness cost of resistance. A more prudent approach is therefore required to obtain 
as much information on the resistance problem as possible. 
 
2.8 Summary of Chapter 2 
This chapter has reviewed the current evidence on the effectiveness of antibiotics in 
the treatment of RTIs and their complications and also the relationship between 
antibiotics and resistance. The evidence so far indicates that for most patients, RTIs 
are self-limiting and last roughly the same duration regardless of whether or not 
antibiotics are prescribed. Therefore antibiotics are not indicated for most of these 
infections. For resistance, the results do show an association between dispensing and 
resistance between certain organisms and antibiotics. The next chapter will describe 
the ecological and individual datasets that were used in this thesis to examine the 
relationship between antibiotic prescribing in primary care and complications arising 
from RTIs, and the general statistical methods used. 
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Chapter 3   Overview of methods and datasets 
3.1 Introduction 
To examine the relationship between antibiotic prescribing, complications arising 
from respiratory tract infections (RTIs), and antibiotic resistance, a number of 
datasets at both the general practice level (using national routinely collected data) 
and individual level (using general practice databases) will be utilised. An overview 
of these datasets is given in this chapter; further details will be given in later chapters 
when relevant. 
 
3.2 Ecological studies  
An ecological study is one in which the unit of observation is at an aggregate level 
rather than at an individual level. Data collection at this level is relatively easier than 
at an individual level, where data is either not readily available, too costly to obtain 
or raises issues of confidentiality. A major disadvantage, however, is that inferences 
made from ecological models regarding the relationship between risk factors and 
outcome may not apply to individuals within those areas. This is sometimes referred 
to as the “ecological fallacy”. Ecological studies however can be useful, especially 
in the generation of hypotheses and to determine whether it is necessary, or useful, to 
proceed to an individual-level analysis. For this reason, the following five chapters (4 
to 8) concentrate on trends in antibiotic dispensing, complications and antibiotic 
resistance, and the relationships between them, at the level of general practice. In this 
thesis, this relationship was firstly examined for a sample of Welsh practices and 
then for all practices in Wales. The datasets and methods used in the individual-level 
analysis are covered later in this chapter. 
 
3.2.1 Study population – Wales  
Data required for this section of the study was obtained from all-Wales data sources 
providing data on all general practices and their populations (people resident in 
Wales) in the study period (1996 to 2006). The exception was data used from the 
General Practice Morbidity Database (GPMD), which was based on a representative 
sample of practices across Wales. The research sample is therefore representative of 
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the Welsh population, which at the 2001 UK Census was 2,903,085 (National 
Statistics). Wales is an ideal country for data analysis; it has a good mix of rural-
urban areas (36%-64%) and of deprived-affluent areas (Rural and Urban 
Classification 2004), and has a relatively stable population (useful when looking at 
trends). It is also advantageous since data flows from different administrative areas, 
such as health trusts and local health boards, to a central repository, ensuring high 
quality and comparable data.  
 
3.2.2 Geographical areas 
Wales was previously subdivided into 22 unitary authority (UAs) areas which were 
responsible for the provision of all local government services, including education 
and social work services. UAs are divided into electoral divisions (n=884 as of April 
2009), and are the base unit of Welsh administrative geography used to elect local 
government councillors to County Councils (local authorities). The 2001 Census 
Output Areas were specifically created for statistical purposes which delivered areas 
with populations of 125 households. Super Output Areas (SOAs) are geographical 
units designed for the collection and publication of small area statistics and were 
introduced at the 2001 Census. There are currently two layers of SOA (middle and 
lower level), with areas intermediate in size between 2001 Census Output Areas 
(OAs) and local authorities, and with each layer nesting inside the layer above. SOAs 
were designed to have similar population sizes and be as socially homogenous as 
possible and will not be subjected to regular boundary change. This makes them 
ideal for analyses as they are comparable across countries and allow trends to be 
monitored. In Wales, there are 413 Middle Layer SOAs (built from groups of Lower 
Layer SOAs) which have a minimum population of 5,000 and 1,896 Lower Layer 
SOAs (built from groups of OAs), which have a minimum population of 1,000. 
 
Local Health Boards (LHBs) are the health administrative areas in Wales and 
manage all primary care services and work with local authorities and other agencies 
to provide health and social care locally. They are comparable to Primary Care 
Trusts (PCTs) in England, Local Health Care Co-operatives (LHCCs) in Scotland 
and Local Health and Social Care Groups (LHSCGs) in Northern Ireland. 
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3.2.3 Identifying general practices  
The Welsh Demographic Service (WDS) is a database of every person registered to a 
general practitioner in the country, and is maintained for NHS purposes by NHS 
Wales Informatics Service (NWIS). The WDS was therefore used to identify the 
number of general practices existing in Wales over the 11-year period of this study 
(January 1996 to December 2006) and also to obtain a monthly practice population 
(list size) by age group and gender for each of these practices. 
 
Each general practice in the UK is allocated a unique identification code. The 
conventional codes are those allocated by the Prescription Pricing Authority (PPA); a 
6-digit code where character 1 is W for Wales (W-codes), S for Scotland and Y for 
England. To ensure complete practice anonymity, NWIS provided unique encrypted 
practice codes to replace the original W-codes. For datasets that were obtained with 
W-codes attached, such as the resistance data and some dispensing data, these were 
linked and replaced with encrypted codes by NWIS, hence preserving the anonymity 
of practices. 
 
3.2.4 Practice populations and characteristics  
The WDS database provides a historical record of person movements within Wales 
and therefore there can be many records for a single individual, showing where a 
person has lived (and de/re-registered) over time. The WDS is also used to produce 
alternative local area population estimates, especially at smaller areas such as 
electoral divisions and LSOAs. While these population estimates are widely 
acknowledged as being slightly inflated due to time lags involved in updating birth 
and death registrations, and also due to double registrations of its university age 
population, its strength is that it can be analysed at a low geographic level, i.e. 
electoral division and postcode (Local Government Data Unit - Wales 2005). The 
main purpose for it in this study, however, is to obtain practice populations and it 
was possible to obtain the number of individuals registered to a general practice at 
any given time period and by age group and gender.  
 
The WDS additionally holds certain practice information and the following practice 
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characteristics were obtained for each practice: the local health board (LHB) in 
which the practice lies, the number of GPs within each practice, the average age and 
gender of these GPs, single-handed status, and deprivation score and quintile of the 
practice population (Townsend scores based on 2001 census) (Townsend et al. 
1988). All information was taken from practices as they were in June 2007. 
 
3.2.5 Deprivation Measures  
Two measures of deprivation were used in this thesis: the Townsend Material 
Deprivation Score (Townsend et al. 1988) and the Index of Multiple Deprivation 
(Office for National Statistics).  
3.2.5.1 The Townsend Material Deprivation Score 
The Townsend Material Deprivation Score uses four Census variables to assess the 
following: general lack of material resources and insecurity (unemployment), 
material living conditions (overcrowding), wealth (owner occupation is used as a 
proxy indicator), and income (car ownership is used as a proxy indicator). These four 
measures can be combined to construct a single measure of deprivation. For the 
purposes of this study, Townsend deprivation scores were derived from 2001 census 
data by linking the postcode of each person currently registered (as of June 2007) in 
the practice to a Townsend score via the LSOA code. For each practice, the 
Townsend scores were summed and divided by the number of persons registered. 
Scores tend to range from -12 (least deprived) to +12 (most deprived) although in 
certain circumstances they can lie outside this range. Quintiles were constructed by 
ordering the practices by their scores and dividing them into five equal population 
groups, so that each quintile had the same total population (around 650,000). Quintile 
1 indicates the least deprived practices and quintile 5 the most deprived practices. 
 
3.2.5.2 The Index of Multiple Deprivation (IMD) 
The Index of Multiple Deprivation (IMD) is the official measure of deprivation for 
small areas in the UK. The IMD is made up of eight separate domains of deprivation, 
including health and income, and can be combined to create an overall deprivation 
(using specific weights for each domain depending on importance). Deprivation 
Chapter 3 
44 
scores have been calculated for each LSOA, with a higher score indicating more 
deprivation. IMDs are constructed separately (and sometimes using different 
measures) for each country in the UK. Therefore, one limitation of the IMD is that 
the deprivation scores cannot be compared with those from the deprivation indexes 
of other UK Countries. 
 
3.3 Ecological level datasets 
3.3.1 Antibiotic dispensing data 
Prescribing Analyses and Cost (PACT) data is the main source of information on 
general practitioners’ (GPs) dispensing in Wales. The Prescribing Services Unit 
(PSU) in NWIS collects information
 
on all prescriptions issued by general 
practitioners (GPs) in Wales that are
 
dispensed by community pharmacists in 
England and Wales, dispensing GPs or personally administered by GPs in Wales, or 
appliance contractors. It is also responsible for the provision of prescribing 
information and information systems to enable drug expenditure to be monitored. 
Data is captured to enable the payment of dispensing contractors in Wales and to 
allow a unique database of dispensing information to be created.  
 
The database contains information on each drug and is classified into 4 levels from 
the British National Formulary (chapter, section, sub-section and chemical) (Joint 
Formulary Committee 2007). For example, information is available for individual 
drugs or chemicals (for example erythromycin), the antibiotic class or sub-section 
(such as macrolides), the section it falls under (such as antibacterial drugs) and the 
chapter (such as infections). The information collected includes
 
the name of the drug, 
the basic cost attributed to the dispensed antibiotic, the number of items dispensed 
and the quantity of the drug dispensed (an item is defined as each preparation on the 
prescription). This information is available from April 1996 onwards and at 
individual
 
practice level, local health board level, and national level,
 
allowing for 
different analyses.  
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3.3.1.1 Dispensing measures  
Items of antibiotics are used as a measure of the quantity of antibiotic dispensing. 
They do not always give a good indication of total use unless total amounts of drugs 
per item are also being considered. However, as well as being easy to measure, items 
are of great value in measuring the frequency of prescribing where treatments are 
given largely or entirely as courses, such as in antibiotics or immunisations 
(Prescription Pricing Division, 2007). The World Health Organisation (WHO) 
recommends using the number of defined daily doses (DDD) as a measurement unit 
for inter-country comparisons of antibiotic usage. The definition of DDD is the 
assumed average maintenance dose (per day) for a drug used for its main indication 
in adults (Jones et al. 2004). The number of DDDs can be calculated by multiplying 
the quantity of each dosage prescribed by the strength of each dosage, then dividing 
by the DDD. In an outpatient setting, a very strong correlation has been shown to 
exist between antibiotic items and DDD, both for total usage and for specific classes 
of antimicrobials (Monnet et al. 2004). Additionally Davey et al. (2008) concluded 
that DIDs (DDD per inhabitant per day) were inadequate as a single measure of 
antibiotic use and that using prescriptions per inhabitant per day (PIDs) provided 
important additional insight. 
 
Dispensing data is an imperfect proxy for antibiotic consumption as there may be a 
very small proportion of patients who receive the antibiotics but do not actually take 
them. This would therefore lead to a very small bias in dispensing data. 
 
3.4 Individual level datasets 
3.4.1 General Practice Morbidity Database 
The General Practice Morbidity Database (GPMD) was a primary care database held 
and maintained by Heath Solutions Wales (Evans et al. 1997). The GPMD recorded 
clinical data (using 5-byte version of Read Codes) held at the level of individual 
consultations from 1996 up to 2000, and included detailed information on 
consultations, risk factor data and prescriptions. It was derived from 45 general 
practices in Wales covering a population of nearly 400,000 patients, thus providing 
approximately a 13% sample of the Welsh population. The age and gender 
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distribution of the GPMD closely mirrored that of the Welsh population for all ages 
(Stats Wales, Wales Assembly Government) (Figure 3.1). Although now old, these 
data are useful as they provide trends during a time of rapid reduction in antibiotic 
prescribing in primary care. 
 
Figure 3.1 Age/sex distribution of the Welsh population and patients included in the 
GPMD in 1999/2000 
 
 
 
3.4.2 Hospital Episodes Statistics 
The Patient Episode Database for Wales (PEDW) is held by NWIS and contains 
records of all inpatient and day case activity undertaken in NHS Wales (including 
community hospitals), together with data for Welsh residents treated in English 
Trusts. Individuals can be traced across different spells of inpatient or day case care 
using personal identifiers, such as NHS number or case record number. PEDW 
contains other personal information such as age, gender and postcode as well as 
registered GP and practice details. The database also holds details relating to the 
spell of care such as date and method of admission/discharge along with diagnosis 
and procedure codes using the World Health Organization (WHO) International 
Statistical Classification of Diseases (ICD). Information is available from 1991 to 
present. 
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3.4.3 Antibiotic resistance data  
Resistance data is available from the Microbiology system called DataStore. 
DataStore is a relational database management system developed by the National 
Public Health Service (NPHS) for Wales. DataStore provides a robust automated 
transfer of bacteriology and virology reports (negative and positive) from 18 Welsh 
and Welsh border laboratories serving Welsh
 
practices. Laboratory results are 
entered into the laboratory information management systems (LIMS), which 
automatically generates an electronic copy of the report and outputs the report in a 
standard format. The formatted reports are input into various databases of which 
DataStore is one.  
 
Data from DataStore is available from 1
st
 January 1998 onwards at an individual 
level. The database contains information on all samples (taken from a patient) or 
isolates (a sample with an identified organism) sent for testing from GPs, including 
the following bacteria: Escherichia coli or lactose-fermenting coliform (referred to 
collectively as coliforms), Methicillin sensitive and resistant Staphylococcus aureus 
(MSSA/MRSA), Streptococcus pneumoniae, Streptococcus pyogenes, and 
Haemophilus Influenza. For each isolate reported the following information is 
available: date of isolation, surgery address, specimen type, hospital number, age and 
gender of the patient, specimen number, organism isolated, duplicate isolate (defined 
as isolates occurring within 91 days of a prior organism from the same patient with 
the same resistance pattern) and resistance results (resistant, sensitive or 
intermediate) for up to 13 antibiotics (where tested). Each isolate record included a 
practice identifier to enable linkage to dispensing data available only at a practice 
level.  
 
Also available was sampling data, again from 1st January 1998 and from each of the 
18 laboratories. This data consisted of the total number of samples sent to a 
laboratory by a practice and included the number of samples sent by the practice per 
month, the site the sample was taken from, and to which laboratory it was sent for 
testing. 
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3.4.4 General Practice Research Database 
The General Practice Research Database (GPRD) is the world’s largest computerised 
database of anonymised longitudinal medical records from primary care with around 
3.4 million active patients (around 5% of the UK population) from around 450 
general practices in the United Kingdom (UK) (http://www.gprd.com). It is managed 
by the GPRD Group within the Medicines and Healthcare products Regulatory 
Agency (MHRA). Individual patient level data can be obtained for a fee, or free to 
UK academics through a Medical Research Council (MRC) licence. Although no 
patient or practice identifiable data are collected, each patient has an encrypted 
unique number, which allows their records to be linked over time. For each patient 
GPRD collects and makes available information such as demographic details 
(gender, year of birth and practice location), all clinical information (diagnoses, 
symptoms, procedures, and medical history using the Read/OXMIS coding system), 
all prescriptions issued, referrals to secondary care, test results, and lifestyle 
information (such as smoking and drinking status). GPRD data is available from 
1990 although the number of practices contributing data and up-to-standard (fulfill 
the routine quality assurance checks) will vary over the years. 
 
3.5 Statistical methods 
Some of the analyses in this thesis use multilevel regression models to account and 
correct for variation at the level of LHBs and Welsh general
 
practices. Analysing 
data at the all-Wales level is of importance as it gives a general picture of dispensing 
over time. However, it does not take into account variations in dispensing data at a 
LHB and/or general practice level. Using a single-level linear regression model of 
dispensing rates on time assumes that observations are independent. However, data 
with a hierarchical or multilevel structure violate this assumption, since correlations 
usually exist between observations within a level (for example, annual dispensing 
rates within a practice or practices within an LHB). If the hierarchical structure is 
ignored, and the observations are regarded as independent, then standard errors are 
generally under-estimated. This can lead to spurious precision of estimates and 
relationships can be interpreted as statistically significant where in fact they are not.  
Multilevel modelling overcomes this by incorporating the hierarchical structure of 
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the data into the model, by allowing for the dependencies that exist between rates 
within a practice. 
 
A single-level linear regression model can be expressed as:  
iii exy  10  
 
where iy  is the outcome, 0 is the intercept, 1  is the slope, ix  is the explanatory 
variable and ie is the Normally distributed error term. For example, iy might be a rate 
of antibiotic dispensing in year i and ix the year, where i=1996 to 2006. The 
parameter 0 is the intercept (or the overall mean) and 1 is the estimate for trend.  
 
For a multilevel linear regression model the outcome iy  (e.g. antibiotic dispensing) 
can vary at different levels (e.g. 2-levels: i (time) and j (general practice)) and the 
model can be written as: 
ijijijij xxy 1100    
where 
ijjij eu 0000    
and  
ijjij eu 1111    
 
 
The parameter ij0 is an intercept which is allowed to vary randomly about the overall 
mean 0 by a random variable ju0 (level 2 residuals) representing each general 
practice’s difference from the mean intercept. The parameter ij1 similarly is a slope 
which is allowed to vary from the mean slope 1  by a random variable 
ju1 representing each general practice’s difference from the mean slope. The terms 
ju0  and ju1 follow a multivariate Normal distribution with mean vector 0 and 
covariance matrix u . The elements of u  are: 
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where variance of ju0 (
2
0u ) is the variation in the intercepts between practices and 
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2
1u is the variation in the slopes between practices. The covariance of ju0 and 
2
1u ( 01u ) is the covariance between the slopes and intercepts.  
 
The terms eoij and e1ij are the individual or level 1 residual terms (between time 
within practice variation) and are independently distributed variables representing the 
parts of dispensing not explained by the other factors. 
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As with any regression analysis, different models are used depending on the type or 
distribution of the outcome. For example for data available at a level of general 
practice, such as antibiotic dispensing data, a 3-level linear regression model was 
used (local health board (LHB) (level k), practice (j) and time (i)). The numbers of 
dispensed antibiotic items per practice per time period are generally large and were 
approximately normally distributed. For hospital episodes of complications the 
counts are smaller and could not be assumed to be normally distributed; therefore a 
3-level Poisson regression model was used. Details of the models used will be 
described in each chapter.   
 
For data available at an individual patient level, such as the antibiotic resistance data, 
and the data arising from the GPRD, a 3-level (LHB, practice and individual) logistic 
regression model was used with a binary outcome (resistant to antibiotics or not, and 
complication diagnosed or not, respectively). Models were fitted using MLwiN 
software (Rasbash et al. Centre for Multilevel Modelling, University of Bristol). 
Models were fitted using a maximum likelihood (ML) method, known as iterative 
generalized least squares (IGLS) which is an iterative procedure based on estimating 
the random and fixed parts of the multilevel model alternately, assuming the 
estimates for the other part are correct. This involves iterating between two 
generalized least squares (GLS) model fitting steps until the estimates converge to 
ML point estimates. Initial estimates were obtained by using the restricted iterative 
generalized least squares (RIGLS) estimation procedure. Final parameters were 
estimated using Markov Chain Monte Carlo (MCMC) methods to give less biased 
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estimates and also to derive confidence intervals for non-symmetrical distributions.  
 
Although Chapter 4 uses multilevel modelling, since it is a preliminary examination 
of the relationship between antibiotic dispensing and complications using a smaller 
sample, the full details of the process of model fitting and interpretation such as 
examining the variation in intercepts and slopes at different levels and the use of 
different estimation techniques are not covered until Chapter 5 (in antibiotic 
dispensing). 
 
Additional statistical analyses were undertaken using SPSS for Windows (SPSS for 
Windows).  
 
3.6 Ethical approval 
Ethical approval for the all-Wales analysis was gained through the South East Wales 
board and, for the General Practice Research Database, approval was granted by the 
Independent Scientific Advisory Committee (ISAC).
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Chapter 4  Antibiotic dispensing and complications arising 
from RTIs: a study of a sample of Welsh practices 
4.1 Introduction 
The aim of this chapter was to test the hypothesis that there is an association between 
antibiotic dispensing and the rate of complications arising from respiratory tract 
infections (RTIs) diagnosed in primary care, using data from the Welsh General 
Practice Morbidity Database (GPMD). Due to the small number of practices 
involved and the aggregated nature of the data, these results do not allow us to draw 
robust conclusions regarding the relationship between antibiotic dispensing and 
complications at an individual level. Instead they allow an exploration into the 
relationship, and assess how feasible it is to carry out further analyses on larger 
datasets.  
 
4.2 Methods 
4.2.1 Complications arising from respiratory tract infections 
The GPMD provided annual numbers (1996 to 2000) of diagnoses for certain 
complications diagnosed in primary care with sufficiently large incidence to enable 
analysis at the general practice level. These are complications arising from common 
RTIs and the Read codes are listed in Table 4.1 (NHS Connecting for Heath). For the 
purpose of this analysis, data were obtained for practices that contributed 
continuously to the GPMD over the five-year period. 
 
4.2.2 Antibiotic dispensing data  
Dispensing data is based on information obtained from prescriptions sent by 
pharmacies to the Prescribing Management System at the Prescribing Services Unit, 
NHS Wales Informatics Service for payment (as described in section 3.3.1). 
Dispensing data therefore covers all routine prescriptions dispensed in the 
community including prescriptions written by General Practitioners (GPs) in Wales, 
community pharmacists, dentists and hospital doctors. Dispensed antibiotics (rather 
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than prescriptions for antibiotics) are a better proxy for antibiotic consumption, 
especially given the rising use of delayed prescribing strategies in primary care.  
 
Table 4.1 Read codes for selected complications arising from RTIs 
 
Read Code Complications 
A38.. Septicaemia 
F00.. Bacterial Meningitis 
F040. Intracranial abscess 
F53.. Mastoiditis and related conditions 
G0… Acute rheumatic fever 
H043. Epiglottitis 
H15.. Peritonsillar Abscess (Quinsy) 
H2... 
 
Pneumonia excluding Influenza (H27..), Other specified or Not 
otherwise specified pneumonia or influenza (H2y.. and H2z..) 
H50.. Pleural empyema 
K00.. Acute glomerulonephritis  
 
Quarterly dispensing data were obtained for the same continuously contributing 
practices from April 1996 until December 2000. For simplicity, the items dispensed 
for the following eight antibiotic groups (based on definitions from Joint Formulary 
Committee, British National Formulary (BNF) section 5.1 (with the exception of 
anti-tuberculosis and antilepromatous drugs) were summed to produce a measure of 
total dispensing for antibiotics most commonly used to treat RTIs:   
 Benzylpenicillins and phenoxymethylpenicillin (Penicillin) 
 Penicillinase-resistant penicillins (Flucloxacillin) 
 Broad-spectrum penicillins (BSPs) 
 Trimethoprim 
 Macrolides 
 Cephalosporins and other beta-lactams (Cephalosporins) 
 Quinolones 
 Tetracyclines 
 Total antibiotics 
 
4.2.3 General practice populations  
Quarterly and annual permanent patient registrations were obtained from the GPMD 
for each general practice. 
Chapter 4 
54 
4.3 Statistical analysis  
Annual rates of diagnoses for complications of acute RTIs (per 100,000 practice 
population (pp)) and quarterly and annual rates of antibiotic dispensing (per 1,000 
pp) were calculated. For complications, a two-level repeated measures Poisson 
regression model was used to account and correct for variation at the level of general
 
practice and time (five study years from 1996 to 2000). Expected counts of 
complications per practice per annum were calculated based on the practice’s list size 
(calculated by multiplying the complication rate over all practices by the practice’s 
list size). An offset variable was created as the loge expected counts.  
 
The Poisson model is as follows:  
 22110)(explog)(log xxcountscountsobs ee   
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For a one-unit change in the predictor variable x, the log of the ratio of observed to 
expected counts would change by β (the regression coefficient), given the other 
predictor variables in the model were held constant. The Standardised Incidence 
Ratio (SIR) (that is the ratio of observed to expected counts) is therefore given by 
exp(β). For example, the SIR, based on the coefficient of time in years, compares the 
ratio of the incidence rates in successive years. Therefore an SIR >1 indicates an 
increase in complication rates between successive years while an SIR <1 indicates a 
decrease in the rates. Results from all Poisson models were reported as SIRs, with 
95% confidence intervals (95% CIs).  
 
Although antibiotic dispensing items were count data, the large numbers of items at 
practice level meant the rates were approximately normally distributed. Therefore 
trends for total and individual antibiotic dispensing were examined using a two-level 
repeated measures linear regression with seasonality adjustment using categorical 
variables to indicate the quarter of the year. Initial estimates were obtained by using 
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the restricted iterative generalized least squares (RIGLS) estimation procedure. Final 
parameters were estimated using Markov Chain Monte Carlo (MCMC) methods to 
give less biased estimates and also to derive confidence intervals for non-
symmetrical distributions (Rasbash et al. Centre for Multilevel Modelling, University 
of Bristol).  
 
4.3.1 Patterns of dispensing and complications 
Pragmatic comparisons were used to examine the association between rates of 
complications (outcome) and rates of antibiotic dispensing (explanatory variable) 
using a two-level repeated measures Poisson regression model after adjusting for 
time (year). Since the first-line antibiotics of choice for acute RTIs are penicillins, 
associations between complications and both penicillin and BSPs were explored. 
Macrolides, tetracyclines and cephalosporins are generally considered as second line 
treatment and were also examined. 
  
Parameters were again estimated using MCMC methods with initial estimates 
obtained by using RIGLS; confidence intervals were derived from the MCMC 
results. In this analysis, the dispensing variables were scaled so that the SIR 
compares the ratio of the incidence rates at the 75
th
 percentile to the 25
th
 percentile of 
dispensing rates for each antibiotic. For example, the 25
th
 and 75
th
 percentiles for 
penicillin dispensing are 48 and 86 items per 1,000 pp (interquartile range is 38 items 
per 1,000 pp). The SIR therefore compares the complication rate in a practice which 
dispenses 86 items per 1,000 pp with one which dispenses 48 items per 1,000 pp; a 
value >1 indicates that the rate of complications is higher at the higher level of 
dispensing.  
 
4.3.2 Changes over time 
To examine whether practice changes in complications during the study period were 
related to changes in dispensing of total antibiotics, practices were divided into two 
equal groups based on their change in total antibiotic dispensing rates between 1996 
and 2000 (the rate in 2000 minus that in 1996). This change was divided into two 
groups; one with the smallest reduction in dispensing rates over time, and the other 
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with the largest reductions. Due to the small number of episodes for some 
complications, only changes in pneumonia were examined. Differences between the 
two groups in the change of complication rates were analysed using a Mann-Whitney 
test since the changes in pneumonia rates had skewed distributions.  
 
All multilevel modelling was performed using MLwiN version 2.10 and all other 
analyses using SPSS version 14.0. 
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4.4 Results  
A total of 26 practices contributed data for all five years between 1996 and 2000, 
with a total registered population of 232,500 per annum. Practice list sizes ranged 
from 2,660 to 19,523 patients.  
 
4.4.1 Trends in dispensed antibiotics  
BSPs were the most commonly dispensed antibiotic in primary care and accounted 
for around 40% of total dispensed antibiotics. For total antibiotics, and for the 
majority of the antibiotics studied, trends in dispensing decreased during the study 
period (Figure 4.1). A two-level multilevel model identified that over the five year 
period, dispensing for total antibiotics fell by 2.89 per 1,000 pp per quarter (p<0.001) 
equating to 11.55 per 1,000 pp per annum (Table 4.2).  
 
Figure 4.1 Quarterly trends in dispensing rates of total antibiotics and flucloxacillin 
from 1996 to 2000 for 26 practices contributing data to the GPMD 
 
__ 
  
Table 4.2 Linear regression models to estimate trends in antibiotic dispensing in general practice per 1,000 practice population from 
1996 to 2000 
 
 
Median (25
th
 to 75
th
 percentiles) 
dispensing rates 
Annual 
rate 
of change 
95% CI for 
change 
p-value Annual % 
change
i
 
Antibiotic 
1996 2000 
Penicillin  68 (50 to 105) 67 (41 to 81) -1.20 -1.63 to -0.81 <0.001 -1.9 
BSPs 348 (304 to 413) 269 (224 to 343) -7.20 -9.20 to -5.29 <0.001 -2.5 
Flucloxacillin 48 (38 to 60) 61 (48 to 69)  0.72 0.42 to 1.02 <0.001 1.1 
Cephalosporins 67 (49 to 81) 63 (51 to 87) -0.90 -2.14 to 0.30 0.145 -1.3 
Tetracyclines 50 (38 to 62) 50 (40 to 59) -0.23 -0.58 to 0.11 0.197 -0.4 
Macrolides 112 (69 to 142) 82 (59 to 110) -2.44 -3.10 to -1.84 <0.001 -2.7 
Trimethoprim 53 (46 to 62) 53 (42 to 64) -0.16 -0.60 to 0.27 0.486 -0.3 
Quinolones 30 (21 to 37) 29 (18 to 38) -0.02 -0.39 to 0.36 0.917 -0.1 
Total antibiotics 822 (723 to 918) 705 (606 to 842) -11.55 -13.96 to -9.18 <0.001 -1.6 
i
 As a % of current annual rates (up to end of June 2003) 
5
7
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This quarterly fall equated to a reduction of 11.55 per 1,000 pp per annum, 
approximately 1.6% of current annual total dispensing rates. Similarly, dispensing 
for BSP, penicillin and macrolides all decreased significantly over the study period 
(p<0.001). The exception to this trend was flucloxacillin, which increased over the 
study period by 0.72 dispensed prescriptions per 1,000 pp per annum (p<0.001), 
approximately 1.1% of current annual flucloxacillin dispensing rates. There were no 
discernible trends in the dispensing of cephalosporins, tetracyclines, trimethoprim 
and quinolones.  
 
4.4.2 Trends in complications arising from RTIs 
The most common complications of RTIs diagnosed in general practice were 
pneumonia and quinsy, with on average 145 and 26 cases per 100,000 pp per annum 
respectively (Table 4.3). Episodes of intracranial abscesses, rheumatic fever and 
epiglottitis were rare, with on average less than 1.1 per 100,000 pp per annum. 
Poisson regression analysis showed considerable variation, both between practices 
and also within practices from year to year, with some evidence to suggest an 
increase in mastoiditis over the five-year period (β=0.327, 95% confidence interval 
(CI)= 0.114 to 0.543). There was also evidence for a decrease in certain 
complications arising from chest infections, such as pneumonia (β =-0.215, 95% 
CI=-0.314 to -0.100) and empyema (β =-1.564, 95% CI=-2.469 to -0.948).  
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Table 4.3 Primary care diagnoses of complications arising from RTIs in 26 general practices between 1996 and 2000 
 
Read code Complications Total 
diagnoses 
Mean rate per 
annum
i
 
Coefficient for 
trend (SE) 
p-value 
H2... Pneumonia (exc. influenza) 1690 145.36 -0.215 (0.057) <0.001 
H15.. Quinsy    306 26.32 -0.084 (0.051) 0.100 
A38.. Septicaemia 176 15.14 -0.241 (0.175) 0.168 
F53.. Mastoiditis  71 6.11 0.327 (0.110) 0.003 
K00.. Acute glomerulonephritis 33 2.84 -0.050 (0.164) 0.760 
H50.. Empyema 27 2.32 -1.564 (0.408) <0.001 
F00.. Bacterial Meningitis  23 1.98 -0.061 (0.207) 0.768 
H043. Epiglottitis 12 1.03 NA NA 
G0… Acute rheumatic fever 12 1.03 NA NA 
F040. Intracranial abscess  2 0.17 NA NA 
i
 Rate per 100,000 practice population 
NA = not analysed 
-  
5
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4.4.3 Associations between complications and dispensed antibiotics 
Analyses were only performed for pneumonia, septicaemia, quinsy and mastoiditis; 
episodes for the remaining complications were too rare to model. Multilevel Poisson 
regression showed several negative associations indicating that lower antibiotic 
dispensing rates were significantly associated with higher episodes of complications 
in general practice (Table 4.4). Specifically, a lower incidence rate of pneumonia and 
mastoiditis was found in practices with a higher dispensing rate of penicillin. The 
SIR for pneumonia was 0.80 (95% CI=0.68 to 0.93, p=0.005), suggesting the 
incidence rate of pneumonia in a practice dispensing penicillin at the 75
th
 percentile 
of 86 items per 1,000 pp per annum would be 80% of that at the 25
th
 percentile of 48 
items per 1,000 pp per annum. Similarly, the incidence rate of mastoiditis in a 
practice dispensing penicillin at the 75
th
 percentile would be 48% (95% CI=23 to 
87%, p=0.024) of that in one at the 25
th
 percentile.  
 
A lower incidence rate of pneumonia, quinsy and septicaemia was found in practices 
with a higher dispensing rate of BSP. This indicates lower rates of these 
complications in practices whose dispensing rate of BSP was at the 75
th
 percentile 
(379 items per 1,000 pp per annum) compared to the 25
th
 percentile (257 items per 
1,000 pp). The model also showed positive relationships between tetracyclines and 
episodes of quinsy, and cephalosporins and episodes of both pneumonia and quinsy. 
The SIR for quinsy and tetracyclines was 1.59 (95% CI=1.14 to 1.89, p<0.001), 
suggesting the incidence rate of quinsy is 59% higher in practices whose 
tetracyclines dispensing rate was at the 75
th
 percentile (61 items per 1,000 pp per 
annum) compared to those at the 25
th
 percentile (40 items per 1,000 pp per annum). 
Similarly, the SIRs for cephalosporins and pneumonia and quinsy are 1.29 (95% 
CI=1.07 to 1.54, p=0.006) and 1.30 (95% CI 1.17 to 1.44, p<0.001) respectively. 
This indicates higher rates of complications in practices whose dispensing rate of 
cephalosporins was at the 75
th
 percentile (97 items per 1,000 pp per annum) 
compared to the 25
th
 percentile (51 items per 1,000 pp per annum). 
  
Table 4.4 Multilevel Poisson regression models examining the relationship between primary care diagnosed complications and 
antibiotic dispensing 
 
 Loge 
Parameter 
estimate 
Standard 
error 
Dispensing  
rate IQR
i
  
SIR 
(IQR)
ii
 
95% 
 Lower limit 
CI  
Upper limit p-value 
Pneumonia (exc. influenza)        
Total antibiotics -0.0007 0.0004 234.61 0.85 0.74 1.05 0.080 
Penicillin -0.0059 0.0021 37.76 0.80 0.68 0.93 0.005 
BSPs -0.0046 0.0007 121.97 0.57 0.46 0.67 <0.001 
Cephalosporins 0.0057 0.0012 45.81 1.30 1.17 1.44 <0.001 
Macrolides -0.0012 0.0010 65.65 0.92 0.84 1.10 0.230 
Tetracyclines 0.0043 0.0038 20.52 1.09 0.93 1.24 0.258 
Quinsy        
Total antibiotics -0.0003 0.0006 234.61 0.93 0.74 1.26 0.617 
Penicillin 0.0062 0.0047 37.76 1.26 0.88 1.80 0.187 
BSPs -0.0038 0.0013 121.97 0.63 0.46 0.85 0.004 
Cephalosporins 0.0055 0.0020 45.81 1.29 1.07 1.54 0.006 
Macrolides -0.0023 0.0027 65.65 0.86 0.66 1.36 0.394 
Tetracyclines 0.0227 0.0062 20.52 1.59 1.14 1.89 <0.001 
Septicaemia        
Total antibiotics -0.0011 0.0012 234.61 0.77 0.38 1.24 0.359 
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Table 4.4 Multilevel Poisson regression models examining the relationship between primary care diagnosed complications and 
antibiotic dispensing 
 
 Loge 
Parameter 
estimate 
Standard 
error 
Dispensing  
rate IQR
i
  
SIR 
(IQR)
ii
 
95% 
 Lower limit 
CI  
Upper limit p-value 
Septicaemia        
Penicillin 0.0013 0.0064 37.76 1.05 0.72 1.94 0.839 
BSPs -0.0064 0.0027 121.97 0.46 0.17 0.67 0.018 
Cephalosporins 0.0040 0.0041 45.81 1.20 0.84 1.79 0.329 
Macrolides -0.0005 0.0040 65.65 0.97 0.00 1.58 0.901 
Tetracyclines 0.0081 0.0111 20.52 1.18 0.64 1.64 0.466 
Mastoiditis        
Total antibiotics -0.0020 0.0016 234.61 0.63 0.39 1.68 0.211 
Penicillin -0.0196 0.0087 37.76 0.48 0.23 0.87 0.024 
BSPs -0.0010 0.0030 121.97 0.89 0.48 1.91 0.739 
Cephalosporins -0.0025 0.0049 45.81 0.89 0.60 1.45 0.610 
Macrolides -0.0075 0.0058 65.65 0.50 0.29 1.30 0.070 
Tetracyclines -0.0218 0.0157 20.52 0.64 0.39 1.39 0.165 
 
i
 Inter quartile range (IQR) = difference between the 75
th
 and 25
th
 percentile of the dispensing rate distribution; 
 
ii 
Standardised Incidence Ratio (SIR) =SIR of complications at 75
th
 percentile of dispensing distribution compared to the 25
th
 percentile
6
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These results show an association between practice dispensing rates and episodes of 
certain complications but they do not imply a causal relationship as other factors 
could account for both high antibiotic dispensing rates and many complications in a 
practice, such as a large elderly population. To further explore the impact of reducing 
antibiotic dispensing on rates of complications, the association between change in 
dispensing and change in complications was examined.  
 
4.4.4 Changes in dispensing of total antibiotics and complications 
Practices did not all change their dispensing of total antibiotics in the same way or 
observe the same changes in the number of complications between 1996 and 2000. 
For total antibiotics, the vast majority of practices decreased their total antibiotic 
dispensing rates but three practices increased. The average change in total antibiotic 
dispensing rates over all 26 practices was -109.03 items per 1,000 pp (SD = 96.65, 
range -284.18 to 155.03 per 1,000 pp). The median rate of change in pneumonia 
diagnoses was 5.41 (25
th
 to 75
th
 percentiles= -71.98 to 45.95 per 100,000 pp). 
 
The 26 practices were divided into two equal groups based on change in total 
antibiotic dispensing rates between 1996 and 2000; one group contained practices 
with the smallest reduction and the other those with the largest reductions. Initial 
rates (1996) for practices that reduced their dispensing the most were higher than for 
practices that reduced their dispensing the least (mean=882.69 and 761.86 items per 
1,000 pp per annum respectively, t=1.88, p=0.072). Mean total antibiotic dispensing 
rates were similar for both groups in 2000.  
 
Practices with the largest reductions in total antibiotic dispensing rates had lower 
rates of pneumonia in 1996 (median=37.23 per 100,000 pp) than practices with the 
smallest reductions in total antibiotic dispensing rates (median=199.40 per 100,000 
pp) (Figure 4.2). They also experienced an increase in the rate of pneumonia, with a 
median increase of 41.7 (range -459.92 to 235.84) per 100,000 pp from 1996 to 
2000. In contrast, practices with the smallest reductions in total antibiotic dispensing 
rates experienced a reduction in the rate of pneumonia over the study period, with a 
median reduction of -18.94 (range -365.45 to 45.33) per 100,000 pp. The difference 
in change between the two groups was statistically significant (Mann-Whitney test = 
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36.0, p = 0.012) (Figure 4.3).  
 
Figure 4.2 Box-whisker plot of pneumonia rates per 100,000 pp in 1996 and 2000 by 
practices’ change in dispensing rates of total antibiotics 
 
 
 
 
Figure 4.3 Box-whisker plot of change (2000-1996) in pneumonia rates per 100,000 
pp by practices’ change in dispensing rates of total antibiotics 
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4.5 Discussion 
4.5.1 Main findings 
This population based study based on a sample of Welsh practices showed that 
during a period when overall dispensing of antibiotics in primary care reduced 
sharply, primary care diagnoses of mastoiditis significantly increased whilst rates in 
both pneumonia and empyema significantly decreased. Only dispensing of 
flucloxacillin saw a significant increase during these 5 years.  
 
Initial results suggest an apparent negative relationship between antibiotic dispensing 
and certain primary care diagnosed complications. For example, practices with lower 
rates of penicillin and broad spectrum penicillin (BSP) dispensing had a higher rate 
of pneumonia, BSP dispensing and quinsy, penicillin dispensing and septicaemia and 
mastoiditis. However a positive relationship was observed between dispensing of 
cephalosporins and primary care diagnosed quinsy and pneumonia, and also between 
tetracycline dispensing and quinsy. 
 
Practices with the largest reductions in total antibiotic dispensing rates over the five-
year period also saw a small increase in pneumonia rates over the time period whilst 
practices with the smallest reductions in total antibiotic dispensing rates saw a 
sizeable decrease in pneumonia rates. The difference in change of pneumonia rates 
between these two groups was statistically significant.    
 
4.5.2 Strengths and weaknesses of the study 
While many studies have examined the relationship between antibiotic prescribing 
and complications at an aggregate level, none have examined the impact of general 
practice level change in antibiotic dispensing on change in complication rates over 
time. While there was some evidence to suggest that a reduction in antibiotic 
dispensing may be related to change in the incidence of pneumonia over time, it 
cannot be concluded that there is a causal link, as other factors not adjusted for could 
also affect changes in complications. Although this study was ecological, the unit of 
aggregation was smaller than levels used in previous studies. Outcomes at the 
general practice level are important since strategies for enhanced antibiotic 
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prescribing are often targeted at practices.  
 
The GPMD practices were broadly representative of all general practices in Wales 
and the age-sex distribution is comparable to that of the Welsh population 
(Delahunty et al. 2001). At present, one major disadvantage of using the GPMD is 
that data collection stopped in 2000 and hence later trends using this data source 
cannot be presented. With only five years of data to analyse, it is also difficult to gain 
an understanding of a trend, as there is considerable variation between both practices 
and years. 
  
Studies have highlighted the possible problem of GPs changing the way they use 
diagnostic codes in order to justify antibiotic prescribing, known as ‘diagnostic drift’. 
It could be argued that a GP may record a diagnosis consistent with their decision on 
whether or not to prescribe an antibiotic. If this had occurred to a substantial extent, a 
shift in classification would have been expected, with a reduction of RTI diagnoses 
not requiring antibiotics and a rise in more severe RTIs or certain complications. 
This might be a factor in the significant increase in mastoiditis diagnoses over time 
and the higher number of quinsy cases in our sample. In this study, trends in acute 
RTIs were not examined; however, other studies examining trends in RTIs have 
considered this unlikely since possible consultations codes for RTIs showed no 
concomitant increases (Ashworth et al. 2005). 
 
Whilst the majority of RTIs present in primary care, complications arising from them 
can appear in either primary or secondary care. There are different pathways by 
which complications are diagnosed; for example a patient could present to, and be 
treated by, their GP, or they may present to their GP and be referred to secondary 
care.  They could even be admitted to, and diagnosed in, secondary care via an 
accident and emergency department without ever contacting primary care.  This 
analysis has only considered complications recorded in primary care. Our figures 
may not, therefore, reflect the true incidence of complications in the practice 
population, since diagnoses made in hospital or out-of-hours (and not previously 
seen by GPs) may not have been captured in the GPs notes. This may account for the 
small number of cases of certain complications.  
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One weakness of the dispensing data is that patient details such as age and gender are 
not recorded, or information relating to the indication for which the antibiotic was 
prescribed. Only overall dispensing of antibiotics for all indications could be 
examined (approximately 50% of all community used antibiotics are prescribed for 
RTIs) (Standing Medical Advisory Committee Sub-Group on Antimicrobial 
Resistance 2003), and not dispensing specifically for RTIs. Thus the proportion of 
patients with an actual RTI could not be ascertained. Currently, this information is 
only obtainable through examination of observational datasets such as the General 
Practice Research Database (GPRD) where individual GP consultations can be 
examined. There is also a risk that there is an underestimation in the dispensing of 
antibiotics, as dispensing by out of hours service providers may not be recorded.  
 
Another weakness of dispensing data (and any data examining antibiotic prescribing 
or dispensing) is that dispensing of antibiotics is an imperfect proxy for antibiotic 
consumption. There may be a very small proportion of patients who receive the 
antibiotics but do not actually take them. However, evidence suggests that the 
majority of adults in the UK (90%) claim to finish their course of antibiotics 
(Pecherer 2001). This would therefore lead to a very small bias in dispensing data 
although this bias may vary by the type of acute RTI (the more serious the infection, 
the higher the likelihood of dispensing the prescription and adhering to the 
antibiotic). Dispensing will however more closely approximate consumption than 
prescribing and it is consumption that is the key issue in relation to complications. 
 
4.5.3 Comparisons with existing literature  
As already discussed in earlier chapters, the reduction in overall antibiotic dispensing 
identified in these 26 practices was consistent with the pattern of antibiotic 
dispensing for the whole of Wales and that found in other studies (Majeed et al. 
2004; Sharland et al. 2005; Ashworth et al. 2004). Comparable data on incidence 
rates and trends in complications arising from respiratory tract infections presenting 
in primary care are limited. The rate of quinsy in our study is nearly four times 
higher than that from a study using data from the General Practice Research 
Database around the same period (Dunn et al. 2007).
 
This discrepancy could be due 
to higher ascertainment of cases in our sample or because GPs may have recorded a 
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severe pharyngeal infection as quinsy to justify use of an antibiotic. The rate of 
mastoiditis in our study is comparable with that found by Sharland and colleagues 
(Sharland et al. 2005).  
 
Several studies have found an association between antibiotic dispensing and 
complications.
 
Little and colleagues used data at the level of health authority, 
combining hospital admissions data and PACT data for the years 1997-1998, and 
found a significant but weak association, with higher penicillin dispensing being 
associated with lower hospital admissions for quinsy and mastoiditis (Little et al. 
2002).
 
Van Zuijlen and colleagues compared the total incidence of acute mastoiditis 
in patients aged 14 years and younger in ten first world countries for a period of 3-5 
consecutive years between 1991 and 1998, and found a lower incidence of acute 
mastoiditis in countries with higher rates of antibiotic prescribing (Van Zuijlen et al. 
2001). The results from these studies, however, are not comparable to ours, as they 
performed cross-sectional analyses and did not compare trends during their study 
periods. It is therefore difficult to infer from such studies that changes in prescribing 
or dispensing are associated with changes in complications rates.  
 
4.5.4 Implications of findings for clinical practice and future research 
Due to both the small number of practices involved and the aggregated nature of the 
data, these results do not allow us to draw conclusions regarding the relationship 
between antibiotic dispensing and complications at an individual level. Nevertheless, 
there is some evidence to support the argument that reduced prescribing could be 
harmful (possibly resulting in higher rates of pneumonia) and that those patients who 
may benefit the most from antibiotics may not have received them. The decline in 
dispensed antibiotics, which may have a bearing on cases of complications arising 
from acute RTIs, can be attributed to either a decline in patient consulting behaviour 
for acute infections and/or the prescribing behaviour of general practitioners and 
nurses (Ashworth et al. 2003; Fleming et al. 2003).
   
 
Conclusions arising from this chapter should therefore be treated as hypothesis 
generating as it has highlighted the areas where further work is required to examine 
trends in, and associations between, antibiotic dispensing, resistance and 
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complications over a longer period of time and for a larger population. The following 
four chapters will deal with these enhancements using other datasets to attempt to 
overcome some of the limitations found here in the dispensing data (such as lack of 
patient demographics and indications) and in the complications data (such as 
determining the true incidence of complications in the population by ensuring 
complete capture of all primary and secondary care data).  
 
4.6 Introduction to All-Wales general practice level analysis 
The following four chapters will be based on general practice level data for the entire 
population of Wales. Longitudinal analyses of three administrative datasets covering 
antibiotic dispensing, antibiotic resistance and hospital admissions (of complications 
arising from RTIs) will be carried out, covering the period between 1996 and 2006. 
In Chapters 5-7 each of the individual datasets will be interrogated and analysed 
fully; the relationship between the three datasets will be analysed and discussed in 
Chapter 8.  
 
These chapters will improve on the model tested in this chapter in three ways. 
Firstly, an extended model of the relationship between antibiotic dispensing in 
primary care and complications arising from RTIs will be considered examining not 
only the direct relationship between the latter but also the relationship between 
antibiotic dispensing, complications and resistance whilst taking certain other 
influencing factors into account, such as practice characteristics. Secondly, the 
sample size will be increased greatly using data from every general practice with 
reliable data in Wales, thus covering the entire Welsh population. Thirdly, the period 
will be extended and updated, covering the years 1996 to 2006. 
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Chapter 5  Antibiotic dispensing in Wales 
5.1 Introduction to antibiotic dispensing data 
This chapter examines the patterns and trends in community antibiotic dispensing in 
Wales. Quarterly and monthly trends in antibiotic dispensing were examined 
retrospectively over the period 1996 to 2006 for all ages and also specifically for 
paediatric dispensing. The variation in trends of antibiotic dispensing by general 
practices and Local Health Boards (LHBs) were examined, and possible practice 
demographic factors were determined that may be associated with variation in 
dispensing. Broad and narrow spectrum dispensing patterns were also examined over 
the period. 
 
5.2 Methods 
5.2.1 Antibiotic dispensing data 
Two datasets on antibiotics dispensed by general practitioners in Wales were 
obtained from the Prescribing Services Unit (PSU) at NHS Wales Informatics 
Service (NWIS) as previously described in section 3.3. The first contained quarterly 
data from April 1996 to June 2003 (inclusive), and the second contained monthly 
data from April 2000 to March 2006 (inclusive). These datasets were then linked to 
create a file of quarterly dispensing data from April 1996 to March 2006. Each 
dataset contained the total number of items of dispensed antibiotics by month or/and 
quarter and year, and subdivided into antibiotic sub-section and chemical (based on 
British National Formulary (BNF) classifications), for each general practice in Wales 
(Joint Formulary Committee. 2007). An item was defined as one preparation on a 
prescription. As already mentioned in Chapter 4, the amount of dispensed antibiotics 
may be different from that prescribed, as fewer antibiotics will be dispensed than 
prescribed due to delayed prescribing and patients not filing their prescriptions filled 
for a variety of reasons. Dispensing will more closely approximate consumption than 
prescribing and it is consumption that is the key issue regarding complications and 
resistance. 
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5.2.2 Type of antibiotics  
Chapter 5.1 of the BNF covers antibacterial drugs for infection, classified by group 
(sub-section) and type of antibacterial (chemical). Total antibiotic dispensing was 
examined to give an indication of overall use in primary care and the antibiotic 
groups most commonly used in the treatment of respiratory tract infections (RTIs) 
were examined individually. Antibiotics used in the treatment of RTIs, and their 
inclusion in the two datasets, are shown in Appendix II. Since the dataset covering 
the earlier time period (April 1996 to June 2003) mostly included only broad 
antibiotic groups rather than type of antibiotics, only these groups will be examined 
in the 1996 to 2006 dataset. The following antibiotics were not included as these 
medications were uncommonly used in the treatment of typical RTIs:  
 BNF 5.1.1.4 Antipseudomonal penicillins 
 BNF 5.1.1.5 Mecillinams 
 BNF 5.1.4 Aminoglycosides 
 BNF 5.1.6 Clindamycin 
 BNF 5.1.7 Some other antibacterials (inc. fusidic acid, chloramphenicol) 
 BNF 5.1.9 Antituberculosis drugs 
 BNF 5.1.10 Antileprotic drugs 
 BNF 5.1.11 Metronidazole and tinidazole 
 BNF 5.1.13 Urinary-tract infections (inc. nitrofurantoin).  
 
Trimethoprim, a drug associated with treatment of urinary tract infections in the UK, 
can also be used for RTIs. This drug was examined on its own, with sulphonamides 
and co-trimoxazole excluded. The items dispensed for the following eight antibiotic 
groups were summed to produce a measure of total antibiotic dispensing for RTIs:   
 Benzylpenicillins and phenoxymethylpenicillin (Penicillin) 
 Penicillinase-resistant penicillins (Flucloxacillin) 
 Broad-spectrum penicillins (BSPs) 
 Trimethoprim 
 Macrolides 
 Cephalosporins and other beta-lactams (Cephalosporins) 
 Quinolones 
 Tetracyclines. 
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5.2.3 Practice characteristics  
It was essential that the variation in antibiotic dispensing was modelled at the level of 
general practice in order to identify factors associated with high dispensing. Monthly 
practice population data, that is the number of individuals registered to a general 
practice (list size), was provided for each practice, month and year by NWIS from 
the Welsh Demographic Service (WDS). To evaluate the importance of practice 
characteristics on antibiotic dispensing, the following factors were obtained from the 
WDS for each practice: LHB, single-handed status, number of GPs, age of GPs, 
proportion of male GPs and practice deprivation based on Townsend 2001 scores. 
All practice characteristics information was taken from the practice’s status when the 
data was requested in June 2007.  
 
5.2.4 Data quality and exclusions 
5.2.4.1 Monthly dispensing data: April 2000 to March 2006 
For the dataset covering the period of April 2000 to March 2006, monthly antibiotic 
dispensing data was provided for 533 general practices with a total population (list 
size) of 3,136,002 (taken on March 2006), which exceeded the total Welsh 
population. The official estimated Welsh population (people resident in Wales) was 
2,965,900 (taken on June 2006) (Welsh Assembly Government Aug 2007). Practices 
with relatively stable populations over time were included in the analyses. To assess 
stability, a coefficient of variation (CV) was calculated for the monthly series of list 
sizes for each practice to examine the variation in monthly populations. Any practice 
with a CV less than 5%, indicating very little monthly variation, was automatically 
included for all analyses. Practices with a CV greater than or equal to 5% (n=147), 
were investigated further by examining the general pattern of the monthly 
populations in conjunction with the monthly dispensing of all antibiotics.  
 
From these 147 practices, 25 were excluded due to small monthly populations (≤100) 
which are not credible values. A further 49 practices were excluded due to sudden 
increases or decreases in monthly populations which were not reflected in the 
number of items dispensed that month, resulting in unstable rates. A partner leaving a 
practice and apparently taking patients with them, or the merging of more than one 
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practice, could explain a sudden change in population. In such changes, dispensing 
and practice population would be expected to change simultaneously, resulting in 
relatively unchanged rates. For five practices, antibiotic dispensing items (based on 
overall dispensing) were missing for the entire period or a large part of the period. 
For practices with data missing for a part of the period, the assumption that no 
antibiotics were dispensed was implausible as this was not consistent with adjacent 
months.  
 
A total of 79 practices were excluded in total, with a population of 233,082 (7.4%). 
The remaining 68 practices were included in spite of their populations having CVs 
greater than 5% (range=5.0% to 27.2%). Although their populations had an 
unexpected pattern (sudden increase, decrease or cyclical), the pattern was also 
reflected in the monthly items dispensed. For example, many practices were areas 
where a large proportion of the population consisted of university students and 
population changes were cyclical with increases in the autumn as term commenced 
and decreases until the next intake (Figure 5.1).  
 
Figure 5.1 Monthly populations and dispensing from a practice based in a university 
area 
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Therefore, a total of 454 practices, with a population of 2,902,920, were included in 
the analyses. Of these, 292 had 72 months of data for each of the 8 antibiotic groups; 
the remaining practices had varying degrees of empty monthly cells per antibiotic. 
Empty data cells indicated that a practice had not dispensed a particular antibiotic for 
that month, not that data was missing. This was because dispensing for adjacent 
months was low and the assumption that no antibiotics were dispensed per month 
was plausible. A flow chart of the process of excluding practices is shown in Figure 
5.2.  
 
Figure 5.2 Flow chart of the process of excluding practices dispensing data from 
April 2000 to March 2006  
 
 
 
5.2.4.2 Quarterly dispensing data: April 1996 to June 2003 
In total, 540 Welsh unique practices had dispensing data recorded between April 
1996 and June 2003, with quarterly antibiotic dispensing data ranging from five 
quarters to the maximum 29 quarters.  These data had previously been cleaned ready 
for analysis as part of a previous study (Welsh Antibiotic Study Group 2005) but 
nevertheless additional checks were made after linking the two datasets.  
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5.2.4.3 Linking the antibiotic datasets 
Since the two antibiotic datasets were provided with differing practice codes (W-
codes and the new encrypted codes) to preserve the anonymity of the practices, 
NWIS carried out the linkage to create one dataset containing dispensing data 
between 1996 and 2006. Three practices were excluded due to imprecise matching 
(one W-code to two encrypted-codes) and a further 17 practices had incomplete 
quarterly dispensing data for the period, with data ranging from 26 to 39 quarters 
(out of a possible 40 quarters). Since there was an overlap of 13 quarters in the two 
datasets, each practice’s dispensing items were compared for this period between the 
two datasets for two reasons: firstly to verify that the antibiotics had been grouped in 
the same way and secondly to verify that practices had been linked correctly. From 
this exercise it was established that the dispensing data from 1996 to 2003 contained 
the BNF chemical phenoxymethyl-penicillin (Penicillin V) and not the BNF sub-
section benzylpenicillin and phenoxymethyl-penicillin as included in the 2000 to 
2006 data. The former was retained. 
 
For each practice and for each quarter, there was perfect agreement between the data, 
apart from one practice that had a lack of agreement for the second quarter (April-
June) of 2000 for seven of the eight antibiotic groups. For this practice, the figures 
from the 2000 to 2006 dataset were higher than the figures from 1996 to 2003 
dataset. After examination of the dispensing data in the adjacent time periods and 
examining the trends using both sets of figures, the figures from the 1996 to 2003 
dataset seemed more plausible and these were used. Additionally, the stability of 
each practice’s antibiotic dispensing rates (dispensed items divided by the practice’s 
population) were checked (by calculating the CV) and eight practices were excluded 
as they were deemed to have a sudden increase or decrease in practice population not 
reflected in the total dispensing items or a sudden increase in the total items 
dispensed not accounted for by an increase in practice population between April 
1996 and March 2000. Therefore, out of a possible 454 practices, 426 (94.5% of the 
official Welsh population) had stable and complete data (40 quarters between April 
1996 and March 2006). Figure 5.3 shows a flow chart of the practices included in the 
analysis of quarterly antibiotic dispensing data from April 1996 to the end of March 
2006.  
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Figure 5.3 Flow chart of the linkage of practices from the April 2000 to March 2006 
dataset and practices from the April 1996 to March 2000 dataset 
 
 
 
 
5.2.5 External validity of the practices 
Only practices with complete and stable population and dispensing data were 
included in these analyses (dubbed as Up-To-Standard practices (UTS)). Therefore, 
all analyses using the quarterly antibiotic dispensing data for the 10 year period 
(April 1996 to March 2006) were based on the 426 practices identified in section 
5.2.4.3. When using the monthly dispensing data or analysing by antibiotic type by 
using the data from April 2000 to March 2006, data from 454 practices were used 
(identified in section 5.2.4.1). However, by excluding practices that were deemed as 
having less reliable data, some bias might have been incurred.  
 
Comparing the characteristics of the 426 included practices against the 107 that were 
excluded, some bias was present, with excluded practices more likely to be run 
single-handedly (p<0.001) and from more deprived areas (p=0.003) (Table 5.1). 
These biases will be considered when the results are interpreted. 
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Table 5.1 Characteristics of included and excluded practices from April 1996 to 
March 2006 
 
 
 
Included 
(UTS) 
N=426 
Excluded 
 
N=107 
Test statistic,  
p-value 
Practices with no 
characteristics data 
 
6 31 - 
Single-handed N (%) 67 (15.9) 
 
29 (35.4) 2=16.91, p<0.001 
Practice deprivation
i
 
mean (SD) 
 
0.13 (1.91) 0.99 (2.02) t=3.60, p=0.001 
Age of GPs (years) 
mean (SD) 
 
50.48 (6.64) 52.04 (8.43) t=1.86, p=0.115 
Male GPs (%) 
median (25
th
 to 75
th
 
percentiles) 
66.7 
(50 to 100) 
70.8 
(50 to 100) 
MW, p=0.267 
i 
Practice deprivation based on Townsend 2001 scores 
MW=Mann Whitney 
 
5.2.6 Sub-group analyses 
5.2.6.1 Antibiotic dispensing in children 
Antibiotic dispensing data are currently recorded without any patient or clinical 
information attached and it is therefore impossible to examine antibiotic dispensing 
rates by age, gender or diagnosis.  However, a recent study on behalf of the 
Specialist Advisory Committee on Antimicrobial Resistance (SACAR) Paediatric 
Subgroup demonstrated how dispensing data could be used to approximate the 
amount of dispensing for children by using liquid formulations of antibiotics as a 
proxy measure (Sharland et al. 2007). To be able to use this proxy, detailed 
dispensing data was obtained from PSU to identify all oral liquid antibiotics. Oral 
liquid antibiotics were classed as preparations recorded as powders, dispersible 
tablets, solutions, liquids, syrups, granules for syrups, elixirs, powders for elixirs, 
sachets, powder sachets, suspensions, powders for suspensions, granule straws and 
infusions (classed as mg/ml). Capsules, tablets, non-dispersible tablets, injections 
(IV), powders for IV, nebuliser solutions and preparations that were specifically 
recorded as adult suspensions (such as Laratrim and Septrim) were all excluded.  A 
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complete list of oral liquid antibiotic preparations is given in Appendix III.  
The SACAR Paediatric Subgroup validated the assumption that virtually all oral 
liquid formulations of antibiotics were prescribed for children, especially younger 
children under the age of 12 years old, although a minority could be dispensed for 
older patients (personal communication with Dr Sharland). The group speculated that 
older children were more likely to receive solid oral antibiotics. Therefore by looking 
at liquid oral antibiotics, dispensing in children would be underestimated. They also 
noted that amoxicillin liquid formulations are also given to children out-of-hours and 
without prescription. These biases will be considered when the results are 
interpreted.  
 
5.2.6.2 Broad- vs. narrow-spectrum antibiotic dispensing  
Antimicrobial agents are classified as being either narrow-spectrum or broad-
spectrum, depending upon their activity against a range of organisms. For example, 
the term broad-spectrum antibiotic refers to an antibiotic with activity against a wide 
range of disease-causing bacteria whilst narrow-spectrum antibiotics are only 
effective against specific families of bacteria.  
 
Although some evidence exists of a decline in antibiotic prescribing, there are still 
concerns that broad-spectrum antibiotics are commonly used in treatment of 
community acquired infections (Steinman et al. 2003a). Broad-spectrum antibiotics 
are properly used empirically, prior to identifying the causative bacteria, when there 
is a wide differential diagnosis and delay may cause deterioration in the patient. Most 
GPs are faced with having to decide upon treatment without identification of the 
bacterium and antibiotic resistance (Wood et al. 2007). Ideally, the narrowest 
spectrum antibiotic most appropriate to the identified bacterium should be used as 
this is believed to limit the development of antibiotic resistance as well as side-
effects and cost (Ball et al. 2002).  
 
The distinction between broad versus narrow is not always clear and classifying 
antibiotics into these categories is not straightforward. For this reason, no such 
generally agreed categorisation of antibiotics exists at present. For example, 
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tetracycline and chloramphenicol were both traditionally classified as broad-
spectrum agents, but the development of resistance to these drugs has changed their 
classification. Imipenem is classed as a broad-spectrum antibiotic whilst 
erythromycin is classified as narrow-spectrum. However, there are at least as many 
organisms that are sensitive to erythromycin but not imipenem (e.g. mycoplasma, 
Chlamydia) as there are that are sensitive to imipenem but not erythromycin (e.g. 
coliforms).  
 
A study published in 2003 categorised the following antibiotics used specifically in 
the treatment of acute RTIs (Steinman et al. 2003b) as broad-spectrum with all other 
antibiotics classed as narrow-spectrum: quinolones, amoxicillin/clavulanate (co-
amoxiclav), the second- and third- generation cephalosporins, azithromycin and 
clarithromycin. However, some of the more obvious broad-spectrum antibiotics were 
omitted from this list such as amoxicillin, the cephalosporins and tetracyclines. The 
categorisation of broad- and narrow-spectrums used in this analysis is listed in 
Appendix IV.  
 
5.3 Statistical analysis  
5.3.1 Population and rates 
Different analyses used different time units (months, quarters and study years) and 
practice populations were aggregated to the relevant level to calculate rates per 1,000 
population. For annual data, study years were used; for example, 1996 denotes the 
study year from April 1996 to March 1997. Rates for antibiotic dispensing in 
children (using dispensed liquid oral formulations as a proxy) were calculated using 
practice populations for age 15 years and under. Rates of antibiotic dispensing for 
children were likely to be under-estimated as the age cut-off point for liquid oral 
formulations was likely to be less than 15 years old but could not be determined 
precisely at this point. 
 
To aid comparison between the data for 1996 to 2006 (quarterly) and 2000 to 2006 
(monthly), monthly rates per 1,000 practice population were converted to quarterly 
rates per 1,000 pp.  
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5.3.2 Multilevel modelling 
Since each practice had counts of dispensed antibiotic items at regular time intervals 
(either monthly or quarterly), a multilevel repeated measures model was used to 
examine trends in longitudinal data. The model had three levels of data: local health 
board (level 3), general practice (level 2) and time (level 1) and intercepts and slopes 
were allowed to vary randomly. Dispensing rates were based on large numbers of 
items and were approximately normally distributed. Trends for antibiotic dispensing 
were therefore modelled using linear regression, with seasonality adjustment using 
categorical variables to indicate the quarter of the year. For all antibiotics, adjusting 
for seasonality in the model reduced the within practice random variation and 
improved the fit of the model, significantly reducing the -2log-likelihood (deviance). 
There was some evidence of non-linearity in the pattern of dispensing rates over time 
and quadratic models were fitted to improve the fit. The goodness of fit of the 
models was assessed by analysis of the residuals and from the change in deviance. 
Significance of the trend was assessed initially using the standardised regression 
coefficients, z=slope/standard error (SE), which are approximately normally 
distributed.  
 
Initial estimates were obtained by using the restricted iterative generalized least 
squares (RIGLS) estimation procedure. Final parameters were estimated using 
Markov Chain Monte Carlo (MCMC) methods to give less biased estimates and also 
to derive confidence intervals for non-symmetrical distributions. The Raftery-Lewis 
diagnostic Nhat was used to estimate the length of Markov chain required to estimate 
the 2.5% and 97.5% quantiles to a given accuracy (Raftery & Lewis 1992). 
 
All multilevel modelling was performed using MLwiN version 2.10 and all other 
analyses using SPSS version 16.0.  
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5.4 Results 
For the analyses, the total number of dispensed items of antibiotics was defined as 
the sum of the items of the following antibiotics most commonly used for the 
treatment of RTIs: phenoxymethylpenicillin (penicillin), broad-spectrum penicillins 
(BSPs), penicillinase-resistant penicillins (flucloxacillin), cephalosporins, 
tetracyclines, macrolides, trimethoprim and quinolones.  
 
5.4.1 Antibiotic dispensing in Wales: 1996 to 2006 (quarterly data) 
Antibiotic dispensing data from 426 UTS practices were available for analysis with 
complete data for 40 quarters. These practices covered 2,802,319 (94.5%) of the 
Welsh population (2,965,900 in 2006). A total of 20,813,964 antibiotic items were 
dispensed over this ten year period (April 1996-March 2006). Of the antibiotics 
analysed, BSPs were most commonly dispensed and accounted for 43% of total 
dispensed antibiotics, followed by macrolides and cephalosporins, which accounted 
for 13% and 10% respectively (Figure 5.4). 
 
Figure 5.4 Dispensing by antibiotic group as a proportion of total antibiotics 
 
 
5.4.1.1 Annual trends in Wales 
There was a marked decline in the dispensing of total antibiotic items over the 
period. Dispensing was at its highest in Wales in 1996 (April 1996 to March 1997), 
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with a dispensing rate of 958 items per 1,000 practice population (pp) per annum 
(Figure 5.5). A marked decline was observed between 1997 and 1998, with a 12% 
decrease in dispensing rates (from 925 to 812 pp per annum). Thereafter, antibiotic 
dispensing declined until 2004, reaching a low of 676 items per 1,000 pp (a decrease 
of 29% from 1996). In 2005, rates increased slightly to 680 items per 1,000 pp. 
Figure 5.6 shows the breakdown of total antibiotics by antibiotic group (sub-section). 
 
Figure 5.5 Dispensed antibiotic items rates in primary care in Wales per 1,000 
practice population, by study year 1996 to 2005 
 
 
Figure 5.6 Stacked bar-chart of dispensing rates in primary care in Wales per 1,000 
practice population, by antibiotic group and study year 1996 to 2005 
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Figure 5.7 shows the year upon year percentage rates of change. For example, a 
negative rate of change, such as -5.28% for BSPs in 1997-96, indicates a decrease in 
dispensing between the study years 1996 (April 1996 to March 1997) and 1997 
(April 1997 to March 1998). Dispensing for most antibiotics decreased over time, 
with the largest reductions seen between 1997 and 1998. The exception to this was 
the dispensing of penicillinase-resistant penicillin (flucloxacillin) which increased 
annually, though the rate of increase reduced over time. Of interest is 
phenoxymethylpenicillin (penicillin) which increased between 2004 (April 2004 to 
March 2005) and 2005 (April 2005 to March 2006) after a continuous decrease in 
dispensing for most of the previous years.  
 
Figure 5.7 Annual percentage change in antibiotic items dispensed in primary care in 
Wales per 1,000 practice population by antibiotic group 1996 to 2005 
 
 
Negative change indicates a decrease in rates between years 
Positive change indicates an increase in rates between years 
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5.4.1.2 Quarterly trends in Wales 
Figure 5.8a to f show the quarterly trends by antibiotic groups as well as total 
antibiotic dispensing in Wales (the vertical scales differ by antibiotic group so 
comparing patterns is meaningful). The decrease in total antibiotic dispensing over 
the 10 year time period can be seen with the greatest decline in primary care 
dispensing of antibiotics taking place in the earlier period (between 1996 and 2000). 
Although the overall rate was significantly decreasing over time with a slope  
β=-7.60 per annum (95% confidence interval (CI) =-9.04 to -6.20, p<0.001) and the 
variation explained by a single-level linear regression model after adjusting for 
seasonality was high (87%), the trend in total antibiotic dispensing appeared to be 
non-linear. For most antibiotic groups, the rate of dispensed antibiotics decreased 
over time; the exception was flucloxacillin, which increased (Figure 5.8d). After an 
initial decrease, trimethoprim increased from 2001 onwards. Most trends were non-
linear, with a greater decline in dispensing at the beginning of the period; there was 
little overall change for tetracyclines and quinolones. 
 
Seasonality is evident in total antibiotic dispensing and in most groups. Generally 
dispensing rates peaked during the winter quarters (quarters 4 and 1: October to 
December and January to March respectively) and were lower in quarters 2 and 3 
(April to June and July to September). There was also some indication that 
seasonality became less pronounced through the study period. Again the exception to 
this was flucloxacillin where the reverse was true, with dispensing rates peaking in 
quarter 3 (July to September). 
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Figure 5.8 Number of antibiotic items dispensed per quarter in primary care in 
Wales per 1,000 practice population, by antibiotic group, 1996 to 2005 
 
a. Total antibiotics  
 
b. BSPs  
 
 
c. Macrolides and Tetracyclines 
 
 
d. Flucloxacillin and Quinolones 
 
 
e. Penicillin and Cephalosporins 
 
 
f. Trimethoprim 
 
NB: Vertical scales differ by antibiotic group 
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There was indication of curvature in total antibiotic dispensing over time with a steep 
decline and a plateau thereafter, with a hint of an upward rise at the winter months of 
2005-06 even after adjusting for seasonality. This trend may therefore be better 
described using a quadratic model (Figure 5.9).  
 
Figure 5.9 Total antibiotic dispensing per quarter per 1,000 pp, with fitted linear and 
quadratic models 
 
 
The fitted quadratic model, after adjusting for seasonality, explained approximately 
93% of the variation in antibiotic dispensing rate and the estimate of the quadratic 
term was positive (β=0.07, 95% CI=0.04 to 0.09) indicating a positive curvature. A 
plot of the residuals against time for both the linear and quadratic model suggests a 
poorer fit to the data in the earlier period (Figure 5.10). However, the residuals in the 
linear case showed a clearer pattern than in the quadratic case. 
 
Figure 5.10 Residual plots (actual antibiotic dispensing rates – predicted rates from 
fitted model) for linear and quadratic models 
a. Linear model 
 
b. Quadratic model 
 
NB. The closer the residuals are to zero, the better the fit of the model 
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5.4.1.3 General Practice variation: the two-level model 
Analysing antibiotic dispensing rates at the all-Wales level is of importance as it 
gives a general picture of dispensing over time. However, it does not take into 
account variations in dispensing data at a general practice level; multilevel modelling 
overcomes this. Full details of the modelling used are shown for total antibiotic 
dispensing only; results for the each of the antibiotic groups are summarised later in 
this chapter. A two-level repeated measures linear regression model with random 
intercept and slopes, for total antibiotic dispensing rates, adjusting for seasonality, 
gave a mean slope (β1) of -2.09 (SE=0.08) (per 1,000 pp per quarter), indicating a 
general decrease in rates over time (Figure 5.11). However, the standard deviation 
(SD) of the practices’ slopes (σu1) of 1.57 (= 2.476 ) implies substantial variation, 
since assuming normality, 5% of the practices have slopes more than two SDs from 
the overall mean.  
 
Figure 5.11 MLwiN output for two-level repeated measures linear model for total 
antibiotic dispensing rates (estimated by RIGLS method) 
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Between-practice variation reduced over time with those with the highest dispensing 
in 1996 reducing the most. For total antibiotic dispensing, the interquartile rate fell 
from 366.15 per 1,000 pp in 1996 to 211.41 per 1,000 pp in 2005 (Figure 5.12). 
 
Figure 5.12 Box-whisker plot of total antibiotic dispensing rates in 1996 and 2005 
 
There was also more variation due to inter-practice differences (σu0=67.83) than 
intra-practice differences (σe0=24.06), with 89% of the total variation due to inter-
practice differences (otherwise known as the intra-class correlation). The model also 
shows that quarters 2 and 3 have lower dispensing rates than quarter 1 (the reference 
category). Comparing the results from the 2-level model (with random slopes) to 
those from a single-level model (fixed slope model), the mean of the random slopes 
was very similar to the slope in the fixed slope model (Table 5.2). However, the 
results showed that in the single-level model the standard errors are underestimated, 
leading to an overstatement of significance. 
 
After deriving initial estimates from the RIGLS method, MCMC methods were used 
to fit the model.  After running the default of 5,000 iterations, the run length required 
to accurately estimate β1 was between 25,350 and 38,358, based on the Raftery-
Lewis statistic. However, after re-running the Markov chain for 40,000 iterations, the 
Raftery-Lewis statistic increased to 57,000 although estimates seemed stable and the 
run was not extended (Figure 5.13). 
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Table 5.2 Comparison of parameter estimates (SE) from the single- and two-level 
repeated measures linear model for total antibiotic dispensing rates (estimated by 
RIGLS method) 
 
Parameter Parameter estimate (SE) 
 Single-level model Two-level model 
Intercept (β0)  266.97 (1.17) 267.14 (3.28) 
Slope (β1) -2.09 (0.04) -2.10 (0.08) 
Quarter 2 -46.21 (1.20) -46.21 (0.52) 
Quarter 3 -55.53 (1.20) -55.53 (0.52) 
Quarter 4 -5.35 (1.20) -5.35 (0.52) 
Between practice slope variance (σu02) Not applicable 2.50 (0.18) 
Between practice intercept variance 
(σu12) 
Not applicable 4636.75 (318.64) 
Within practice variance (σe02) 3049.67 (33.03) 578.81 (6.40) 
 
Figure 5.13 Diagnostics for the slope parameter β1 for total antibiotic dispensing 
rates (after 40,000 iterations) 
 
 
 
The 95% confidence interval (CI) for the slope β1 was -2.25 to -1.95, which was 
highly significant. This slope equated to an annual decrease of about 8.4 items per 
1,000 practice population per annum, around 0.9% of the annual total. 
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Figure 5.14 MLwiN output for two-level repeated measures linear model for total  
antibiotic dispensing rates (estimated by MCMC methods) 
 
 
 
Figure 5.15 shows the predicted values from the fitted model for each of the 426 
UTS general practices. Almost all of the practices decreased their dispensing rates 
over time. Although the dispensing trends of individual practices are hard to see, 
anomalies can be identified. For example, one practice (highlighted in red) had a 
high intercept and a steep negative slope, and another practice (highlighted in green) 
had a lower intercept and a positive slope. Therefore, conclusions based on the whole 
dataset did not necessarily hold at individual practice level.  
 
Figure 5.15 Fitted total antibiotic dispensing rates from the fitted two-level model by 
general practices 
 
 
 
A histogram of the individual practices’ slopes shows that most have decreased their 
dispensing over time but a few had also increased (Figure 5.16). 
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Figure 5.16 Histogram of the practices slopes from the fitted two-level model for 
total antibiotic dispensing rates 
 
 
 
The two highlighted practices in Figure 5.15 are also highlighted in the caterpillar 
plots in Figure 5.17. These plots display the ranks of the 426 practices against their 
raw residuals ( 1.96SD); the top plot is for the intercept and the lower plot for the 
slope or trend. The top plot shows the variation in practices’ intercepts which 
corresponded to the dispensing rate in quarter 1 of 1996, the period immediately 
before the study period. 
 
Figure 5.17 Caterpillar plots: practice-level residuals for total antibiotic dispensing 
rates ( 1.96SD) vs. rank  
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Practices with an intercept residual greater than zero had a larger intercept than the 
average intercept of 267.92 items per 1,000 pp while those with a residual less than 
zero had an intercept lower than average. The lower plot essentially shows 
departures, at practice-level, from the average slope, that is the rate of change of 
dispensing. The overall average trend was -2.095; practices with a residual greater 
than 2.095 had an overall upward trend. The practice highlighted in red displayed a 
higher than average intercept, although it is not the practice with the highest, and the 
steepest decreasing slope. Alternatively, the practice highlighted in green had a slope 
residual greater than 2.095 and so had an increasing slope (as was seen in Figure 
5.15), but had a lower than average intercept. A scatter plot of these residuals show 
that practices with the highest intercepts tended to decrease their dispensing the most 
(Figure 5.18). This negative correlation between the slopes and intercept (shown by 
the covariance term of -85.94 in Figure 5.14) might reflect the fact that practices with 
the highest dispensing initially have more scope for reduction. 
 
Figure 5.18 Practice-level standardised residuals for total antibiotic dispensing rates: 
slope vs. intercept 
 
 
 
As previously seen, it was difficult to graphically show the variation in trends for 
each of the 426 individual general practices. Therefore, for illustration, the ten 
practices within Anglesey Local Health Board (LHB) in North Wales and the 21 
practices within Neath Port Talbot LHB in South Wales were examined in depth 
(Figure 5.19a and b). In the latter figure, one practice can be seen to reduce their 
dispensing a great amount over time, with a high intercept and a steep slope.  
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Figure 5.19 Actual and fitted total antibiotic dispensing rates over time: 
a. for practices in Anglesey Local Health Board 
 
 
 
 
b. for practices in Neath Port Talbot Local Health Board 
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5.4.1.4 Local Health Board variation: the three-level model 
As trends in dispensing rates varied substantially between practices, variation may 
also have been present at the LHB level, of which 22 existed in Wales until 2009. A 
three-level model, incorporating variation between LHBs, between practices and 
within practices, showed that whilst variation due to inter-practice differences had 
reduced, there was still nearly eight times as much variability due to inter-practice 
differences (within LHBs) (SD=σu0=64.05) as there was between LHBs 
(SD=σv0=26.31) (Figure 5.20).  However, a total of 13% of variation was explained 
by inter-LHB differences which should not be disregarded and will therefore be 
taken into account in further models.  
 
Figure 5.20 MLwiN output for three-level repeated measures linear regression 
model for total antibiotic dispensing rates (estimated by MCMC methods) 
 
 
 
 
LHB 
Practice 
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A plot of the fitted model (Figure 5.21) by LHB showed that whilst there was wide 
variation in total antibiotic dispensing rates at the beginning of the time period in 
1996, they converged over the eleven year period. As with practices, the LHB level 
residuals (slope and intercept) were negatively correlated indicating that the LHBs 
with the highest initial dispensing reduced their dispensing the most (Figure 5.22). 
 
Figure 5.21 Fitted total antibiotic dispensing rates from the fitted three-level model 
by Local Health Board 
 
 
 
Figure 5.22 Local Health Board-level standardised residual plot for total antibiotic 
dispensing rates: slope vs. intercept 
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Figure 5.23 shows caterpillar plots at the LHB level; the top plot shows each LHB’s 
residual (± 1.96SD), that is the LHB’s departure from the average intercept (β0), and 
the bottom plot shows each LHB’s departure from the overall slope (β1). Three LHBs 
(Merthyr in red/Rhondda in blue/ Caerphilly in black) all had significantly higher (at 
the 5% level) total antibiotic dispensing rates than the intercept (β0 =267.27 items 
dispensed per 1,000 pp). These three LHBs also had the steepest decline in rates over 
time with negative slopes significantly different from the average slope (β1=-2.07).  
 
Figure 5.23 Caterpillar plots: Local Health Board-level residuals for total antibiotic 
dispensing rates ( 1.96SD) vs. rank 
 
 
 
5.4.1.5 The quadratic model 
As was seen in Figure 5.10, including a quadratic term increased the goodness of fit 
of the model. The results from a three-level model incorporating a quadratic term for 
time (centred on zero to prevent correlation with the time variable), and random 
effects at both the LHB and practice level are shown in Figure 5.24. The likelihood 
statistic (-2LL) decreased by 3366.7, demonstrating that a quadratic time term 
improved the model. The model showed a positive average quadratic term (β5=0.07) 
which indicated either a flattening of the downward trend or an upward curvature. 
Whilst there was considerable variation in this term between practices 
(SD=σu5=0.063), there was a small amount of between LHB variation 
(SD=σv5=0.014).  
 
Chapter 5 
98 
Figure 5.24 MLwiN output for three-level repeated measures quadratic model for 
total antibiotic dispensing rates (estimated by MCMC methods)  
 
 
 
The fitted model in Figure 5.25 shows the variation in intercepts, slopes and 
curvature for each of the LHBs. It shows the initial large variation in antibiotic 
dispensing, the early rapid decrease and also the flattening out and converging of 
rates. These differences are highlighted even more in the caterpillar plot (Figure 
5.26). The LHB highlighted in red can be seen to have the highest initial dispensing 
rates and the steepest decline. From the third plot, it can be seen that none of the 
LHBs differ significantly from the overall quadratic term (β5 =0.07). 
 
Figure 5.25 Fitted total antibiotic dispensing rates from the fitted three-level model 
by Local Health Board 
 
 
 
 
LHB 
Practice 
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Figure 5.26 Caterpillar plot: Local Health Board-level residuals for total antibiotic 
dispensing rates ( 1.9SD) vs. rank  
 
 
 
5.4.1.6 Dispensing trends by antibiotic group 
Three-level quadratic models were run for each of the antibiotic groups (Table 5.3). 
For some of the antibiotics, the variations in the quadratic term (β5) at the LHB were 
small and including it as a random term improved the goodness of fit of the model by 
an insignificant amount. In these cases, the quadratic time coefficients were fixed at 
the LHB level. As already noted, BSPs had the highest dispensing rate of all the 
antibiotic groups (β0=121.88), and quinolones the least (β0=9.18). For the majority of 
antibiotics, the average slope (β1) was negative indicating a decrease in rates over 
time; flucloxacillin however, significantly increased over the study period (β1=0.50 
per 1,000 pp, p<0.001). Dispensing of trimethoprim did not change significantly over 
time (β1=-0.01, p=0.317). Again, for the majority of antibiotics the models showed a 
significant positive average quadratic term (β5); the exception was flucloxacillin for 
which β5 was negative (β5=-0.003, p<0.001) indicating a flattening out or a 
downward curve. Although on average flucloxacillin dispensing increased over time, 
many practices actually decreased their dispensing (Figure 5.27). In particular, one 
practice had a very high intercept (highlighted in red), with around 65 items per 
1,000 pp (compared to the average of 11.83 per 1,000 pp) and had the steepest 
decline and a greater downwards curvature to the trend. 
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Figure 5.27 Caterpillar plots: practice-level residuals of flucloxacillin dispensing 
rates ( 1.96SD) vs. rank  
 
 
 
The percentage of variation in antibiotic dispensing attributable to practice 
differences was greater than those due to LHB differences and within-practice 
differences (differences in dispensing over time) for all antibiotic groups, with ICCs 
of over 72% (Table 5.4). The variation due to LHB differences ranged from 3% in 
tetracycline dispensing to 19% in BSP dispensing. The highest between practice 
variation was seen in dispensing of cephalosporins (85%) and the smallest seen in 
BSPs (72%).
  
Table 5.3 Parameter estimates for quarterly antibiotic dispensing rates per 1,000 pp, by antibiotic group (estimated by MCMC methods) 
 
 Parameter estimates p-value Median (25
th 
to 75
th
 quartile) dispensing 
rates per 1,000 pp per annum 
Antibiotic Intercept 
(SE
i) β0 
Time (slope) 
(SE) β1 
Time
2
  
(SE) β5 
β1 β5 1996 2005 
Penicillin 19.55  
(0.88) 
-0.20 
(0.02) 
0.007 
(0.001) 
<0.001 <0.001 
76.78 
(50.96 to 102.32) 
49.52 
(35.29 to 63.86) 
Flucloxacillin 11.83 
(0.54) 
0.12  
(0.01) 
-0.003 
(0.001) 
<0.001 <0.001 
45.84  
(30.22 to 62.20) 
66.55 
(53.06 to 82.50) 
BSPs 121.88  
(4.22) 
-1.21 
(0.09) 
0.040  
(0.002) 
<0.001 <0.001 
429.72 
(344.49 to 565.91) 
271.76 
(233.64 to 342.56) 
Trimethoprim 15.32 
(0.64) 
-0.01  
(0.02) 
0.002 
(0.001) 
0.617 0.046 
57.97 
(45.46 to 72.10) 
61.88 
(51.72 to 71.04) 
Macrolides 34.46  
(0.13) 
-0.31  
(0.03) 
0.008 
(0.001) 
<0.001 <0.001 
112.48 
(80.39 to 150.97) 
77.19 
(61.28 to 98.80) 
Cephalosporins 29.92 
(1.52) 
-0.39 
 (0.03) 
0.009 
(0.001) 
<0.001 <0.001 
89.30 
(57.63 to 143.28) 
48.96 
(28.97 to 75.62) 
Quinolones 9.18 
(0.46) 
-0.07  
(0.01) 
-0.0001 
(0.001) 
<0.001 0.920 
27.70 
(16.66 to 41.86) 
21.64 
(13.83 to 29.96) 
Tetracyclines 16.27  
(0.49) 
-0.07  
(0.01) 
0.005 
(0.001) 
<0.001 <0.001 
56.34 
(42.78 to 79.24) 
50.80 
(39.49 to 64.62) 
Total antibiotics 259.46 
(6.70) 
-2.15  
(0.17) 
0.07 
(0.004) 
<0.001 <0.001 
951.12 
(797.47 to 1163.62) 
675.91 
(578.50 to 789.91) 
i
 SE= Standard error 
 
 
 
 
1
0
0
 
  
Table 5.4 Local Health Board and practice variation for dispensing rates by antibiotic group (estimated by MCMC methods) 
 
 Between LHB variation Between practice variation Within 
practice  
ICC
i
 (LHB/ 
Practice) 
Antibiotic Intercept 
σ2v0 
Time 
σ2v1 
Time
2 
σ2v5 
Intercept 
σ2u0 
Time 
σ2u1 
Time
2 
 σ2v5 
variation 
σ2e0 
 
Penicillin 9.55 0.004 NA 130.99 0.10 <0.001 17.55 6%/ 83% 
Flucloxacillin 3.29 0.002 <0.001 54.00 0.03 <0.001 8.93 5%/ 82% 
BSPs 405.07 0.15 NA 1523.49 0.84 0.002 182.82 19%/ 72% 
Trimethoprim 6.18 0.003 NA 50.75 0.04 <0.001 8.18 9%/ 78% 
Macrolides 25.05 0.02 <0.001 215.12 0.14 <0.001 30.22 9%/ 80% 
Cephalosporins 28.37 NA NA 383.78 0.27 <0.001 38.49 6%/ 85% 
Quinolones 2.34 <0.001 <0.001 34.75 0.02 <0.001 6.33 5%/ 80% 
Tetracyclines 2.08 0.001 NA 52.71 0.05 <0.001 9.77 3%/ 82% 
Total antibiotics 693.52 0.47 0.0002 4046.73 2.23 0.004 449.42 13%/ 78% 
i
 ICC = Intra-class correlation  
NA = Not applicable. Linear and/or quadratic terms were fixed at LHB level since variation between LHBs did not significantly improve the model.
1
0
1
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5.4.1.7 Factors associated with antibiotic dispensing 
It has been ascertained that general practices’ antibiotic dispensing rates vary over 
time, in both their intercepts and their slopes, but are there any practice level factors 
that can explain any further variation? Table 5.5 shows the raw mean and standard 
deviations for total antibiotic dispensing by practice characteristics. Three-level 
linear repeated measures models (allowing for random slopes and intercepts) were 
fitted to examine the univariate associations between total antibiotic dispensing and 
these characteristics, after adjusting for time, time squared, seasonality and the 
interaction between time and practice characteristics. 
 
Practices that were run multi-handed had lower total antibiotic dispensing rates than 
practices run single-handed (β=38.89, SE=8.47), although over time the difference 
between the two categories decreased (β=0.713, SE=0.194) when an interaction term 
between time and status was fitted (Figure 5.28). Multi-handed practices had an 
average of 4.41 GPs (SD=1.89). Practices from more deprived areas were also more 
likely to have higher initial dispensing rates and again the dispensing rates between 
the groups converged over time (Figure 5.29). Practices with older GPs and a higher 
proportion of male GPs were more likely to dispense more.  
 
Table 5.5 Univariate associations between total antibiotic dispensing rate per 1,000 
and practice characteristics (estimated by RIGLS methods) 
 
Practice characteristics Mean 
dispensing rate 
(sd) (2000-2006)  
Parameter 
estimates (SE)
i
 
p-value 
Deprivation quintile    
Least deprived =1 179.21 (47.55) Ref  
2 187.10 (55.06) 10.19 (9.90) 0.303 
3 204.90 (63.48) 30.25 (10.07) 0.003 
4 206.71 (65.65) 39.84 (10.23) <0.001 
Most deprived =5 209.07 (79.45) 51.28 (10.28) <0.001 
Single-handed status    
Single-handed 219.12 (78.71) Ref  
Multi-handed 193.17 (60.26) -38.89 (8.47) <0.001 
GP gender % Male - 0.48 (0.13) <0.001 
Average GP age (year) - 2.84 (0.48) <0.001 
i
 adjusted for time, quadratic time term, seasonality and the interaction between time and practice 
characteristics 
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Figure 5.28 Fitted total antibiotic dispensing rates from the fitted three-level model 
by single/multi-handed status of the practice 
 
 
 
Figure 5.29 Fitted total antibiotic dispensing rates from the fitted three-level model 
by practice deprivation quintile 
 
 
 
When all of the practice characteristics were included in a multivariate model, 
(adjusted for time, the quadratic time term, seasonality, and the interaction between 
time and the practice characteristic), the average age of the GP, single-handed status 
and deprivation remained independently associated with total antibiotic dispensing 
(Table 5.6). The addition of practice characteristics to the model only explained a 
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further 6% of total variation in antibiotic dispensing due to practice differences (from 
78% to 84%) and reduced the variation due to LHB differences by 10% (from 17% 
to 7%). 
 
For separate antibiotic groups, the results of each multivariate analysis are shown in 
Table 5.6. Factors associated with dispensing of these antibiotics varied by antibiotic 
group. Similarly to total antibiotic dispensing, higher levels of broad-spectrum 
penicillin dispensing were independently associated with practices with older GPs, 
practices from a more deprived area and those that were run single-handedly.  
 
Phenoxymethylpenicillin and flucloxacillin dispensing were initially negatively 
associated with the average age of the GP (β=-0.175, SE=0.047, p<0.001 and β =-
0.102, SE=0.040, p=0.011 respectively), with practices run by younger GPs 
dispensing a higher quantity of these antibiotics. In both cases, after adjusting for the 
interaction term (time x age), both of these associations became non-significant  
(β=-0.109, SE=0.082 and β=-0.035, SE=0.048 respectively). No practice 
characteristics were associated with the dispensing of cephalosporins and tetracylines 
after adjusting for time and seasonality.  
 
Higher levels of macrolide and trimethoprim dispensing were both associated with 
practices from more deprived areas. Higher levels of trimethoprim dispensing were 
additionally independently associated with practices that were run single-handedly 
(β=-3.607, SE=0.991, p<0.001). Higher levels of macrolide dispensing were 
associated with practices with older GPs (β =0.312, SE=0.108, p=0.004) and higher 
levels of quinolones associated with practices with a higher proportion of male GPs 
(β=0.038, SE=0.011, p=0.001) 
 
  
Table 5.6 Multivariate analysis for antibiotic dispensing and practice characteristics by antibiotic group (estimated by MCMC methods) 
(parameter estimates β (SE) for significant practice characteristics shown onlyi) 
 
Antibiotic Average age 
of GP per 
practice 
Proportion 
of male GPs 
per practice 
Multi-handed 
practice
ii
 
Deprivation quintile of practice
iii
 
    2 3 4 5 (most 
deprived) 
Penicillin 
 
- - - - - - - 
Flucloxacillin 
 
- - - - - - - 
BSPs 1.95 
(0.33) 
- -10.39  
(5.51) 
6.70  
(5.66) 
15.16 
(5.71) 
25.43 
(5.52) 
29.93 
(6.52) 
Trimethoprim - - -3.61  
(0.99) 
0.43  
(1.00) 
1.03 
(1.13) 
2.04 
(1.05) 
3.16  
(1.31) 
Macrolides 0.32 
(0.11) 
- - 3.07  
(2.20) 
5.71 
(2.15) 
5.76 
(2.01) 
7.66  
(2.28) 
Cephalosporins 
 
- - - - - - - 
Quinolones - 0.04 
(0.01) 
- - - - - 
Tetracyclines - - - - - - - 
 
Total antibiotics 
 
1.88 
(0.46) 
- -22.00 
(9.81) 
11.94 
(9.62) 
24.86 
(12.25) 
36.59 
(9.32) 
42.25 
(10.14) 
i
 Adjusted for time, quadratic time term, seasonality and the interaction between time and practice characteristics 
ii
 Single-handed practice= reference category 
iii
 Deprivation quintile 1 (least deprived) = reference category
1
0
5
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5.4.2 Antibiotic dispensing in Wales: 2000 to 2006 (monthly data) 
This section examines the variation in monthly antibiotic dispensing rates by detailed 
type of antibiotic in our nine groups of antibiotic. In total, 454 practices with a total 
population of 2,902,920 patients (97.9% of the Welsh population) were available for 
analysis and a total of 12,032,078 antibiotic items were dispensed over the six year 
period (April 2000-March 2006). 
 
Figure 5.30 illustrates the most commonly dispensed antibiotics in Welsh general 
practices between 2000 and 2006, by antibiotic type (BNF chemical group). 
Amoxicillin was the most commonly dispensed antibiotic in primary care, 
accounting for 34.0% (N=4,093,204) and 9.6% (N=1,151,542) of total dispensing 
was accounted for by erythromycin. Other antibiotics included minocycline 
hydrochloride (1.4%), lymecycline (0.6%) and cefradine (0.6%).    
 
Figure 5.30 Most commonly dispensed antibiotics in primary care from 2000 to 
2006 by antibiotic type (BNF chemical) 
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5.4.2.1 Monthly time trends in antibiotic dispensing  
Figures 5.31a to e show detailed trends in monthly dispensing for antibiotics 
specifically used in the treatment of RTIs. As before, there was significant seasonal 
variation, with peak antibiotic use over the winter months (mainly December) and 
troughs in August. Flucloxacillin is the exception, where the highest rate of 
dispensing was in the summer months and lowest in the winter months (Figure 5.32).  
 
Figure 5.31 Monthly trends in antibiotic dispensing rates by antibiotic group: April 
2000 to March 2006 
a. Total antibiotics and BSPs 
 
b. Macrolides and Tetracyclines 
 
c. Flucloxacillin and Quinolones 
 
d. Cephalosporins and Penicillin 
 
e. Trimethoprim 
 
 
 
NB: Scales differ by antibiotic group 
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Figure 5.32 Monthly trends for flucloxacillin dispensing rates compared to 
remaining penicillins 
 
 
Three-level (LHB, practice, time) quadratic models were fitted for each of the 
antibiotic groups. For some antibiotics, the variations in the linear and quadratic 
terms (β1 and β5) at the LHB level were small and improved the goodness of fit of 
the model by an insignificant amount. In these cases, both the linear and quadratic 
term were fixed at the LHB level. Parameter estimates were converted from monthly 
change to quarterly change to aid comparison with Table 5.3.  
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Table 5.7 Parameter estimates for quarterly antibiotic dispensing rates per 1,000 pp, by antibiotic group: 2000 to 2006 (estimated by MCMC 
methods)  
 
 Parameter estimates p-value Median (25
th
 to 75
th
 quartile)  
dispensing rates per 1,000 pp per annum 
Antibiotic Intercept 
(SE) β0 
Time (slope) 
(SE) β1 
Time
2
  
(SE) β5 
β1 β 5 2000 2005 
Penicillin 16.08  
(0.42) 
-0.034 
(0.004) 
0.0006 
(0.0015) 
<0.001 0.689 54  
(34.56 to 76.32) 
47.28  
(31.68 to 65.04) 
Flucloxacillin 14.04  
(0.39) 
0.026 
(0.005) 
-0.0005 
(0.0001) 
<0.001 <0.001 56.64  
(39.6 to 75.96) 
65.28  
(48.6 to 83.4) 
BSPs 96.96  
(2.94) 
-0.177  
(0.026) 
0.0017 
(0.0008) 
<0.001 0.027 299.16  
224.76 to 405.24) 
269.28 
(201.36 to 353.76) 
Trimethoprim 14.67  
(0.51) 
0.009  
(0.007) 
0.000006 
(0.0002) 
0.171 0.972 55.56  
(42.6 to 70.32) 
61.2  
(48.36 to 73.92) 
Macrolides 26.85  
(0.72) 
-0.047 
(0.012) 
0.000015 
(0.0003) 
<0.001 0.957 82.68  
(57.72 to 116.52) 
75.24 
(54.36 to 102.36) 
Cephalosporins 21.18  
(1.20) 
-0.072 
(0.009) 
0.0007 
(0.0003) 
<0.001 0.013 60.24 
(32.88 to 99.72) 
47.04  
(26.04 to 78.00) 
Quinolones 7.59  
(0.48) 
-0.023 
(0.02) 
0.0002 
(0.0001) 
<0.001 0.065 24  
(14.16 to 38.16)  
20.28  
(12.6 to 31.32) 
Tetracyclines 14.49  
(0.48) 
0.002 
(0.005) 
-0.000005 
(0.0002) 
0.669 0.978 48  
(35.16 to 63.72) 
50.28  
(37.44 to 66.00) 
Total antibiotics 212.41  
(3.07) 
-0.315  
(0.032) 
0.0026 
(0.0009) 
<0.001 0.003 726.24  
(593.16 to 894.12) 
663.96 
(550.32 to 803.16) 
  
1
0
9
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In this period (2000 to 2006), dispensing for most antibiotics was still decreasing 
over time albeit at a much lower rate than before, the exception being flucloxacillin, 
with an annual rate of increase of 0.10 per 1,000 pp (p<0.001). Tetracyclines and 
trimethoprim were more stable from April 2000 onwards (Annual rate β1=0.008, 
p=0.669 and β1=0.003, p=0.171 respectively).  
 
The quadratic term was significant only for flucloxacillin, cephalosporins and broad-
spectrum penicillins (p<0.001, 0.013 and 0.027 respectively), indicating either a 
flattening of the downward trend or an upward curvature. The variation in trends of 
cephalosporin dispensing rates from the fitted model by LHB, are shown in Figure 
5.33. In particular, one LHB’s dispensing of cephalosporins was much higher with 
some indication of a slight increase over time. 
 
Figure 5.33 Fitted cephalosporin dispensing rates by Local Health Board 
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5.4.3 Antibiotic dispensing in Wales for children: 2000 to 2006 
In total, 454 practices with a total population of 501,191 patients aged 0-15 were 
available for analysis and a total of 2,336,852 liquid oral antibiotic items (taken as a 
proxy for dispensing in children) were dispensed over the six year period (April 
2000-March 2006), making up 18% of all antibiotic items dispensed. When total 
antibiotic dispensing was broken down into antibiotic group (BNF sub-section), 
liquid oral broad-spectrum penicillins were most frequently dispensed in primary 
care (Figure 5.34). 
 
Figure 5.34 Most commonly dispensed liquid oral antibiotics in primary care from 
2000 to 2006 by antibiotic group 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 5.35a to f show the trends in dispensing for antibiotics in children more 
commonly used in the treatment of RTIs, with similar trends and seasonality to 
dispensed antibiotics for all ages. For most antibiotics, dispensing significantly 
decreased over time after April 2000 (Table 5.8). The exception to these decreasing 
trends was tetracyclines which increased, with an annual rate of change of 0.01 per 
1,000 <15 years practice population (pp) (p=0.041).  
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Figure 5.35 Monthly trends in antibiotic dispensing in children by antibiotic group 
 
a. Total antibiotics and BSPs 
 
b. Flucloxacillin and Trimethoprim 
 
c. Cephalosporins 
 
d. Penicillin 
 
e. Macrolides 
 
f. Tetracyclines and Quinolones 
 
NB: Vertical scales differ by antibiotic group 
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Table 5.8 Parameter estimates for quarterly antibiotic dispensing rates for children per 1,000 pp, by antibiotic group: 2000 to 2006 
(estimated by MCMC methods) 
 
 Parameter estimates p-value Median (25
th
 to 75
th
 quartile) dispensing 
rates per 1,000 pp per annum 
Antibiotic Intercept 
(SE) β0 
Time (slope) 
(SE) β1 
Time
2
  
(SE) β5 
β1 β5 2000 2005 
Penicillin 25.23  
(0.81) 
-0.039 
(0.009) 
-0.0005 
(0.0004) 
<0.001 0.194 72.6  
(33.36 to 122.16) 
65.04 
(31.8 to 105.96) 
Flucloxacillin 14.31 
(0.54) 
-0.028 
(0.006) 
-0.0003 
(0.0002) 
<0.001 0.112 55.32  
(29.16 to 85.2) 
51.84 
(27.96 to 78.24) 
BSPs 148.53  
(5.19) 
-0.440 
(0.056) 
0.0043 
(0.0015) 
<0.001 0.004 437.52  
(286.92 to 639.48) 
346.92  
(228.12 to 522.24) 
Trimethoprim 10.77  
(0.51) 
-0.035 
(0.006) 
0.0002 
(0.0002) 
<0.001 0.281 34.08  
(16.92 to 56.28) 
29.76  
(13.8 to 46.68) 
Macrolides 37.68  
(1.17) 
-0.140 
(0.014) 
0.0009 
(0.0004) 
<0.001 0.053 98.64  
(51.48 to 169.2) 
71.52  
(37.44 to 124.8) 
Cephalosporins 22.74  
(1.65) 
-0.122 
(0.012) 
0.0009 
(0.0004) 
<0.001 0.013 47.16  
(18.84 to 97.2) 
27.48 
 (6.84 to 62.16) 
Quinolones 0.93 
(0.09) 
-0.005 
(0.001) 
0.0001 
(0.00004) 
0.001 0.124 0.00 
(0.00 to 0.00) 
0.00 
(0.00 to 0.00) 
Tetracyclines 0.15  
(0.03) 
0.0014 
(0.0007) 
0.00004 
(0.00003) 
0.041 0.111 0.00 
(0.00 to 0.00) 
0.00 
(0.00 to 0.00) 
Total antibiotics 259.56  
(6.69) 
-0.801 
(0.090) 
0.0055 
(0.0024) 
<0.001 0.026 825.36 
(600.96 to 1120.56) 
659.4  
(480 to 896.88) 
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The quadratic terms for most of the antibiotic groups were not significant. The 
exceptions were broad-spectrum penicillins (BSPs), cephalosporins and total 
antibiotics (due to the high proportion of BSPs), which had positive parameters for 
the quadratic term (p=0.004, 0.013 and 0.026 respectively). This upwards curvature 
might represent a slowing down of the rate of decrease or even an increase. Figure 
5.36 shows the variation in total antibiotic dispensing over time by LHB.  
 
Figure 5.36 Fitted total antibiotic dispensing rates for children from the fitted three-
level model by Local Health Board 
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5.4.4 Comparisons in trends between the two datasets: antibiotic 
dispensing for all ages vs. children, 2000 to 2006 
For the period 2000 to 2006, in comparison with trends in antibiotic dispensing for 
all ages, the trends in dispensing for children were very similar, with decreases over 
time for phenoxymethylpenicillin, BSPs, macrolides, cephalosporins, and quinolones 
(Table 5.9). Relating the annual rate of change figures to dispensing in 2000, an 
annual fall in BSPs of 0.71 per annum (dispensing for all ages) and of 1.76 per 
annum (dispensing for children) can be equated to around 0.24% and 0.40% of BSP 
dispensing in 2000. The exception to these decreasing trends was flucloxacillin 
which increased significantly over time for all formulations (all ages) but 
significantly decreased for liquid oral formulations (children). Trimethoprim 
dispensing was stable for all formulations but a decrease was seen for liquid oral 
formulations (annual rate of change of 0.04 and -0.14 per 1,000 pp respectively).  
 
Again, variation due to inter-practice differences was greater than inter-LHB (where 
three-level models were used) and intra-practice differences for all antibiotic groups 
(Table 5.10). Variation in quinolones and tetracycline dispensing was very low 
mainly due to low dispensing rates in children (75
th
 quartile=0). The variation due to 
inter-LHB differences ranged from 2% in flucloxacillin and trimethoprim dispensing 
to 10% in BSPs dispensing. The dispensing of cephalosporins had the highest 
between practice variation (70%) and quinolones the least variation (40%). Intra-
practice variation was higher in children than for all ages but this could be accounted 
for by smaller numbers of dispensed antibiotics resulting in less stable rates. 
  
Table 5.9 Comparison of annual rate of change (per 1,000 pp) between antibiotics dispensed for all ages and for children: 2000 to 2006 
 
 All ages Children All ages Children 
Antibiotic 
Annual rate 
of change p-value 
Annual rate 
of change
i
 p-value 
Median (25
th
 to 75
th
 quartile) 
Dispensing rates in 2000 per 1,000 pp 
Penicillin -0.14 <0.001 -0.16 <0.001 54.00 
(34.56 to 76.32) 
72.60 
(33.36 to 122.16) 
Flucloxacillin 0.11 <0.001 -0.11 <0.001 56.64  
(39.60 to 75.96) 
55.32  
(29.16 to 85.20) 
BSPs -0.71 <0.001 -1.76 <0.001 299.16  
(224.76 to 405.24) 
437.52  
(286.92 to 639.48) 
Trimethoprim 0.04 0.171 -0.14 <0.001 55.56  
(42.60 to 70.32) 
34.08  
(16.92 to 56.28) 
Macrolides -0.19 <0.001 -0.56 <0.001 82.68  
(57.72 to 116.52) 
98.64  
(51.48 to 169.20) 
Cephalosporins -0.29 <0.001 -0.49 <0.001 60.24 
(32.88 to 99.72) 
47.16  
(18.84 to 97.20) 
Quinolones -0.09 <0.001 -0.02 0.001 24.00 
(14.16 to 38.16)  
0.00 
(0.00 to 0.00) 
Tetracyclines 0.01 0.669 0.01 0.041 48.00 
(35.16 to 63.72) 
0.00 
(0.00 to 0.00) 
Total antibiotics -1.25 <0.001 -3.20 <0.001 726.24  
(593.16 to 894.12) 
825.36 
(600.96 to 1120.56) 
i
 practice population <15 years of age 
 
 
 
 
 
1
1
6
 
  
Table 5.10 Local Health Board and practice variation for dispensing rates in children by antibiotic groups (estimated by MCMC 
methods) 
 
 Between LHB variation Between practice variation Within 
practice 
variation σ2e0 
ICC
i
 
(LHB/ 
Practice) 
 Intercept 
σ2v0 
Time 
σ2v1 
Time
2
 
σ2v5 
Intercept 
σ2u0 
Time 
σ2u1 
Time
2
 
σ2v5 
Penicillin 1.19 NA NA 25.44 0.003 <0.001 16.99 3%/58% 
Flucloxacillin 0.30 NA NA 8.93 0.002 <0.001 8.81 2%/50% 
BSPs 51.17 0.005 <0.001 297.56 0.039 <0.001 171.10 10%/57% 
Trimethoprim 0.28 NA NA 7.40 0.002 <0.001 4.86 2%/59% 
Macrolides (2-level 
model) 
- - - 67.50 0.001 <0.001 27.45 - / 71% 
Cephalosporins 5.78 NA NA 52.20 0.007 <0.001 16.36 8%/70% 
Quinolones 0.0015 NA NA 0.30 <0.001 <0.001 0.46 0.2%/40% 
Tetracyclines 0.0013 NA NA 0.02 <0.001 <0.001 0.13 1%/13% 
Total antibiotics 73.11 0.01 <0.001 695.10 0.10 <0.001 331.01 7%/63% 
i
 ICC = Intra-class correlation;  
NA = Not applicable. Time and time squared terms are fixed at LHB level since variation between LHBs is not significant.
1
1
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5.4.5 Broad- vs. narrow-spectrum antibiotic dispensing 
In total, 7,803,395 (64.9%) and 4,228,683 (35.1%) broad- and narrow-spectrum 
antibiotics respectively were dispensed over the six-year period for the 454 practices 
(total of 12,032,078 antibiotics dispensed for antibiotics most commonly used in 
RTIs). Figure 5.37 shows the monthly trend in dispensing of these two categories of 
antibiotics. It appears that narrow-spectrum dispensing is static over the period, with 
some indication of a decline in dispensing of broad-spectrum antibiotics, although 
seasonality is the same as for total antibiotics (mainly because of the high proportion 
of broad-spectrum penicillins) with peaks in dispensing over the winter period and 
troughs during summer.  
 
Figure 5.37 Broad- and narrow-spectrum antibiotic dispensing monthly rates over 
time (April 2000 to March 2006) 
 
 
Of the broad-spectrum antibiotics, 52.5% (n=4,093,204) were made up of 
amoxicillin, 10.3% (800,424) of co-amoxiclav and 8.9% (696,402) of Cefalexin  
(Figure 5.38). For narrow spectrum antibiotics, 27% (1,151,542) were made up of 
erythromycin, 26% of flucloxacillin (1,101,852), 24% of trimethoprim (1,028,770) 
and 22% of penicillin (benzathinepenicillin, penicillin V and G and procaine 
benzylpenicillin) (946,518). 
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Figure 5.38. Monthly broad-spectrum antibiotic dispensing per 1,000 practice 
population (April 2000 to March 2006) 
 
 
 
A three-level quadratic repeated measures model for broad-spectrum antibiotic 
dispensing, after adjusting for seasonality, showed an average slope (β1) of -0.37 
(SE=0.044, 95% CI=-0.46 to -0.28) (per 1,000 practice population per quarter) 
indicating a general decrease in rates over time. The model showed a significant 
quadratic term (β5=0.00096 (0.00041)) indicating an upwards curvature. This term 
varied significantly between LHBs and practices (SD=σv5=0.0014 and σu5=0.004 
respectively). Figure 5.39 shows the variation in practices’ dispensing of broad-
spectrum antibiotics. In particular, one practice had a very high intercept (highlighted 
in red) and had the steepest decline over time and a greater upwards curvature to the 
trend.  
 
Figure 5.40 shows the fitted values from the fitted model for each of the 22 LHBs. 
There was more than three times as much variability due to inter-practice differences 
within LHBs (SD=σu0=0.141) as there was between LHBs (SD=σv0=0.042).  
However, a total of 7% of variation was explained by inter-LHB differences and 
73% by inter-practice variation. 
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Figure 5.39 Caterpillar plots: practice-level residuals for broad-spectrum dispensing 
rates ( 1.96SD) vs. rank 
 
 
 
Figure 5.40 Fitted monthly broad-spectrum dispensing rates by Local Health Board 
 
  
 
A three-level linear repeated measures model for narrow-spectrum antibiotic 
dispensing after adjusting for seasonality, showed an average slope (β1) of -0.048 
(SE=0.028, 95% CI=-0.104 to 0.001) (per 1,000 practice population per quarter) 
indicating no general trend in rates. The model showed a non-significant quadratic 
term (β5=-0.00013 (0.00018)).  
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Although there was no general trend in overall dispensing of narrow-spectrum 
antibiotics there was still considerable variation between LHBs (SD=σv1=0.027) and 
practices (SD=σu1=0.079).  The variation in practice dispensing can be seen in the 
caterpillar plot with great variation in the practices’ slopes with one practice initially 
with a high rate of dispensing and reducing the most over time (Figure 5.41). Figure 
5.42 shows the predicted dispensing rates from the fitted model by LHBs.  
 
Figure 5.41 Caterpillar plots: practice-level residuals for narrow-spectrum antibiotic 
dispensing rates ( 1.96SD) vs. rank 
 
 
 
Figure 5.42 Fitted monthly narrow-spectrum dispensing rates from the fitted three-
level model by Local Health Board  
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5.5 Discussion 
5.5.1 Main findings 
In Wales, overall levels of community dispensing of antibiotics most commonly used 
to treat RTIs decreased between the study years 1996 and 2005, with the majority of 
the reduction seen in the early period. There was some indication that this reduction 
had slowed down in later years. These reductions were observed across all antibiotic 
groups with the exception of flucloxacillin, which increased over the study period. 
Seasonality was also evident with peaks in the winter periods (October to March) and 
troughs in the summer period, again with the exception of flucloxacillin where 
dispensing rates peaked in quarter 3 (July-September). General trends in the 
dispensing of broad-spectrum antibiotics were also downwards but there were no 
notable trends in the dispensing of narrow-spectrum antibiotics.  
 
Trends and seasonality in the dispensing of liquid oral antibiotics (a proxy for 
dispensing in children) between 2000 and 2006 were similar to those seen for 
dispensing for the whole practice population. However, the dispensing of liquid oral 
flucloxacillin significantly decreased over time, and there was a notable decline in 
the dispensing of trimethoprim. The low dispensing of both tetracyclines and 
quinolones can be explained by these antibiotics being contraindicated in children as 
they may result in permanent staining of teeth and increase the risk of damage to the 
musculoskeletal system. 
 
To date this is one of the few studies to examine the variation in trends of antibiotic 
dispensing between general practices and on such a large scale and over a large 
period of time. Although conclusions based on the whole dataset identified that 
overall antibiotic dispensing had decreased over time (by 29% between 1996 and 
2005), this did not happen for all practices (although it did for most). Antibiotic 
dispensing not only varied greatly between practices, with a six-fold difference in 
total antibiotic dispensing rates at the extremes in 2005, but also over time with some 
practices increasing their dispensing over the study period. Practices with the highest 
dispensing rates initially, tended to decrease their dispensing the most, perhaps as 
there was more scope for reduction. There was also some variation between the 22 
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Local Health Boards (LHBs), but they all decreased their dispensing over time.  
Practices with older general practitioners (GPs) and who served more deprived areas 
were more likely to dispense a higher number of overall antibiotics, after adjusting 
for any effect of time and seasonality. 
 
5.5.2 Strengths and weaknesses of the study 
The data that informs this analysis was obtained from the PSU in NWIS and is 
equivalent to the Prescription Pricing Authority’s Prescribing Analysis and Cost 
Tabulation (PACT) data in England. This data covers all practices that existed in 
Wales between 1996 and 2006; therefore a large amount of detailed antibiotic 
dispensing data was analysed at a general practice level over time. In this study, 
monthly and quarterly trends were examined for specific antibiotics most commonly 
used in the treatment of respiratory tract infections, and also for a proxy for 
children’s prescribing, namely liquid oral antibiotics. Broad and narrow spectrum 
antibiotic dispensing was also examined but it was not possible to examine whether 
prescriptions were appropriate, since no information was available on the dosage, 
duration or indication of the drug or on patient characteristics. 
 
Although data for a total of 533 practices were initially obtained, 107 practices were 
excluded on the basis of having unstable or small practice populations for the study 
period. The remaining 426 practices covered a total of 94.5% (2,802,319 of the 
Welsh population). It is likely that the excluded practices either stopped practising or 
merged with another practice, and due to anonymisation their data could not be 
combined. Including these practices would have introduced bias into the dispensing 
data. Excluded practices were more likely to be single-handed and from a more 
deprived area and this possible bias should be taken into consideration when 
interpreting the results.  
 
Many of the weaknesses of the dispensing data have already been covered in Chapter 
4. Results are for overall antibiotic dispensing for all indications, not specifically for 
RTIs, dispensing data do not represent consumption, and there is possible 
underestimation of out-of-hours dispensing. Caution should be taken regarding the 
interpretation of dispensing of liquid oral antibiotics as a proxy for dispensing in 
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children. Since amoxicillin liquid formulations are amongst the most frequently 
supplied medicines via out-of-hours services, they are likely to be under-represented 
in this dataset (Sharland 2007). Additionally, liquid oral antibiotics are not 
exclusively dispensed to children, but could also be given to elderly patients. 
 
Whilst the variation in antibiotic dispensing attributable to differences in practices 
and LHBs (which accounted for over 78% of total variation) was examined, the 
practice demographics studied did not account for a great amount of the variation, 
only explaining an additional 2% of total antibiotic dispensing. Other factors 
therefore need to be examined as possible drivers of dispensing in primary care, 
perhaps not accounted for by variation in practice demographic factors or even 
variation in the incidence of infections. For example, it has been suggested that the 
widening of prescribing to healthcare professionals such as pharmacists or nurses 
could increase dispensing (Wise 2007). This data has been on dispensing at a 
practice level and does not take into account variation in antibiotic dispensing by 
individual GPs; this cannot be measured accurately at present.  
 
The freezing (in April 2001) and reduction (between October 2004 and April 2007) 
(and then abolition) of prescribing charges in Wales could also have had an effect on 
dispensing rates in Wales. However, a recent study found a modest increase in 
dispensing rates (4%) between October 2003 and March 2008 for the most 
commonly dispensed antibiotics (combination of amoxicillin 250mg and 500mg, 
erythromycin 250mg, phenoxymethylpenicillin 250mg and trimethoprim 200mg) 
when compared to those in North East England (decrease of 7%) (Cohen et al. 2010).   
 
5.5.3 Comparisons with existing literature 
5.5.3.1 Antibiotic prescribing for all ages 
The trends in antibiotic dispensing found in this study are similar to those found  in 
other UK data studies (Majeed et al. 2004; Sharland et al. 2005; Fleming et al. 2005; 
Prescribing Review 2006). These studies suggested that most of the decrease in 
overall antibiotic prescribing in primary care had occurred by 2000 when rates 
reached a plateau. Data from the English Prescription Cost Analysis database 
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(covering all prescriptions dispensed in the community in England) demonstrate that 
antibiotic use fell from 44.5 million items in 1996 to 32.8 million in 2004, but had 
since risen slightly to 33.3 million in 2006. Trends in antibiotic prescribing in Wales 
between 1999 and 2005 in a primary care or outpatient setting saw a reduction in 
prescriptions per 1,000 inhabitants per day (PIDs) whereas an increase was found in 
DDD per 1,000 inhabitants per day (DIDs) (Davey et al. 2008). They also found a 
significant reduction in PIDs for England and Scotland. This suggests that the 
initiatives introduced in the late 1990s to reduce antibiotic usage did have an impact 
on antibiotic prescribing in primary care. Little evidence was found to support the 
finding of an increase of flucloxacillin dispensing but one study by Hayward et al. 
(2008) detected a 1.8-fold increase in flucloxacillin prescription rates between 1991 
and 2006.  
 
Decreases in antibiotic prescriptions in an outpatient setting have also been observed 
for the US (McCaig et al. 2003; Roumie et al. 2005), and Australia where 
prescribing rates fell by 24.3% between 1990 and 2002 (Pan et al. 2006). In Europe, 
data from the European Surveillance of Antimicrobial Consumption (ESAC) project 
provided DID data on outpatient antibiotic use in 34 European countries. A paper by 
Ferech et al. (2006) specifically examined trends between 1997 and 2003 and found 
that DIDs had increased in many of the countries, including Denmark, Portugal and 
Greece. Patterns varied between countries; in some countries such as France and 
Belgium, DIDs initially increased then decreased while in the UK and Spain DIDs 
initially decreased and then increased.  
 
A number of studies have found that broad spectrum antibiotics and macrolides are 
prescribed most frequently in primary care in the UK (Ferech et al. 2006; Petersen 
and Hayward 2007) and specifically in acute cough (Butler et al. 2009). Meropol et 
al. (2009) found a decrease between 1990 and 2004 in the UK in both the overall 
antibiotic prescribing rate, and also that of broad spectrum antibiotics in acute RTIs, 
in the UK, a finding supported by US data (Vanderweil et al. 2007).  
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5.5.3.2  Antibiotic prescribing in children 
A study by Sharland (2007), using data from the Prescription Pricing Authority's 
database (covering dispensing of antibiotic prescriptions from general practices in 
England), used the same proxy of oral liquid formulations of antibacterials for 
antibiotics in children. They similarly showed a decline in dispensed items between 
1996 and 2004 and evidence of a slight increase after 2004 (an increase of 0.92%  of 
items was seen between 2004 and 2005). Using monthly dispensed items, the same 
seasonal variations were seen with peaks in the winter months and troughs in the 
summer months for most antibiotics, with the exception of flucloxacillin where the 
reverse occurred. Another study using data from 125 UK practices (using data from 
the IMS Mediplus UK database), examined community antibiotic prescribing in 0-18 
year olds between 1996 and 2006. They found that total antibiotic prescribing rates 
fell by 24% between 1996 and 2000 but rates were then stable until 2002 (Thompson 
et al. 2009b). Thereafter, prescribing increased by 10% between 2003 and 2006 with 
the increase being more marked between 2005 and 2006. More recently, Schneider-
Lindner et al. (2011) observed a turn in the tide of antibiotic prescribing rates in 
children with rates at their lowest at 419 per 1000 pp in 2000 increasing to 568 per 
1000 pp in 2007 (comparable to those in the late 1990s).  
 
Similar reductions in dispensing for children have also been observed in the USA 
(McCaig et al. 2002; Finkelstein et al. 2003), and Europe (Otters et al. 2004). 
Sharland et al. (2007) additionally identified from Unicef data that certain European 
countries (France, Germany, Italy, Spain, UK) and the USA had decreased their 
prescribing for children between 2002/03 and 2004/05. Seasonal variation was 
observed in all countries with prescribing lowest in September and highest in March 
for all countries except the UK.  
 
5.5.3.3 Practice characteristics 
A number of studies have also found that certain prescriber and practice 
characteristics are associated with higher prescribing of antibiotics. The findings that 
male and older GPs were more likely to prescribe antibiotics were supported by 
several other studies from the UK, Europe, Canada and Taiwan (Gill and Roalfe 
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2001; Arnold et al. 2005; Fischer et al. 2005; Huang et al. 2005; Wang et al. 2009). 
Single-handed practices (Unsworth and Walley 2001; Wilson et al. 1999) and 
practices in areas of greater deprivation (Wilson et al. 1999; Unsworth and Walley 
2001; Curtis and Marriott 2008) also had higher prescribing rates. Practices serving 
populations with greater morbidity were more likely to have higher prescribing of all 
drugs, not only antibiotics (Omar et al. 2008; Wang et al. 2009). Otters et al. (2004) 
found that a prescription of a broad spectrum antibiotic was associated with single-
handed practices and having a high proportion of children registered with the 
practice. 
  
5.5.4 Implications of findings for clinical practice and future research 
Analysis of this general practice level dispensing data has been crucial to our 
understanding of antibiotic dispensing in primary care, how dispensing of specific 
types of antibiotics varies over time and between practices and health administrative 
area. Despite a number of limitations, this seems the best way to estimate reliably 
antibiotic prescribing in primary care, both at a macro level for the whole population 
of Wales and also at a micro level for LHBs and general practices.  
 
Surveillance of national trends in antibiotic dispensing is important, firstly at a 
national level in order to monitor overall trends in antibiotic use and secondly to 
identify any problems or unexpected increases. For example, there is now a 
possibility that the reduction in antibiotic dispensing in Wales that was seen in the 
late 1990s was not sustained and that dispensing has since increased for most 
antibiotics (Welsh Antimicrobial Resistance Programme Surveillance Unit 2009). 
The factors associated with this change in dispensing patterns in general practice 
need to be investigated; are GPs not following guidelines or are patients asking for 
antibiotics more frequently or is the change due to diagnostic uncertainty?   
 
Almost all practices decreased their dispensing rates over the study period but there 
were variations in decreases with those with the highest initial dispensing reducing 
the most. It would be useful to investigate these practices to determine whether they 
were reducing all antibiotic dispensing or just inappropriate dispensing and if there is 
a blanket reduction then could reducing prescribing have negative as well as positive 
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effects?  
 
Trends could also be used to assess the effectiveness of interventions designed to 
change the dispensing of antibiotics such as nurse prescribing, devolution or free 
prescriptions (in Wales). At an LHB and practice level, it allows feedback and 
reflection on GP prescribing behaviours and gives an indication on whether 
guidelines are being followed. A study recently completed in Wales revealed to 
general practices both their own dispensing rates and also those of their LHB and of 
Wales; practices generally reported this as being really useful (Simpson et al. 2009). 
Even without the indication of why the antibiotic was given, guidance could be 
provided. For example, amoxicillin was the antibiotic most frequently prescribed by 
GPs. These are usually used in the treatment of RTIs, and for most patients are not 
useful. Guidance could then be given as to who would benefit the most from them. 
This could improve the quality of prescribing in general practice and would allow 
LHBs to introduce appropriate prescribing initiatives. Identifying certain practice 
characteristics that are associated with higher prescribing would give further insight 
into who should be targeted (for example single-handed practices).  
 
The monitoring of antibiotic dispensing data by type of antibiotic is of great 
importance and should be continued, with timely reports which are relevant to both 
practitioners and policy makers. As already stated, one flaw of the dispensing data 
used here is that no patient level data exists and thus no patient identifiers such as 
age and gender. Thus analysis can only be done at an aggregate level over the 
practice population. Plans are underway to record this information, (using an 
identifier such as the NHS number) from scripts and this would allow more detailed 
analysis, including further research into antibiotic dispensing in children instead of 
using liquid oral antibiotics as a proxy. This would also allow the linkage via an 
NHS number of dispensing data to other datasets, such as antibiotic resistance, at an 
individual level. Further questions of interest include why dispensing of liquid oral 
tetracyclines is increasing and the reason for the increase in flucloxacillin over time 
for all ages. Flucloxacillin syrups, given mainly to children, could not explain the 
increase and one theory is that flucloxacillin may be being used as a substitute for co-
amoxiclav.  
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Reassuringly, the direction of the trends in dispensing in the sample of Welsh 
practices in Chapter 4 mirrors that found at the all-Wales level, albeit a stronger 
decreasing trend due to the different study periods. It would therefore be of interest 
to examine the complications arising in primary care to see whether the same trends 
are found for all practices in Wales. Unfortunately, the General Practice Morbidity 
Database (GPMD) will not have 100% coverage in Wales and currently no other 
source routinely collects primary care data for all practices in Wales. Hospital 
admissions data however is a plausible source although it would be preferable to 
capture complications arising in both primary and secondary care.  
  
5.6 Introduction to Welsh resistance data 
In summary, this chapter uniquely used a large dataset at the general practice level 
and robust methods to examine recent trends in antibiotic dispensing in Wales. 
Overall dispensing decreased over time but at what consequence to antibiotic 
resistance and adverse outcomes such as hospital admissions of serious infections? 
Chapter 6 will explore patterns of antibiotic resistance in Wales by examining trends 
in community resistance rates for common respiratory pathogens using retrospective 
Welsh antibiotic resistance data. Chapter 7 will similarly examine the changing 
patterns of hospital admissions of complications arising from respiratory tract 
infections using Welsh hospital admissions data. 
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Chapter 6  Antibiotic resistance in Wales 
6.1 Introduction 
Chapter 5 showed that a decrease in community dispensing of antibiotics most 
commonly used to treat respiratory tract infections (RTIs) decreased between April 
1996 and April 2006, with the majority of the reduction seen in the early period. 
With the increasing problems of antimicrobial resistance, and the mounting evidence 
of a link with antibiotic usage, it is important to ascertain whether this decrease in 
dispensing has had a beneficial effect on antibiotic resistance in the community with 
the hope that reducing usage of antibiotics might lead to a reduction in resistance 
rates.  
 
The merging of regional microbiology laboratory databases in Wales has provided 
the opportunity of using routinely collected antibiotic resistance data for community 
and hospital infections with bacteria, parasites and viruses. The main intention of this 
dataset is for surveillance purposes, directed to monitor trends and changes in 
resistance in both community and hospital infections, and to provide current 
estimates of local resistance in infection. The aim of this chapter was not only to 
identify such trends in community resistance rates for common respiratory pathogens 
using retrospective Welsh antibiotic resistance data but to examine variations in these 
rates and trends at a local level (laboratory and general practice). The relation 
between resistance and antibiotic dispensing and any practice characteristics that 
may influence rates was also examined. In particular associations between changes in 
antibiotic dispensing and changes in antibiotic resistance at a general-practice level 
were investigated.  
 
6.2 Methods 
6.2.1 Microbiology data  
Community microbiology data are derived from samples taken from patients 
presenting to a GP with a suspected infection. Patient samples and swabs are then 
sent to microbiology laboratories to identify an isolate (a sample with an identified 
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bacterium) and this is tested for resistance to a set of antibiotics. Routine 
antimicrobial resistance testing data is sent by laboratories to the Laboratory 
Information Management Systems (LIMS). All data stored on LIMS is extracted by 
each regional DataStore system and the information mapped into a pseudo-
anonymised standardized format. This data is then held by the National Public Health 
Service for Wales (NPHS) for extraction and analysis.  
 
For this study microbiological data for samples submitted by Welsh general practices 
were obtained from 11 of the 18 Welsh and Welsh border Public Health and NHS 
laboratories. Those included were Aberystwyth, Bangor, Bridgend, Cardiff, 
Carmarthen, Haverfordwest, Newport, Pontypridd, Rhyl, Swansea and Wrexham. 
Data from the practices served by the Merthyr and Abergavenny laboratories, and the 
practices served by the Welsh border laboratories (Chester, Hereford and 
Shrewsbury) were not included in this report as their LIMS were not linked to 
DataStore at the time of data extraction.  
 
The dataset covered nine years of retrospective data (January 1998 to December 
2006) and were based on samples sent by GPs for testing. Results were extracted for 
those identified with the following identified organisms: Haemophilus influenzae (H. 
influenzae), Streptococcus pneumoniae (S. pneumoniae) and Streptococcus pyogenes 
(S. pyogenes). These organisms were examined since they are the main cause of 
bacterial RTIs; H. influenzae and S. pneumoniae both cause lower RTIs such as 
bronchitis and pneumonia, and also acute sinusitis and ear infections, whereas S. 
pyogenes are the causative bacteria in many upper RTIs such as sore throats, 
although they are known to also cause skin infections such as impetigo.  
 
For each isolate reported as either H. influenzae, S. pneumoniae or S. pyogenes, the 
following information was obtained: patient identification number, age and gender of 
patient, address from where the sample was sent, laboratory, date of specimen 
collection, specimen type and site (e.g. ear, throat swab), specimen number, and 
result (R=Resistant, S=Sensitive, I =Intermediate, blank =not tested) for certain 
antibiotics (Table 6.1). The set of antibiotics for which resistance is tested varies 
between laboratories and isolates but those shown in the table are tested in the great 
majority of these isolates.  
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Table 6.1 Antibiotics commonly tested for resistance by organism 
 
 Organism 
Antibiotic S. pneumoniae S. pyogenes H. influenzae 
Amoxicillin    
Augmentin/ Co-amoxiclav    
Cefuroxime    
Erythromycin    
Penicillin    
Quinolones
i
    
Tetracyclines    
i 
All laboratories test Ciprofloxacin except for Bangor and Wrexham which test Norfloxacin and 
Levofloxacin respectively 
 
The proportion of results recorded as intermediate, varied between 0.1 and 0.5%, 
according to the organism and the antibiotic tested for resistance; these were 
included in the resistant category as is common practice (Heginbothom et al. 2004). 
The recording of specimen site varied by laboratory, with some laboratories 
providing more detail than others (e.g. Left nostril as opposed to Ear, Nose and 
Throat (ENT)). In order for the data to be pooled across laboratories, specimens were 
re-coded to the following groups: ENT, Sputum, Eye, Genital and Other (including 
blood, skin, wounds and urine).  
 
6.2.2 Allocating practice codes to individual samples 
For each isolate an address of the establishment that submitted the sample for testing 
was provided. Since our main aim was to examine the association between antibiotic 
consumption and resistance at a general practice level, all general practices from this 
list of establishments (n=811) were identified. Locations identified as non-general 
practice establishments (occupational health units, child health centres, family 
planning clinics, prisons, rehabilitation day units, private clinics and also English 
practices sending samples to Welsh laboratories), were excluded (n=75).  
 
Each unique location was manually allocated a unique identification W-code (see 
section 3.2.3) using a variety of methods such as the NHS directory 
(http://www.wales.nhs.uk/directory.cfm) and internet searching tools (e.g. Google). 
W-codes were then cross-checked with a limited list of practice W-codes, names and 
addresses provided by DataStore. Any location names that could not reliably be 
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linked to a W-code were excluded (n=14). Codes were combined where the location 
name of the practice could not allow a definite match to a W-code, to ensure that it 
could be linked appropriately to dispensing data. For example, codes for practices 
were combined and data pooled if branches of a main practice merged over the time 
period or several separate practices within one area were indistinguishable and could 
not be reliably allocated to a unique W-code. This could happen due to ambiguous 
location names and because GPs were not identified by name. 
 
In total, 722 general practice names were allocated a W-code. This number is greater 
than the number of actual practices in Wales because of duplication. Some practice 
names were recorded differently by the same laboratory or samples from practices 
were sent to more than one laboratory and they recorded the practice name 
differently. For example, samples from a practice in Llanrwst, North Wales were sent 
to the Bangor, Rhyl and Cardiff laboratories and the location name recorded 
differently in each, therefore creating three different location names for allocation of 
a W-code. After these were resolved, there were 437 unique general practices from 
which data could be analysed. Again, to ensure complete practice anonymity the 
Prescribing Services Unit (PSU) based in NWIS allocated the encrypted practice 
codes to replace the identifiable W-codes; all identifiable datasets were subsequent 
destroyed. This allowed the linkage of this data to antibiotic dispensing data and 
practice characteristics (practice deprivation quintile (based on Townsend scores), 
single-handed status of the practice (single or multi-handed)) used in Chapter 5. 
 
Some practices (n=62 out of 438) were served by many laboratories (13 served by 
three laboratories, 49 served by two laboratories). In all cases, one laboratory 
processed the majority of samples with the other laboratories handling a small 
number. For the purpose of analysis, the laboratory in which the majority of samples 
were tested was used to ensure that practices were nested exclusively within one 
laboratory.   
 
6.2.3 Data quality within laboratories 
In the past, many methods of antimicrobial resistance testing were used in different 
laboratories leading to variations in laboratory definition of resistance (for example, 
Chapter 6 
135 
differing minimum inhibitory concentration (MIC) breakpoints). In 1998, the 
standardized method of disc testing was published by the British Society for 
Antimicrobial Chemotherapy (BSAC) Working Party on Susceptibility Testing, with 
a further update in 2000 (British Society for Antimicrobial Chemotherapy Working 
Party 2008). In the late 1990s, uptake of this method was variable in Wales but 
general adoption of the method was seen from early 2001. By 2006, all but one 
laboratory used a combination of the BSAC standardized disc sensitivity method, 
and the BD Phoenix automated AST/ID system. All laboratories involved 
participated in the United Kingdom National External Quality Assessment Service 
scheme and attained acceptable results. With laboratories using the same method 
there is a real opportunity to combine data, so that levels of resistance in Wales can 
be examined, and changes detected. 
 
6.2.4 Potential bias in resistance data 
Although methodologies used within Welsh microbiology laboratories have become 
standardised, allowing resistance rates to be compared, bias may still occur in 
resistance data. Two papers have been published on potential biasing/confounding 
effects in resistance data and their impact on regional surveillance of resistance 
(Magee et al. 2004; Heginbothom et al. 2004). They found that as a result of certain 
laboratory practices, published resistance rates may be biased and not representative 
of the true rate in the population. Therefore, to ensure appropriate interpretation of 
results, three potential sources of bias were examined: (1) variation between 
practices regarding submission of microbiological samples to laboratories for 
analysis; (2) variations in resistance testing by laboratories and (3) repeated testing of 
isolates with the same resistance pattern from the same patient. 
 
6.2.4.1 Selective sampling at practice level 
A GP will not submit for testing a sample from every patient presenting with a 
suspected bacterial infection or with symptoms of an infection. Routine resistance 
data only covers community infections in samples that are actually submitted by GPs 
and these are bound to be selective in some way.  For example, one study found that 
GPs were more likely to send in urine samples from children and also from patients 
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who were young, pregnant or had recurrent infections/symptoms (Hillier et al. 2006). 
It is also believed that specimen submission strategies are biased, with more 
specimens submitted from patients with resistant pathogens and thus not responding 
to antibiotic therapy (Magee et al. 2004); if this is the case then there is a potential 
overestimation of true population resistance rates. The effects of bias caused by the 
selective submission of samples could partly be quantified by examining the 
relationship between the practices’ resistance rates (number of resistant samples per 
100 tested isolates) and sampling rates (number of samples per 100 practice 
population). Therefore, sampling data, consisting of the total number of samples sent 
to a laboratory by a practice during the period January 1998 to December 2006, was 
obtained from Datastore for 11 of the 18 Welsh and Welsh border laboratories 
serving Welsh practices. These gave the number of samples sent by the practice per 
month, subdivided by the site the specimen was taken from (ENT, Sputum, Eye, 
Genital and Other) and the laboratory to which it was sent for testing.  
 
If the data do show sampling bias, there may be an association between sampling and 
resistance rates. To investigate this, an annual sampling rate per 100 practice 
population was calculated for each practice based on all samples submitted by the 
practice and the relationship between resistance and sampling was explored. 
 
6.2.4.2 Selective testing at laboratory level 
Selective testing could occur if a laboratory only tested resistance to a certain 
antibiotic against selected subgroups of an organism type. There are many reasons 
why a minority of isolates might have been tested for resistance to a particular 
antibiotic. For example, laboratories may have changed their policy on which 
antibiotics were tested and therefore the proportion of isolates tested may vary over 
time. Laboratories may also be more likely to test isolates if they came from a 
particular site (e.g. isolates from eyes given ‘topical antibiotics’). Selective testing 
could also occur if isolates were tested with specific antibiotics due to lack of 
response to first-line antibiotics or because the antibiotic had been identified as 
having been prescribed to the patient.  
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To identify any possible biases occurring at laboratory level, and to reduce the effect 
of selective testing on the published rates, the proportion of isolates tested against an 
antibiotic by laboratory was chosen as a useful indicator of selective testing (number 
of isolates tested for resistance/total number of isolates submitted for testing x 100).  
For the purposes of this study, if a laboratory had <80% of isolates tested this would 
indicate possible selective testing. Resistance rates were pooled from the laboratories 
deemed as non-selective (≥80% isolates tested) for comparison with the selective 
laboratory resistance rate.  
 
If a laboratory demonstrated possible selective testing for an antibiotic/organism 
combination and had a higher resistance rate than the pooled non-selective laboratory 
estimate, then further investigations were carried out to examine what reasons may 
account for selective testing. Inconsistent patterns were sought in the percentage of 
isolates tested by year of specimen submission (testing due to policy changes), 
specimen group (site-specific testing) and multiple-resistance to other antibiotics 
(second-line testing). For laboratories demonstrating higher resistance rates and 
evidence of selective testing then the relevant data were excluded. 
 
If a laboratory had <80% of isolates tested and had a lower resistance rate than the 
pooled non-selective laboratory estimate, then no further examination was carried out 
and that particular laboratory/organism/antibiotic combination was included for 
analysis. No further analysis was undertaken if a laboratory had <80% of isolates 
tested but only a small number of isolates submitted for testing (<10). 
 
6.2.4.3 Duplicate testing 
Repeat testing occurred if a patient had multiple specimens submitted and tested 
from a single infection episode, possibly because initial treatment failed or because 
the infection resolved slowly despite appropriate therapy. Duplicate isolates were 
defined as multiple isolates of the same organism with the same resistance pattern 
from the same patient and were flagged by Datastore. Matching on resistance pattern 
was carried out using soft matching so resistance did not match if an antibiotic for 
the first isolate was R and the second isolate was S (or vice-versa). They would 
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match however if the resistance combinations were R-I or S-I, and a blank result 
(indicating that it was not tested) would be matched with any other result.  
Duplicates could potentially lead to a biased estimate of the prevalence of resistance 
in a population, although previous work in this area showed that the inclusion of 
repeat isolates made little difference to resistance estimates (Magee et al. 2004). To 
ensure that only new infections were included, duplicates that occurred within 91 
days of the initial isolate were removed from the dataset. The cut-off of 91 days was 
taken to reflect the maximum duration between two samples being part of the same 
infection or organism and this threshold is recommended for distinction of 
continuing from repeat infections for infectious diseases in Wales (Wales Office of 
Research and Development for Health and Social Care Report 2005; Magee et al. 
2004).  
 
6.3 Statistical analysis 
For the purpose of all analyses the following organism/antibiotics were considered 
due to their high level of resistance and/or clinical importance because of usage for 
these infections:  
 H. influenzae and amoxicillin resistance 
 H. influenzae and tetracycline resistance 
 S. pneumoniae and penicillin (including amoxicillin) resistance 
 S. pneumoniae and erythromycin resistance 
 S. pyogenes and erythromycin resistance. 
 
All analyses were restricted to “Up-to-Standard” (UTS) practices as defined in 
Chapter 5 that submitted an isolate. The representativeness of the UTS included 
practices were compared to those practices deemed as not UTS on practice based 
characteristics (e.g. single handed status, age  of GPs, sampling rate) using t-tests, 
Mann Whitney test and  test depending on the type of outcome.  
 
6.3.1 Trends in resistance rates 
Resistance rates (number of resistant isolates / number of isolates tested) and testing 
rates (number of isolates tested / number of isolates submitted) were calculated per 
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annum. A basic single-level linear regression was undertaken initially to establish 
overall trends in resistance rates. Multilevel modelling was then used to ascertain 
trends in resistance rates (using the above organism/resistance combinations). 
6.3.1.1 Logistic regression 
A three-level logistic regression model using the result of testing resistance as a 
binary outcome variable (yijk = 1 if an isolate i in practice j and laboratory k was 
resistant, and 0 if sensitive) was used to account and correct for variation at the level 
of the laboratory, general practice, and individual isolate. The three-level random 
intercept model logit model takes the form: 
 
  ijkjk
ijk
ijk
ijkijk xlogitlogy 10
1



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








  
 
where 
jkkjk uv 0000    
 
The intercept consists of three terms: a fixed component β0 and a laboratory and 
general practice specific component, v0k and u0jk. As before, these are assumed to 
follow Normal distributions with mean zero and variances σ2v0 and σ
2
u0.   
 
For discrete response models, maximum likelihood estimation is computationally 
intensive and therefore quasi-likelihood methods are used (Rasbash et al. Centre for 
Multilevel Modelling, University of Bristol). These procedures use a linearisation 
method based on the Taylor series expansion which transforms a discrete response 
model to a continuous response model. After applying the linearisation, the model is 
then estimated using iterative generalised least squares (IGLS) or reweighted IGLS 
(RIGLS). The transformation to a linear model requires an approximation to be used. 
The types of approximation available in MLwiN are: marginal quasi-likelihood 
(MQL) and predictive (or penalized) quasi-likelihood (PQL). Both of these methods 
can include either 1st order terms or up to 2nd order terms of the Taylor series 
expansion. The 2
nd
 order using a second order penalised quasi-likelihood (2nd order 
PQL) approach is preferred as the default of 1
st
 order marginal quasi-likelihood 
(MQL) can sometimes give crude approximations that are biased downwards 
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especially if level 2 units are small or the response proportion is extreme. For this 
reason we began with the 1st order MQL procedure to obtain starting values for the 
2nd order PQL procedure.  
 
6.3.1.1.1 Interpretation of coefficients 
Given: 
  ijkjk
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1



 









  
Taking exponentials of each side then: 
 
 
 
If x is increased by 1 unit then: 
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This can be interpreted as the multiplicative effect on the odds for a 1-unit increase in 
x. If x is binary then 1

exp can be interpreted as the odds ratio (OR), comparing the 
odds for units with x=1 relative to the odds for units with x=0. Parameter estimates 
and standard errors (SEs) are presented alongside the ORs and 95% confidence 
interval (CIs). 
 
For the multilevel modelling, time was recalculated as study years (from April to 
March) to reflect the study period used by the dispensing data. Therefore the study 
period ran from April 1998 to March 2006, thus covering 8 years (for example April 
1998 to March 1999 is referred to as 1998 for simplicity). The model also included 
the following important individual sample and practice characteristics as explanatory 
variables: age group (0-4, 5-15, 15-64, 65-84, 95+ years) and gender of the person 
from whom the sample was taken, site where the specimen was taken (sputum, ENT, 
eye, genitalia, other), the year the specimen was submitted (study year), practice 
deprivation quintile (based on Townsend scores), single-handed status of the practice 
(single or multi-handed), the average age of GPs and the percentage of male GPs 
ijkjk x
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within a practice, and sampling rate (as described in section 6.2.4.1).  
 
6.3.2 Association between antibiotic dispensing and resistance 
Associations between resistance (using the above organism/resistance combinations) 
and antibiotic dispensing (using broad spectrum penicillin (BSP), beta-lactams, 
macrolides, tetracyclines) were analysed. Lagged dispensing is calculated as the sum 
of items dispensed in the quarter that the isolate was submitted plus the three quarters 
prior to that. As before, a three-level logistic regression model was used and where 
there were significant associations between resistance and lagged antibiotic 
dispensing, significant individual and practice characteristics were also incorporated 
in the model. Interactions between the study year and lagged dispensing were 
modelled to allow for different associations between resistance and lagged 
dispensing in different study years. Again parameter estimates and SEs are presented 
alongside ORs with 95% CIs. The ORs presented show the odds of resistance at the 
75
th
 percentile of the lagged dispensing distribution compared to the 25
th
 percentile.  
 
6.3.3 Duplicate isolates 
Duplicate isolates were excluded from all main analyses but were also compared to 
non-duplicate isolates to explore any differences with regards to resistance, 
dispensing and individual patient and practice characteristics. A three-level logistic 
regression model was fitted with the individual binary outcome (duplicate or not) as 
the outcome and included study year, individual patient, isolate (including resistance) 
and practice characteristics. All significant variables were included in the final 
multivariate model.  
 
6.3.4 Changes in antibiotic dispensing and resistance  
Practices that submitted isolates in both 1998 and 2005 were included in a separate 
analysis to explore the relationship between practice level changes in total antibiotic 
dispensing and changes in antibiotic resistance. Practices were grouped into quartiles 
based on their change in total antibiotic dispensing data between 1998 and 2005. 
Resistance rates for 1998, 2005 and the actual change in rates (with 95% CIs) were 
compared between these quartiles. Additionally practices were also grouped into 
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quartiles based on their separate changes of BSP, tetracycline and macrolide 
dispensing, and these were compared to changes in resistance for appropriate 
isolates. For example, in S. pneumoniae, change in erythromycin resistance was 
compared between quartiles based on the reduction of both total antibiotic and 
macrolide dispensing.  
 
6.3.5 Sensitivity analyses 
Since the main aim of this thesis was to examine RTIs, all models were fitted using 
data on all isolates (from all specimen sites) and separately on isolates from sputum 
samples (taken to determine a chest infection) and swabs taken from ENT regions.  
Statistical analyses were undertaken using SPSS for Windows (version 16.0) and 
MLwiN (version 2.11) after transfer of data as Access and Excel files. 
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6.4 Results 
6.4.1 Microbiology data 
Over the nine year study period (January 1998 to December 2006) the eleven Welsh 
laboratories received 27,614 H. influenzae isolates from 431 practices, 13,307 S. 
pneumoniae isolates from 422 practices and 19,640 S. pyogenes isolates from 423 
practices. These three datasets were restricted to isolate data from practices deemed 
to have reliable populations, previously identified during the quality process of 
dispensing data (section 5.2.4). Although around 65 practices had been excluded 
from each dataset (accounting for 16% of practices), on average only 8% of isolates 
were excluded.  
 
A total of 25,453 H. influenzae isolates remained from 363 UTS practices (covering 
84% of the Welsh population), 12,256 S. pneumoniae isolates from 358 practices and 
17,927 S. pyogenes isolates from 360 practices. Table 6.2 shows the practice 
characteristics for practices included in, and excluded from, the main analyses for H. 
influenzae isolates.  
 
Table 6.2 Practice characteristics for included and excluded practices for H. 
influenzae isolates 
 
 Included 
N=363 
Excluded 
N=68 
Test statistic,  
p-value 
Practice population  
Total (% of Welsh population
i
) 
2,481,342 (84%) 228,060 (8%) - 
Practice population Median 
(25
th
 to 75
th
 percentile) 
6,422  
(4,303 to 8,783) 
4,216  
(2,190 to 6,555) 
MW, p<0.001 
Single-handed N (%) 49/359  
(13.6) 
14/51 
(27.5) 
2=6.54,p=0.011 
Practice deprivation
ii
  
Mean (sd) 
0.12 (1.86) 0.59 (2.14) t=1.57, p=0.116 
Age of GPs (years)  
Mean (sd) 
49.81 (6.37) 49.38 (6.84) t=0.44, p=0.657 
% of male GPs  
Median (25
th 
to 75
th
 percentile) 
66.67  
(50-100) 
62.50  
(50-100) 
MW, p=0.238 
Average sampling per 100 
practice population (98-06) 
Median (25
th 
to 75
th
 percentile)  
18.14  
(12.85 to 23.13) 
13.17  
(2.40 to 22.51) 
MW, 
 p<0.001 
i
 Official estimated Welsh population was 2,965,900 (taken on June 2006) (Welsh Assembly 
Government Aug 2007), 
ii
 Practice deprivation based on Townsend 2001 scores  
All other practice characteristics taken as practice’s current state (June 2007) 
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As found previously, excluded practices were more likely to have been single-
handed and hence have a lower practice population (p=0.011 and p<0.001 
respectively) than included practices. They also did not submit as many samples over 
the total period. Although only results for H. influenzae isolates are displayed, the 
results for both S. pneumoniae and S. pyogenes isolates are similar. Some practices 
were not included in these analyses since they either did not submit any samples to a 
laboratory using Datastore. This will be taken into consideration in the discussion. 
Table 6.3 shows the characteristics of the patients from whom these isolates were 
obtained and at a practice level.  
 
Table 6.3 Characteristics of the patients with H. influenzae, S. pneumoniae and S. 
pyogenes infections 
 
 H. influenzae S. pneumoniae S. pyogenes 
Total isolates submitted  
(number of practices) 
25,453 (363) 12,256 (358) 17,927 (360) 
Average number of isolates 
submitted per annum 
2,822 1,362  
 
1,992 
Average number of isolates 
submitted per annum, range 
by laboratory 
100 to 457 33 to 231 77 to 379 
 
Age group (years) N (%)    
0-4 7,007 (27.7) 5,170 (42.5) 2717 (15.3) 
5-15 918 (3.6) 970 (8.0) 4595 (25.8) 
16-24 494 (2.0) 206 (1.7) 2075 (11.7) 
25-44 2,512 (9.9) 1,113 (9.1) 4643 (26.1) 
45-64 6,971 (27.5) 2,171 (17.8) 2158 (12.1) 
65-84 6,884 (27.2) 2,303 (18.9) 1290 (7.2) 
85+ 528 (2.1) 243 (2.0) 328 (1.8) 
Gender N (%) Male 11,610 (46.4) 5,762 (48.3) 6,072 (34.7) 
Specimen N (%)  
      Sputa 
 
17,081 (67.1) 
 
4,997 (40.8) 
 
150 (0.8) 
ENT 2,187 (8.6) 2,220 (18.1) 7977 (44.5) 
Eye 4,329 (17.0) 3,358 (27.4) 114 (0.6) 
Genitalia 487 (1.9) 160 (1.3) 2528 (14.1) 
Other 1,369 (5.4) 1,521 (12.4) 7158 (39.9) 
Duplicates (≤91 days between 
samples) N (%) 
2,368 (9.3) 964 (7.9) 973 (5.4) 
 
H. influenzae isolates tended to be submitted from older patients (median age 52 
years old) whereas S. pyogenes and S. pneumoniae isolates were submitted from 
younger patients (median ages of 21 and 19 years old respectively). The majority of 
H. influenzae and S. pneumoniae isolates were found in sputum samples whereas S. 
pyogenes isolates were found in ENT sites and the other category (around 35% were 
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taken from wound swabs). The proportion of duplicates identified varied by 
organism; duplicates were excluded from the main analyses. All laboratories 
continuously supplied data over the 9 year period apart from one which contributed 
data only from 2001. 
 
6.4.2 Selective testing at laboratory level  
For the five organism/antibiotic combinations of interest, a minimal amount of 
selective testing (<80% of isolates tested) was seen by laboratories. Where ≥80% of 
isolates were tested by laboratory and year of sample, inter-laboratory variation 
estimates were likely to have been attributed to other effects, e.g. methodology or 
real variation in resistance levels. For H. influenzae isolates, selective testing for 
resistance to tetracycline was practised in one laboratory in 2002 and 2003, resulting 
in the exclusion of 3103 (12.2%) isolates (275 were also duplicates). For S. 
pneumoniae isolates, selective testing of resistance to penicillin was practised in one 
laboratory in 2002 resulting in the exclusion of 168 (1.4%) isolates (13 were also 
duplicates). These isolates were excluded since the percentage of tested samples was 
low and resistance was higher than the overall average. They were excluded from 
any further analyses to avoid potential bias to resistance rates. There was no evidence 
of selective testing in S. pyogenes isolates. The final numbers of submitted isolates 
available for analysis are shown in Table 6.4. 
  
Table 6.4 Summary of testing and resistance incidence (N) and rates (%) by year of isolate - submission for all isolates (excluding 
duplicates and selectivity)  
Organism – 
Antibiotic resistant to  
1998 1999 2000 2001 2002 2003 2004 2005 2006 Total Change
i
 
H. influenzae – 
Amoxicillin 
N isolates 2,447 2,393 2,476 2,643 2,784 2,784 2,525 2,526 2,507 23,085  
N tested  2,328 2,275 2,382 2,511 2,664 2,657 2,412 2,416 2,386 22,031  
N resistant 500 442 515 512 543 479 404 395 460 4,250  
% tested
ii
 95.1 95.1 96.2 95.0 95.7 95.4 95.5 95.6 95.2 95.4 0.1 
% resistant
iii
 21.5 19.4 21.6 20.4 20.4 18.0 16.7 16.3 19.3 19.3 -2.2 
            
H. influenzae – 
Tetracyclines 
N isolates 2,140 2,091 2,146 2,359 2,463 2,462 2,232 2,196 2,168 20,257  
N tested  1,563 1,514 1,506 1,703 1,716 1,596 1,383 1,389 1,093 13,463  
N resistant 39 37 26 26 20 17 14 15 17 211  
% tested 73.0 72.4 70.2 72.2 69.7 64.8 62.0 63.3 50.4 66.5 -22.6 
%resistant 2.5 2.4 1.7 1.5 1.2 1.1 1.0 1.1 1.6 1.6 -0.9 
            
S. pneumoniae – 
Erythromycin 
N isolates 1,224 1,107 1,116 1,259 1,293 1,334 1,260 1,341 1,358 11,292  
N tested  1,071 974 1,029 1,163 1,221 1,256 1,186 1,258 1,296 10,454  
N resistant 81 75 70 80 88 131 103 128 152 908  
% tested 87.5 88.0 92.2 92.4 94.4 94.2 94.1 93.8 95.4 92.6 7.9 
%resistant 7.6 7.7 6.8 6.9 7.2 10.4 8.7 10.2 11.7 8.7 4.1 
            
S. pneumoniae – 
Penicillin 
N isolates 1,224 1,108 1,116 1,259 1,138 1,334 1,260 1,341 1,358 11,138  
N tested  1,178 1,081 1,088 1,225 1,114 1,304 1,220 1,313 1,335 10,858  
N resistant 50 35 28 30 30 47 46 45 51 362  
% tested 96.2 97.6 97.5 97.3 97.9 97.8 96.8 97.9 98.3 97.5 2.1 
%resistant 4.2 3.2 2.6 2.4 2.7 3.6 3.8 3.4 3.8 3.3 -0.4 
            
 S. pyogenes – 
Erythromycin 
N isolates 1,839 1,790 2,093 2,019 1,853 2,068 1,933 1,655 1,704 16,954  
N tested  1,798 1,732 2,047 1,987 1,833 2,047 1,913 1,641 1,680 16,678  
N resistant 72 44 66 92 70 85 75 63 75 642  
% tested 97.8 96.8 97.8 98.4 98.9 99.0 99.0 99.2 98.6 98.4 0.8 
%resistant 4.0 2.5 3.2 4.6 3.8 4.2 3.9 3.8 4.5 3.8 0.5 
i 
Change between 1998 and 2006, 
ii
 Percentage tested for resistance from all isolates (samples with identified organism) submitted for testing 
iii
 Percentage of resistant samples from all tested isolates 
1
4
5
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6.4.3 Trends in isolate testing and resistance data  
For all isolates (from all sites), the proportion of organisms tested and proportion 
resistant were calculated for all organism/antibiotic combinations of interest 
excluding duplicates and selective testing (Table 6.4). Although testing differed 
between laboratories, 99.0% of H. influenzae isolates were tested for resistance to 
amoxicillin and this percentage remained static over the study period (0.7% change 
between 1998 and 2006). Overall, 19.1% of all tested H. influenzae isolates were 
resistant to amoxicillin and resistance decreased by 2.1% over the study period (from 
21.2% to 19.1%). After fitting a single level linear regression, the trend indicated a 
decrease in resistance rates of 0.51% per annum (95% CI =0.06 to 0.95%, p=0.031). 
Over time, resistance to amoxicillin in H. influenzae appeared to be falling until 
2004/05 with a rise in 2006 (Figure 6.1).  
 
Only 70.5% of H. influenzae isolates were tested for resistance to tetracycline, and 
testing decreased by 19.6% between 1998 and 2006 (from 73.0% to 53.4% 
respectively). Overall, 1.6% of all H. influenzae isolates were resistant to 
tetracyclines and resistance significantly decreased over the study period by 0.16% 
per annum (95% CI=0.04 to 0.27%, p=0.017).  
  
Overall, 97.5% and 99.3% of S. pneumoniae isolates were tested for resistance to 
erythromycin and penicillin (including amoxicillin) respectively, both of which 
increased slightly over time. Overall, 9.4% of tested S. pneumoniae isolates were 
resistant to erythromycin and resistance increased significantly over time by 0.52% 
per annum (β=0.52%, 95% CI=0.17 to 0.87%, p=0.010) with a slight peak in 2003. 
Resistance to penicillin was lower and stable with only 4.0% of isolates resistant.  
Overall, 98.7% of S. pyogenes isolates were tested for resistance to erythromycin, 
and testing increased by 1.0% between 1998 and 2006. Overall, 3.9% of tested S. 
pyogenes isolates were resistant to erythromycin with no significant change in rates 
over time.  
 
Similar trends were seen across all organism/ antibiotic combinations of interest 
when only sputum and ENT samples were considered (Table 6.5 and Figure 6.2). 
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Figure 6.1 Trends in resistance rates by organism (excluding duplicates and 
selectivity) - All isolates 
 
 
 
Figure 6.2 Trends in resistance rates by organism (excluding duplicates and 
selectivity) - Sputum and ENT isolates 
 
 
  
Table 6.5 Summary of testing and resistance incidence (N) and rates (%) by year of isolate - submission for Sputum and ENT samples 
(excluding duplicates and selectivity) 
Organism – 
Antibiotic resistant to  
1998 1999 2000 2001 2002 2003 2004 2005 2006 Total Change
i
 
H. influenzae – 
Amoxicillin 
N isolates 1,834 1,810 1,918 2,038 2,121 2,097 1,909 1,898 1,829 17,454  
N tested  1,816 1,788 1,895 2,002 2,110 2,086 1,898 1,888 1,798 17,281  
N resistant 385 333 400 402 427 391 317 304 343 3302  
% tested
ii
 99.0 98.8 98.8 98.2 99.5 99.5 99.4 99.5 98.3 99.0 -0.7 
% resistant
iii
 21.2 18.6 21.1 20.1 20.2 18.7 16.7 16.1 19.1 19.1 -2.1 
            
H. influenzae – 
Tetracyclines 
N isolates 1,636 1,608 1,684 1,844 1,907 1,864 1,692 1,668 1,625 15,528  
N tested  1,194 1,192 1,237 1,421 1,418 1,312 1,134 1,167 867 10,942  
N resistant 32 33 21 23 15 15 12 12 15 178  
% tested 73.0 74.1 73.5 77.1 74.4 70.4 67.0 70.0 53.4 70.5 -19.6 
%resistant 2.7 2.8 1.7 1.6 1.1 1.1 1.1 1.0 1.7 1.6 -1.0 
            
S. pneumoniae – 
Erythromycin 
N isolates 755 694 652 771 803 806 760 766 802 6,809  
N tested  727 659 628 749 786 790 747 757 794 6,637  
N resistant 56 51 47 54 65 90 77 80 101 621  
% tested 96.3 95.0 96.3 97.1 97.9 98.0 98.3 98.8 99.0 97.5 2.7 
%resistant 7.7 7.7 7.5 7.2 8.3 11.4 10.3 10.6 12.7 9.4 5.0 
            
S. pneumoniae – 
Penicillin 
N isolates 755 694 652 771 803 806 760 766 802 6,809  
N tested  743 688 644 765 800 804 755 763 798 6,760  
N resistant 41 28 17 21 28 38 34 31 35 273  
% tested 98.4 99.1 98.8 99.2 99.6 99.8 99.3 99.6 99.5 99.3 1.1 
%resistant 5.5 4.1 2.6 2.7 3.5 4.7 4.5 4.1 4.4 4.0 -1.1 
            
 S. pyogenes – 
Erythromycin 
N isolates 890 914 929 928 896 930 918 734 754 7,893  
N tested  873 889 914 916 889 918 911 730 747 7,787  
N resistant 33 20 27 48 39 43 36 23 37 306  
% tested 98.1 97.3 98.4 98.7 99.2 98.7 99.2 99.5 99.1 98.7 1.0 
%resistant 3.8 2.2 3.0 5.2 4.4 4.7 4.0 3.2 5.0 3.9 1.2 
i 
Change between 1998 and 2006, 
ii
 Percentage tested for resistance from all isolates (samples with identified organism) submitted for testing 
iii
 Percentage of resistant samples from all tested isolates
1
4
8
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6.4.4 Multilevel modelling of all isolates 
6.4.4.1 Trends and characteristics of resistance 
A three-level logistic regression model using resistance or sensitive as a binary 
outcome variable was used to account for variation at the level of the laboratory, 
general practice, and individual. Univariate analyses were performed for each of the 
organism/resistance combinations to examine the trends in resistance data. Also 
examined were the possible explanatory variables of resistance data in relation to the 
patient characteristics of the submitted sample (age, gender, site) and the practice 
that submitted it (deprivation, single or multi-handed status, % male GPs, average 
age of the GPs, sampling rate per 100 practice population). Significant predictors 
were retained in the multivariate analysis to ascertain which variables independently 
predicted resistance.  
  
6.4.4.1.1 H. influenzae isolates and resistance to amoxicillin 
Over the whole study period, from 23,085 samples submitted with a H. influenzae 
isolate, 22,031 (95.4%) were tested. From those tested 4,250 (19.3%) were resistant 
to amoxicillin and 17,781 (80.7%) were sensitive. Univariate level analyses showed 
that resistance to amoxicillin was significantly lower between 2003 and 2005 (when 
compared to 1998) (Table 6.6). Resistance was also significantly lower in the 5-15 
and 16-24 year old age group than in the 0-4 year age group and samples sent from 
the ENT and genitalia area had significantly lower resistance to amoxicillin than 
those sent from sputum samples. There was significant unexplained variation in 
resistance rates between laboratories (σ2v0=0.047 (SE=0.023)) but not between 
practices. When these significant variables were included in a single model, all 
remained independently significant predictors of resistance although the association 
between ENT and 16-24 year olds disappeared.  
 
No associations were found between resistance and gender (=0.014 (SE=0.035)), 
practice level deprivation tertile, single-handed status (-0.077 (SE=0.077)) average 
age of GPs (0.005 (SE=0.004)), percentage of male GPs (0.0006 (SE=0.0010)) 
or sampling rate (=-0.034 (SE=0.026).  
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Table 6.6 Univariate models between amoxicillin resistance and sample 
characteristics in H. influenzae isolates  
 
    95% CI 
 Loge 
parameter 
estimate 
SE OR Lower 
limit 
Upper 
limit 
Year sample       1998 Ref  - - - - 
collected             1999 -0.041  0.074 0.96 0.83 1.11 
2000 0.084 0.072 1.09 0.94 1.25 
2001 0.038 0.072 1.04 0.90 1.20 
2002 -0.061 0.072 0.94 0.82 1.08 
2003 -0.215 0.074 0.81 0.70 0.93 
2004 -0.278 0.077 0.76 0.65 0.88 
2005 -0.206 0.075 0.81 0.70 0.94 
Age group            0-4 Ref  - - - -  
5-15 -0.349 0.106 0.71 0.57 0.87 
16-24 -0.308 0.136 0.73 0.56 0.96 
25-44 0.049 0.064 1.05 0.93 1.19 
45-64 0.045 0.048 1.05 0.95 1.15 
65-84 0.080 0.048 1.08 0.99 1.19 
85+ 0.027 0.123 1.03 0.81 1.31 
Specimen          Sputa Ref  - - - -  
ENT -0.244 0.068 0.78 0.69 0.90 
Eye 0.065 0.050 1.07 0.97 1.18 
Genitalia -0.662 0.149 0.52 0.39 0.69 
Other (inc. wound) 0.096 0.084 1.10 0.93 1.30 
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6.4.4.1.2 H. influenzae isolates and resistance to tetracyclines 
For the purposes of the multilevel modelling, one laboratory had only one practice 
that submitted only 3 samples; these were excluded. A total of 20,254 isolates 
remained after selectivity to testing for tetracycline resistance had been taken into 
account. Over the whole study period, 13,460 (67%) isolates were tested with 211 
(1.6%) testing resistant to tetracycline (and 13,249 (98.4%) sensitive). At a univariate 
level, resistance was significantly lower from 2000 to 2005 when compared to 
resistance for 1998 and samples submitted from the 25-84 age groups had 
significantly higher resistance to tetracyclines than samples submitted from the 0-4 
age group (Table 6.7). There was no significant variation in tetracycline resistance 
between laboratories or practices. When these significant variables were put in a 
single model, all remained independently significant predictors of resistance.  
 
Table 6.7 Univariate models for tetracycline resistance and sample characteristics in 
H. influenzae isolates 
 
    95% CI 
 Loge 
parameter 
estimate 
SE OR Lower 
limit 
Upper 
limit 
Year collected    1998 Ref - - - - 
1999 -0.044 0.235 0.96 0.60 1.52 
2000 -0.652 0.279 0.52 0.30 0.90 
2001 -0.572 0.269 0.56 0.33 0.96 
2002 -1.133 0.327 0.32 0.17 0.61 
2003 -0.786 0.299 0.46 0.25 0.82 
2004 -0.796 0.312 0.45 0.24 0.83 
2005 -0.616 0.301 0.54 0.30 0.97 
Age group            0-4 Ref - - - -  
5-15 0.149 0.468 1.16 0.46 2.90 
16-24 0.632 0.470 1.88 0.75 4.73 
25-44 0.684 0.268 1.98 1.17 3.35 
45-64 0.516 0.230 1.68 1.07 2.63 
65-84 0.483 0.232 1.62 1.03 2.55 
85+ 1.188 1.066 3.28 0.41 26.51 
 
Chapter 6 
153 
6.4.4.1.3 S. pneumoniae isolates and resistance to erythromycin 
Over the study period, from 11,292 reliable S. pneumoniae isolates, 10,454 (93%) 
were tested for resistance. From these a total of 908 (8%) tested resistant to 
erythromycin and 9,546 (92%) tested as sensitive. Resistance to erythromycin was 
marginally significantly higher in 2005 when compared to 1998, and there was an 
age effect with the 5-15 and 25-44 age groups having lower levels of resistance when 
compared to the 0-4 age group (Table 6.8). Most specimen types had significantly 
lower resistance level than sputum samples, apart from samples taken from genitalia, 
and multi-handed practices were more likely to have higher resistance to 
erythromycin. When these significant variables were put in a single model, all 
remained independent predictors of resistance apart from single-handed status.  
 
Table 6.8 Univariate models between erythromycin resistance and sample and 
practice characteristics in S. pneumoniae isolates 
 
    95% CI 
 Loge 
parameter 
estimate 
SE OR Lower 
limit 
Upper 
limit 
Year collected    1998 Ref - - - - 
1999 -0.109 0.168 0.90 0.65 1.25 
2000 -0.148 0.163 0.86 0.63 1.19 
2001 -0.178 0.164 0.84 0.61 1.15 
2002 0.033 0.154 1.03 0.76 1.40 
2003 0.135 0.151 1.14 0.85 1.54 
2004 0.117 0.152 1.12 0.83 1.51 
2005 0.288 0.145 1.33 1.00 1.77 
Age group            0-4 Ref - - - -  
5-15 -0.888 0.186 0.41 0.29 0.59 
16-24 -0.217 0.286 0.80 0.46 1.41 
25-44 -0.342 0.141 0.71 0.54 0.94 
45-64 0.075 0.096 1.08 0.89 1.30 
65-84 0.137 0.093 1.15 0.96 1.38 
85+ 0.28 0.218 1.32 0.86 2.03 
Specimen          Sputa Ref - - - -  
ENT -0.330 0.101 0.72 0.59 0.88 
Eye -0.308 0.095 0.73 0.61 0.89 
Genitalia -0.314 0.31 0.73 0.40 1.34 
Other (inc. wound) -0.481 0.131 0.62 0.48 0.80 
Single-handed Single Ref - - - - 
status                 Multi 0.339 0.167 1.40 1.01 1.95 
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6.4.4.1.4 S. pneumoniae isolates and resistance to penicillin 
Over the study period, from 11,138 reliable S. pneumoniae isolates (after selectivity 
to testing for penicillin resistance had been taken into account), 10,857 (97.5%) were 
tested for resistance. From these, 361 (3%) tested resistant to penicillin and 10,496 
(97%) as sensitive. Resistance to penicillin was significantly lower in 2001 (when 
compared to 1998), significantly lower in the 5-15 age group and significantly higher 
in the 45 years plus (when compared to the 0-4 year age group) (Table 6.9). 
Additionally, samples sent from ENT sites, eye, genitalia and other sites had 
significantly lower resistance than those sent from sputum samples. There was 
significant unexplained variation in resistance rates between practices (σ2v0=0.211 
(SE=0.093)) but not between laboratories. Again when these significant variables 
were put in a single model, all remained independently significant predictors of 
penicillin resistance. 
 
Table 6.9 Univariate models between penicillin resistance and sample characteristics 
in S. pneumoniae isolates 
 
  
Loge 
parameter 
estimate 
  95% Confidence 
interval 
 SE OR Lower 
limit 
Upper 
limit 
Year collected   1998 Ref - - - - 
 1999 -0.284 0.237 0.75 0.47 1.20 
2000 -0.296 0.231 0.74 0.47 1.17 
2001 -0.706 0.261 0.49 0.30 0.82 
2002 -0.356 0.236 0.70 0.44 1.11 
2003 -0.210 0.221 0.81 0.53 1.25 
2004 -0.123 0.219 0.88 0.58 1.36 
2005 -0.125 0.214 0.88 0.58 1.34 
Age group            0-4 Ref - - - -  
5-15 -0.893 0.346 0.41 0.21 0.81 
16-24 -0.015 0.483 0.99 0.38 2.54 
25-44 -0.200 0.209 0.82 0.54 1.23 
45-64 0.484 0.153 1.62 1.20 2.19 
65-84 0.537 0.15 1.71 1.28 2.30 
85+ 1.08 0.281 2.94 1.70 5.11 
Specimen          Sputa Ref - - - -  
ENT -0.600 0.161 0.55 0.40 0.75 
Eye -0.838 0.158 0.43 0.32 0.59 
Genitalia -2.128 1.055 0.12 0.02 0.94 
Other (inc. wound) -0.813 0.237 0.44 0.28 0.71 
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6.4.4.1.5 S. pyogenes isolates and resistance to erythromycin 
No trend existed in resistance to erythromycin in S. pyogenes isolates and no sample 
or practice characteristics were associated with resistance. No other variables were 
significantly associated with resistance. There was significant unexplained variation 
in resistance rates between practices (σ2v0=0.238 (se=0.067)) but not between 
laboratories. 
 
6.4.4.2 The relationship between antibiotic resistance and dispensing 
A three-level multilevel logistic regression model was fitted with the individual 
binary resistance as the outcome and in the first instance included lagged antibiotic 
dispensing as an explanatory variable. The model was then adjusted for study year 
and any significant factors identified in the previous section. Table 6.10 shows the 
initial results from the univariate multilevel model examining the association 
between antibiotic resistance and lagged dispensing for isolates from all specimens 
(using ORs and 95% CIs). For any significant associations, the adjusted ORs are also 
shown. 
 
For H. influenzae isolates, there was a significant positive association between 
amoxicillin resistance and lagged dispensing of BSPs, macrolides, and beta-lactams. 
For BSPs, resistance was 8% (95% CI=3% to 13%) higher in practices with a lagged 
dispensing rate at the 75th percentile (3089 dispensed items in the previous year) 
compared to practices with a lagged dispensing rate at the 25th percentile (1428 
dispensed items per annum). Similarly in macrolides, resistance was 5% (0% to 
10%) higher for practices that dispensed at the 75th percentile (979 dispensed items) 
compared to practices that dispensed at the 25th percentile (407 dispensed items). 
Resistance to beta-lactams was 7% (2% to 13%) higher for practices that dispensed 
at the 75th percentile (5118 dispensed items respectively) compared to practices that 
dispensed at the 25th percentile (2418 dispensed items respectively). There were no 
significant associations between amoxicillin resistance and tetracycline dispensing or 
between tetracycline resistance and dispensing in any of the antibiotics groups. 
 
After adjusting for year, age and site of specimen the positive association between 
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resistance to amoxicillin and BSP dispensing remained. The resistance was 5% (0 to 
11%) higher in practices that dispensed BSPs at the 75
th
 percentile compared to 
practices that dispensed at the 25
th
 percentile. For both macrolides and beta-lactams, 
the associations between dispensing and resistance to amoxicillin became non-
significant on inclusion of confounders. More specifically it was the inclusion of the 
year in the model that diluted the effect and not the site of the specimen or age group.  
 
For S. pneumoniae isolates there was a significant positive association between 
resistance to penicillin and dispensing of tetracyclines; the odds of resistance were 
23% (OR=1.23, 95% CI=1.08 to 1.41) higher for practices dispensing at the 75th 
percentile (595 dispensed items per annum) compared to practices dispensing at the 
25th percentile (262 dispensed items per annum). There were no significant 
associations between resistance to penicillin and BSP, macrolide and beta-lactam 
dispensing or between resistance to erythromycin and dispensing for any of the 
antibiotics. After adjusting for year, age and site of specimen, the relationship 
between penicillin resistance and tetracycline dispensing remained (1.19, 1.04 to 
1.37).  
 
For S. pyogenes isolates there were significant positive associations between 
penicillin resistance and dispensing of macrolides and beta-lactams. For macrolides, 
the odds of resistance were 17% (1.17, 1.05 to 1.31) higher in practices with a 
dispensing rate at the 75th percentile (1037 dispensed items per annum) compared to 
practices with dispensing rate at the 25th percentile (434 dispensed items per 
annum). For beta-lactams, the odds of resistance were 14% (1.14, 1.00 to 1.30) 
higher in practices with a dispensing rate at the 75th percentile (5061 dispensed items 
per annum) compared to practices with dispensing rate at the 25th percentile (2555 
dispensed items per annum). After adjusting for year and age the relationship 
between erythromycin resistance and dispensing of macrolides and beta-lactams 
remained (1.28, 1.14 to 1.45 and 1.04, 1.04 to 1.40). 
  
Table 6.10 Modelling for antibiotic resistance and lagged dispensing in H. influenzae, S. pneumoniae and S. pyogenes isolates for all 
isolates 
 
Organism 
Antibiotic 
resistance 
Lagged 
antibiotic 
dispensing 
Loge 
parameter 
estimate 
SE Dispensing 
rate  
IQR
i
 
OR (IQR)
ii
  
(95% CI) 
Adjusted iii 
 OR (IQR)  
(95% CI) 
H. influenzae Amoxicillin BSPs 0.62 0.18 0.12 1.08 (1.03 to 1.13) 1.05 (1.00 to 1.11) 
  Tetracyclines -0.18 1.15 0.02 1.00 (0.95 to 1.05) - 
  Macrolides 1.02 0.51 0.05 1.05 (1.00 to 1.10) 1.03 (0.98 to 1.08) 
  Beta-lactams 0.37 0.14 0.19 1.07 (1.02 to 1.13) 1.04 (0.98 to 1.10) 
H. influenzae Tetracycline BSPs 1.16 0.68 0.12 1.15 (0.98 to 1.35) - 
  Tetracyclines 5.46 4.04 0.02 1.12 (0.95 to 1.33) - 
  Macrolides 2.14 1.87 0.05 1.11 (0.93 to 1.31) - 
  Beta-lactams 0.52 0.51 0.19 1.10 (0.92 to 1.33) - 
S. pneumoniae Erythromycin BSPs -0.36 0.38 0.12 0.96 (0.87 to 1.05) - 
  Tetracyclines -0.07 2.32 0.02 1.00 (0.91 to 1.10) - 
  Macrolides -0.56 1.02 0.05 0.97 (0.89 to 1.07) - 
  Beta-lactams -0.34 0.29 0.19 0.94 (0.85 to 1.04) - 
S. pneumoniae Penicillin BSPs 0.94 0.54 0.12 1.12 (0.99 to 1.28) - 
  Tetracyclines 9.78 3.14 0.02 1.23 (1.08 to 1.41) 1.19 (1.04 to 1.37) 
  Macrolides 1.69 1.50 0.05 1.08 (0.94 to 1.24) - 
  Beta-lactams 0.28 0.42 0.19 1.05 (0.90 to 1.23) - 
S. pyogenes Erythromycin BSPs 0.77 0.50 0.12 1.10 (0.98 to 1.24) - 
  Tetracyclines 0.70 2.89 0.02 1.02 (0.90 to 1.15) - 
  Macrolides 3.32 1.21 0.05 1.17 (1.05 to 1.31) 1.28 (1.14 to 1.45) 
  Beta-lactams 0.70 0.36 0.19 1.14 (1.00 to 1.30) 1.21 (1.04 to 1.40) 
i
 Inter quartile range (IQR) is the difference between the 75
th
 and 25
th
 percentile of the dispensing rate distribution 
ii
 Odds Ratio (OR) is the odds of resistance at 75
th
 percentile of lagged dispensing distribution compared to the 25
th
 percentile 
iii
 Adjusted for year sample collected, age group and site of sample 
1
5
6
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6.4.5 Multilevel modelling for sputum and ENT samples 
The analyses were re-run for sputum and ENT samples only, to examine how 
associations would differ for the subset of samples which were more relevant to RTIs 
than all infections.   
 
For H. influenzae isolates, resistance to amoxicillin was significantly lower in 
samples collected in 2004 and 2005 when compared to 1998 (a similar trend to that 
seen in all samples). Resistance was also lower in ages between 45-84 years old 
(rather than in the 5-15 age group for all samples). Resistance to tetracycline was 
comparable to that in all isolates. At the univariate level, the same positive 
associations held between amoxicillin resistance and dispensing of BSP (1.07, 1.02 
to 1.13), macrolides (1.06, 1.00 to 1.12) and beta-lactams (1.07, 1.01 to 1.13) in H. 
influenzae isolates. After adjusting for age and year, only the positive association 
between BSP dispensing and resistance held (1.06, 1.01 to 1.12). These results are 
shown in Appendix V. 
 
S. pneumoniae isolates submitted in 2003 were significantly more resistant to 
erythromycin than those in 1998 and resistance in isolates submitted by 5-15 and 25-
44 year olds was significantly lower than in those submitted by 0-4 year olds. This 
differs from all isolates, where resistance was higher in 2005 and across all age 
groups (with the exception of those aged 85 and over). For penicillin resistance the 
same associations held; specimens collected in 2001 were significantly less resistant 
than those collected in 1998 and specimens submitted by 5-15year olds were 
significantly less resistant than those submitted by 0-4 year olds. There were no 
associations between antibiotic dispensing and erythromycin or penicillin resistance 
in S. pneumoniae sputum and ENT isolates.  
 
For S. pyogenes isolates, resistance to erythromycin was higher in 2003 when 
compared to 1998. However, the same associations held between erythromycin 
resistance and macrolide dispensing in S. pyogenes isolates (1.29, 1.12 to 1.48).  
 
There was no significant variation in the relationship between any lagged antibiotic 
dispensing and resistance at the laboratory and practice level.  
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6.4.6 Changes in antibiotic dispensing and resistance 
6.4.6.1 H. influenzae isolates 
Of the 363 UTS practices that submitted H. influenzae isolates during 1998 to 2005, 
275 (76%) practices submitted H. influenzae isolates in both 1998 and 2005, with 
249 (69%) practices submitting both sputum and ENT samples. Practices submitting 
samples in both years were included in the following analyses. These practices had 
significantly larger list sizes, were less likely to be run single-handedly and also had 
slightly higher sampling rates (Table 6.11). They also had slightly lower levels of 
antibiotic dispensing than excluded practices in both 1998 and 2005, but these 
differences were not significant. 
 
Table 6.11 Practice characteristics for included and excluded practices 
 
 
 
Included practices 
N=275 
Excluded 
practices 
N=88 
Test 
statistic, 
p-value 
Practice deprivation 
Mean (sd) 
0.14 (1.80) 0.04 (2.07) t=0.45,  
p=0.656 
Average sampling rate 
(1996-2006) Mean (sd) 
0.19 (0.07) 0.13 (0.08) t=6.84,  
p<0.001 
Sampling rate (2006) 
Mean (sd) 
0.22 (0.10) 0.17 (0.11) t=3.38,  
p=0.001 
Single-handed N (%) 27 (9.9) 22 (25.6) 2=13.66,  
p<0.001 
Practice population  
(March 2007)  
Median (25th to 75th percentile) 
6843  
(5107 to 9339) 
4338 
(2604 to 6935) 
MW,  
p<0.001 
Total antibiotic dispensing 
rate per 1,000 Median (25th 
to 75
th 
percentile)              1998  
 
 
798.55 
(671.00 to 931.52) 
 
 
834.40 
(686.53 to 979.86) 
 
 
MW,  
p=0.127 
2005 674.61  
(578.0 to 786.89) 
684.94 
(591.67 to 795.39) 
MW,  
p=0.554 
 
Four practices did not have any dispensing data for 1998 and 2005 and therefore 271 
(all isolates) and 245 practices (sputum and ENT) were included in the analyses. 
During the study period, reductions in dispensing were found for all antibiotics 
except for flucloxacillin and trimethoprim (Table 6.12). Only 5% of the 271 practices 
increased their total antibiotic dispensing over the period, whilst 18% increased their 
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BSP dispensing and 36% increased their dispensing of tetracyclines. 
 
Table 6.12 Median dispensed antibiotic items (per 1,000 practice population per 
annum) in 1998 and 2005 in 271 Welsh practices 
 
Antibiotics 1998 2005 Reduction 
(% decrease) 
Penicillin 62.6 51.4 11.2 (18) 
BSPs 327.2 262.0 65.2 (20) 
Flucloxacillin 54.3 67.8 -13.5 (-25) 
Cephalosporins 72.0 49.6 22.4 (31) 
Tetracyclines 52.8 52.3 0.5 (1) 
Macrolides 94.9 77.1 17.8 (19) 
Quinolones 26.4 21.6 4.8 (18) 
Trimethoprim 58.0 62.7 -4.7 (-8) 
Beta-lactams 537.8 459.3 78.5 (15) 
Total antibiotics 795.0 674.0 121.0 (15) 
 
Quartiles were calculated based on reductions in antibiotic dispensing rates with 
equal number of practices in each quartile and defined according to the values shown 
in the final row of Table 6.13. Quartile 1 (75
th
 to 100
th
 percentile) refers to practices 
that reduced their dispensing the most and quartile 4 (0 to 25
th
 percentile) refers to 
the practices that reduced it least, or increased their dispensing. For total antibiotics, 
quartile 1 reduced dispensing by at least 195 items per 1,000 practice population per 
annum; quartile 2 by between 93 and 195; quartile 3 by between 33 and 93; and 
quartile 4 by less than 33. 
 
Table 6.13 Quartiles with 5
th
 and 95
th
 percentiles, for reductions in dispensed 
antibiotic rates (per 1,000 practice population per annum) between 1998 and 2005 
 
 Percentile 
Antibiotics  95
th
 75
th
 50
th
 25
th
 5
th
 
Penicillin 42.3 22.1 9.3 -2.4 -21.1 
BSPs 237.9 110.1 57.5 12.1 -49.6 
Flucloxacillin 19.4 -2.4 -13.3 -24.9 -43.3 
Cephalosporins 111.4 49.3 18.0 -3.0 -31.3 
Tetracyclines 36.1 12.7 2.2 -9.1 -24.8 
Macrolides 94.0 42.3 15.9 -1.2 -32.0 
Quinolones 39.2 13.2 3.8 -2.5 -13.4 
Trimethoprim 26.7 8.3 -3.7 -13.7 -31.2 
Beta-lactams 307.9 147.3 81.1 27.0 -61.5 
Total antibiotics 386.5 194.6 93.3 33.3 -61.3 
 
Chapter 6 
161 
Table 6.14 shows the reduction in amoxicillin and tetracycline resistance by change 
in dispensing (total, BSPs and tetracyclines) quartile for all isolates. Amoxicillin 
resistance significantly reduced overall but it fell non-significantly in all quartiles of 
total antibiotic and BSP dispensing. The differences between quartiles (fourth minus 
first practice quartiles) were also not significant. For total dispensing, the difference 
was 0.6% (95% CI= -6.0% to 7.0%); BSPs= 0.6% (95% CI=-6.3% to 7.4%)). For 
sputum and ENT isolates, the same patterns were seen although the second quartile 
saw a significant decrease in resistance over time (Appendix VI). Again there was no 
significant difference between quartiles (fourth minus first practice quartiles) (total 
dispensing=1.7% (95% CI=-5.7% to 9.1%); BSPs=2.6% (95% CI=-5.1% to 10.4%).  
 
There was no pattern in reductions in tetracycline resistance and quartiles of total 
antibiotic dispensing reduction for all isolates or in sputum and ENT samples. For all 
isolates, in practices in the first quartile resistance increased over time whilst for 
practices in the fourth quartile, resistance fell. There was a significant difference 
between the change in tetracycline resistance in the first and fourth practice quartiles 
(3.3%,95% CI= 0.5% to 6.2%). The same pattern was seen in sputum and ENT 
samples but the difference between the change in tetracycline resistance in the first 
and fourth practice quartiles was no longer significant (3.0%,95% CI= -0.3% to 
6.4%) (Appendix VI). 
 
Tetracycline resistance significantly reduced overall but it fell non-significantly in all 
quartiles of tetracycline dispensing. The difference between decreases in tetracycline 
resistance in the first and fourth practice quartiles was also not significant (1.3% 
(-1.7% to 4.3%). The same pattern was seen in sputum and ENT samples and the 
difference between the change in tetracycline resistance in the first and fourth 
practice quartiles was 2.1% (-1.4% to 5.7%) (Appendix VI). 
  
Table 6.14 Changes (%) in resistance to amoxicillin and tetracycline over an 8-year period, in all H. influenzae isolates, by quartile of 
reductions in:  
(a) Total antibiotic dispensing 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Amoxicillin resistance 
1998, %  20.3 21.5 19.5 19.9 20.3 
2005, %  18.4 17.3 15.7 17.5 17.3 
Change, % (95% CI)  1.9  (-3.0 to 6.9) 4.2 (-0.4 to 8.9) 3.8 (-1.0 to 8.5) 2.5 (-1.8 to 6.7) 3.0 (0.8 to 5.4) 
Tetracycline resistance 
1998, % 1.9  2.9 2.8  3.1 2.7 
2005, % 2.5 0.3 2.1 0.3 1.3 
Change, % (95% CI)   0.6 (-1.9 to 3.1) 2.5 (0.5 to 4.7) 0.7 (-2.2 to 3.3) 2.7 (0.8 to 4.8) 1.4 (0.3 to 2.5) 
 
(b) Broad Spectrum Penicillin dispensing 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Amoxicillin resistance 
1998, % 22.4 18.8 20.2 20.4 20.3 
2005, % 18.7 16.1 18.6 16.1  17.3 
Change, % (95% CI) 3.7 (-1.5 to 9.0) 2.7 (-1.6 to 7.0) 1.6 (-3.1 to 6.2) 4.3 (-0.2 to 8.7) 3.1 (0.8 to 5.4) 
 
(c) Tetracycline dispensing 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Tetracycline resistance 
1998, % 2.2 2.0 3.1 3.5 2.7 
2005, % 1.3 1.4 1.3 1.3 1.3 
Change, % (95% CI) 1.0 (-0.9 to 2.8) 0.6 (-2.3 to 3.4) 1.8 (-0.9 to 4.1) 2.3 (-0.6 to 5.1) 1.4 (0.3 to 2.5) 
1
6
1
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6.4.6.2 S. pneumoniae isolates  
Resistance data for 1998 to 2005 were available for 245 practices for all submitted  
S. pneumoniae isolates and 193 practices for sputum and ENT samples. 
Characteristics of the practices included in the analysis were similar to those found in 
the H. influenzae isolates except that the total antibiotic dispensing rate in 2005 was 
slightly (but not significantly) higher in the included practices for S. pneumoniae. 
Two practices did not have any dispensing data and therefore 243 and 191 practices 
were included in the analyses.   
 
Again reductions were seen in the dispensing of all antibiotics except for 
flucloxacillin and trimethoprim during the study period. Although the number of 
practices changed for each type of isolate examined the results are comparable with 
those found in submitted H. influenzae isolate samples (as seen in Table 6.12). Just 
over 6% of the 243 practices increased their total antibiotic dispensing over the 
period, whilst 19% increased their BSP prescribing and 30% increased their 
prescribing of tetracycline. Once again, quartiles were calculated based on change in 
total dispensing rates with equal number of practices in each quartile and defined 
according to the values shown in the final row of Table 6.15.  
 
Table 6.15 Quartiles with 5
th
 and 95
th
 percentiles for decrease in dispensed 
antibiotics rates (per 1,000 practice population) between 1998 and 2005 
 
 Percentile 
Antibiotics  95
th
 75
th
 50
th
 25
th
 5
th
 
Penicillin 41.9 22.6 9.5 -2.0 -22.0 
BSPs 231.2 107.4 56.7 12.2 -51.0 
Flucloxacillin 12.6 -2.5 -12.8 -24.6 -42.8 
Cephalosporins 109.9 47.9 14.9 -5.1 -33.0 
Tetracyclines 35.5 12.1 2.6 -9.4 -24.1 
Macrolides 88.6 40.2 15.9 1.0 -34.4 
Quinolones 44.5 13.2 3.7 -2.9 -14.6 
Trimethoprim 25.8 7.2 -4.6 -14.4 -31.4 
Beta-lactams 294.8 142.5 76.7 21.8 -66.9 
Total antibiotics 370.0 184.9 90.9 28.1 -73.2 
 
Table 6.16(a) shows the reduction in erythromycin and penicillin resistance by 
change in total antibiotic dispensing quartile for all isolates. The results for sputum 
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and ENT samples are shown in Appendix VII(a).  
 
For all isolates, most quartiles saw an increase in resistance to erythromycin between 
1998 and 2005 with practices in the third quartile significantly increasing. The 
exception was the fourth practice quartile (practices reducing dispensing the least or 
increasing). The difference between the changes in erythromycin resistance in the 
first and fourth practice quartiles was 5.0% (-2.3 to 12.3%). Similar patterns were 
seen in sputum and ENT isolates with a change between the first and fourth quartiles 
of 1.7% (-7.3 to 10.8%). Erythromycin resistance was also examined alongside 
quartiles of change in macrolide dispensing (Table 6.16(b)). For all isolates, a 
reduction was only seen in the third quartile and quartile 4 had a significant increase 
in resistance of 7.5% (1.9 to 13.0%). The difference between changes in 
erythromycin resistance in the first and fourth practice quartiles was -7.3% (-15.0 to 
0.4%). A similar difference was seen in sputum and ENT isolates (-6.7%, -16.4 to 
3.1%) (Appendix VII(b))  
 
There was no pattern in changes in penicillin resistance by quartiles of dispensing 
reduction for all isolates or in sputum and ENT samples. For all isolates, the 
difference between changes in penicillin resistance in the first and fourth practice 
quartiles was 0.1% (-4.6 to 4.3%). There was no significant difference between 
decreases in penicillin resistance in the first and fourth practice quartiles for sputum 
and ENT samples (0.04%, -6.1 to 6.1%).  
 
Penicillin resistance was also examined alongside quartiles of change in BSP 
dispensing (Table 6.16(c)). For all tested isolates, both the first and fourth quartiles 
saw a non-significant reduction in penicillin resistance. The difference between 
decreases in penicillin resistance in the first and fourth practice quartiles was 1.4% 
(-3.6 to 6.4%). A similar difference was seen in sputum and ENT isolates (1.8%, -5.3 
to 8.8%) (Appendix VII(c)). 
   
Table 6.16 Changes (%) in resistance to erythromycin and penicillin over an 8-year period, in all S. pneumoniae isolates, by quartile of 
reductions in: 
 
(a) Total antibiotic dispensing 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Erythromycin resistance 
1998, %             8.4         9.91         4.5              11.0        8.5  
2005, %           11.7       12.30         9.6                9.3       10.7  
Change, % (95% CI) 3.3 (-2.3 to 8.9)  2.4 (-2.9 to 8.1)  5.1 (0.6 to 9.5)  1.7 (-3.1 to 6.7)  2.1 (-0.4 to 4.6)  
  
Penicillin (including amoxicillin) resistance  
1998, %             4.5         2.4         5.1            4.3         4.1  
2005, %             3.2         4.4         3.8            3.1         3.6  
Change, % (95% CI) 1.3 (-2.2 to 5.1) 2.0 (-1.2 to 5.2)  1.3 (-2.2 to 5.1)  1.2 (-1.8 to 4.3)  0.5 (-1.1 to 2.2) 
 
(b) Macrolide dispensing 
  
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Erythromycin resistance 
1998, % 10.8 6.8 10.0 5.6 8.5 
2005, % 11.1 9.8 9.5 13.1 10.7 
Change, % (95% CI) 0.2 (-5.4 to 5.8) 3.0 (-1.5 to 7.8) 0.5 (4.3 to 5.3) 7.5 (2.0 to 13.1) 2.1 (-0.4 to 4.7) 
 
(c) BSP dispensing 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Penicillin resistance 
1998, %  5.4 2.4 3.4 5.6 4.1 
2005, % 3.9 3.8 4.4 2.7 3.6 
Change, % (95% CI) 1.5 (-2.5 to 5.9) 1.4 (-1.6 to 4.3) 1.0 (-2.4  to 4.5) 2.9 (-0.2 to 6.2) 0.5 (-1.1 to 2.2) 
1
6
4
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6.4.6.3 S. pyogenes isolates 
Resistance data for 1998 and 2005 were available for 268 practices for all samples 
and 151 practices for the sputum and ENT samples, and were used in the analysis. 
Included practices had lower levels of antibiotic dispensing than excluded practices 
in both 1998 and 2005. Three practices did not have any dispensing data and 
therefore 265 practices were analysed for all isolates and 148 for sputum and ENT 
isolates. The same reductions in dispensing were seen in this sample of practices of 
all antibiotics except for flucloxacillin, trimethoprim and tetracyclines during the 
study period. Once again, quartiles were calculated based on change in total 
dispensing rates with equal number of practices in each quartile and defined 
according to the values shown in the final row of Table 6.17. 
 
Table 6.17 Quartiles with 5
th
 and 95
th
 percentiles for decrease in dispensed 
antibiotics rates (per 1,000 practice population) between 1998 and 2005 
 
 Percentile 
Antibiotics  95
th
 75
th
 50
th
 25
th
 5
th
 
Penicillin 44.9 23.5 9.8 -1.9 -20.4 
BSPs 235.5 109.8 59.0 13.6 -42.5 
Flucloxacillin 16.5 -2.9 -12.7 -24.5 -43.5 
Cephalosporins 111.3 49.1 18.1 -2.2 -32.7 
Tetracyclines 36.4 12.7 2.2 -9.1 -24.3 
Macrolides 92.7 45.0 16.5 0.9 -30.9 
Quinolones 43.8 13.2 4.0 -3.0 -15.8 
Trimethoprim 26.6 8.5 -3.7 -14.1 -30.5 
Beta-lactams 294.5 144.9 81.1 29.4 -54.7 
Total antibiotics 383.9 191.4 97.8 38.7 -59.7 
 
For all isolates, erythromycin resistance fell in both the second and fourth practice 
quartiles (based on total dispensing) over time but these changes were not significant 
(Table 6.18(a)). The difference between quartiles (fourth minus first practice 
quartiles) was 3.0% (95% CI=-0.5 to 6.5%). In sputum and ENT isolates, an increase 
was seen across all quarters except for quartile 4 where a significant reduction in 
resistance rates was observed (3.7%, 0.4% to 6.8%) (Appendix VIII(a)). The change 
in erythromycin resistance between the first and fourth practice quartiles (fourth 
minus first practice quartiles) was significantly different (6.1%, 0.8 to 11.3%).  
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Erythromycin resistance was also examined alongside quartiles of change in 
macrolide dispensing (Table 6.18(b)). Again no significant reductions were seen and 
the difference between changes in erythromycin resistance in the first and fourth 
practice quartiles was -0.8% (-4.3 to 2.7%). For sputum and ENT samples, only the 
fourth quartile reduced their erythromycin resistance over the period and the 
differences between quartiles (fourth minus first practice quartiles) were non-
significant (1.9% (-3.1 to 7.0%)) (Appendix VIII (b)). 
  
Table 6.18 Changes (%) in resistance to erythromycin over an 8-year period, by quartile of reductions in total antibiotic dispensing in S. 
pyogenes isolates   
 
(a) Total antibiotic dispensing 
 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Erythromycin resistance 
1998, %  3.7 4.6 2.9 4.2 3.8 
2005, %  4.4 3.2 4.2 1.9 3.4 
Change
i
, % (95% CI) 0.8 (-2.2 to 3.6) 1.4 (-1.7 to 4.4) 1.3 (-1.6 to 4.0) 2.3 (-0.1 to 4.5) 0.4 (-0.9 to 1.7) 
   
 
(b) Macrolide dispensing  
 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Erythromycin resistance` 
1998, %  5.1 2.7 4.2 3.2 3.8 
2005, %  3.2 4.2 4.0 2.1 3.4 
Change, % (95% CI) 1.9 (-0.9 to 4.7) 1.5 (-1.4 to 4.1) 0.2 (-2.7 to 2.9) 1.1 (-1.4 to 3.6) 0.4 (-0.9 to 1.7) 
i 
Resistance in 1998 minus 2005 
 
 
1
6
7
 
Chapter 6 
169 
6.4.7 Sampling data 
To examine the extent of the sampling bias in the dataset, an annual sampling rate 
was calculated for each practice based on specimens from all sites (sputum, wound, 
urine etc). As there is limited evidence on general practices’ rates of submissions of 
samples no prior hypothesis is offered. It is therefore unclear whether practices with 
low or high sampling rates have higher resistance rates. For the 363 UTS practices 
that submitted H. influenzae isolates, sampling rates (number of samples submitted 
per 100 practice population per annum) ranged from 0.01 to 76.01 per 100 practice 
population (mean rate =18.08 (SD=8.80)). On average, in these practices sampling 
rates increased over the study period from 16.69 in 1998 to 20.74 in 2006 per 100 
practice population (Figure 6.3).  
 
Figure 6.3 Trends in sampling rates for practices submitting H. influenzae isolates 
between 1998 and 2006 (average rate and 95% confidence interval)   
 
 
In section 6.4.4.1 we identified that practice level annual sampling rates were not 
significantly associated with resistance in any of the isolates examined. What 
practice characteristics are associated with high sampling? At the univariate level, 
multi-handed practices (=2.661, (SE=1.164)), younger GPs (=-0.382 (SE=0.060)), 
fewer male GPs per practice (=-0.058 (SE=0.018) were associated with higher 
sampling. The sampling rate increased over the study period (=0.560 (SE=0.034 )). 
When these significant explanatory variables were entered into a multivariate model 
only year (=0.547 (SE=0.034), p<0.001) and average age of the GPs (=-0.380 
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(SE=0.060), p<0.001) independently predicted the sampling rate per 100 practice 
population. There was significant unexplained variation in resistance rates between 
practices (σ2v0=53.64 (SE=4.32)). 
 
6.4.8 Duplicate isolates 
6.4.8.1 Trends in duplicates 
As described in Table 6.3, from 25,453 H. influenzae isolates from 363 UTS 
practices, 2,368 (9%) were flagged as duplicates (using the 91 day rule), in S. 
pneumoniae isolates 964 (8%) and in S. pyogenes isolates 973 (5%). These 
percentages were stable over time and no trends in duplicates were identified 
between 1998 and 2005. 
 
6.4.8.2 Association with resistance 
Table 6.19 shows the resistance rates for duplicate and non-duplicate isolates for 
each organism and the difference (with 95% CIs). H. influenzae isolates, amoxicillin 
resistance was significantly higher in non-duplicates than in duplicates but there was 
no significant difference in resistance to tetracyclines. In tested S. pneumoniae 
isolates, resistance was higher in non-duplicates although these differences were non-
significant. In S. pyogenes isolates resistance to erythromycin was significantly 
higher in duplicates than non-duplicates. 
 
Table 6.19 Resistance rates (%) (N isolates tested) for duplicate and non-duplicate 
isolates 
 
Organism Antibiotic Duplicates Non-
duplicates 
Difference 
(95% CI) 
H. influenzae Amoxicillin 15.4 
(2,244) 
19.3  
(22,031) 
-3.9 
(-5.4 to -2.3) 
 Tetracycline 1.7  
(1,544) 
1.6 
(13,463) 
0.1  
(-0.5 to 0.9) 
S. pneumoniae Erythromycin 7.8  
(874) 
8.7 
(10,454) 
-0.9 
(-2.6 to 1.1) 
 Penicillin  
(inc. amoxicillin) 
3.1  
(928) 
3.3  
(1,1011) 
-0.2  
(-1.2 to 1.2) 
S. pyogenes Erythromycin 5.7  
(944) 
3.8 
(16,678) 
1.9  
(0.5 to 3.6) 
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6.4.8.3 Sample and practice characteristics of duplicate isolates 
In an attempt to further understand duplicates, a three-level regression model was 
fitted with the individual binary outcome (duplicate or not) as the outcome and 
individual patient, sample and practice characteristics as explanatory variables.  
 
In H. influenzae isolates, the multivariate multilevel model showed that amoxicillin 
resistance, age group, and specimen site were all independently associated with 
duplicate status (Table 6.20). Duplicates were likely to have lower resistance to 
amoxicillin and there were significantly fewer of them in the age groups 5 to 44 
years and the elderly when compared to the 0 to 4 age group. There were also 
significantly fewer duplicates in specimens sent from the genitalia area, when 
compared to sputum samples and significantly more sent from the high sampling 
practices. There was significant unexplained variation in duplicates between 
practices (σ2u0=0.169 (SE=0.029)) but none between laboratories. 
 
Table 6.20 Multivariate model for duplicates in H. influenzae isolates 
 
 Loge parameter 
estimate 
SE OR (95% CI) 
Amoxicillin resistance -0.27 0.07 0.76 (0.66 to 0.88) 
Age group               0-4 Ref - - 
5-15 -0.59 0.17 0.55 (0.39 to 0.78) 
16-24 -1.28 0.29 0.28 (0.16 to 0.50) 
25-44 -0.63 0.16 0.53 (0.39 to 0.73) 
45-64 -0.18 0.15 0.84 (0.62 to 1.13) 
65-84 -0.20 0.15 0.82 (0.61 to 1.11) 
85+ -0.70 0.23 0.50 (0.31 to 0.79) 
Specimen             Sputa Ref - - 
ENT -0.24 0.15 0.79 (0.58 to 1.06) 
Eye -0.21 0.15 0.81 (0.60 to 1.09) 
Genitalia -1.15 0.30 0.32 (0.17 to 0.58) 
Other (inc. wound) 0.06 0.17 1.06 (0.76 to 1.49) 
 
In S. pneumoniae isolates, age group and specimen site were both independently 
associated with duplicates. Duplicates were more likely to be observed in samples 
from 0-4 year olds and also in eye specimens (OR=1.40, 95 CI%=1.04 to 1.90) and 
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less likely to be seen in ENT samples (0.55, 0.39 to 0.77) relative to sputa. Again 
there was significant variation in duplicates by practice (σ2u0=0.117 (SE=0.039)) but 
not by laboratory.  
 
In S. pyogenes isolates, erythromycin resistance and age group were both 
independently associated with duplicates. Duplicates were more likely to be resistant 
to erythromycin than non-duplicates (1.40, 1.02 to 1.93), less likely to occur in the 
younger age groups (5 to 24 years old) and more likely in the older age groups (25 
years plus). 
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6.5 Discussion  
6.5.1 Main findings 
This study included 25,453 H. influenzae isolates, 12,256 S. pneumoniae isolates and 
17,927 S. pyogenes isolates from samples submitted for resistance testing between 
1998 and 2006 by around 360 general practices in Wales (covering at least 84% of 
the Welsh population). In all isolates, significant reductions over time were found in 
resistance to both amoxicillin and tetracycline in H. influenzae isolates, and a 
significant increase in resistance to erythromycin in S. pneumoniae isolates. Similar 
trends were observed for samples taken from sputum and ENT (linked to the 
respiratory tract). No such trends were found in resistance to penicillin in S. 
pneumoniae isolates or resistance to erythromycin in S. pyogenes isolates. Resistance 
rates also varied by age group and specimen site for most observed organism/ 
antibiotic resistance combinations. In particular sputum samples had the highest 
resistance to tetracyclines and erythromycin in H. influenzae isolates, and S. 
pneumoniae and S. pyogenes isolates respectively.  
 
The relationship between lagged antibiotic dispensing in the community and 
resistance was assessed again in isolates from all sites and samples taken from 
sputum and ENT separately. This was to examine whether practices with higher 
resistance rates also had higher antibiotic dispensing rates (based on dispensing for 
the past year), after adjusting for other factors that could also affect resistance rates. 
In H. influenzae isolates, a positive association held between resistance to 
amoxicillin and the dispensing of BSP, in S. pneumoniae isolates between penicillin 
resistance and tetracycline dispensing, and in S. pyogenes isolates between 
erythromycin resistance and dispensing of macrolides and beta-lactams. For sputum 
and ENT samples, the same relationship held in H. influenzae isolates and also in S. 
pyogenes between resistance to erythromycin and macrolide dispensing. Adjusting 
for significant confounders such as age group and specimen site made little 
difference to the strength of the association. Inclusion of the year in which the 
sample was submitted diluted the association.  
 
If high dispensing is associated with higher resistance, will reducing dispensing lead 
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to reduced resistance? The potential effectiveness of reducing antibiotic dispensing 
to contain antibiotic resistance has been questioned (Heinemann et al. 2000; 
Livermore D. 2004) but has been demonstrated in coliform isolates in tested urine 
samples submitted by GPs (Butler et al. 2007). For a subset of practices, the 
relationship between changes in antibiotic dispensing by general practices and 
changes in local levels of antibiotic resistance in all and respiratory isolates was 
examined. There was no clear pattern between changes in dispensing and changes in 
resistance. In particular, general practices with the greatest reduction in dispensed 
antibiotics did not show significantly different changes in resistance in any of the 
isolates and for any of the antibiotics tested, compared with practices that reduced 
dispensed antibiotics the least.  
 
This study enabled a further exploration into duplicate samples and revealed that, 
contrary to expectation, duplicates do not have higher resistance to most antibiotics. 
In fact H. influenzae isolates duplicates were likely to have lower resistance to 
amoxicillin with significantly fewer of them in the 5 to 44 years and elderly age 
group when compared to those aged 0 to 4 years. However, duplicates in S. pyogenes 
isolates did have higher resistance to erythromycin. There were also significantly 
more duplicates sent from high sampling practices. This study also allowed the 
exploration of practices’ annual sampling rates (the number of samples sent per 
practice population). No clear patterns existed between resistance rates and sampling 
rates and overall rates of sampling increased over the time period of the study. 
 
6.5.2 Strengths and weaknesses of the study 
This study has allowed an exploration of the trends in the proportion of submitted 
isolate samples tested for resistance and the proportion of these samples resistant to 
the antibiotics tested. We were also able to see how resistance varied by certain 
sample, patient and practice characteristics, by laboratory and general practice, and 
examine any associations between resistance and lagged dispensing rates. To our 
knowledge, this is the first observational study to examine the association between 
reductions in the rate of antibiotic dispensing at the level of general practice and 
change in antibiotic resistance in H. influenzae, S. pneumoniae and S. pyogenes 
isolates. 
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Resistance data could only be obtained from 11 of the 18 laboratories which serve 
Welsh general practices but the main analysis still included data from at most 363 
practices, covering a population at risk of 84% of the official Welsh population. 
Whilst the included practices were not entirely representative of the whole of Wales 
(higher practice populations and less likely to be run single-handedly) and also 
geographically biased, they were broadly similar to the remaining Welsh practices 
with respect to their deprivation levels, in the pattern of their sampling, and 
dispensed antibiotics rate when these data were available for excluded practices.  
 
An attempt has been made to address and quantify any possible bias present in the 
data to ensure that rates are as true a reflection as possible of resistance in the Welsh 
population. Routinely collected data using samples submitted by GPs may not 
necessarily be typical of all infections. Little is known about how representative 
reported levels of resistance are as the practice of submitting samples to 
microbiology by general practices vary widely. Systematic sampling of all patients 
with symptoms of an infection would be ideal but not feasible. A study in which 
resistance data was obtained from systematic sampling in patients with symptoms 
suggesting a urine tract infection showed similar resistance rates to a study using 
routinely collected data (Hillier et al. 2007; Butler et al. 2007). From this data there 
is no evidence to suggest that lower sampling rate (practices possibly with selective 
sampling) are associated with higher resistance rates. Selective testing at a laboratory 
level was also assessed and laboratories demonstrating selectivity in the samples that 
were tested were excluded from all analyses.  
 
Whilst duplicates were excluded, as their inclusion may bias estimates of resistance 
rates, in most cases they were less likely to be resistant (e.g. in the case of 
amoxicillin resistance in H. influenzae isolates). Fewer duplicates were identified in 
this dataset in comparison with similar community isolates data from Wales (Magee 
et al. 2004). Duplicates however were more likely to be resistant to erythromycin in 
S. pyogenes duplicates although the difference between duplicates and non-
duplicates was small (1.9%). When infections from the respiratory tract are 
examined, by looking at sputum samples and those taken from the ENT regions, 
there may be even more bias in resistance rates as it is thought that these samples are 
not submitted routinely unlike, for example, urine samples. The fact that duplicates 
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are not more resistant is surprising as practitioners are more likely to submit another 
sample after a non-response to initial antibiotic therapy. The 91 day threshold for 
identifying duplicates was an arbitrary cut off, adopted due to “recommendation for 
distinction of continuing from repeat infection for infectious disease surveillance in 
Wales” (Magee et al. 2004). Defining the cut-off is difficult as it is likely to vary 
within person and by organism. It may be that this period is too long; samples 
identified as duplicates could be isolates from a new period of infection of the same 
organism. If the cut-off was lower, a proportion of previously defined duplicates 
would be classed as initial isolates. This would increase the number of samples 
submitted but given that, for most organisms, duplicates are not more resistant, the 
resistance rate would decrease. 
 
It would have been of use to have further information regarding the patients that had 
samples submitted to microbiology and an isolate identified. Whilst we knew their 
age, gender and the location where the sample was taken from (wound, sputum etc.), 
we did not have any information such as any co-morbidities or the diagnosis code 
that was subsequently recorded by the GP. This information would have been useful 
to further characterise these patients that had an identified isolate and also who were 
having duplicate samples taken. 
  
As described in section 5.2.1, the amount of dispensed antibiotics at practice level is 
a proxy for antibiotic consumption in those patients from whom specimens were 
submitted. Although resistance data was at an individual level, dispensing data was 
only available at a practice level and data on individual usage were not available. 
Any effects found in this study between dispensing and resistance are likely to be 
underestimated as Donnan et al. (2004) showed.  
 
Lagged dispensing data, defined here as dispensing summed over the four quarters 
up to and including the quarter in which the sample was submitted, was used. There 
is limited evidence to suggest what is an appropriate time lag between being 
dispensed an antibiotic and an increased risk of resistance to that antibiotic 
occurring; different (longer) lag periods could have been examined. Albrich et al. 
(2004) suggested that a period of one to two years seemed plausible but varying this 
period could affect the association between dispensing and resistance.  The study of 
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Hillier et al. (2007) found that up to 6 months seemed the most important time period 
between dispensing of the antibiotic and resistance. 
 
The relationship between antibiotic dispensing and resistance, after adjusting for 
practice, sample and patient characteristics, is not easy to interpret; there may be 
confounders that we have not been able to take into account. Adjusting for time 
allows for the possibility of a systematic change in resistance over time, not related 
to dispensing. Antibiotic dispensing is also correlated with time (collinearity), 
making the association harder to interpret. It is also possible that adjusting for year 
could have resulted in over-adjusting, masking any true associations.     
 
The analysis looking at change in dispensing and resistance was restricted to a sub-
sample of practices (N=275, around 65%) of practices in Wales with reliable data. 
Again these practices were not entirely representative of either the Welsh population 
or the set of general practices but this is unlikely to introduce much bias. Sensitivity 
analyses were run on these practices examining the relationship between lagged 
antibiotic dispensing and resistance and results were comparable for most 
organism/antibiotic combinations to using all practices with resistance data. 
  
6.5.3 Comparisons with existing literature 
6.5.3.1 Prevalence and trends in resistance 
6.5.3.1.1 H. influenzae 
From our data, resistance rates in 2006 for amoxicillin and tetracyclines in  
H influenzae isolates were 19.3% and 1.6% respectively and both decreased 
significantly over time. These rates were lower than the published all-Wales figures 
of 20.1% and 2.4% respectively (which included specimens sent from hospitals as 
well as the community) (Welsh Antimicrobial Resistance Programme Surveillance 
Unit 2007). Figures from a UK based surveillance programme showed similar trends 
in amoxicillin resistance in community-acquired lower RTIs, between 1999/2000 and 
2003/04 at around 20%, before dropping to 16% in 2004/05 (Morrissey et al. 2008). 
They did however observe a higher increase in resistance of around 30% in 2006/07. 
In the same study, tetracycline resistance was higher (3.5% in 1999/2000) than our 
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figure but also decreased over time (1.2% in 2006/07). The Alexander Surveillance 
Project, a longitudinal study of antimicrobial resistance in participating European 
countries, found wide between country variations in beta-lactamase resistance in H. 
influenzae isolates e.g. from 2.9% in Italy to 35.6% in France in 2001(Felmingham et 
al. 2005). Increasing trends in resistance between 1992 and 2001 were seen in 
France, Belgium and the UK although it decreased in Poland, Switzerland, Germany, 
Spain and Italy (percentages not stated). In 2001, Wales and the UK had relatively 
high beta-lactamase resistance in comparison to other countries but high resistance 
was also seen in the US (24.5% in 2001), Hong Kong (22%) and Saudi Arabia 
(28.2%). 
 
6.5.3.1.2 S. pneumoniae 
Resistance rates in 2006 for erythromycin and penicillin in S. pneumoniae isolates 
were 11.7% and 3.8% respectively with resistance to erythromycin significantly 
increasing over time. These rates were comparable to the all-Wales figures published 
of 11.9% and 4.5% respectively (which included hospital specimens as well as the 
community) (Welsh Antimicrobial Resistance Programme Surveillance Unit 2007). 
Figures from the British Society for Antimicrobial Chemotherapy (BSAC) resistance 
website showed no real trend in erythromycin non-susceptibility (resistance and 
intermediate results) between 2001 and 2006 (14.1% and 14.3% respectively) 
(British Society for Antimicrobial Chemotherapy). Non-susceptibility to penicillin 
fell between 2001 and 2006 (from 8.8% to 4.8%) although here non-susceptibility 
consisted of intermediate results only.  
 
Several studies have shown that the prevalence of resistance to penicillin and 
erythromycin in S. pneumoniae isolates varied widely. The Alexander Project 
showed that penicillin resistance was lowest in the UK and Germany with 1.1% and 
1.4% respectively, and highest in Spain and France (30.2% and 35.8% respectively) 
(Felmingham et al. 2005). Another study examining resistance rates between eight 
European countries found that overall, 26.8% of S. pneumoniae isolates were non-
susceptible to penicillin (including amoxicillin) between 2001 and 2003 but again 
rates varied between countries (Austria 4.4% to 70.9% in Spain) (Reinert et al. 
2005). Data from the European Antimicrobial Resistance Surveillance System 
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(EARSS) suggested huge variation in non-susceptibility to penicillin across 
European countries in 2005 with Romania, Bulgaria and Israel having the highest 
(over 30%) and the UK, Sweden, Norway having less than 5% (SWEDRES 2005). 
The Alexander Project showed that erythromycin resistance in 2001 exceeded that of 
penicillin resistance in France, Germany, Italy, the UK and USA; Poland had the 
lowest resistance rates with 8.3% and France the highest 56.4% (Felmingham et al. 
2005). Resistance to erythromycin (measured by clarithromycin resistance) varied 
within European countries, from 10% in Austria to 43.6% and 46.1% in Spain and 
France respectively (Reinert et al. 2005). Outside Europe, resistance to both 
antibiotics was also particularly high in the USA and Hong Kong (Felmingham et al. 
2005). 
 
Significant increases (between 1992 and 2001) have been shown worldwide in 
resistance to penicillin in S. pneumoniae isolates (Felmingham et al. 2005). In 
Europe there was an overall average increase in penicillin resistance of 8.1% over 
this 10 year period with the greatest increase seen in France, from 7.7% to 35.8%. 
Resistance rates also increased in the USA from 5.6% to 20.4%. Penicillin resistance 
decreased between 1996 and 2001 for Belgium and Poland. In Sweden, trends in 
penicillin resistance (or reduced susceptibility) decreased between 1997 and 2005 
(from 10.1 to 7.3 per 100,000 population) (Cars et al. 2005). Between 1996 and 
2001, increases were observed in erythromycin resistance in several countries with 
only Poland decreasing (Felmingham et al. 2005).  
 
6.5.3.1.3 S. pyogenes 
In 2006, erythromycin resistance in S. pyogenes isolates was 4.5%, comparable to the 
all-Wales figures published of 3.5% (Welsh Antimicrobial Resistance Programme 
Surveillance Unit 2007). Significant increases have been shown in resistance to 
macrolides in S. pyogenes isolates in many countries such as Italy, Poland and 
Belgium (Cornaglia et al. 1998; Szczypa et al. 2004; Malhotra-Kumar et al. 2005). 
For example in Poland, Szczypa et al. (2004) found that resistance to erythromycin 
increased from 1.8% in 1996/97 to 12% in 1998/99 and to 25.1% in 2000/02, and in 
Belgium, Malhotra-Kumar et al. (2005) demonstrated a 13% increase in macrolide 
resistance between 1999 and 2003. Although a general increase in Europe has been 
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observed, resistance rates to macrolides still varied between countries. Between 1994 
and 2000, resistance rates to macrolide resistance varied, with northern European 
countries showing low levels (0 to 4%) and Greece, Italy and Spain demonstrating 
the highest levels (29% to 38%) (Albrich et al. 2004). The PROTEKT antimicrobial 
surveillance programme (with 25 participating countries worldwide), found that 
overall, almost 10% of all S. pyogenes isolates were resistant to erythromycin A (in 
1999/2000) (Cantón et al. 2002). Similarly, northern European countries such as 
Austria, Belgium, the Netherlands and the UK showed little resistance and the 
highest rates of macrolide resistance were observed in Poland, Italy and Portugal 
(42%, 25% and 24% respectively). 
  
6.5.3.2 Risk factors 
A limited number of studies have examined factors associated with resistance. One 
study examined non-susceptibility to penicillin in S. pneumoniae isolates from 
invasive samples (from blood and cerebrospinal fluid) and found that rates were 
higher in the elderly and in young children (Buccholz et al. 2001). Additionally 
Bédos et al. (1996) found that resistance to penicillin in S. pneumoniae isolates was 
higher in samples taken from patients under 15 years of age and in samples from the 
upper respiratory tract or from the sinus and middle ear. These findings differ from 
our results where resistance to penicillin was significantly lower in 5-15 year olds 
(when compared to 0-4 year olds) and higher in the 85 plus age group. Resistance 
was also higher in sputum samples.  
 
Resistance to penicillin in H. influenzae was more likely in younger (0-19 years) and 
older (70 and over) patients (Reynolds et al. 2002). Conversely in tetracyclines, 
susceptibility decreased with age indicating that non-susceptibility was higher in the 
elderly. Again, these findings differ from our results where resistance to amoxicillin 
was lower in the younger age groups and no association was found between 
tetracycline resistance and age.   
 
6.5.3.3 Associations between antibiotic dispensing and resistance 
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The association between overall antibiotic use in the community and antibiotic 
resistance has been well described at European (Bronzwaer et al. 2002; Albrich et al. 
2004; Goossens et al. 2005; van de Sande-Bruinsma et al. 2008), regional (Arason et 
al. 1996; Granizo et al. 2000; Boccia et al. 2002; Garcia-Rey et al. 2002), general 
practice (Priest et al. 2001) and individual levels (Melander et al. 1998; Nasrin et al. 
2002; Chung et al. 2007; Malhotra-Kumar et al. 2007). Most of these studies have 
been in S. pneumoniae isolates, examining associations between penicillin and 
erythromycin resistance, and total antibiotic, beta-lactam, penicillin and macrolide 
use. The majority of these studies found a significant correlation between antibiotic 
use (or sales) and antibiotic resistance. One study found no clear relationship 
between penicillin and erythromycin resistance in S. pneumoniae isolates and 
prescribing of penicillin or beta-lactams (Priest et al. 2001).  
 
For H. influenzae isolates, only one study has examined the effect of beta-lactam use 
and resistance (Chung et al. 2007). This study, performed at the individual level in 
children, found that prescribing amoxicillin to a child doubles the risk of isolation of 
beta-lactamase resistant Haemophilus species from that child’s throat two weeks 
later.  They concluded that there is a short term effect of resistance in children being 
prescribed amoxicillin which is sufficient to sustain a high level of antibiotic 
resistance in the population. In S. pyogenes isolates, macrolide resistance was 
significantly correlated with macrolide use between 1994 and 2000 at a country 
level, for 20 countries (r=0.71, p= 0.004) (Albrich et al. 2004). Another study carried 
out at country level also found a weaker significant correlation (r=0.65, p=0.0015) 
between erythromycin use and macrolides in 1999/2000 in 21 European countries 
(Goossens et al. 2005).   
 
Few studies have demonstrated that reductions in antibiotic prescribing are 
associated with reduced levels of antibiotic resistance in the community especially in 
the organisms under examination in this study. In S. pyogenes isolates, two studies in 
Japan and Finland have shown that reductions in macrolide use were associated with 
reductions of resistance to erythromycin (Fujita et al. 1994; Seppälä et al. 1997). In 
S. pneumoniae isolates in Iceland the prevalence of penicillin-resistant pneumococci 
isolates fell after a campaign to reduce antibiotic prescribing for children (Arason et 
al. 1996). A controlled study in France showed that an education intervention 
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resulted in fewer antibiotics being prescribed in a community setting which led to 
significant reductions in rates of colonisation with penicillin G-nonsusceptible S. 
pneumoniae in children (Guillemot et al. 2005). A reduction in antibiotic prescribing 
was followed by a reduction in the percentage of penicillin-resistant pneumococci 
between 1997 and 2000 (Vardhan et al. 2003). More recently in E. coli isolates, a 
reduction in antibiotic dispensing between 1996 and 2003 at a general practice level 
was associated with reduced antibiotic resistance to ampicillin and trimethoprim 
(Butler et al. 2007).  
 
6.5.4 Implications of findings for clinical practice and future research 
Analysis of this individual level resistance data has been crucial to our understanding 
of antibiotic resistance for a large population of individuals in Wales; how they vary 
over time, by type of organism and antibiotic they are resistant to and also the 
variation in rates between general practices and laboratory. As previously discussed 
with antibiotic dispensing data, surveillance of trends is important, especially in 
identifying any problems or unexpected increases. Surveillance is required to track 
any such changes to see if these trends continue. In Wales, up to date information on 
antimicrobial resistance rates in primary and secondary care is monitored by the 
Welsh Antimicrobial Resistance Programme, established by Public Health Wales as 
a response to the increasing problems of antimicrobial resistance. Surveillance of 
resistance is essential when rates are fairly low, and is possible at a national level. 
This is harder at a local level due to the small number of isolates of organisms that 
are tested each year and so large studies are required, but the ability to examine local 
factors is then limited. 
 
Although ecological level dispensing data was used to examine the association 
between antibiotic resistance and dispensing levels in general practices, sophisticated 
methodological techniques such as multilevel modelling as opposed to simple 
correlations were used. Multilevel modelling not only allowed variations in 
resistance at both general practice and laboratory levels to be examined, but 
confounders such as age, gender, the site of the specimen, and time trends could be 
adjusted for. As has been highlighted before, there are limitations to ecological 
analyses, as findings found at this level may hide associations at the individual level. 
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This study identified positive associations between resistance to several different 
organism/antibiotic combinations and antibiotic dispensing. Therefore, whilst these 
data cannot be used to make predictions about antibiotic use and resistance in 
individual patients, it would be worthwhile in future research to examine individual-
patient records linking individual clinical, microbiology, and prescribing records on a 
large scale (such as the General Practice Research Database (GPRD) and the Secure 
Anonymised Information Linkage (SAIL)).  
 
No associations were found between reductions in dispensing and reductions in 
resistance rates over the eight-year period. There may be a number of reasons for 
this. Firstly the number of isolates may be insufficient to warrant looking at 
reductions in resistance by quartiles of reductions in dispensing and categorising 
reductions in this way may hide important associations. Secondly antibiotic 
resistance may take longer to return to previous levels than the time it took for 
antibiotic resistance to increase after excessive use (Albrich et al. 2004). For 
example, if resistance decreased slowly, such situations may lead to different 
associations between use and resistance. Further analysis therefore may be required 
when more current data becomes available and more sophisticated methodology 
could be used, e.g. by using change in resistance as an outcome and looking at its 
association with change in dispensing whilst adjusting for practice, patient and 
sample characteristics. Future work would be beneficial in the area of exploring the 
impact of different lag periods of dispensing on resistance, and also defining 
duplicate isolates as the results are surprising in that resistance rates are not higher 
than the ‘non-duplicates’. The cut-off of 91 days from the initial isolate is arbitrary 
and exploration is required to see if it varies by the organism under examination.  
 
6.6 Introduction to hospital events for complications in Wales 
In summary, this chapter uniquely used a large dataset at the individual patient level 
using robust methods, to examine up to date trends in antibiotic resistance in Wales 
and any associations between resistance and antibiotic dispensing. Chapter 7 will 
similarly examine the status of hospital admissions of complications arising from 
respiratory tract infections using Welsh hospital admissions data.   
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Chapter 7  Hospital events for acute RTIs and 
complications in Wales 
7.1 Introduction 
Chapters 5 and 6 identified that both overall antibiotic dispensing in Wales and 
amoxicillin and tetracycline resistance in H. influenzae isolates had significantly 
decreased over the study period whilst erythromycin resistance in S. pneumoniae 
isolates had significantly increased.   
 
As a result of GPs reducing their antibiotic prescribing, concerns have been raised 
that instead of reducing inappropriate antibiotic prescribing, a ‘blanket’ reduction in 
prescribing has occurred indicating that prescribing that may benefit patients may 
also be decreasing. Patients most likely to benefit from antibiotics may therefore be 
harmed through unintended adverse events such as complications that can arise from 
untreated RTIs, such as pneumonia and rheumatic fever. It is hypothesised that a 
decrease in antibiotic dispensing might lead to an increase in hospital admissions 
from these complications.  
 
Therefore, to complete the picture of the relationship between antibiotic dispensing, 
resistance and clinical outcomes in Wales, all-Wales trends in hospital admissions 
for acute RTIs, and complications that can arise from them, were investigated using 
routinely collected data. Annual and quarterly trends were examined retrospectively 
over the period 1996 to 2006 for all ages and for children aged 0-14 years. Where 
numbers allowed, the variation in trends of certain RTIs and complications by 
general practices and LHBs were examined, and possible factors that may be 
associated with these variations using practice demographic factors were determined.  
 
The reason for examining acute RTIs alongside complications is that if a patient was 
admitted as an in-patient to hospital and subsequently diagnosed with an acute RTI, 
then the infection must be at the more severe end of the spectrum of infections. 
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7.2 Methods 
7.2.1 Data source - Patient Episode Database for Wales (PEDW) 
The function of the Patient Episode Database for Wales (PEDW) is to provide data 
on hospital admissions in Wales; it is the equivalent of the hospital episodes statistics 
database in England. Data are supplied by all NHS Trusts in Wales on completion of 
a patient's episode of care to the NHS Wales Informatics Service (NWIS), which 
collates, validates and stores the data on behalf of the Welsh Assembly Government 
and the NHS in Wales. Monthly submissions are received and added to PEDW, with 
over 800,000 records captured every year.  
 
PEDW was implemented in April 1991 and contains all inpatient and day case 
activity (as well as regular attendees and maternity admissions) in NHS Wales 
(including non-Welsh treated in Wales), together with data for Welsh residents 
treated in English Trusts. It excludes patients treated in private hospitals and any 
patients admitted to beds that are not under the care of a consultant e.g. in a nurse-led 
or midwifery-led unit. PEDW records contain patient demographics such as age, sex, 
place of residence and ethnicity, administrative details such as key dates, hospital, 
specialty and consultant, and clinical details such as diagnoses and operative 
procedures. Diagnoses included in the patient’s records use a coding system known 
as ICD10 (International Statistical Classification of Diseases and Related Health 
Problems, 10
th
 revision) and procedure codes use the OPCS coding system (versions 
4.2 to 4.5) (Office of Population, Censuses and Surveys Classification of Surgical 
Operations and Procedures). 
 
7.2.2 PEDW records 
Individual records are submitted to PEDW on the basis of a patient's consultant 
episode, that is the time an admitted patient spends in the continuous care of one 
consultant within one NHS trust. A new consultant episode record is generated if the 
patient is transferred to the care of another consultant. A new consultant episode 
record is also generated if the patient is discharged and re-admitted at a later date.  
 
PEDW consultant episodes can be linked into larger hospital spells. According to the 
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PEDW definition of a hospital spell, any episodes that take place during the same 
continuous stay in one hospital (i.e. between admission and discharge) are said to be 
part of the same hospital spell. Where a patient is transferred from one hospital to 
another, a new hospital spell is generated. Compared to episodes, hospital spells 
provide more of an admissions-based view of the data, which more closely aligns 
with a patient event-based view of the world. However, it should be noted that 
hospital spells are still highly dependent on NHS organisational structures, and have 
been developed mainly with the requirements of finance or performance 
management in mind, where it may be reasonable to count activity in different 
hospitals separately. From the point of view of the actual patient, however, or indeed 
a researcher in public health, the entire continuous spell of care (independent of 
which hospitals are involved) is more likely to be of interest. 
 
7.2.3 Identifying acute RTIs and complications 
Episodes with acute RTIs or complications were identified according to whether their 
hospital diagnosis met any of the conditions listed in Appendix IX and Appendix X, 
looking only at the primary diagnosis. By examining the primary diagnosis we can 
attribute a single diagnosis to the admission i.e. it would be the main reason a patient 
came into hospital rather than any chronic or other condition they may have.  
Identifying a comprehensive list of ICD codes to capture all acute RTIs and 
complications was an extensive process. An academic GP searched all chapters of 
ICD10 to identify a list of the relevant acute RTIs and complications and this was 
double-checked by a further two GPs. An initial data request was put in to NWIS for 
overall patient numbers in Wales per annum for each ICD10 code, in order to 
identify which codes were feasible to analyse individually and which codes would 
require grouping with others.  
 
7.2.4 Linking episodes 
The requirements for our analysis could not be met using traditional PEDW 
currencies such as spells or admissions, due to the NHS organisational dependence 
issues mentioned previously. Instead, an alternative definition of an event was 
developed, which took an initial episode (containing either an acute RTI or 
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complication) and linked with it all subsequent episodes of an acute RTI or 
complication starting within 91 days of its end date. The belief was that episodes 
within 91 days of each other were likely to arise from the same underlying infection 
(or organism) and therefore a single event represented a single infection (containing 
a number of episodes and diagnoses). The cut-off point of 91 days not only replicated 
that used in the antibiotic resistance data in Chapter 6 to identify duplicate samples, 
reflecting the likely maximum duration between two samples being part of the same 
infection, but also other papers that used a 3 month follow up to identify hospital 
admissions in patients (Winchester et al. 2009).  
 
Patients may have had more than one event if their episodes were more than 91 days 
apart, assuming a new infection. If a patient was diagnosed with the same ICD10 
code more than once within an event then it was only counted once, again to avoid 
double counting diagnoses within an event. Figure 7.1 shows the different scenarios 
that could arise in the dataset.  
 
Figure 7.1 Scenarios of patients’ events and consultant episodes in hospital 
 
Patient 2
Patient 1
91 days after end date of initial episode of event
Event 1
Event 1
Episode 1
Episode 1
Episode 2
Episode 3
Episode 3
Episode 4
Event 2
Patient 3
Episode 1
Event 1
Episode 4
Event 2
Episode 2
 
 
Patient 1 had one episode with no subsequent episodes in the 91 days after the end 
date of episode 1, thus the event contained the single event. Patient 2 had two events; 
both events contained two episodes (within 91 days of each other) but since episode 
3 occurred more than 91 days after the end date of episode 1, a new event was 
generated. Thus although episode 3 was close to episode 2 it is the duration from 
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episode 1 that is important. Similarly patient 3 had three episodes within 91 days of 
each other but episode 4 started after 91 days, hence generating a new event. 
 
7.2.5 Study population and period 
Data were requested on hospital events for acute RTIs and complications for the 
whole population of Wales (Welsh residents treated anywhere). The dataset was 
constrained to cover events with an initial episode starting between January 1996 and 
December 2006. Therefore initial episodes of events starting in late 2006 may have 
had subsequent related episodes in early 2007. Events were excluded if their first 
episode started before 1996.  
 
7.2.6 Dataset fields 
For each event per patient the following information was obtained: event and patient 
identification number, episode number, episode start and end dates, diagnoses for 
each episode, (using ICD10 codes to 3 and 4 digits and descriptions), method of 
discharge (death, patient discharged him/herself, clinical discharge), age and gender 
of patient, deprivation score of the area in which the patient lived (based on 
Townsend scores) and the patient’s encrypted general practice code. Prior to receipt 
of the data, patient details were fully anonymised so no identifiable information, such 
as date of birth or postcode, was included.  
 
7.3 Statistical analysis 
7.3.1 Counting acute RTIs and complications 
An event contains episodes of either (a) acute RTIs only, (b) complications only or 
(c) both acute RTIs and complications. When counting the overall number of acute 
RTI events then all events falling into categories (a) and (c) will be included. Each 
event will be counted once irrespective of the number of distinct ICD10 codes within 
the event
1
. Similarly, the overall number of complication events will comprise of 
 
1
 Where a group of ICD10 codes is used to define an acute RTI or complication, e.g. Pneumonia with 
the group of codes J13 to J18, then if more than one of these diagnoses codes appeared within an 
event, they would only be counted once. 
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events falling into categories (b) and (c). When counting events for individual RTI or 
complication diagnoses (using ICD10 codes) each distinct diagnosis will be counted. 
If a single event contained several different acute RTI episodes with distinct 
diagnoses e.g. two episodes within one event, one of acute serous otitis media and 
one of acute sinusitis, these would each be counted for each relevant acute RTI 
category (Sinusitis and OM). 
 
7.3.2 Main analysis 
For each event, the year and quarter at the first episode start date were extracted and 
used for all subsequent episodes within that event. Counts of all-Wales hospital 
events for acute RTIs and complications (overall and individual) were converted into 
rates (per 10,000 or 100,000 population) and examined between 1996-2006, using 
Wales mid-year estimates of population data from the Office for National Statistics 
(Stats Wales, Welsh Assembly Government). For acute RTIs and complications with 
more than 50 events over the period, a basic single-level linear regression analysis 
was undertaken to establish all-Wales trends in rates of events for the individual 
acute RTIs and complications listed in Appendix IX and Appendix X. 
  
Counts of hospital events for acute RTIs and complications in Wales were 
aggregated at general practice level per annum to allow multilevel modelling (at the 
level of LHB (22 in Wales), Welsh general
 
practices (426 UTS) and time (1996-
2006)) . Due to the small numbers when data was aggregated at the general practice 
level, only events of overall acute RTIs, complications, pneumonia and septicaemia 
were examined for all ages. In children (aged 0-14 years), the numbers were even 
smaller and only overall acute RTIs and complications were studied.  
 
7.3.2.1 Poisson regression 
A three-level repeated measures Poisson regression model was fitted with 
independent counts of acute RTIs or complications as the outcome variable, to 
account and correct for variation at the level of LHB, practice and time. The model 
also included time and the following significant practice characteristics as 
explanatory variables:  
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 Percentages of the practice population aged 0-14 years, 15-64, and 65 and 
over  
 Single-handed status of the practice (single or multi-handed) 
 Practice deprivation quintile (based on Townsend 2001 scores) 
 Average age of GPs in a practice 
 Proportion of male GPs in a practice. 
 
Poisson regression was used since the data are constrained to be non-negative. Fitting 
a normal model could produce negative predicted counts. Therefore a Poisson model 
is fitted to the hospital events data using a log link function. An offset variable was 
created as the loge expected counts of complications per annum based on the 
practice’s list size (calculated by multiplying the complication rate over all practices 
by the practice’s list size). Including the offset allows comparison of the observed to 
expected counts taking account of the practice’s list size. 
 
Therefore, the Poisson regression model can be written in the following form:  
 22110 xx)countsexp(log)countsobs(log ee   






22110 xx
exp
obs
loge   
Standardised Incidence Ratio (SIR) = 
)xβxβ(β 22110exp
exp
obs 





 
 
For a one unit change in a predictor variable x, the log ratio of observed to expected 
counts would change by β, given the other predictor variables in the model were held 
constant. The ratio of observed to expected counts (or the Standardised Incidence 
Ratio (SIR)) would therefore change by exp(β). The aim was therefore to examine 
the distribution of this ratio over time and by practice characteristics. 
 
A characteristic of the Poisson distribution is that its mean is equal to its variance. 
For some sets of count data, when a Poisson model is a candidate, overdispersion 
occurs in which the observed variance is greater than the mean (usually in datasets 
with long-tailed distributions). An over-dispersed Poisson model can be assessed by 
allowing the level-1 error to be estimated. In these circumstances the Poisson model 
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is not appropriate. If the count in a practice has a Poisson distribution, but the mean 
varies between practices as a Gamma distribution, then the overall distribution is 
negative binomial which allows for this type of over-dispersion. The consequence of 
not taking overdispersion into account is that the standard errors are underestimated 
and so the null hypothesis may be rejected when it should not be. Therefore estimates 
from the negative binomial (NB) regression model were used as a comparison; these 
estimates are more conservative and standard errors are larger when dispersion is 
allowed for.  
 
In the case of the Poisson models, parameters were estimated using Monte Carlo 
Markov Chains (MCMC) methods to give less biased estimates, with initial estimates 
obtained by using the restricted iterative generalized least squares (RIGLS) 
estimation procedure (1
st
 order PQL). MCMC methods were used also to derive 
confidence intervals for non-symmetrical distributions. The Deviance Information 
Criterion (DIC) diagnostic was used to assess goodness of fit. MCMC in MLwiN 
often produces highly correlated chains (in part due to the fact that the parameters of 
the model are highly correlated; variance=mean) and therefore requires a substantial 
number of simulations, typically much larger than for Normal or for Binomial. 
MCMC methods cannot currently be used in NB models and estimates were obtained 
using the RIGLS procedure (1
st
 order PQL). 
  
All multilevel modelling was performed using MLwiN version 2.16 and all other 
analyses using SPSS version 16.0. 
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7.4 Results 
7.4.1 All-Wales events of hospital infections for acute RTIs and 
complications arising from RTIs  
A total of 320,752 events of infections (containing an acute RTI, a complication or 
both) were identified from 253,081 individual patients residing in Wales. These 
patients had a range of one to 28 events over the study period. A total of 162,950 
(50.8%) events were in males, 89,868 (28.0%) were in 0-14 year olds, 82,406 
(25.7%) in 15-64 year olds and 148,442 (46.3%) in the 65 and over age group. The 
majority of events (91.8%, 294,210 events) came from patients registered in 585 
unique Welsh practices, with 0.5% (1,751 events) from patients registered in 401 
non-welsh practices and 7.7% (24,791 events) where the practice was not recorded 
(but most likely to be Welsh). This section will examine the All-Wales data, based 
on 320,752 events. 
 
Within the 320,752 events were a total of 341,459 episodes (with distinct ICD10 
codes to 4 digits). The majority of events (301,236 (93.9%)) contained only one 
episode (no subsequent episodes within 91 days) and 19,516 (6.1%) events contained 
more than one episode (18,371 with 2 distinct episodes, 1,101 with 3 episodes, 42 
with 4 episodes and 2 with 5 episodes).  
 
Table 7.1 shows a breakdown of the number of episodes within an event by acute 
RTI or complication. Although for the first episode within an event there were 
roughly equal numbers of acute RTIs and complications, subsequent episodes were 
more likely to be complications. 
 
Table 7.1 Breakdown of acute RTI and complication episodes within an event 
 
 Episodes within an event N(%)  
 1st 2nd 3rd 4th 5
th
 Total 
Complications  166,260 
(51.8) 
14,995 
(76.8) 
929  
(81.1) 
34 
(77.3) 
2 
(100) 
182,220 
(53.4) 
Acute RTIs 
 
154,492 
(48.2) 
4,521 
(23.2) 
216 
(18.9) 
10 
(22.7) 
0 
(0) 
159,239 
(46.6) 
Total 
 
320,752 
(100) 
19,516 
(100) 
1145 
(100) 
44 
(100) 
2 
(100) 
341,459 
(100) 
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If an event has only one episode, this can either be an acute RTI or a complication. 
For events with more than one episode, these can either be all distinct diagnoses of 
an acute RTI (e.g. a first episode of ‘Acute tonsillitis’ followed by an episode of 
‘Other diseases of upper respiratory tract’ within 91 days) or a complication, or a 
combination of both (the above scenario followed by ‘Other abscess of pharynx’). Of 
the 320,752 events 150,441 (47%) contained only an RTI episode, 163,399 (51%) a 
complication episode and 6,912 (2%) contained at least one acute RTI and at least 
one complication episode. Thus, there was a total of 157,353 (150,441+6,912) events 
that contained an RTI episode and 170,311 that contained a complication 
(163,399+6,912). 
 
7.4.1.1 Trends in events of hospital infections 
The number of events (320,752) with a respiratory tract related infection (containing 
episodes of acute RTIs and/or complications arising from RTIs) per 10,000 
population increased by 32.4% between 1996 and 2006 (from 85.60 to 113.33 per 
10,000 population respectively) (Figure 7.2). After fitting a single-level linear 
regression, the trend indicated an increase of 2.19 events per 10,000 population per 
annum (95% confidence interval (CI) =1.38 to 3.00, p<0.001). 
 
Figure 7.2 Annual overall incidence of hospital events (for both acute RTIs and 
complications) (per 10,000 population) in Wales 
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Table 7.2 shows the rates and trends in acute RTIs and complications by age-group 
and gender. The number of events comprising of at least one RTI (157,353) per 
10,000 population increased by 13.6% between 1996 and 1999 (from 44.79 to 50.88 
per 10,000 population respectively) but thereafter the trend was more sporadic, 
finally rising to 53.29 per 10,000 population in 2006 (Figure 7.3). No significant 
increase over time was indicated by the single-level regression model (β=0.31, 95% 
CI=-0.30 to 0.92, p=0.280). The number of events comprising of at least one 
complication (170,311) per 10,000 population increased by 48.2% between 1996 and 
2006 (from 42.27 to 62.65 per 10,000 population) respectively and this trend was 
significant (an increase of 1.99 events per 10,000 population per annum, 95% 
CI=1.66 to 2.31, p<0.001) (Figure 7.3).  
 
Figure 7.3 Annual incidence of events (per 10,000 population) by acute RTIs and 
complications in Wales 
 
  
 
 
 
 
 
 
 
 
 
 
A smoother pattern of hospital events for complications over time is apparent 
compared to the more sporadic pattern of events for acute RTIs. The quarterly rates 
show the seasonal variation with higher rates in quarter 1 (January to March) and 
lower in quarter 3 (July to September) (Figure 7.4). 
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Figure 7.4 Quarterly incidence of events (per 10,000 population) by acute RTIs and 
complications arising from RTIs in Wales 
 
Time=1 (January-March 1996) to 44 (October-December 2006) 
 
Trends of event rates of acute RTIs by gender were stable. The 0-14 year age group 
had higher rates of acute RTIs than the 15-64 and 65 and over age groups but again 
all trends were stable over time (Figure 7.5).  
 
Figure 7.5 Quarterly incidence of acute RTIs events (per 10,000 population) by age 
group, in Wales 
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Table 7.2 Annual incidence of events (per 10,000 population) of acute RTIs and complications by age group and gender in Wales, 
1996-2006 
 
 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
 % 
change 
96-06 
All Events 
 
85.60 93.04 94.07 99.68 95.02 100.20 99.62 109.24 99.31 108.74 113.33 32.4 
Acute RTI events              
Total acute RTIs 44.79 48.50 49.31 50.88 48.15 50.98 46.42 52.17 44.40 49.91 53.29 19.0 
Age group 0-14 118.38 129.27 131.00 124.74 115.89 125.10 115.00 139.07 118.51 129.25 152.66 29.0 
 15-64 15.67 16.42 17.38 18.84 19.83 20.98 17.50 18.97 16.26 18.58 20.75 32.4 
 65+ 68.51 75.23 74.96 86.32 77.82 80.63 79.40 82.90 71.37 84.44 73.69 7.6 
Gender Male 46.93 50.76 52.63 51.66 48.53 52.01 47.83 52.66 44.20 49.39 54.65 16.5 
 Female 42.75 46.29 46.13 50.13 47.77 49.99 45.07 51.70 44.58 50.41 51.98 21.6 
             
Complication events             
Total complications 42.27 46.09 46.73 50.89 49.01 51.56 55.34 59.34 57.23 61.59 62.65 48.2 
Age group 0-14 18.83 25.19 24.42 24.42 21.83 22.07 28.29 26.61 23.87 27.68 29.63 57.4 
 15-64 17.46 19.28 19.26 21.13 20.86 22.62 24.37 24.87 23.89 25.93 27.03 54.8 
 65+ 158.38 166.90 171.36 189.15 182.25 189.65 197.58 219.84 213.82 226.40 225.71 42.5 
Gender Male 46.60 51.09 50.58 54.52 52.69 55.43 59.52 62.02 60.99 64.01 65.63 40.8 
 Female 38.17 41.31 43.05 47.42 45.52 47.90 51.40 56.81 53.66 59.28 59.82 56.7 
1
9
5
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For complications, event rates were higher in males than females and both increased 
over time. Adults aged 65 and over had a higher rate of events and also saw a 
significant increase over time (β=7.08 per 10,000 population aged 65 years and over 
per annum, 95% CI=5.82 to 8.34, p<0.001) (Figure 7.6). There was also a significant 
increase in the 15-64 age group (β=0.90 per 10,000 population aged 15-64 years per 
annum, 95% CI=0.75 to 1.06, p<0.001). Rates for children (0-14 age group) were 
more stable over the period (β=0.67 per 10,000 population aged 0-14 years per 
annum, 95% CI=0.15 to 1.18, p=0.017). 
 
Figure 7.6 Quarterly incidence of complication events (per 10,000 population) by 
age group, in Wales 
 
 
Time=1 (January-March 1996) to 44 (October-December 2006) 
 
7.4.2 Events of hospital infection by type of acute RTI 
In Wales between 1996 and 2006, there were 158,948 episodes of acute respiratory 
tract related hospital infection of which 77,576 (49%) were in children aged 0-14 
years. There were fewer episodes of acute RTIs than reported in table 7.1 (159,239) 
since within an event there may be more than one acute RTI episode with a distinct 4 
digit ICD10 code but since in these analyses, codes are combined (such as J20/J22) 
then they would only be counted once (Table 7.3). Therefore some events may have 
more than one J20/J22 episode but these are only counted once i.e. one event had a 
code of either J20 or J22. 
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Table 7.3 Example of two events containing several episodes 
 
Event ID Episode 1 Episode 2 Episode 3 Note 
1 J202   J22X                                                                                                                                                                                                                                                            -                   Event counted once in
J20/J22 acute RTI 
2 J209  J208                                                                                                                                                                                                                                                            J157                      Event counted once in 
J20/J22 and once in J15 
 
Table 7.4 and Table 7.5 show these events classified by type of acute RTIs, for all 
ages and children respectively. The most common acute RTI for all ages was acute 
bronchitis and unspecified acute lower respiratory infections (ICD10 codes J20 and 
J22 respectively) with a total of 68,958 (21.5%) events over the 11 year period, and a 
mean rate per annum of 214.65 (per 100,000 Welsh mid-year population). Only 
9,224 (13.4%) of these events were attributable to children (0-14 age group) with 
40,580 (58.8%) attributable to adults in the 65 and over age group. The next most 
common across all ages were acute nasopharyngitis and acute upper respiratory 
infections of multiple and unspecified sites (J00 and J06 respectively) with a total of 
44,474 events over the 11 year period and a mean rate per annum of 138.47 (per 
100,000 population). Acute nasopharyngitis and acute upper respiratory infections of 
multiple and unspecified sites were the most common in children with 39,448 events 
(89% of events for all ages). The second most common acute RTI in children were 
acute pharyngitis and tonsillitis (J02 and J03 respectively) which appeared in 19,831 
events (62.4% of all events for all ages). Events of otitis media were also common in 
children 0-14 years of age, constituting over 72% of OM events for all ages. 
  
Table 7.4 Hospital events of infections in Wales by diagnosis of acute RTIs between 1996 and 2006-all ages
i 
 
   Rate per 100,000 population    
ICD10 
codes  
Description Total events  Mean rate  
per annum 
  
1996 2006 % change β
ii
 (se),  
p-value 
J20/J22 Acute bronchitis (exc. viruses) 
and unspecified acute lower 
respiratory infections                                                                                                                                                                                                                              
68,958 
 
214.65 182.93 220.10 20.3 2.304 (1.459) 
p=0.149 
J00/J06 Acute nasopharyngitis and acute 
upper respiratory infections of 
multiple and unspecified sites                                                                                                                                                                                                                                                                                                                                                                                                                                   
44,474 138.47 130.74 141.04 7.9 -0.139 (1.167) 
p=0.908 
J02/J03 Acute pharyngitis and acute 
tonsillitis                                                                                                                                                                                                                                                
31,761 98.77 87.75 145.18 65.5 3.649 (1.259)  
p=0.018 
H659 
H664 
H669 
Unspecified otitis media (non-
suppurative and suppurative) 
10,900 33.99 41.02 26.16 -36.2 -2.142 (0.237) 
p<0.001 
H650 
H651 
H660 
Acute otitis media (serous, non-
suppurative and suppurative)                                                                                                                                                                                                                                      
1,016 3.17 3.77 2.50 -33.8 -0.187 (0.069) 
p=0.024
J04 Acute laryngitis and tracheitis                                                                                                                                                                                                                                  937 2.92 2.49 1.99 -20.1 -0.078 (0.045)
p=0.115 
J01 Acute sinusitis                                                                                                                                                                                                                                                  902 2.81 2.80 2.29 -18.2 -0.064 (0.030)
p=0.057 
H67 Otitis media in diseases classified 
elsewhere                                                                                                                                                                                                     
0 - - - - - 
i
 Table sorted by total events 
 
ii 
Coefficient for trend using single-level linear regression model with rates as the outcome variable 
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Table 7.5 Hospital events of infections in Wales by diagnosis of acute RTIs between 1996 and 2006-children aged 0-14 years
i 
 
   Rate per 100,000 children population   
ICD10 
codes  
Description Total 
events  
(% of all 
ages) 
Mean rate 
per annum 
1996 2006 % change β
ii
 (se),  
p-value 
J20/J22 Acute bronchitis (exc. viruses) 
and unspecified acute lower 
respiratory infections                                                                                                                                                                                                                              
9,224 
(13.4) 
153.81 121.81 197.79 62.4 4.760 (1.870) 
p=0.031 
J00/J06 Acute nasopharyngitis and acute 
upper respiratory infections of 
multiple and unspecified sites                                                                                                                                                                                                                                                                                                                                                                                                                                   
39,448 
(88.7) 
657.78 608.86 720.68 18.4 5.225 (5.559) 
p=0.372 
J02/J03 Acute pharyngitis and acute 
tonsillitis                                                                                                                                                                                                                                                
19,831 
(62.4) 
330.67 289.45 511.18 76.6 1.469 (0.470) 
p=0.012 
H659 
H664 
H669 
Unspecified otitis media (non-
suppurative and suppurative) 
7,920 
(72.7) 
132.06 161.76 115.22 -28.8 -7.837 (1.429) 
p<0.001 
H650 
H651 
H660 
Acute otitis media (serous, non-
suppurative and suppurative)                                                                                                                                                                                                                                      
726 (71.5) 12.11 13.73 9.60 -30.1 -0.540 (0.320) 
p=0.126
J04 Acute laryngitis and tracheitis                                                                                                                                                                                                                                  281 (30.0) 4.69 3.39 2.30 -32.0 -0.262 (0.123)
p=0.063 
J01 Acute sinusitis                                                                                                                                                                                                                                                  146 (16.2) 2.43 1.78 2.50 40.0 -0.027 (0.067)
p=0.694 
H67 Otitis media in diseases classified 
elsewhere                                                                                                                                                                                                     
0 - - - - - 
i
 Table sorted by total events for all ages 
 
ii 
Coefficient for trend using single-level linear regression model with rates as the outcome variable 
1
9
9
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7.4.2.1 Trends in acute RTIs 
Trends over all ages by type of acute RTI are shown in Figure 7.7 and results from a 
single-level linear regression model used to estimate the trend in acute RTI rates are 
shown in the last column of table 7.4 and 7.5. Significant decreases were found in 
event rates of otitis media (OM), which fell by 36.0% between 1996 and 2006 (from 
44.65 to 28.56 per 100,000 population respectively). This decrease was seen in both 
acute OM (H650/H65/H660) and unspecified OM (non-suppurative and suppurative) 
(H659/H664/H669) with rates significantly falling by 0.187 (95% CI= 0.031 to 
0.343, p=0.024) and 2.142 (95% CI=1.607 to 2.677, p<0.001) per annum per 
100,000 population respectively (an absolute decrease of 33.8% and 36.2% between 
1996 and 2006).  
 
Figure 7.7 Annual incidence of events (per 100,000 population) by acute RTI type, 
in Wales 
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Unspecified OM was most common in children, whose rates decreased 28.8% 
between 1996 and 2006 (from 161.76 to 115.22 per 100,000 children population 
respectively) (Figure 7.8). For the 15-64 and 65 plus age groups, rates of unspecified 
OM were much lower, peaking in 2000 but thereafter decreasing. 
 
Figure 7.8 Annual incidence of unspecified otitis media events (per 100,000 
population) by age group, in Wales 
 
 
 
 
 
 
 
 
 
 
 
Event rates for acute pharyngitis and tonsillitis significantly increased over the period 
by 65.5% between 1996 and 2006 (from 87.75 to 145.18 per 100,000 respectively). 
Trends in acute pharyngitis and tonsillitis examined separately showed that this trend 
was mainly due to acute tonsillitis; rates for acute pharyngitis were stable (Figure 
7.9).  
 
Figure 7.9 Annual incidence of acute pharyngitis and tonsillitis events (per 100,000 
population) in Wales 
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Broken down by age group, events for acute pharyngitis and tonsillitis were more 
common in children although there was still an upward trend in the 15-64 age groups 
(rate of increase of 1.469 per annum per 100,000 population (96% CI=0.405 to 
2.532) p=0.012) (Figure 7.10). More specifically in children, acute pharyngitis and 
tonsillitis events were more common in the 1-4 year olds and the 5-9 year olds with 
an 89.4% and 92.4% increase respectively between 1996 and 2006. Significantly 
increasing trends were found in these age groups (β=3.003, 95% CI=1.546 to 4.459, 
p=0.001 and β=1.638, 95% CI=0.305 to 2.971, p=0.021 respectively). 
 
Figure 7.10 Annual incidence of acute pharyngitis and tonsillitis events (per 10,000 
population) by age group, in Wales 
 
 
 
The increase in tonsillitis may be accounted for by the decision to stop 
tonsillectomies in September 2002, with only emergency tonsillectomies being 
performed until February/March 2003 when tonsillectomies were restarted. Figure 
7.11 shows the European age standardised rates (EASRs) for Wales for tonsillectomy 
admissions (Heath Solutions Wales, Health Maps Wales). Tonsillectomy rates 
dropped in 2002 (taken as financial year 2002/03) in Wales and rose again in 2003. 
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Figure 7.11 Hospital admissions for tonsillectomies (European age standardised 
rates (EASRs)) in Wales, 2001 and 2006 
 
 
 
 
 
 
 
 
 
 
 
7.4.3 Events of hospital infection by type of complication 
Tables 7.6 and 7.7 show the overall number of events of complications, the average 
rate per annum as well as the rates in 1996 and 2006, the percentage change in rates 
between these years and the coefficient for trend from a single-level linear regression 
model for all ages and children.  
 
The most common complications seen in hospital were for pneumonia (ICD10 codes 
J13 to J18) with 71,823 events over the study period and a mean rate per annum of 
223.35 per 100,000 population, and COPD with acute lower respiratory infections 
(J440) and COPD with acute exacerbation unspecified (J441) which had 28,608 and 
37,223 events respectively (mean rates per annum of 88.88 and 115.85 per 100,000 
population respectively) (Table 7.6).  
 
Pneumonia was also the most common complication in children aged between 0-14 
years with 13% of total pneumonia events and a mean rate of 159.08 per annum 
(Table 7.7). Second most common in children was meningococcal infection (A39) 
making up 78% of total meningococcal events (mean rate per annum of 27.79). 
Children made up 97% of all scarlet fever events (A38) and acute lymphadenitis of 
face, head and neck, other sites and unspecified (L040/L048/L049) were also more 
common in children with 72% of all events.
  
Table 7.6 Hospital events of infections in Wales by complications arising from RTIs between 1996 and 2006-all ages
i 
 
   Rate per 100,000 population   
ICD10 codes  Description Total 
events  
Mean rate 
per annum 
1996 2006 % change β
ii
 (se),  
p-value 
J13 to J18 Pneumonia 71,823 223.35 189.95 277.86 46.3 9.361 (1.297) 
p<0.001 
J18 Pneumonia, organism 
unspecified                                                                                                                                                                                                                                  
67,686 210.48 177.26 262.05 47.8 9.040 (1.215) 
p<0.001
J441 COPD with acute 
exacerbation, unspecified                                                                                                                                                                                                  
37,223 115.85 94.63 116.66 23.3 1.781 (0.788) 
p=0.05
J440 COPD with acute lower 
respiratory infections 
(excludes with influenza) 
28,608 88.88 43.23 120.10 177.8 7.531 (0.681) 
p<0.001 
A40/A41 Septicaemia 10,860 33.73 22.07 51.52 133.5 2.815 (0.257) 
p<0.001 
A41 Other septicaemia                                                                                                                                                                                                                                                9,935 30.93 19.78 47.64 140.8 2.648 (0.245) 
p<0.001 
J90/J91 Pleural effusion  9,336 29.02 20.96 38.98 86.0 1.697 (0.150) 
p<0.001 
J36/ J390/ 
J391 
Peritonsillar, 
retropharyngeal, 
parapharyngeal and other 
pharynx abscesses 
5,059 15.74 12.94 16.86 30.3 0.365 (0.103) 
p=0.006 
J36 Peritonsillar abscess 
(quinsy)                                                                                                                                                                                                                                        
4,946 15.39 12.66 16.39 29.4 0.348 (0.102) 
p=0.008
J47 Bronchiectasis                                                                                                                                                                                                                                                   3,252 10.11 8.34 12.21 46.4 0.417 (0.044)
p<0.001 
J15 Bacterial pneumonia, not 
elsewhere classified                                                                                                                                                                                                                    
2,702 8.40 6.61 11.50 74.0 0.452 (0.088) 
p=0.001 
A39 Meningococcal infection 2,154 6.72 7.26 4.38 -39.7 -0.523 (0.136) 
p=0.004 
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Table 7.6 Hospital events of infections in Wales by complications arising from RTIs between 1996 and 2006-all ages
i 
 
   Rate per 100,000 population   
ICD10 codes  Description Total 
events  
Mean rate 
per annum 
1996 2006 % change β
ii
 (se),  
p-value 
J40 Bronchitis, not specified as 
acute or chronic                                                                                                                                                                                                                    
2,093 6.52 7.30 7.22 -1.1 -0.007 (0.076) 
p=0.927
M001/M002/ 
M008/M009 
Pyogenic arthritis 1,872 5.83 5.29 6.10 15.3 0.053 (0.048) 
p=0.298 
I00/I01/I02/ 
I301/I33/I38 
Rheumatic fever 1435 4.47 4.18 4.45 6.3 -0.040 (0.035) 
p=0.286 
J13 Pneumonia due to 
Streptococcus pneumoniae                                                                                                                                                                                                                        
1,233 3.84 4.63 4.69 1.1 0.042 (0.064) 
p=0.529 
A40 Streptococcal septicaemia                                                                                                                                                                                                                                        954 2.97 2.32 3.98 71.7 0.173 (0.029)
p<0.001 
J86 Pyothorax (includes 
empyema, abscess of 
pleura, thorax, 
pyopneumothorax)                                                                                                                                                                                                                                                        
942 2.93 2.28 4.18 83.2 0.177 (0.042) 
p=0.002 
J398/J399 Other specific and 
unspecific diseases of 
upper respiratory tract 
850 2.66 3.15 0.71 -77.5 -0.264 (0.210) 
p=0.240 
H70/H75 Mastoiditis and related 
conditions and other 
disorders of middle ear 
and mastoid 
840 2.62 2.80 1.82 -35.0 -0.179 (0.052) 
p=0.007 
G00/G01/G042 
/G048/G050 
Bacterial meningitis, 
encephalitis, myelitis, 
encephalomyelitis. 
820 2.55 2.94 2.83 -3.7 -0.049 (0.038) 
p=0.232 
L040/L048/ 
L049 
Acute lymphadenitis of 
face, head and neck, other 
sites and unspecified  
758 2.36 1.49 2.36 58.7 0.062 (0.039) 
p=0.148 
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Table 7.6 Hospital events of infections in Wales by complications arising from RTIs between 1996 and 2006-all ages
i 
 
   Rate per 100,000 population   
ICD10 codes  Description Total 
events  
Mean rate 
per annum 
1996 2006 % change β
ii
 (se),  
p-value 
G00 Bacterial meningitis 718 2.24 2.84 2.60 -8.5 -0.052 (0.039) 
p=0.215 
J14 Pneumonia due to 
Haemophilus influenzae                                                                                                                                                                                                                          
500 1.56 1.87 1.75 -6.1 -0.025 (0.020) 
p=0.239 
J340 Abscess, furuncle and 
carbuncle of nose                                                                                                                                                                                                                          
338 1.05 1.04 0.98 -5.8 0.029 (0.018) 
p=0.141 
G06 Intracranial and intraspinal 
abscess and granuloma                                                                                                                                                                                                               
281 0.87 0.62 1.05 67.9 0.043 (0.014) 
p=0.015
J85 Abscess of lung and 
mediastinum                                                                                                                                                                                                                                  
262 0.82 0.80 0.57 -27.9 0.006 (0.014) 
p=0.707
J051 Acute epiglottitis                                                                                                                                                                                                                                               259 0.80 0.52 1.11 114.5 0.062 (0.020)
p=0.013 
A491/A492/ 
A493 
Bacterial infection of 
unspecified site 
(Streptococcal, 
Haemophilus influenzae, 
Mycoplasma) 
239 0.74 0.38 0.81 112.7 0.023 (0.015) 
p=0.165 
M028/M029 Reactive arthropathies  216 0.67 0.55 0.78 40.1 0.025 (0.019) 
p=0.226 
N00/N01 Acute and rapidly 
progressive nephritic 
syndrome                                                                                                                                                                                    
200 0.62 1.18 0.30 -74.2 -0.041 (0.022) 
p=0.092 
A481 Legionnaires' disease                                                                                                                                                                                                                                            145 0.45 0.35 0.94 173.0 0.037 (0.014) 
p=0.028 
A38 Scarlet fever                                                                                                                                                                                                                                                    122 0.38 0.38 0.37 -2.5 0.004 (0.013)
p=0.780 
G08 Intracranial and intraspinal 110 0.34 0.38 0.44 15.2 0.016 (0.016) 
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Table 7.6 Hospital events of infections in Wales by complications arising from RTIs between 1996 and 2006-all ages
i 
 
   Rate per 100,000 population   
ICD10 codes  Description Total 
events  
Mean rate 
per annum 
1996 2006 % change β
ii
 (se),  
p-value 
phlebitis and 
thrombophlebitis                                                                                                                                                                                                   
p=0.342 
 
 
The following codes had <50 events in total and could not be analysed for trends: 
J16 Pneumonia due to other infectious 
organisms (not elsewhere classified)  
B961 Klebsiella pneumoniae as the cause of disease 
classified to other chapters                                                                                                                                                                                                               
A70 Chlamydia psittaci infection A36 Diptheria 
B960 Mycoplasma pneumoniae as the cause of 
disease classified to other chapters                                                                                                                                                                                                               
M010/M013 Meningococcal arthritis and arthritis in other 
bacterial diseases classified elsewhere                                                                                                  
J170/J178 Pneumonia in bacterial and other 
diseases classified elsewhere 
L540 Erythema marginatum in acute rheumatic fever 
   M03 Postinfective and reactive arthropathies in disease 
classified elsewhere 
i 
Table sorted by total events 
 
ii 
Coefficient for trend using single-level linear regression model with rates as the outcome variable 
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Table 7.7 Hospital events of infections in Wales by complications arising from RTIs between 1996 and 2006-children aged 0-14 
years
i 
 
   Rate per 100,000 children 
population 
  
ICD10 codes  Description Total events  
(% of all ages) 
Mean rate 
per annum 
1996 2006 % 
change 
βii (se),  
p-value 
J13 to J18 Pneumonia 9,506 (13) 159.08 109.68 204.13 86.1 0.032 (0.047) 
p=0.517 
J18 Pneumonia, organism 
unspecified                                                                                                                                                                                                                                  
8,901 (13) 148.95 103.26 190.11 84.1 0.113 (0.063) 
p=0.107
A39 Meningococcal infection 1,676 (78) 27.79 26.57 19.97 -24.8 -1.820 (0.638) 
p=0.019 
A40/A41 Septicaemia 630 (6) 10.55 8.20 14.21 73.2 0.546 (0.146) 
p=0.005 
L040/L048/ 
L049 
 
Acute lymphadenitis of face, 
head and neck, other sites and 
unspecified   
 
544 (72) 9.11 4.28 11.14 160.2 0.550 (0.173) 
p=0.011 
J15 Bacterial pneumonia, not 
elsewhere classified                                                                                                                                                                                                                    
508 (19) 8.51 4.46 12.87 188.6 0.457 (0.069) 
p<0.001
A41 Other septicaemia                                                                                                                                                                                                                                                472 (5) 7.92 6.24 11.71 87.7 0.531 (0.112) 
p=0.001 
J36/ J390/ 
J391 
Peritonsillar, retropharyngeal, 
parapharyngeal and other 
pharynx abscesses 
417 (8) 6.96 3.92 6.14 56.6 0.052 (0.074) 
p=0.501 
J36 Peritonsillar abscess (quinsy)                                                                                                                                                                                                                                        396 (8) 6.61 3.92 5.38 37.0 -0.057 (0.111) 
p=0.622 
G00/G01/ 
G042/G048/ 
G050 
Bacterial meningitis, 
encephalitis, myelitis, 
encephalomyelitis. 
357 (44) 5.96 4.99 7.11 42.3 0.127 (0.111) 
p=0.281 
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Table 7.7 Hospital events of infections in Wales by complications arising from RTIs between 1996 and 2006-children aged 0-14 
years
i 
 
   Rate per 100,000 children 
population 
  
ICD10 codes  Description Total events  
(% of all ages) 
Mean rate 
per annum 
1996 2006 % 
change 
βii (se),  
p-value 
G00 Bacterial meningitis 334 (47) 5.57 4.99 6.91 38.4 0.070 (0.119) 
p=0.571 
H70/H75 Mastoiditis and related 
conditions and other disorders 
of middle ear and mastoid 
311 (37) 5.18 3.92 4.99 27.3 -0.010 (0.090) 
p=0.916 
M001/M002/
M008/M009 
Pyogenic arthritis 250 (13) 4.17 4.10 4.61 12.4 -0.057 (0.111) 
p=0.622 
J40 Bronchitis, not specified as 
acute or chronic                                                                                                                                                                                                                    
203 (10) 3.32 6.96 0.19 -97.2 -0.815 (0.142) 
p<0.001 
J86 Pyothorax (includes 
empyema, abscess of pleura, 
thorax, pyopneumothorax)                                                                                                                                                                                                                                                        
160 (17) 2.71 1.96 5.76 193.7 0.457 (0.069) 
p<0.001 
A40 Streptococcal septicaemia                                                                                                                                                                                                                                        159 (17) 2.65 1.96 2.50 27.3 0.020 (0.056)
p=0.723 
A38 Scarlet fever                                                                                                                                                                                                                                                    118 (97) 1.97 1.96 2.11 7.7 0.062 (0.071)
p=0.410 
A491/A492/ 
A493 
Bacterial infection of 
unspecified site 
(Streptococcal, Haemophilus 
influenzae, Mycoplasma) 
110 (46) 1.84 0.36 1.92 438.4 0.123 (0.074) 
p=0.133 
J441 COPD with acute 
exacerbation unspecified                                                                                                                                                                                                     
107 (0.3) 1.84 0.00 9.03 - 0.618 (0.176) 
p=0.007 
J90/J91 Pleural effusion  105 (1) 1.76 1.96 2.69 37.0 0.113 (0.063) 
p=0.107 
J13 Pneumonia due to 101 (8) 1.69 1.25 2.11 69.2 0.076 (0.046) 
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Table 7.7 Hospital events of infections in Wales by complications arising from RTIs between 1996 and 2006-children aged 0-14 
years
i 
 
   Rate per 100,000 children 
population 
  
ICD10 codes  Description Total events  
(% of all ages) 
Mean rate 
per annum 
1996 2006 % 
change 
βii (se),  
p-value 
Streptococcus pneumoniae                                                                                                                                                                                                                        p=0.134  
M028/M029 Reactive arthropathies  96 (44) 1.60 1.25 1.15 -7.7 0.052 (0.074) 
p=0.501 
N00/N01 Acute and rapidly progressive 
nephritic syndrome                                                                                                                                                                                    
81 (41) 1.34 4.46 0.96 -78.5 -0.152 (0.100) 
p=0.165 
J398/J399 Other specific and unspecific 
diseases of upper respiratory 
tract 
81 (10) 1.34 2.68 0.96 -64.1 -0.152 (0.100) 
p=0.165 
J47 Bronchiectasis                                                                                                                                                                                                                                                   77 (2) 1.29 0.54 1.15 115.3 0.032 (0.047)
p=0.517 
I00/I01/I02/ 
I301/I33/I38 
Rheumatic fever 62 (4) 1.04 1.07 1.92 79.5 0.061 (0.048) 
p=0.241 
The following codes had <50 events in total and could not be analysed for trends: 
A36 Diptheria J16 Pneumonia due to other infectious organisms 
(not elsewhere classified) 
A481 Legionnaires' disease                                                                                                                                                                                                                                            J170/J178 Pneumonia in bacterial and other diseases
classified elsewhere 
A70 Chlamydia psittaci infection J340 Abscess, furuncle and carbuncle of nose                                                                                                                                                                                                                          
B960 Mycoplasma pneumoniae as the cause of 
disease classified to other chapters                                                                                                                                                                                                              
J440 COPD with acute lower respiratory infections 
(excludes with influenza)
B961 Klebsiella pneumoniae as the cause of disease 
classified to other chapters                                                                                                                                                                                                            
J85 Abscess of lung and mediastinum                                                                                                                                                                                                                                  
G06 Intracranial and intraspinal abscess and 
granuloma                                                                                                                                                                                                               
L540 Erythema marginatum in acute rheumatic 
fever  
G08 Intracranial and intraspinal phlebitis and M03 Postinfective and reactive arthropathies in 
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Table 7.7 Hospital events of infections in Wales by complications arising from RTIs between 1996 and 2006-children aged 0-14 
years
i 
 
   Rate per 100,000 children 
population 
  
ICD10 codes  Description Total events  
(% of all ages) 
Mean rate 
per annum 
1996 2006 % 
change 
βii (se),  
p-value 
thrombophlebitis                                                                                                                                         disease classified elsewhere-
J051 Acute epiglottitis                                                                                                                                                                                                                                               M010/M013 Meningococcal arthritis and arthritis in other
bacterial diseases classified elsewhere                                                                                                                                                                                                       
J14 Pneumonia due to Haemophilus influenzae                                                                                                                                                                                                                           
i
 Table sorted by total events; 
 
ii 
Coefficient for trend using single-level linear regression model with rates as the outcome variable 
  
2
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7.4.3.1 Trends in complications 
7.4.3.1.1 COPD and pneumonia 
Over all ages, the most common complications were pneumonia and COPD; they 
showed significant increases in rates and changes over time are shown in Figure 
7.12. For COPD with acute lower respiratory infections (excludes with influenza) 
(J440), the rate of infection significantly increased over the 11 year period by  
7.531 per 100,00 population per annum (95% CI=5.992 to 9.071, p<0.001). For 
COPD with acute exacerbation, unspecified (J441), the trend was not significant 
(β=1.781, 95% CI=-0.001 to 3.563, p=0.05). 
 
For pneumonia, the rate of infection significantly increased over the 11 year period 
by 9.361 events per 100,000 population per annum (95% CI=6.426 to 12.296, 
p<0.001) (Figure 7.12).  
 
Figure 7.12 Annual incidence of pneumonia and COPD events (per 100,000 
population) in Wales 
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The increase in overall pneumonia rates was mainly from two ICD10 codes: bacterial 
pneumonia, not elsewhere classified (J15) and pneumonia, organism unspecified 
(J18) which increased by 0.452 (95% CI=0.253 to 0.650) and 9.040 (95% CI=6.290 
to 11.789) events per 100,000 population per annum, respectively (Figure 7.13). For 
both codes, the increases were seen in the predominantly elderly age group (65 year 
and over) (J15: β=1.529, 95% CI=0.813 to 2.246, p<0.001 and J18: β=29.442, 95% 
CI=18.115 to 40.770, p<0.001) (Figure 7.14 and Figure 7.15). A significant increase 
was also seen for children (0-14 years of age) in bacterial pneumonia (β=0.457, 95% 
CI=0.301 to 0.613, p<0.001).  
 
Figure 7.13 Annual incidence of pneumonia events by type (per 100,000 population) 
in Wales 
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Figure 7.14 Annual incidence of bacterial pneumonia, not elsewhere classified (J15) 
events by type (per 100,000 population), by age group 
 
 
 
Figure 7.15 Annual incidence of pneumonia, organism unspecified (J18) events by 
type (per 100,000 population), by age group 
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7.4.3.1.2 Septicaemia, pleural effusion, peritonsillar abscess and 
bronchiectasis 
Events of septicaemia, pleural effusion, peritonsillar abscess (quinsy), and 
bronchiectasis also showed increases in rates over time (Figure 7.16). The increase in 
the rate of septicaemia infections (A40 and A41) was highly significant over time 
(β=2.815, 95% CI=2.233 to 3.397, p<0.001) with a 133.5% increase over time (from 
22.07 events per 100,000 population in 1996 to 51.52 events per 100,000 population 
in 2006). This result was again replicated in children with a 73.2% increase over time 
(from 8.20 to 14.21 events per 100,000 children population respectively). Although 
most of the cases of septicaemia were classified as “other septicaemia” (A41), 
positive trends were also observed in “streptococcal septicaemia” (A40), although 
the latter was not replicated in children. 
 
Figure 7.16 Annual incidence of bronchiectasis, peritonsillar abscess, pleural 
effusion and septicaemia events (per 100,000 population) in Wales 
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The increase in streptococcal septicaemia (A40) was seen in both the 15-64 and the 
65 and over age group (β=0.103, 95% CI=0.066 to 0.14, p<0.001 and β=0.590, 95% 
CI=0.288 to 0.892, p=0.002 respectively). For events coded as other septicaemia 
(A41), rates were higher in the under 1 and 65+ age groups where significant 
increases were observed (β=5.302, 95% CI=2.387 to 8.217, p=0.003 and β=10.566, 
95% CI=8.637 to 12.494, p<0.001 respectively) (Figure 7.17). 
 
Figure 7.17 Annual incidence of other septicaemia (A41) events (per 100,000 
population) by age group, in Wales 
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7.4.3.1.3 Other complications 
Figure 7.18 shows the change over time of some less common complications such as 
for pyothorax (including empyema), epiglottitis, intracranial and intraspinal abscess 
and granuloma, and legionnaire’s disease. These results should be interpreted with 
caution as the numbers of events per annum were small (on average <25 events per 
annum), with the exception of pyothorax (on average 85 events per annum). 
 
Figure 7.18 Annual incidence of pyothorax, acute epiglottitis, legionnaire’s disease 
and intracranial and intraspinal abscess events (per 100,000 population), in Wales 
 
   
 
Events of infection for both pyothorax (includes empyema) (J86) and intracranial and 
intraspinal abscess and granuloma (G06) significantly increased over time. In 
pyothorax, these significant increases were mainly seen in the 15-64 and 65 and over 
age group. The trend in intracranial and intraspinal abscess and granuloma was also 
seen in children aged 0-14 years. The significant increases over the time period in 
events of acute epiglottitis (J051), and legionnaire’s disease (A481) were not seen in 
children 0-14 years of age.  
 
Complications that significantly increased over time for all ages but were not seen in 
children were pleural effusion (J90 and J91), peritonsillar abscess (including quinsy) 
(J36/ J390/J391) and bronchiectasis (J47). For pleural effusion, an 86.0% increase 
was seen between 1996 and 2006 (from 20.96 to 38.98 per 100,000 population 
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respectively) (β=1.697, 95% CI=1.357 to 2.037). Increases were mainly seen in 
pleural effusion and bronchiectasis in the 65 and over age group (β=6.640, 95% 
CI=5.178 to 8.103, p<0.001) and (β=2.217, 95% CI=1.587 to 2.846, p<0.001 
respectively) and in the 15-64 age group for peritonsillar abscess (β=0.498, 95% 
CI=0.176 to 0.820, p=0.007). Acute lymphadenitis of face, head and neck 
(L040/L048/L049), abscess, furuncle and carbuncle of nose (J340) were both seen to 
increase in children only (Figure 7.19) although the numbers of events for abscess, 
furuncle and carbuncle of nose were very small. 
 
Figure 7.19 Annual incidence of abscess, furuncle and carbuncle of nose and acute 
lymphadenitis of face, head and neck events (per 100,000 children population) in 
children, in Wales 
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7.4.3.1.4 Complications decreasing over the study period 
For all ages, the rate of meningococcal infection and mastoiditis significantly 
decreased over the period by 39.7% and 35.0% respectively (Figure 7.20). In 
meningococcal infection, a significant decrease was seen over all age groups. In 
mastoiditis, the decrease was seen in all age groups apart from in the 0-4 year olds, 
where rates increased from 3.34 to 8.74 events per 100,000 population (β =0.525, 
p=0.05, 95% CI=0.001 to 1.049). The rate of bronchitis also decreased significantly 
over time in children (β=-0.815, 95% CI=-1.137 to -0.493). 
 
Figure 7.20 Annual incidence of mastoiditis and meningococcal infection events  
(per 100,000 population), in Wales 
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7.4.4 Multilevel modelling of hospital events  
7.4.4.1 Acute RTIs 
To examine how hospital events varied by general practice this section of the 
analysis was restricted to the 426 UTS practices in Wales and covered 2,802,319 
(94.5%) of the Welsh population. In total 127,306 events of hospital based RTIs 
were identified from these practices during the study period (1996 to 2006). The 
number of hospital events for acute RTIs per practice per annum ranged from 0 to 
152 with a median of 23 (25th to 75th percentile =14 to 37) (Figure 7.21). The median 
acute RTI rate was 41.02 per 10,000 practice population (25th to 75th percentile =29.47 
to 54.55) and ranged from 0 to 240.66 per annum.  
 
Figure 7.21 Histogram of the rate of acute RTIs (per 10,000 practice population) 
practice per annum 
 
 
 
For acute RTIs over all ages, a Poisson model which incorporated time, deprivation 
quintile, average age of the GP and percentages of the practice population that were 
children (aged 0-14) and aged 65 and over was found to be the best fit (DIC 
=32922.04 when compared to model with time only DIC =33536.11) (Table 7.8). For 
all ages, time and deprivation quintile were treated as continuous terms rather than 
categorical since a linear association was found with respect to acute RTIs. For 
children, time was treated as a categorical variable as no linear association was found 
with event of acute RTIs. There was some indication of over-dispersion with a level 
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1 variance of 2.27. A negative binomial (NB) model was therefore run for 
comparison purposes although resulted in small differences in the parameter 
estimates. Therefore estimates from the Poisson model were used.  
 
The Poisson (MCMC) model found that the SIR (i.e. observed / expected count of all 
acute RTIs) increased over time by a factor of 1.034 (95% CI=1.015 to 1.052) per 
annum. That is, the risk of an acute RTI hospitalisation increased by 3.4% each year. 
This result differed from that found in the single level model where the trend was not 
significant. 
 
Table 7.8 Multilevel model for standardised incidence rates (SIRs) for acute RTI 
hospital events-all ages and children 
 
 Loge parameter estimate (SE) SIR
i
 (95% CI) 
Parameters Negative 
binomial 
Poisson 
(MCMC)  
Poisson 
(MCMC) 
All ages    
Year (1996 to 2006) 0.032 (0.008) 0.033 (0.009) 1.034 (1.015 to 1.052) 
Deprivation quintile
ii
 0.070 (0.011) 0.068 (0.010) 1.070 (1.050 to 1.092) 
% practice pop aged 
0-14 
0.052 (0.004) 0.056 (0.004) 1.058 (1.049 to 1.066) 
% practice pop aged 
65 and over 
0.021 (0.004) 0.021 (0.003) 1.021 (1.015 to 1.027) 
Average age of GPs 
 (years) 
0.006 (0.002) 0.004 (0.002) 1.004 (1.000 to 1.008) 
Children     
1996 Ref Ref 1.000 
1997 0.109 (0.031) 0.101 (0.022) 1.106 (1.060 to 1.155) 
1998 0.316 (0.030) 0.322 (0.021) 1.380 (1.324 to 1.438) 
1999 0.338 (0.030) 0.342 (0.021) 1.408 (1.351 to 1.467) 
2000 0.267 (0.030) 0.274 (0.021) 1.315 (1.262 to 1.370) 
2001 0.344 (0.030) 0.355 (0.021) 1.426 (1.369 to 1.486) 
2002 0.261 (0.031) 0.275 (0.021) 1.317 (1.263 to 1.372) 
2003 0.449 (0.030) 0.459 (0.020) 1.582 (1.522 to 1.646) 
2004 0.281 (0.030) 0.293 (0.021) 1.340 (1.286 to 1.397) 
2005 0.368 (0.030) 0.376 (0.021) 1.456 (1.398 to 1.518) 
2006 0.539 (0.030) 0.539 (0.020) 1.714 (1.648 to 1.783) 
Deprivation quintile 0.093 (0.013) 0.090 (0.013) 1.094 (1.067 to 1.122) 
i 
Observed over expected counts 
ii 
1 =least deprived to 5 =most deprived 
 
 
 
 
Chapter 7 
223 
A positive association also existed between the rate of acute RTIs and deprivation 
quintile, indicating that more deprived practices (based on the average deprivation 
score of the practice population) were more likely to have patients presenting in 
hospital with an acute RTI. Acute RTIs were also more likely to have been seen in 
practices with a higher proportion of children aged 0-14 and also of patients aged 65 
and over. That is, the risk of an acute RTI hospitalisation increased by 58% with 
every 10% increase of 0-14 year olds in the practice population and by 21% with 
every 10% increase of 65 year olds and over in the practice population. There was 
also some indication that the risk of acute RTIs in hospital was higher in practices 
with older GPs. 
 
There was nearly twice as much variability in log SIRs between practices 
(σ2u0=0.121 (SE=0.010)) than between local health boards (LHBs) (σ
2
v0=0.075 
(SE=0.028)). There was still however significant variation in the LHBs’ departure 
from the average intercept (β0) and slope (β1) as shown in the caterpillar plots below 
(Figure 7.22).  
 
Figure 7.22 Caterpillar plots: LHB-level residuals ( 1.96SD) vs. rank 
 
 
 
 
 
 
 
Chapter 7 
224 
At the practice level, one practice in particular had a greater positive departure from 
the overall intercept but this practice initially had a high number of hospital events 
for acute RTIs which reduced over time (Figure 7.23). 
 
Figure 7.23 Caterpillar plots: Practice-level residuals ( 1.96SD) vs. rank 
 
 
 
A similar relationship held for acute RTI hospitalisations in children; rates in all 
acute RTIs significantly increased over time and the same positive association with 
deprivation was shown. There was still significant variation at both LHB and general 
practice level. 
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7.4.4.2 Complications 
In total 130,023 events of complications arising from acute RTIs were identified 
from the 426 UTS practices during the study years (April 1996 to March 2006). The 
number of hospital events for complications per practice per annum ranged from 0 to 
157 with a median of 27 (25
th 
to 75
th
 percentile =15 to 40) (Figure 7.24). The median 
complication rate (per 10,000 practice population) was 46.16 (25
th 
to 75
th
 percentile 
=33.48 to 60.23) and practice rates ranged from 0 to 166.32. 
 
Figure 7.24 Histogram of complication rates (per 10,000 practice population) per 
practice per year 
 
 
 
A model which incorporated time, deprivation quintile, average age of the GP and 
percentages of the practice population that were aged 15 to 64 and 65 plus was found 
to be the best fit (DIC 32210.53 when compared to the null model=DIC 38021.73) 
(Table 7.9). Time and deprivation were treated as continuous variables rather than 
categorical since a linear association was found with respect to complications. Again 
there was some indication of over-dispersion with a level 1 variance of 1.89 and a 
negative binomial (NB) model was also run for comparison purpose. The NB model 
showed little differences in the parameter estimates and results from the Poisson 
model were used. The Poisson model confirmed that the SIR increased over time by 
a factor of 1.068 per annum, a stronger effect than in RTIs. A positive association 
also existed between complications and deprivation quintile, indicating that practices 
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with a lower deprivation quintile (based on the average deprivation score of the 
practices population) were more likely to have patients presenting in hospital with a 
complication. 
 
Table 7.9 Multilevel model for standardised incidence rates (SIRs) for hospital 
events for complications-all ages and children 
 
 Loge parameter estimate (SE) SIR
i
 (95% CI) 
Parameters Negative 
binomial 
Poisson 
(MCMC) 
Poisson 
(MCMC) 
All ages    
Year (1996 to 2006) 0.060 (0.007)  0.066 (0.006) 1.068 (1.056 to 1.081) 
Deprivation quintile
ii
 0.094 (0.008) 0.093 (0.008) 1.097 (1.080 to 1.115) 
% practice pop aged 
0-14 
0.031 (0.003) 0.035 (0.003) 1.036 (1.030 to 1.042) 
% practice pop aged 
65 and over 
0.039 (0.003) 0.040 (0.003) 1.041 (1.035 to 1.047) 
Average age of GPs 
 
0.004 (0.002) 0.004 (0.001) 1.004 (1.002 to 1.006) 
Children     
Year  0.039 (0.011) 0.039 (0.010) 1.040 (1.020 to 1.060) 
Deprivation quintile 0.043 (0.012) 0.043 (0.011) 1.044 (1.022 to 1.067) 
i 
Observed over expected counts 
ii 
1 =least deprived to 5 =most deprived 
 
Complications were also more likely to have been seen in practices with a higher 
proportion of elderly patients aged under 15 and 65 and over. There was also some 
indication that the risk of complications was higher from practices with older GPs. 
Variability between practices (σ2u0=0.075 (SE=0.007)) and between LHBs 
(σ2v0=0.065 (SE=0.023) were similar. There was significant variation in the LHBs’ 
departures from the average intercept (β0) and slope (β1) and those with the steepest 
positive slopes were LHBs from the more deprived areas in Wales (Figure 7.25). 
Similarly, hospital events of complications in children increased significantly 
linearly over time and the same positive association with deprivation was shown. 
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Figure 7.25 Caterpillar plots: LHB-level residuals ( 1.96SD) vs. rank 
 
 
 
7.4.4.3 Pneumonia 
The number of hospital events for pneumonia over all ages per practice per annum 
ranged from 0 to 65 with a mean of 12.57 (SD=8.95) events. Practice rates in 2006 
varied greatly, from 0 to 4019.67 per 100,000. For pneumonia a very similar pattern 
to overall complications existed albeit a weaker association; an upward trend over 
time and a positive association with deprivation quintile and percentage of the 
practice population aged under 15 and 65 and over (Table 7.10). The level 1 variance 
was 1.51 and a negative binomial (NB) model was again run for comparison 
purposes. From the Poisson model, there was more variation between practices 
(σ2u0=0.083 (SE=0.010)) than LHBs (σ
2
v0=0.056 (SE=0.021)).  
   
Table 7.10 Multilevel model for standardised incidence rates (SIRs) for pneumonia 
hospital events-all ages 
 
 Loge parameter estimate (SE) SIR
i
 (95% CI) 
Parameters Negative 
binomial 
Poisson 
(MCMC) 
Poisson 
(MCMC) 
All ages    
Year (1996 to 2006) 0.065 (0.006) 0.063 (0.005) 1.065 (1.055 to 1.076) 
Deprivation quintile
ii
 0.057 (0.008) 0.053 (0.008) 1.054 (1.038 to 1.071) 
% practice pop aged 
0-14 
0.026 (0.004) 0.025 (0.003) 1.025 (1.019 to 1.031) 
% practice pop aged 
65 and over 
0.041 (0.003) 0.038 (0.002) 1.039 (1.035 to 1.043) 
i 
Observed over expected counts; 
ii 
1 =least deprived to 5 =most deprived 
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7.4.4.4 Septicaemia 
The number of hospital events for septicaemia per practice per annum ranged from 0 
to 20 with a mean of 1.95 (SD=2.12). Practice rates in 2006 varied greatly between 0 
to 284.81 per 100,000 population in 2006. For septicaemia a very similar pattern to 
that for pneumonia existed, with an upward trend over time and a positive 
association with the practice’s deprivation quintile where septicaemia rates were 
significantly higher in deprivation quintile 5 (most deprived) when compared to 
quintile 1 (least deprived). Septicaemia was also more likely to have been seen in 
practices with a higher proportion of patients aged under 15 and 65 and over (Table 
7.11). The level 1 variance was 1.092. There was more variation between LHBs 
(σ2v0=0.078 (SE=0.028) than practices (σ
2
u0=0.021 (SE=0.005)). 
 
Table 7.11 Multilevel model for standardised incidence rates (SIRs) for septicaemia 
hospital events-all ages 
 
 Loge parameter estimate (SE) SIR
i
 (95% CI) 
Parameters Negative 
binomial 
Poisson 
(MCMC)  
Poisson 
 (MCMC) 
All ages    
Year (1996 to 2006) 0.099 (0.004) 0.100 (0.004) 1.105 (1.097 to 1.114) 
Deprivation quintile 
1 (least deprived) 
 
Ref 
 
Ref 
 
1 
2 0.050 (0.043) 0.049 (0.044) 1.050 (0.963 to 1.145) 
3 0.016 (0.046) 0.024 (0.047) 1.024 (0.934 to 1.123) 
4 0.059 (0.047) 0.062 (0.048) 1.064 (0.968 to 1.251) 
5 (most deprived) 0.128 (0.050) 0.124 (0.051) 1.132 (1.024 to 1.257) 
% practice pop aged 
0-14 
0.015 (0.006) 0.015 (0.005) 1.015 (1.005 to 1.025) 
% practice pop aged 
65 and over 
0.048 (0.004) 0.047 (0.005) 1.048 (1.038 to 1.058) 
i 
Observed over expected counts 
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7.4.5 Comparison of results from single- and multi-level modelling 
Table 7.12 shows the estimates for the parameter year (1996 to 2006) from the 
single- and multi-level models for each diagnosis over all ages. The actual estimates 
here are not comparable; only the direction and significance of the trend indicated by 
the confidence intervals. For most diagnoses (complications, pneumonia, 
septicaemia) the estimates demonstrate a significant trend in events but in acute 
RTIs, the single level showed no significant trend but a weak trend was shown using 
multilevel modelling.  
 
Table 7.12 Comparison of estimates for year from the single- and multilevel 
modelling - parameter estimate (confidence interval) 
 
Diagnosis Single-level linear 
regression 
Multi-level poisson 
regression 
Acute RTIs 0.31 (-0.30 to 0.92)
i
 1.034 (1.015 to 1.052) 
Complications 1.99 (1.66 to 2.31)
i
 1.068 (1.056 to 1.081) 
Pneumonia 0.94 (0.64 to 1.23)
ii
 1.065 (1.055 to 1.076) 
Septicaemia 0.28 (0.22 to 0.34)
ii
 1.105 (1.097 to 1.114) 
 i 
rate per 10,000 population
 
ii 
rate per 100,000 population 
iii
 Standardised incidence rates (observed over expected counts)
 
 
In acute RTIs, the difference in results of the trend in rates obtained from the single 
and multilevel models can perhaps be partly explained by the different number of 
practices used in both analyses. The single-level model used all-Wales rates per 
annum based on Wales mid-year population estimates. The multilevel model used 
practice level rates for the 426 “Up-to-Standard” (UTS) Welsh practices only. 
 
Figure 7.26 a and b show the impact of restricting the analysis to UTS practices, on 
annual acute RTI and complication rates. From 1999 onwards, rates from UTS 
practices, although lower, reflect the same pattern seen in the all-Wales data. 
However, some discrepancies are highlighted in the early period, particularly 
between 1996 and 1998, when rates appear to have been consistently much lower in 
the UTS practices. The only explanation that could be given for this is that there 
were a high proportion of patients (24,791, 7.7% of the total population with an 
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event) not allocated to a genuine practice code (as it was unknown); when the dataset 
was restricted to the UTS practices these patients would have been excluded. The 
explanation in the inconsistency over time may come from improvements in data 
quality; as improvements were made, the proportion of patients allocated to a 
genuine practice code would increase. Therefore the number of patients excluded as 
a result of restricting the analysis to UTS practices would decrease over time. For 
example, 25% of the unallocated patients were in 1996, which reduced to 4% in 2006 
(6,210 unallocated patients to 1,002 respectively).  
 
Figure 7.26 Comparison of acute RTI and complication event rates (per 10,000 
population) from all-Wales and ‘Up to Standard’ (UTS) practices 
 
(a) Acute RTI event rates 
 
(b) Complication event rates 
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7.5 Discussion 
7.5.1 Main findings  
This study sought to examine trends in hospital admissions of acute respiratory tract 
infections (RTIs) and complications for the population of Wales over a 10 year 
period. Between 1996 and 2006, hospital events (comparable to admission rates) of 
acute RTIs had increased by 19% and after adjusting for practice characteristics, 
significant increases in trends remained. There was great variation in the rate of acute 
RTIs by Local Health Board (LHB) and general practices in Wales, both in the 
number of events and trends. Not all practices saw an increase in acute RTIs over 
time with some observing a reduction which is not surprising given that the trend 
was barely significant. A positive association existed between events and deprivation 
quintile (practices with a more deprived practice population were more likely to have 
patients presenting in hospital with an acute RTI), and were also more likely to have 
been seen in practices with a higher proportion of children aged 0-14 and also of 
patients aged 65 and over. There was also some indication that the risk of acute RTIs 
was higher in practices with on average older practising GPs. Similarly, hospital 
events of acute RTIs in children increased significantly over time. 
 
Events of acute bronchitis were the most common hospitalisation over all ages and in 
children significantly increased over time (using single-level regression). Events of 
acute nasopharyngitis and acute upper respiratory infections were most common in 
children aged 0-14 years. Rates of acute pharyngitis and acute tonsillitis significantly 
increased over the study period, mainly due to increases in acute tonsillitis in 
children, but an increase was also observed in the 15-64 age group. Rates of otitis 
media (OM) significantly decreased over the study period for all ages. 
 
Between 1996 and 2006, events of complications increased by 48% and again 
significant increases were identified after adjusting for practice characteristics. 
Events of complications were also more likely to have been seen in practices with a 
higher proportion of elderly patients aged under 15 and 65 and over, and from 
practices with older GPs. A similar pattern was found specifically in hospital events 
of complications in children, which significantly increased over time. Again there 
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was variability in rates of complications both between LHBs and practices.  
 
Other significant increases detected in all ages, and in children, over the study period 
were for chronic obstructive pulmonary disease (COPD) (with acute exacerbation, 
unspecified, septicaemia and pyothorax (pleural empyema)). Additionally, pleural 
effusion and bronchiectasis were found to have significantly increased over time, 
mainly in the elderly age group, whilst peritonsillar abscesses significantly increased 
in the 15-64 age group. Mastoiditis and meningococcal infection were the only 
complications which had significantly decreasing rates over the time period. Events 
of meningococcal infection decreased over all age groups, but there was a significant 
increase in mastoiditis events in children aged 0-4 years of age.  
 
7.5.2 Strengths and weaknesses of the study 
This study is the first to examine trends in a wide array of hospital admissions for 
outcomes of acute RTIs and their complications, on a national level over a long time 
period, for all ages and for the paediatric population. It is also the first to examine the 
variation in these outcomes at a general practice level. As a result of this study we 
have identified increases in certain acute RTIs and complications that warrant future 
monitoring and further investigation into the cause of the increase.  
 
Quality and using events of infections 
The Patient Episode Database for Wales (PEDW) database is based on routinely 
collected administrative data using Welsh Hospital Episode Statistics (HES) and 
covers all 3 million residents in Wales. The data quality of PEDW is of a high 
standard and is monitored by the Welsh Assembly Government.  
 
PEDW data is based on episodes of consultant care which are usually combined to 
create hospital admissions (or spells) to ensure that double counting of diagnoses is 
kept to a minimum. The use of a 91 day cut-off (linking episodes within 91 days of 
the initial infection) to create an event of infection may mean that we have under-
estimated the number of complications. It is arguable that the cut-off is quite long 
and that episodes of infection over two months apart may be separate complications. 
Our measure of infection is therefore likely to be conservative but is unlikely to 
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change over time and trends should be unaffected. Reassuringly, examination of 
trends in admission rates (European age standardised rates (EASRs) per 100,000) for 
pneumonia (ICD10 codes J12 to J18), showed an increase of 30% between 2001 and 
2006 (from 158.62 to 206.55 respectively) (Health Solutions Wales, Health Maps 
Wales), compared to a 38% increase for pneumonia using the codes J13-J18 (J12 is 
for viral pneumonia) demonstrated by this study.  
 
True incidence rate of acute RTIs and complications 
The study was limited to the available evidence in the database. Data arising from the 
PEDW database does not capture the true incidence rate of complications in the 
population; it contains data only on those patients whose condition is severe enough 
to be admitted as an inpatient to hospital. These are of course of importance since it 
is these serious complications that might cause concern if there were suggestions that 
they could arise from not being prescribed antibiotics. A proportion of patients will 
have been treated in the community solely by their GP or treated in accident and 
emergency and then discharged. When comparing primary care diagnosed 
complications in Chapter 4 (albeit from a small sample of practices between 1996 
and 2000), an increase in mastoiditis and a decrease in pneumonia and empyema 
were found. This contrasts the findings from the Welsh hospital admissions data 
where a decrease was seen in mastoiditis and an increase in pneumonia. These data 
highlight the need to examine complications diagnosed in both settings but it also 
may be showing the locations where patients present with their complications are 
changing. For example, patients with mastoiditis may be more likely to be diagnosed 
and treated by their GP rather than in secondary care.     
 
Explanation for a change in events over time 
Although the data showed an increase in rates of certain complications, we are not 
able to identify the reasons for these increases. We were only able to adjust for the 
characteristics and population structure of a practice, available through 
administrative datasets. These included the age structure of GPs, single-handed status 
and practice deprivation, some of which are known to be associated with higher risk 
of complications. We also examined rates of hospital events, divided into age groups, 
to take into account a changing and ageing population in Wales. 
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Other reasons for these changes over time could be coding changes or changes to 
organisation of health services. Diagnoses are coded by clinical coders within each 
trust and therefore, whilst there is undoubtedly some variability in diagnoses codes 
between NHS trusts, this variability mainly affects secondary diagnoses and not 
primary diagnoses. Also if clinicians changed the way they coded certain diseases 
(e.g. from a general pneumonia code to a bacterial pneumonia code, perhaps to 
justify prescribing) then this would have been revealed by looking at the codes in 
pairs to try to detect a decrease in one code and an increase in another. For this 
reason we grouped codes from the same sub chapter such as ICD10 codes J13-J18 
for pneumonia. Overall, pneumonia events increased over time but within these 
codes trends varied. In 2003 the GP contract changed and GPs were allowed to opt 
out of out-of-hours care from April 2004. New arrangements were put in place to 
ensure coverage of care, such as with Accident and Emergency (A&E) Units. 
Therefore patients may be more likely to put themselves in a position where they 
could be admitted to hospital instead of waiting to see their GP. The largest increases 
seen in our study happened before 2004 and so it is unlikely that this is the main 
reason behind the increase. 
 
There is evidence to suggest that consultation rates for acute RTIs decreased in the 
community over this ten-year period, especially for upper RTIs (Smith et al. 2006; 
Gulliford et al. 2009). Acute RTIs have either become less common, or people are 
less likely to present to their GP with a minor infection.  If the latter is true then 
patients may be more likely to present to A&E, especially if the infection develops 
into a complication. 
 
We have already demonstrated that for most practices in Wales, overall antibiotic 
dispensing decreased between 1996 and 2006. This decrease also applies to antibiotic 
prescribing for patients specifically presenting with an RTI, as shown by Gulliford et 
al. (2009). It is therefore plausible that reduced usage of antibiotics in primary care 
for acute RTIs may have contributed to an increase in hospitalisations for RTIs and 
complication, especially if a blanket reduction was employed. Resistance may also 
be playing a part as resistance rates to certain antibiotics have been shown to be 
increasing in Wales (Chapter 6) and in certain countries (Felmingham et al. 2005). 
Patients with a resistance to an antibiotic could be less likely to respond to treatment 
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and therefore be more likely to develop a complication. 
 
7.5.3 Comparisons with existing literature 
The findings in this study raise the questions of whether these trends in acute RTIs 
and complications are a true reflection of what is happening in the population and, if 
so, what has caused them. Few studies have examined hospitalisations for acute RTIs 
and their complications. One study using official hospital episode statistics (HES) in 
England, examined trends in episodes with a primary diagnosis of pneumonia 
(ICD10 code J12-J18) (Trotter et al. (2008)). Numbers were based on persons 
admitted at least once a year, as opposed to the number of admissions. They found 
that, between April 1997 and March 2005, rates increased by 34% (from 1.48 to 1.98 
per 1,000 population). This increase was noted in all age groups, but was most 
marked in older adults, and rates were higher in males than females. They observed 
that most of the increase over the study period was observed after 2000/01 in lobar 
pneumonia (J181) and pneumonia unspecified (J189). Although they included an 
extra ICD10 code-J12 (viral pneumonia), they found a slightly lower increase in rates 
over the study period than the 46% in our study (J13-J18)). This may be related to 
the fact that they counted patients, as opposed to linked episodes or admissions. 
However, other results between the studies were consistent in that pneumonia, 
organism unspecified (J18) made up the majority of cases in both (94% of all our 
pneumonia events) and that rates increased most in the elderly. A study by Koshy et 
al. (2010) examined hospital admissions for bacterial pneumonia and empyema 
between 1997 and 2008 in children (<15 years) in England using HES data. They 
found an increase of 31% in bacterial pneumonia admissions and that empyema 
admissions nearly tripled over the study period. 
 
A review of peritonsillar abscess cases in three hospitals in Northern Ireland during 
2001/02 found 128 inpatient cases (equivalent to 1 in 10,000 per population per 
annum) which again were comparable figures to ours (1.54 per 10,000) (Hanna et al. 
2005). In another study carried out in England using hospital admissions data, 
standardised admissions ratios for RTIs increased over the time period (1996-2002) 
and varied four-fold between PCTs (Majeed et al. 2004). More recently, a study by 
Koshy et al. (2012) observed trends between 1999 and 2010 in acute throat 
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infections (ATI) (pharyngitis and tonsillitis) and peritonsillar abscess in children 
using emergency admissions data from HES in England. They found a comparable 
increase in ATI of 76% over the decade and similarly found no such trend in 
emergency admissions of peritonsillar abscesses. The study found a decline in 
tonsillectomies over the period.  
 
Several studies have reported trends in complications in children. Sharland et al. 
(2005) reported an increase of 19% in mastoiditis admissions in children (aged 15 
and under) between 1993 and 2002 (from 6.9 to 8.2 per 100,000 children) based on 
HES data for England. This increase was mainly seen in children aged 4 years of age 
or less (from 5.2 to 8.6 per 100,000). We similarly observed an increase in event 
rates of mastoiditis in children between 1996 and 2003 (from 3.92 to 5.77 per 
100,000 population) but this trend was not significant, mainly due to the small 
numbers (in children aged 4 or less the trend was weakly significant from 3.34 to 
6.88 per 100,000). They also found no trends in peritonsillar abscesses or rheumatic 
fever in children.  
 
Ho et al. (2008) found no evidence of a trend in mastoiditis in children between 1996 
and 2005 using data collected from one hospital in Australia (although numbers were 
small with fewer than 20 cases per annum). In Scotland hospital admissions of 
pneumonia (ICD10 codes J12-J18) increased between 1980 and 2005, by an average 
of 50 per million children per annum in the 1-4 year age group (Roxburgh et al. 
(2008)). We found a larger increase of 213.0 per million children per annum, in rates 
of pneumonia in children aged 1-4 years between 1996 and 2006. Conversely, data 
from SWEDRES showed that hospital admissions in pneumonia, acute mastoiditis, 
quinsy and rhinosinusitis in children were stable or decreased between 1987 and 
2003 (Cars et al. 2005). 
 
Roxburgh et al. (2008) also found a significant positive trend in empyema 
admissions between 1998 and 2005 with the highest rates seen in 1-4 year olds (8.3 
admissions per million per annum). This significant trend in 1-4 year olds was also 
replicated in an English study by Gupta and Crowley (2006) where rates (per 
million) increased from 14 in 1995/6 to 46 in 2002/3. We found similar results with 
children aged 0-4 years having the highest pyothorax (including empyema) rates, 
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which had also significantly increased.  
7.5.4 Implications of findings for clinical practice and future research 
We have found that event rates of a number of acute RTIs and complications 
increased over the study period. We can be reasonably confident that our findings are 
reliable and generalisable as they are based on an entire population and results are in 
agreement with the majority of population based published evidence. Whilst the 
numbers involved for some of the complications are small, these increases are of 
concern and warrant further investigation. There is a need for these trends to be 
monitored, which is not currently routinely done. For surveillance of infections to be 
worthwhile, monitoring needs to be timely and use standardised high quality data 
that is comparable within and between countries. In Wales, data from the Patient 
Episode Database for Wales (PEDW) would be the obvious and best choice although 
surveillance would be limited to hospitalisations of infections and complications 
arising from them, highlighting the more severe end of the spectrum of infections 
(i.e. the infection was severe enough to be admitted to hospital).  
 
7.6 Introduction to antibiotic dispensing and complications at an 
All-Wales level  
Until now we have examined trends in dispensing, resistance and clinical outcomes 
on an all-Wales basis but using practice-level models. Future research is required to 
identify causes of these increases in rates so that their implications can be 
understood. One way of proceeding would be to link PEDW data to other routinely 
collected and, in most cases, administrative datasets such as antibiotic dispensing by 
GPs and resistance data. Results from these linked datasets could then start to inform 
clinical decisions to try and reduce complications, either by examining and possibly 
changing GPs’ prescribing behaviour or by regularly submitting samples to test the 
resistance status of patients. This is the basis of the next chapter in which we wish to 
explore these associations. This chapter will investigate how these are related by 
examining associations between the three datasets at a general practice level.  
 
 
Chapter 8 
238 
Chapter 8  Antibiotic dispensing and complications arising 
from RTIs: an All-Wales study 
8.1 Introduction 
The aim of this chapter is to examine in greater depth the relationship explored in 
Chapter 4 using the data described in Chapters 5 to 7. These three datasets will be 
linked together at the general practice level for each year. The hypothesis is that at 
the level of general practice in Wales, reduced overall levels of community antibiotic 
dispensing may be associated with increases in hospital admissions in complications 
arising from common respiratory tract infections (RTIs). In addition the effects that 
practice characteristics and resistance have on the relationship will be investigated.  
 
 
8.2 Methods 
8.2.1 Linking antibiotic dispensing to hospital events of infections 
Antibiotic dispensing items using Prescribing Analyses and Cost (PACT) data and 
hospital infection events using Patient Episode Database for Wales (PEDW) were 
aggregated at a general practice level and study year as described in chapters 5 and 7 
respectively. These two datasets were linked using the general practice code and 
study year common to each dataset. Data were available for the period April 1996 to 
March 2006 and study years were created (e.g. 1996=April 1996 to March 1997) 
leaving ten years of data to analyse (1996 to 2005).  
 
8.2.2 Linking to antibiotic resistance 
The number of resistant isolates and the number of samples sent for resistance testing 
by GPs (with the H. influenzae, S. pneumoniae and S. pyogenes organisms) (using 
Datastore data) were aggregated at a general practice level. When resistance data was 
included in any model the study period was defined as from April 1998 to March 
2006 creating eight years of data. Again these datasets were linked using the general 
practice encrypted practice code and study year common to each dataset. Annual 
practice populations (pp) and characteristics were obtained as before from the Welsh 
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Demographic Service (WDS).  
 
8.2.3 General practices 
The 426 “Up-To-Standard” (UTS) general practices in Wales with stable list sizes, 
described in Chapter 5, were used in this analysis. Hospital events for complications, 
dispensing and practice population data were available for all 426 practices. 
Resistance data was only available for a sample of these practices, numbers varying 
by type of organism.  For example 341 practices had data on resistance to H. 
influenzae isolates. The dataset analysed was therefore reduced when resistance was 
included in any of the models. 
 
8.3 Statistical analysis 
8.3.1 Main analysis 
Hospital infection events for total acute RTIs, total complications and a sub-group of 
pneumonia were examined over all ages, as were dispensing for total antibiotics, 
broad spectrum penicillins (BSPs), macrolides, cephalosporins, quinolones (used in 
the treatment of upper respiratory tract infections), and tetracyclines. Apart from 
pneumonia, individual categories of acute RTIs and complications (including 
septicaemia) were not examined due to the small numbers per practice. Dispensing 
items and hospital events for children were not linked and analysed due to the 
possible imprecise nature of liquid oral antibiotics as a proxy for antibiotic 
dispensing in children.  
 
For each practice and study year, hospital infection event rates were calculated for 
total acute RTIs, total complications and pneumonia per 100,000 practice population 
(pp) per study year. Antibiotic dispensing rates were also calculated per 1,000 pp per 
study year. The percentage of resistant isolates was calculated for each practice and 
study year for the following organism/antibiotic combinations (excluding duplicate 
samples and certain laboratory selectivity as defined in section 6.2.4): 
 Amoxicillin resistance in H. influenzae isolates; 
 Erythromycin and penicillin resistance in S. pneumoniae isolates; 
 Erythromycin resistance in S. pyogenes isolates. 
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Resistance to tetracyclines in H. influenzae isolates was not examined due to the 
small numbers of both hospital events and tested isolates when examined at 
practice/study year level. All samples were used, regardless of the source, rather than 
just sputum and ENT samples, again due to the small numbers involved.  
 
8.3.1.1 Negative Binomial regression 
As described in section 7.3.2.1, both a Poisson and negative binomial (NB) model 
were used to account for the overdispersion with independent counts of hospital 
admissions as the outcome variable, to account and correct for variation at the level 
of LHB, Welsh general
 
practices and time. The NB model resulted in more 
conservative parameter estimates although the standard errors were similar and thus a 
three-level repeated measures negative binomial (NB) regression model was used. 
Estimates were obtained by using the restricted iterative generalized least squares 
(RIGLS) estimation (1
st
 order penalised quasi-likelihood (PQL)) procedure; Monte 
Carlo Markov Chains (MCMC) estimation cannot be used at present with the NB 
method. 
 
The results are summarised using the standardised incidence ratio (SIR) and 95% 
confidence intervals (CIs), which compares the ratio of the observed to expected 
counts at the 75
th
 percentile to that at the 25
th
 percentile (measured over all practices 
between 1996 and 2005) for each antibiotic. A value >1 means the rate of hospital 
infections was higher at the higher level of dispensing and a value <1 means the rate 
was lower at the higher level of dispensing. For example, the 25
th
 and 75
th
 percentiles 
for the BSP dispensing rate were 249.7 and 410.7 per 1,000 pp respectively 
(interquartile range (IQR) =161.0 per 1,000 pp).  
 
8.3.2 Adjusting for confounders 
Using NB regression analysis, the relationship between hospital events and antibiotic 
dispensing was adjusted for the following practice characteristics:  
 Percentages of the practice population aged 0-14 years, 15-64, and 65 and 
over; 
 Single-handed status of the practice (single or multi-handed); 
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 Practice deprivation quintile (based on the Townsend 2001 score of the 
practice population); 
 Average age of GPs in a practice; 
 Proportion of male GPs in a practice.  
 
8.3.3 Comparisons of antibiotics, infections and resistance 
Pragmatic comparisons were used to examine the association between hospital 
events for infections, antibiotic dispensing and resistance. The following 
comparisons were examined:   
 Hospital admissions for all acute RTIs, all complications and pneumonia and: 
 antibiotic dispensing rates per 1,000 pp for total antibiotics, BSPs, 
quinolones, and tetracyclines and: 
 resistance to amoxicillin in H. influenzae isolates;  
 resistance to penicillin in S. pneumoniae isolates; 
 resistance to erythromycin in both S. pneumoniae and S. 
pyogenes isolates. 
 
 Hospital admissions for all acute RTIs, all complications and pneumonia and: 
 antibiotic dispensing rates per 1,000 pp of macrolides and:  
 resistance to erythromycin in S. pneumoniae isolates;  
 resistance to erythromycin in S. pyogenes isolates. 
 
 Hospital admissions for all acute RTIs, all complications and pneumonia and: 
 antibiotic dispensing rates per 1,000 pp of cephalosporins (beta 
lactams) and: 
 resistance to amoxicillin in H. influenzae isolates; 
 resistance to penicillin in S. pneumoniae isolates. 
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8.3.4 Sensitivity analyses 
The analysis was re-run for the data period 1998 to 2005 to determine whether 
excluding the period between 1996 and 1998, where the greatest decline in antibiotic 
dispensing, made an impact on the relationship between hospital events and 
antibiotic dispensing. 
 
8.3.5 Changes in antibiotic dispensing and complications 
Change in dispensing rates per 1,000 pp and complications for individual practices 
were analysed between 1998 (April 1998 to March 1999) and 2005 (April 2005 to 
March 2006). Practices with data on dispensing in both 1998 and 2005 were included 
in this analysis to explore the relationship between practice level reductions in total 
antibiotic dispensing and changes in overall complications over the same period. 
Practices were grouped into quartiles based on their reduction of total antibiotic 
dispensing between 1998 and 2005. Complication rates for 1998, 2005, and the 
actual change in rates (with 95% CIs) were compared between these quartiles. 
  
All multilevel modelling was performed using MLwiN version 2.16 and all other 
analyses using SPSS version 16.0.   
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8.4 Results 
This analysis uses hospital events and community antibiotic dispensing data from 
426 ‘Up-to-Standard’ (UTS) practices covering 94.5% (2,802,319 population) of the 
official Welsh population. These two datasets have previously been summarised in 
Chapters 5 and 7.  
 
A three-level Poisson multilevel model was fitted with the observed number of 
hospital events per annum at a general practice level as the outcome variable and in 
the first instance included antibiotic dispensing rates (per 1,000 pp) as an explanatory 
variable. The association was then adjusted for significant practice characteristics. 
Finally the same analysis was repeated on a subset of practices with reliable 
resistance data to examine the impact of adding resistance rates to the models.  
 
Three separate models for hospital events were examined: total number of hospital 
events for complications, acute RTIs and pneumonia events.  
 
8.4.1 The relationship between hospital events for complications arising 
from acute RTIs and antibiotic dispensing at a general practice 
level 
Table 8.1 shows the parameter estimates from the univariate NB multilevel model 
examining the association between hospital events for overall complications and 
antibiotic dispensing. It also shows the ratio of the complication rates at the 75
th
 
percentile of the dispensing distribution (over all practices and years) to the 25
th
 
percentile for each antibiotic (SIR (IQR)). The 25
th
 and 75
th
 percentiles for each 
antibiotic dispensing rate are displayed for this reason. There were significant 
negative associations between hospital events for all complications arising from an 
acute RTI and antibiotic dispensing (by type and total). This indicates that practices 
with higher levels of dispensing per annum were associated with lower levels of 
complications. For BSPs, the rate of complications were 22% lower (SIR=0.78, 95% 
CI=0.71 to 0.86) in practices with a dispensing rate at the 75th percentile (410.7 
dispensed items per 1,000 pp per study year) compared to practices with dispensing 
rate at the 25th percentile (249.7 dispensed items per 1,000 pp per study year). For 
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other antibiotics, the rate of complications ranged from 22% (SIR=0.78, 0.68 to 0.89) 
lower in cephalosporins to 4% (SIR=0.96, 0.93 to 0.99) lower in tetracyclines. 
 
Table 8.1 Unadjusted multilevel models for hospital events for complications and 
antibiotic dispensing per 1,000 pp: 1996 to 2005 
 
Antibiotic 
Loge parameter 
estimate (SE) 
 
x 10
3i
  
Dispensing rate 
25
th 
to 75
th
 
percentile 
 95% CI 
SIR 
(IQR)
ii
 
Lower 
limit 
Upper 
limit 
BSPs -1.53 (0.31) 249.7 to 410.7 0.78 0.71 0.86 
Macrolides -2.54 (0.65) 66.1 to 119.8 0.87 0.81 0.93 
Cephalosporins  -3.89 (1.04) 37.2 to 102.2 0.78 0.68 0.89 
Quinolones -4.23 (1.52) 15.4 to 35.7 0.92 0.86 0.98 
Tetracyclines -1.47 (0.61) 39.6 to 66.4 0.96 0.93 0.99 
Total antibiotics -0.84 (0.17) 626.0 to 905.9 0.79 0.72 0.87 
i 
For total antibiotics the parameter estimate would be -0.000838 (0.000174)   
ii 
SIR (IQR) = SIR of complications at 75
th
 percentile of dispensing distribution compared to the 25
th
 
percentile 
 
Significant variation can be observed in complications at the LHB and practice levels 
(σ2v0 =0.430 (SE=0.146) and σ
2
u0 =0.455 (0.059) respectively) and thus a three-level 
model was retained. Significant variations were also seen in the association between 
total dispensing rates and complications (σ2v1 =0.773 (0.258) and σ
2
u1 =0.608 (0.087) 
respectively) with greater variation at the LHB level. Figure 8.1 shows the NB model 
with total antibiotic dispensing rate (totr) as an explanatory variable.  
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Figure 8.1 MLwiN output for three-level repeated measures NB model for hospital 
events for complications 
 
 
 
 
All groups of antibiotics except for tetracyclines used a three-level model. For 
tetracylines, the variations at both the practice and LHB level were small and 
including it as a random term improved the goodness of fit of the model by an 
insignificant amount. In this case the antibiotic dispensing term was fixed at both 
levels. Figure 8.2 shows the predicted values from the fitted models (a) for each of 
the 22 LHBs and (b) of the 426 UTS general practices in the case of total antibiotic 
dispensing. Almost all LHBs and practices show a negative association between 
complications and total antibiotic dispensing rates. Two LHBs were identified as 
having a positive association. This demonstrates that conclusions based on the whole 
dataset did not necessarily hold at an individual LHB or practice level.  
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Figure 8.2 Fitted association between hospital events for complications (predicted 
SIR) and total antibiotic dispensing rate 
 
(a) by Local Health Boards (N=22)  
 
b) by UTS practices (N=426) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 8 
247 
8.4.1.1 Addition of practice characteristics 
Unadjusted NB regression was performed to determine any significant explanatory 
variables that could be added to attempt to explain variation in complications. 
Complications were more likely to be found in practices with older GPs (SIR=1.007, 
95% CI=1.003 to 1.011) and with an older practice population (aged 65 plus) 
(SIR=1.019, 95% CI=1.013 to 1.025). This indicates that an increase in one year in 
GP average age and an increase in one percentage of the practice population that is 
aged 65 plus would increase the complication rate by 0.7% and 1.9% respectively. 
The proportion of the practice aged 0-14 years was negatively associated with 
complications (SIR=0.943, 95% CI=0.935 to 0.950). Deprivation quintile (entered as 
a continuous term due to its linear association with complications) was also 
associated with complications, with the more deprived quintile having an increased 
probability of hospital events for complications (SIR=1.088, 95% CI=1.069 to 
1.107). 
 
 When these variables were included in the multivariate model, all variables 
remained independently associated with complications. How these characteristics 
modified the relationships between complications and antibiotic dispensing rates are 
shown in Table 8.2 (alongside the unadjusted estimates from Table 8.1). After 
adjusting for significant practice characteristics, the relationship between antibiotics 
and hospital events of complications were weaker but remained for all type of 
antibiotics under examination.  As already demonstrated in Chapter 7, a significant 
positive association held between year and complications (SIR=1.062, 95% 
CI=1.058 to 1.066). When study year was included in the antibiotics model, the 
associations between complications and dispensing disappeared for all antibiotic type 
(Table 8.2). This suggests that study year is a confounder in this model and an 
unknown factor caused dispensing to fall and another factor caused complications to 
rise.  
   
Table 8.2 Unadjusted and adjusted models for hospital events for complications and dispensing rate per 1,000 pp by type of antibiotic, 
1996 to 2005 (Parameter estimates (standard error) shown for dispensing rate only)  
 
 Loge parameter estimate (SE) x 10
3
  95% CI 
Antibiotic 
Unadjusted Adjusted for 
practice chars.
i
 
Adjusted for practice 
chars and time
ii
 
SIR 
(IQR)
iii
 
Lower 
limit 
Upper 
limit 
BSPs -1.53 (0.31) -1.72 (0.34) -0.11 (0.27) 0.98 0.90 1.07 
Macrolides -2.54 (0.65) -1.96 (0.64) 0.43 (0.48) 1.02 0.97 1.08 
Cephalosporins  -3.89 (1.04) -3.27 (0.96) -0.44 (0.58) 0.97 0.90 1.05 
Quinolones -4.23 (1.52) -3.52 (1.59) -0.06 (1.05) 1.00 0.96 1.04 
Tetracyclines -1.47 (0.61) -1.31 (0.62) 0.48 (0.47) 1.01 0.99 1.04 
Total antibiotics -0.84 (0.17) -0.86 (0.19) -0.01 (0.16) 1.00 0.91 1.09 
i
 Adjusted for deprivation quintile, average age of GP, percentage of practice population aged 0-14 and 65 plus 
ii 
Adjusted for deprivation quintile, average age of GP, percentage of practice population aged 0-14, 65 plus and  time (study year)  
iii
 Standardised Incidence Ratio (SIR)(IQR) = rate of complications at 75
th
 percentile of dispensing distribution compared to the 25
th
 percentile 
2
4
7
 
  
8.4.1.2 Excluding data from 1996 and 1997 
The greatest reduction in total antibiotic dispensing, and the largest increase in 
hospital admissions of complications, both occurred between 1997 and 1998. For 
example, total dispensing rates fell from 946.54 per 1,000 pp in 1997 to 830.65 in 
1998, and hospital admissions of overall complications rose from 3.36 events per 
1,000 pp in 1997 to 4.52 in 1998 (Figure 8.3).  
 
Figure 8.3 Trends in total antibiotic dispensing and complication rates, 1996 to 2005 
 
 
 
After excluding data for 1996 and 1997, the associations (unadjusted and adjusted for 
practice characteristics) between complications and antibiotic dispensing rates were 
re-examined and compared to the estimates for the whole period (1996 to 2005) 
alongside the reduction in dispensing rates between 1996 and 1998 (Table 8.3). After 
the exclusion of the first two years of data the unadjusted estimates for dispensing 
were diluted and became non-significant, with the exception of cephalosporins and 
quinolones. The dispensing of quinolones only reduced by 2.3% from 1996 which 
may explain why excluding data from 1996 and 1997 made little impact on the on 
the result. These associations did not hold after adjusting for significant practice 
characteristics mainly due to the addition of time (year) to the model.  
Chapter 8 
 
Table 8.3 NB models for hospital events for complications and dispensing per 1,000 pp by type of antibiotic: 1996 to 2005 and 1998 to 
2005 (Parameter estimates (standard error) shown for dispensing rate only) 
 
 
Reduction
i
 
(% change) 
Loge parameter estimate (SE) x 10
3
 
 1996 to 2005 1998 to 2005 
Antibiotic Unadjusted  Adjusted
ii
   Unadjusted Adjusted
ii
   
BSPs 92.0 (20.4) -1.87 (0.36) -0.11 (0.27) -0.28 (0.17) 0.43 (0.14) 
Macrolides 13.3 (10.8) -2.54 (0.65) 0.43 (0.48) -0.33 (0.41) 0.73 (0.29) 
Cephalosporins  22.0 (19.8) -3.89 (1.04) -0.44 (0.58) -0.92 (0.30) 0.24 (0.23) 
Quinolones 0.7 (2.3) -4.23 (1.52) -0.06 (1.05) -1.89 (0.75) 0.07 (0.64) 
Tetracyclines 7.1 (10.8) -1.47 (0.61) 0.48 (0.47) 0.55 (0.50) 0.62 (0.41) 
Total antibiotics 148.8 (15.2) -0.97 (0.20) -0.01 (0.16) -0.14 (0.11) 0.26 (0.08) 
i
 Reduction in dispensing rates between 1996 and 1998 per 1,000 practice population and as a % of 1996 rate 
ii 
Adjusted for deprivation quintile, average age of GP, percentage of practice population aged 0-14, 65 plus and time (study year) 
 
 
2
4
9
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8.4.2 General practice level resistance data 
Resistance data was only available for a sample of practices and covered the years 
1998 to 2006 inclusive. For example, in S. pneumoniae isolates 337 practices had at 
least one isolate tested for resistance (Table 8.4). This number is slightly different 
from the 358 practices quoted in section 6.4.1 due to the restricted period used in this 
analysis (spanning March 1998 to April 2006 instead of January 1998 to December 
2006). In Chapter 6, resistance data was examined at an individual level but since 
complications are only available at practice level, analysis must also be carried out at 
this level. The median number of H. influenzae isolates that were submitted for 
amoxicillin resistance testing was 6 isolates per practice (pp) per annum (range 0 to 
70). The pattern of the number of isolates submitted pp per annum is shown in Figure 
8.4.  
 
Table 8.4 Summary of isolates and resistance per practice (pp) per annum 
Organism Antibiotic 
resistance 
Practices 
with data  
Isolates tested 
pp per annum 
% resistant 
pppa 
  N Median (25
th
 to 75
th
 quartile) 
H. influenzae Amoxicillin 341 5 (2 to 10) 15.8 (0 to 30) 
S. pyogenes Erythromycin 339 4 (2 to 7) 0 (0 to 0) 
S. pneumoniae Erythromycin 337 2 (1 to 5)  0 (0 to 10.8) 
 Penicillin 337 2 (1 to 5) 0 (0 to 0) 
 
Figure 8.4 Histogram of the number of H. influenzae isolates tested for amoxicillin 
resistance per practice per annum, 1998 to 2005 
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Of the isolates that were tested, a median of 15.8% were resistant. S. pyogenes and S. 
pneumoniae isolates were tested less frequently for resistance per annum and for all 
organisms, the distributions of the number of the number tested per practice were 
positively skewed. 
 
Since 35% of practices had no resistant isolates per annum it seems prudent to 
restrict any future analyses using resistance data to practices that had at least five 
isolates tested per annum. This was only possible in H. influenzae isolates where the 
restriction resulted in 88 possible practices to analyse the impact of resistance on the 
relationship between antibiotic dispensing and complications. For S. pneumoniae and 
S. pyogenes isolates only four and 24 practices respectively remained after the 
restriction. Although these 88 practices covered 21% (833,232 population) of the 
Welsh population, they were not a representative sample of the 426 Welsh practices. 
On average, these practices had significantly more complications presenting in 
hospital (p<0.001), were prescribed significantly fewer antibiotics (p<0.001), had a 
greater proportion of female and younger GPs (p<0.001), a smaller proportion of 
younger (p=0.002) and older practice population (0.041), and were more likely to be 
multi-handed (p<0.001).  
 
The association between complications and total antibiotic dispensing was compared 
using the two samples: (1) from the 426 practices and (2) from the sub sample of 88 
practices for the period 1998 to 2005. The unadjusted association seen between 
hospital events for complications and total antibiotic dispensing rates at a practice 
level for the UTS practices (=-0.97 (SE=0.20)) was not observed for the sample of 
88 practices (-0.09 (SE=0.20), thus confirming that the sample of 88 practices 
were not a representative sample of the 426 practices. Amoxicillin resistance in H. 
influenzae isolates was negatively associated with hospital events of complications at 
a GP level based on the 88 practices (-0.002 (SE=0.001). After adjusting for 
resistance, the association between complications and total antibiotic dispensing did 
not change (-0.06 (SE=0.20)).   
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8.4.3 The relationship at the Local Health Board level 
As the impact of antibiotic resistance could not be fully explored at a general practice 
level, complications, dispensing and resistance data were aggregated for the 426 
practices to the Local Health Board (LHB) level. At this level, the counts per annum 
(1998 to 2005) were greater and thus analyses were more robust (Figure 8.5).  
 
Figure 8.5 Histogram of number of hospital events for complications and resistance 
by LHB per annum 
 
 
 
The initial results from the univariate two-level (LHB and time) NB regression 
model examining the association between resistance from all specimens and 
complications show a significant negative association between hospital events of 
complications and amoxicillin resistance in H. influenzae isolates (= -0.0032 
(SE=0.0014)). This indicated that LHBs with higher complication rates per annum 
had lower resistance in the same year. No associations held between complications 
and erythromycin resistance in S. pneumoniae (0.00343 (SE=0.00264)) and S. 
pyogenes isolates (-0.00402 (SE=0.00516)) or penicillin resistance in S. 
pneumoniae (0.00092 (SE=0.00434)). 
 
The relationship between complications and antibiotic dispensing was examined at a 
LHB level and where appropriate adjusted for amoxicillin resistance in H. influenzae 
isolates and also year (Table 8.5). Negative associations were observed between 
antibiotic dispensing rates and hospital events for complications for all type of 
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antibiotics. These associations remained after adjusting for resistance rates except for 
tetracyclines. In conclusion, LHB level resistance rates do not seem to modify the 
relationship between complications and dispensing although the resistance data are 
too few in number for analyses to be robust. After adjusting for secular trends, none 
of the negative associations held and significant positive associations were seen 
between complications and BSP, macrolide and total antibiotic dispensing. 
  
Table 8.5 NB models for hospital events for complications and dispensing per 1,000 pp by type of antibiotic at LHB level, 1998 to 2005 
(Parameter estimates (standard error) shown for dispensing rate only) 
 
 Loge parameter estimates (SE) x 10
3
    
 1998 to 2005  95% CI 
Antibiotic Unadjusted Adjusted
i
 Adjusted
ii
 SIR (IQR)
iii
 Lower limit Upper limit 
BSPs -3.11 (0.65) -2.05 (0.56) 2.42 (0.56) 1.48 1.24 1.76 
Macrolides -10.55 (2.21) -5.52 (1.27) 3.72 (1.71) 1.22 1.02 1.46 
Cephalosporins  -11.08 (2.27) -7.56 (1.35) -0.91 (1.33) 0.94 0.80 1.12 
Quinolones -39.29 (8.42) -19.82 (4.16) -2.95 (3.87) 0.94 0.81 1.10 
Tetracyclines -11.33 (3.83) -3.11 (4.55) 2.49 (3.25) 1.07 0.90 1.27 
Total antibiotics -1.81 (0.41)  -1.25 (0.56) 1.21 (0.35) 1.40 1.16 1.70 
i 
Adjusted for amoxicillin resistance in H. influenzae isolates 
ii 
Adjusted for amoxicillin resistance in H. influenzae isolates and time (study year) 
iii
 SIR (IQR) = SIR of complications at 75
th
 percentile of dispensing distribution compared to the 25
th
 percentile 
2
5
4
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8.4.4 The relationship between hospital infections for acute RTIs and 
antibiotic dispensing at a general practice level 
The models in the previous sections modelled the rate of complications in terms of 
antibiotic dispensing over time but adjusting for temporal trends and certain practice 
characteristics. This section models the rate of hospital events for acute RTIs and 
pneumonia using the same methods.  
 
The negative binomial (NB) regression model found a significant negative 
association between hospital events for acute RTIs and the dispensing of 
tetracyclines (Table 8.6). Again the percentage of variation in hospital events for 
acute RTIs attributable to practice differences was greater than those due to LHB 
differences. After adjusting for significant practice characteristics (deprivation 
quintile, average age of GP and percentage of practice population aged 0-14 and 65 
plus) and year, the relationship between acute RTI hospital events and antibiotic 
dispensing disappeared. 
 
Excluding 1996 and 1997 changed the relationship between hospital events for acute 
RTIs and antibiotic dispensing in that most associations reversed and became 
significantly positive. The exception was for tetracycline dispensing which remained 
negatively associated but non-significant.  
 
 257 
Table 8.6 Multivariate model for hospital events for acute RTIs and dispensing per 1,000 pp by type of antibiotic, 1996 to 2005  and 
1998 to 2005 (Parameter estimate (standard error) shown for dispensing rate only)  
 
 
Reduction
i
 
(% change) 
Loge parameter estimate (SE) x 10
3
 
 1996 to 2005 1998 to 2005 
Antibiotic Unadjusted  Adjusted
ii
   Unadjusted Adjusted
ii
   
BSPs 92.0 (20.4) -0.61 (0.35) -0.07 (0.33) 0.85 (0.16) 0.84 (0.14) 
Macrolides 13.3 (10.8) -0.50 (0.72) 0.63 (0.66) 1.48 (0.48) 1.22 (0.44) 
Cephalosporins  22.0 (19.8) -1.95 (1.10) -0.69 (0.90) 0.90 (0.33) 0.79 (0.29) 
Quinolones 0.7 (2.3) -0.86 (1.56) 0.78 (1.34) 1.79 (0.95) 1.24 (0.81) 
Tetracyclines 7.1 (10.8) -1.43 (0.58) -0.30 (0.56) -0.77 (0.64) -0.40 (0.61) 
Total antibiotics 148.8 (15.2) -0.33 (0.20) 0.02 (0.19) 0.57 (0.08) 0.42 (0.10) 
i
 Reduction in dispensing rates between 1996 and 1998 per 1,000 practice population and as a % of 1996 rate 
ii 
Adjusted for deprivation quintile, average age of GP per practice, and percentage of practice population aged 0-14, 65 plus and time (study year). 
 
2
5
6
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8.4.5 The relationship between hospital infections for pneumonia and 
antibiotic dispensing at a general practice level 
The NB model found that for all hospital infections for pneumonia, there were 
significant negative associations with dispensing of all types of antibiotics at a 
general practice level, except for tetracycline dispensing (Table 8.7). After adjusting 
for significant explanatory variables (deprivation quintile, average age, the age 
distribution of the practice and year), these associations disappeared.  
  
Excluding 1996 and 1997 weakened the unadjusted relationship between hospital 
events for pneumonia and antibiotic dispensing and the estimates decreased. 
However, significant associations still remained for all antibiotics apart for macrolide 
and total antibiotic dispensing. Again these negative associations disappeared when 
adjusted for practice characteristics and time.  
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Table 8.7 Multivariate model for hospital events for pneumonia and dispensing per 1,000 pp by type of antibiotic, 1996 to 2005 and 
1998 to 2005 (Parameter estimate (standard error) shown for dispensing rate only)  
 
 
Reduction
i
 
(% change) 
Loge parameter estimate (SE)
 
x 10
3
 
 1996 to 2005 1998 to 2005 
Antibiotic Unadjusted  Adjusted
ii
 Unadjusted Adjusted
ii
   
BSPs 92.0 (20.4) -1.37 (0.29) 0.14 (0.26) -0.42 (0.20) 0.27 (0.15) 
Macrolides 13.3 (10.8) -1.80 (0.53) 0.62 (0.46) -0.41 (0.45) 0.55 (0.33) 
Cephalosporins  22.0 (19.8) -2.10 (0.66) 0.12 (0.52) -0.81 (0.34) 0.27 (0.29) 
Quinolones 0.7 (2.3) -3.13 (1.22) -0.10 (0.98) -2.23 (0.93) -0.24 (0.80) 
Tetracyclines 7.1 (10.8) -0.91 (0.56) 0.79 (0.50) 0.57 (0.61) 0.56 (0.50) 
Total antibiotics 148.8 (15.2) -0.71 (0.16) 0.13 (0.14) -0.21 (0.11) 0.17 (0.08) 
i
 Reduction in dispensing rates between 1996 and 1998 per 1,000 practice population and as a % of 1996 rate 
ii 
Adjusted for deprivation quintile, average age of GP per practice, and percentage of practice population aged 0-14, 65 plus and time (study year) 
2
5
8
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8.4.6 Changes in antibiotic dispensing and complications  
The models in previous sections modelled the rate of complications and RTIs in 
terms of dispensing over time but adjusting for temporal trends by including the 
study year. Here the changes in complication rates are explicitly modelled in terms of 
changes in dispensing rates over the study period.  
 
Reductions were seen in the mean dispensing of all antibiotics between 1998 and 
2005 in the set of 426 UTS practices (Table 8.8). Quartiles were calculated based on 
change in total dispensing rates with equal number of practices in each quartile and 
defined according to the values shown in the final row of Table 8.9. Quartile 1 (75
th
 
to 100
th
 percentile) refers to practices that reduced their dispensing the most and 
quartile 4 (0 to 25
th
 percentile) refers to the practices that reduced it least, or 
increased their dispensing. For total antibiotics, quartile 1 reduced dispensing by at 
least 237 items per 1,000 practice population per annum; quartile 2 by between 114 
and 237; quartile 3 by between 39 and 114; and quartile 4 by less than 39. 
 
Table 8.8 Median dispensed antibiotic items (per 1,000 practice population) in 1998 
and 2005 in 426 Welsh practices 
 
Antibiotics 1998 2005 Reduction 
(% decrease) 
BSPs 346.2 271.8 74.4 (21) 
Cephalosporins 71.9 49.0 22.9 (32) 
Tetracyclines 51.8 50.8 1.0 (2) 
Macrolides 100.1 77.2 22.9 (23) 
Quinolones 26.5 21.6 4.9 (18) 
Total antibiotics 820.4 675.3 145.1 (18) 
 
Table 8.9 Quartiles with 5
th
 and 95
th
 percentiles, for reductions in dispensed 
antibiotic rates (per 1,000 practice population) between 1998 and 2005 
 
 Percentile 
Antibiotics  95% 75
th
 50th 25th 5%  
BSPs 299.2 128.8 61.8 21.0 -47.9  
Cephalosporins 125.1 49.6 18.3 -3.1 -34.6  
Tetracyclines 43.1 14.2 1.7 -9.1 -27.9  
Macrolides 109.0 46.8 17.3 0.6 -33.4  
Quinolones 44.8 14.5 3.9 -3.0 -15.1  
Total antibiotics 551.7 236.7 114.4 39.9 -67.2  
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Table 8.10 shows the changes in overall complications and in pneumonia by quartile 
of change in total antibiotic dispensing. A significant increase was observed in rates 
of overall complications between 1998 and 2005 in each dispensing quartile. 
Practices in the first quartile (that reduced their dispensing the most) saw an increase 
in hospital event for complications arising from acute RTIs by 117.0 per 100,000 
population (95% CI=69.16 to 164.5) and the fourth quartile (practices that reduced 
their dispensing the least or increased it) saw an increase of 140.3 events per 100,000 
population (106.1 to 174.5). Practices in the first quartile had the highest rate of 
complications in 1998 (520.0 events per 100,000 population); the other quartiles had 
similar rates of complication events.  
 
For pneumonia there was a significant increase in rates between 1998 and 2005 in 
each dispensing quartile. Practices in the first quartile (that reduced their dispensing 
the most) saw an increase in hospital events for pneumonia by 94.2 per 100,000 
population (95% CI=67.9 to 120.6) and the fourth quartile (practices that reduced 
their dispensing the least or increased it) saw an increase of 83.2 (63.9 to 102.5). The 
second quartile saw the highest increase in rates over the period of 96.1 pneumonia 
events per 100,000.  
 
These analyses suggest that there is no association between changes in total 
antibiotic dispensing and changes in hospital event rates of complication and 
pneumonia when examined at an aggregate level. If there is an association between 
complications and antibiotic dispensing, it is not apparent by using aggregated levels 
of dispensing. 
  
  
Table 8.10 Change (mean (sd)) in all complications and pneumonia (per 100,000 population) over an 8-year period, by quartile of 
reductions in total antibiotic dispensing per 1,000 population  
 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
 N=106 107                        106 107 426 
All complications 
1998, mean (sd) 520.0 (212.1) 427.9 (159.0) 428.7 (174.4) 420.0 (156.0) 449.0 (180.8) 
2005, mean (sd) 637.1 (230.4) 549.7 (232.9) 558.1 (172.4) 560.3 (177.9) 576.2 (207.7) 
Change, mean  
(95% CI)  
117.0  
(69.2 to 164.5) 
121.8 
(82.1 to 161.4) 
129.4 
(95.1 to 163.7) 
140.3  
(106.4 to 174.2) 
127.2  
(107.78 to 146.5) 
     
Pneumonia      
1998, mean (sd) 179.6 (88.8) 154.0 (84.2) 170.4 (72.9) 166.7 (72.9) 167.6 (81.7) 
2005, mean (sd) 273.8 (115.7) 250.1 (116.1) 248.5 (90.7) 249.8 (99.3) 255.5 (106.2) 
Change, mean 
(95% CI) 
94.2  
(67.9 to 120.6) 
96.1  
(72.7 to 119.5) 
78.1  
(58.7 to 97.5) 
83.2  
(63.9 to 102.5) 
87.9  
(76.9 to 98.9) 
 
2
6
1
 
Chapter 8 
263 
8.5 Discussion 
8.5.1 Main findings 
Association between hospital events and antibiotic dispensing 
Initial results from this all-Wales ecological level study suggested an apparent 
negative relationship between hospitalised complications and antibiotic dispensing in 
the community even after adjusting for practice characteristics (average age of GP, 
deprivation, % of patients aged 0-14 and 65 plus). Practices with a higher rate of 
these hospitalisations had a lower rate of antibiotic dispensing per annum. However, 
this relationship largely disappeared when the first two years (1996 and 1997) of data 
are excluded or when adjustments for study year were made. High hospital rates of 
acute RTIs were associated with lower dispensing of tetracyclines but again 
excluding 1996 and 1997 or adding year removed the association. Similarly, the 
associations found between hospital events of pneumonia and the dispensing of all 
types of antibiotics (apart from tetracyclines) disappeared after excluding 1996 and 
1997 and/or year.  
 
It is plausible that low rates of dispensing may be associated with high rates of 
complications, suggesting that reducing dispensing might lead to an increase in 
complications. Therefore, to further examine whether antibiotic dispensing was the 
main driver of complications, the  relationship between changes in dispensing by 
general practices and changes in hospital events of complications and pneumonia 
were examined. All quartiles of change in total antibiotic dispensing demonstrated a 
significant increase in the rate of overall complications admitted to hospital between 
1998 and 2005. In particular, general practices that reduced their total dispensing the 
most showed the smallest increase in complication rates. Conversely, practices that 
reduced their antibiotic dispensing the least (or increased) showed the largest 
increase in complication rates. This suggests that there is no association between 
changes in dispensing and changes in complication rates. This adds to the evidence 
that the apparent associations found between dispensing and complications are 
spurious and that study year is a confounder in this model. 
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Impact of resistance on the relationship 
Using resistance data aggregated at the local heath board (LHB) level, the 
associations between antibiotic dispensing and complications did weaken after 
adjusting for amoxicillin resistance in H. influenzae but remained significant, with 
the exception of tetracycline dispensing.  
 
8.5.2 Strengths and weaknesses of the study 
Many of the strengths and weaknesses regarding the content, quality and coverage 
(and bias) of each of the individual datasets have been discussed in chapters 4 to 7. 
This study has major strengths compared with previous ecological studies. It is the 
only study to link up these datasets at a general practice level for a whole country 
and examine the relationship using general practices as the unit of analysis. This unit 
of aggregation was smaller than levels used in other studies, and whilst it is at an 
ecological level, it is important to examine the association at this level since 
strategies for enhanced antibiotic prescribing are often targeted at GPs. More 
sophisticated methodological techniques were used such as multilevel modelling as 
opposed to simple correlations or regression. Multilevel modelling not only allowed 
examination of variations in complications and their relationship with antibiotic 
dispensing at both general practice and LHB levels but confounders such the age 
structure and deprivation status of the registered practice population and certain 
practice characteristics could be adjusted for.  
 
Resistance was also examined as a possible modifier of the relationship but the small 
number of isolates per annum at practice level meant the analysis was either limited 
to a restricted biased sample of practices with a sufficient number of isolates 
submitted per annum or to an analysis based on data aggregated to a much larger 
geographical area (LHB). The LHB level analysis is problematic in itself as it is at 
the aggregation of a considerable number of practices; results are harder to interpret 
and it is difficult to account for possible LHB factors that may drive complications 
(e.g. different types and frequency of hospitals serving in the LHB area).  
 
The main limitation to this study is its ecological nature. It could be speculated that 
the apparent association between complications and dispensing is spurious and that 
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we can consider study year is a confounder in this model. That could occur if an 
unknown factor caused dispensing to fall (such as initiatives to reduce antibiotic 
prescribing) and another factor caused complications to rise (such as a change in 
pathways to treatment, for example such as changes in out of hours and organisation 
of care). However, due to the aggregate nature of the data, the causal pathways are 
unclear. Whilst we can speculate as to why complications could increase (change in 
coding or change in presentation of these illnesses) and dispensing decrease, a 
mechanism linking one to the other cannot be produced.  
 
Another of the limitations of this study was the small numbers of certain hospital 
events (e.g. mastoiditis) at a general practice level which restricted the scope for 
examining more complications over all ages and for those in children only. These 
small numbers of events meant that modelling could not be carried out at a small area 
level for such diagnoses. Further analyses could only have been carried out for a 
wider range of complications at LHB level but, as previously discussed, this unit of 
analysis was too large (with only 22 in Wales) for results to be very meaningful. 
  
True rate of antibiotic dispensing for RTIs, complications 
This study has related complications arising from acute RTIs resulting in a 
hospitalisation with all antibiotic dispensing in primary care from any diagnosis. 
Some dispensing will not be related to a diagnosis of an acute RTI (for example, 
tetracyclines in soft tissue and skin infections) and its inclusion here will result in an 
overestimation of the relevant dispensing rate. Also some antibiotics will not have 
been consumed (only dispensed) and this in turn will lower the true rate antibiotic 
exposure in the community. Antibiotic dispensing data in this study does not take 
into account low or suboptimal dose or the length of treatment controlled by the 
prescriber. This makes it a weak measure of exposure to antibiotics. The number of 
defined daily dose (DDD) may be a better measure as it is the assumed average 
maintenance dose (per day) for a drug used for its main indication in adults. 
 
As discussed in Chapter 7, the incidence of complications may also be 
underestimated since some are managed in the community and do not result in a 
hospitalisation. This deficit in complications should be similar across all areas and a 
comparable underestimate may possibly apply across the whole of Wales. By 
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observing hospital events of infection, complications at the severest end of the 
spectrum are compared with overall antibiotic dispensing. Although these 
complications are the ones of greatest concern, observing all complications is vital if 
this association is to be thoroughly explored. 
 
Adjusting for confounders 
We were able to adjust for a number of practice and practice population based 
variables believed to be associated with hospital events of acute RTIs and 
complications and/or antibiotic dispensing. However, there are unmeasured factors 
that could account for some of the variation, including practice population (e.g. co-
morbidity levels) and factors that change the patterns of disease (e.g. vaccination 
programmes). Whilst the impact of resistance on the relationship was examined it 
was in a biased sample of practices. Nevertheless, our results at practice and LHB 
level showed that resistance modified the relationship by only a small amount. This 
could reflect the positive association between prescribing and resistance.  
 
8.5.3 Comparisons with existing literature 
Several papers have examined the relationship between complications and antibiotic 
dispensing using routine health care databases at a primary care trust (PCT), health 
authority (HA) or country level. Only one paper could be found that examined the 
relationship (alongside urinary tract infections) at a GP level but none at a general 
practice level. Furthermore no papers could be found that examined the impact of 
resistance on the relationship.  
 
Results from these ecological level analyses also suggest that reductions in GP 
prescribing of antibiotics may be associated with increases in complications of 
bacterial infection. Data based on 162 general practitioners in Spain (around 300,000 
population) found significant negative associations between antibiotic dispensing 
rates and hospital admissions due to respiratory and urinary tract infections and 
complications arising from these infections (Urussuno et al. 2008).  In another cross-
sectional study, Little and colleagues examined primary care prescribing of penicillin 
and hospital admissions for complications and acute RTIs at the HA level, for the 
years 1997-1998 (Little et al. 2002). They found evidence that higher levels of 
Chapter 8 
267 
primary care prescribing of penicillin were significantly associated with lower rates 
of admissions for both quinsy and mastoiditis after adjusting for age, gender, 
deprivation and standardised mortality ratio.  
 
At the country level, a study in the USA compared the percentage of antibiotic 
prescribing for acute bronchitis and cough, and hospitalisations for RTIs (including 
pneumonia and empyema), in the US, between 1996 and 2003 (Mainous III et al. 
2006). Antibiotic prescribing (over the period) had a weak negative correlation with 
hospitalizations for all RTIs (rs=-0.22). Another study found that countries practising 
a restrictive use of antibiotics for acute otitis media (between 1991 and 1998), such 
as the Netherlands, Norway and Denmark, had a higher incidence rate of mastoiditis 
when compared to countries such as the UK, Canada, Australia and the US (Van 
Zuijlen et al. 2001). Finally, a study in England and Wales examined aggregate data 
for pneumonia mortality,  and the incidence of primary care visits for influenza or 
influenza-like illness, and their relationship with antibiotic prescribing for LRTIs in 
12-week winter periods between 1993/4 and 1999/2000 (Price et al. 2004b). The 
results demonstrated that antibiotic prescribing for LRTI had a significant association 
with excess winter pneumonia mortality even after adjusting for influenza incidence. 
   
8.5.4 Implications of findings for clinical practice and future research 
At the beginning of this chapter, the hypothesis proposed was that, at the level of 
general practices in Wales, reduced levels of community antibiotic dispensing in the 
community were associated with increases in hospital admissions in complications 
arising from common infections. Although at first glance there seemed to be an 
association, when study year was included as a confounder this relationship 
disappeared, suggesting there may be other factors driving complications. In 
addition, the lack of association found between changes in both dispensing and 
complications reinforce this finding. Thus we cannot conclude that there is an 
association but this may be due to the aggregate nature of the data and analysis. The 
results of these ecological level analyses are therefore unlikely to change current 
practice although they may be of interest to GPs due to the population that is 
covered, albeit at a practice level.  
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The impact of resistance on the model was hard to assess because small numbers of 
isolates at practice level necessitated a high level of aggregation. To investigate the 
input at practice level robust general practice level data will rely on practices sending 
samples more routinely for all sites but especially ENT. This is unlikely to happen in 
practice. More realistic is the development of near patient testing to identify the 
bacteria (if any) to prescribe appropriate antibiotics.  
 
In order to assess the true protective effect of antibiotics on complications arising 
from acute RTIs, individual patient information is required with a large enough 
sample to be able to examine individual complications. Of particular interest will be 
examining sub-groups of patients to identify the impact of an absence in antibiotics; 
will there be a higher risk of complications whether in primary or secondary care?  
An analysis at individual level is required and this will be examined in the next 
chapter, albeit in a different geographical area. 
 
8.6 Introduction to individual level analysis of antibiotic 
prescribing and complications arising from RTIs 
The following chapter will be based on individual level data for 60 practices in the 
UK. An analysis of individual patient level data presenting with an acute RTI, their 
prescribing behaviour and outcomes will be examined for one year period. This 
chapter improves on the model tested in this chapter in three ways. Firstly, it 
circumnavigates the problem of ecological analyses by using data on individual 
patients. Secondly, further data on patient characteristics is available to allow 
adjustment for possible confounders of complications and this will allow analysis of 
important sub-groups such as the children and the elderly. 
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Chapter 9  Antibiotic prescribing and complications arising 
from RTIs: Individual patient level analysis 
9.1 Introduction to individual level 
Chapter 8 examined the association between rates of antibiotic dispensing and 
hospital events at a general practice level. Whilst these data suggest no association 
between dispensing and hospital events, the analysis does not provide sufficient 
evidence to begin to change current practice. To attempt to do this, studies have to be 
carried out at an appropriate level, in this case at the individual patient level. Datasets 
should also be of good quality and representative of the larger population so that 
results are not biased and any inferences made are precise. Also of importance is to 
improve the inferences made by adjusting for known and measured confounders (risk 
factors) and using appropriate methods (multivariate analysis or propensity scores). 
  
This chapter attempts to address these issues and aims to investigate the effect of 
prescribing antibiotics in primary care against the risk of developing a complication 
arising from an RTI in both primary and secondary care using individual level data. 
It will also aim to identify sub-groups of patients benefiting most from antibiotics 
and examine whether this level of protection has changed over time, over a period 
when antibiotic prescribing declined.  
 
The null hypothesis being tested is that there are no differences in complication rates 
in patients presenting with an RTI between those prescribed an antibiotic and those 
not. 
 
9.2 Methods 
9.2.1 General Practice Research Database 
The General Practice Research Database (GPRD) is the world’s largest computerised 
database of anonymised longitudinal medical records from primary care with around 
3.5 million active patients (around 5% of the UK population) from around 460 
general practices in the United Kingdom (UK) (GPRD website). It is managed by the 
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GPRD Group within the Medicines and Healthcare Products Regulatory Agency 
(MHRA).  
 
Individual patient level data could be obtained for a fee, or free to UK academics 
through a Medical Research Council (MRC) licence. Although no patient or practice 
identifiable data are provided, each patient has an encrypted unique number which 
allows their records to be linked over time. For each patient, GPRD collects and 
makes available information such as demographic details (gender, year of birth and 
practice location), all clinical information (diagnoses, symptoms, procedures, and 
medical history using the Read/OXMIS coding system), all prescriptions issued, 
referrals to secondary care, test results, and lifestyle information. GPRD data is 
available from 1987 although the number of practices contributing data and up-to-
standard (fulfill the routine quality assurance checks) varies over the years.  
 
The quality of the GPRD records is validated and maintained by the GPRD group 
with a good relationship maintained with contributing practices to ensure up-to-date 
data collection. Validation studies
 
show that the quality and completeness of the 
GPRD data are high (Hollowell J 1997). The ‘Up-to-Standard’ (UTS) marker is a 
practice-based quality marker generated for each practice, indicating when data 
recording by the practice complied with specific quality measures, based on an 
assessment of the completeness, continuity and plausibility of data recording in key 
areas.   
 
Data from Full Feature (FF)-GPRD was accessed under an MRC licence which was 
gained in July 2007. The FF-GPRD has been available since 2001 and has 
considerably enhanced features compared to the former GPRD dataset. Under the 
licence, a maximum of 100,000 patient records were available from registered UTS 
practices across the UK.  
 
9.2.2 Study population 
Our study population consisted of patients who had presented in primary care and 
received a diagnosis of an acute respiratory tract infection (RTI) during 2005. 
Patients were identified from a number of UTS practices which were chosen at 
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random by the GPRD analysis team whilst keeping within the 100,000 patient 
records limit. To ensure that each record was the first presentation of a new acute 
RTI (called the index RTI), patients must not have presented with an acute RTI in the 
8 weeks (60 days) prior to the RTI. Therefore, any prior RTIs were checked for in 
November and December of 2004, for patients presenting with an RTI in January 
2005. 
 
Patients with an RTI diagnosis were identified using a list of Read codes previously 
identified by Ashworth and colleagues (Ashworth et al. 2005) and Smith and 
colleagues (Smith et al. 2006), and were used with permission. These codes were 
checked by several GP colleagues. These codes are listed in Appendix XI and 
grouped to allow for sub-group analysis as follows: sore throat, ear infection, 
sinusitis, laryngitis/tracheitis, chest infection, and pneumonia. A number of codes 
could not be grouped as they were too vague, such as viral illness and acute 
respiratory infections. These codes were included in the overall analysis for 
complications but excluded from any sub-group analyses. 
 
9.2.3 Exposure 
We were interested in ascertaining whether patients with an acute RTI were exposed 
to an antibiotic or not. In this study, we used prescribed antibiotics as a proxy for 
exposure to antibiotics since no other measures were currently available (such as 
dispensed or consumed antibiotics). Our primary aim was to investigate, at an 
individual level, if patients who did not receive an antibiotic prescription at first 
presentation of the acute RTI (or the index RTI) were more likely to develop a 
serious complication than those who did receive an antibiotic. This explored the 
hypothesis that early or immediate prescribing of antibiotics prevented 
complications.  
 
Patients who are not prescribed an antibiotic on their first presentation with an acute 
RTI may subsequently consult again and possibly receive an antibiotic. Therefore to 
avoid under reporting exposure, we also explored the association between patients 
who were prescribed an antibiotic, either at or after the index RTI event, and 
presenting with a serious or complicated infection. This was defined as an antibiotic 
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prescribed either on the same day as the index RTI or subsequently (defined as 
between 1 and 60 days of the index RTI); for those who presented with a serious 
complication, subsequent antibiotic prescribing was only examined up until that 
event. This explored the hypothesis that prescribing antibiotics in primary care 
prevented complications.  
 
For patients who were prescribed an antibiotic on the same day as the RTI, the type 
and strength of antibiotic was ascertained. Data on the dose and duration were 
available but were either not well populated or not consistently recorded (for 
example it may have been recorded either as a frequency per day, such as three times 
a day, or the daily dose such as 250mg three times a day).  
 
Antibiotics of interest are those listed in the British National Formulary (BNF) 
section 5.1 Antimicrobials (see section 5.2.2), with the exception of the following 
antibiotics which were not included, as these medications were uncommonly used in 
the treatment of common RTIs:  
 BNF 5.1.1.4 Antipseudomonal penicillins 
 BNF 5.1.1.5 Mecillinams 
 BNF 5.1.4 Aminoglycosides 
 BNF 5.1.6 Clindamycin 
 BNF 5.1.7 Some other antibacterials (inc. fusidic acid, chloramphenicol) 
 BNF 5.1.9 Antituberculosis drugs 
 BNF 5.1.10 Antileprotic drugs 
 BNF 5.1.11 Metronidazole and tinidazole 
 BNF 5.1.13 Urinary-tract infections (in. nitrofurantoin).  
 
Some patients were prescribed more than one antibiotic on the same day within the 
same consultation. In these cases, the last prescription was taken as it was assumed 
that the last prescription printed was a replacement for the first; for example, a 
possible scenario is that a patient may have first been prescribed amoxicillin but then 
a history of allergy was identified and it was replaced by erythromycin. Similarly 
tablets of some antibiotics may have been prescribed initially but then replaced by 
syrups of the same type of antibiotic, because the patient reported having difficulty 
swallowing tablets.  
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9.2.4 Clinical outcome of interest 
9.2.4.1 Complications diagnosed in primary care 
The primary clinical outcomes were any serious or complicated common infections 
presenting in primary care. These were ascertained using the same methods as in 
section 7.2.3 and the Read codes are listed in Appendix XII. Complications that 
presented between day one and day 60 after the RTI were included. Complications 
that presented on the same day as the index RTI were excluded as it is unlikely that 
the patient developed the complication as a result of not being prescribed an 
antibiotic.  
 
9.2.4.2 Complications diagnosed in secondary care 
A subset of practices had consented to linkage of their patient-level general practice 
data to hospital admission data (using Hospital Episodes Statistics (HES)). Linkage 
of these records was carried out in-house by GPRD. As with standard GPRD data, to 
maximise the quality of data, HES data are limited to acceptable patients only, for 
example when certain data quality conditions have been met such as no events 
recorded before the birth date, age <115 years, and a completed gender field. 
Acceptable patients in GPRD were linked to the HES using a combination of the 
patient’s NHS number, gender, DOB, and postcode (defined as strong matching). 
Not all patients in GPRD were eligible to be linked to HES data, for example those 
residing outside England, or without a valid NHS identifier. For some patients, the 
only record of hospitalisation fell outside their active follow-up period in the GPRD. 
 
Hospital admissions for patients from these consenting practices were arranged into 
files relating to hospitalisations, and referred to the total period of in-patient hospital 
stay from admission to discharge (also known as spells in HES and PEDW). A 
patient may have had more than one HES hospitalisation or spell. Serious or 
complicated infections presenting in hospital were identified using ICD10 codes 
(Appendix XIII) and were recorded alongside their discharge date, as opposed to an 
admission date.  
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9.2.5 Observation period  
Patients presenting with a first episode of acute RTI between 1
st
 January 2005 and 
31
st
 December 2005 were identified. For patients with an acute RTI at the end of the 
study period (December 2005), their consultations were followed up for 60 days to 
identify any associated serious or complicated infections. The history of all patients 
was examined for one year prior to the presentation of the index RTI. The study 
period therefore spanned over two years from 1
st
 January 2004 to 1
st
 March 2006. 
  
9.3 Statistical analysis 
9.3.1 Patient level characteristics  
Patient level characteristics potentially associated with both antibiotic prescribing 
and serious or complicated common infections included demographic factors (age at 
RTI diagnosis and gender), body mass index (BMI) and smoking status (nearest to 
index date), and co-morbidity. Also examined was the patient’s history (number of 
antibiotics prescribed, whether they had previously been diagnosed with a 
complication, and number of consultations for any illness) in the one year prior to the 
index RTI date. The number of consultations was defined as the number of days on 
which the patient visited their GP, so that multiple attendances on one day would 
count as a single consultation. It had been hoped to obtain information regarding 
samples sent for testing for antibiotic resistance but these data fields were poorly 
populated.  
 
9.3.1.1 Deprivation 
Deprivation score was calculated by the GPRD team using the Index of Multiple 
Deprivation (IMD) by linking both the individual patient’s postcode and the 
practice’s postcode to a suitable small area and then to an IMD score (Office for 
National Statistics). Since the score is calculated differently for each of the four 
countries of the UK, quintiles were created based on the spread of the scores within 
each country so that they could be compared. A high score (80) and high rank (5) 
indicated the most deprived and a low score (1) and rank (1) indicated the least 
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deprived. 
9.3.1.2 BMI 
Recorded BMI was categorized into four groups (underweight, normal, overweight 
and obesity) using different cut-offs for children and adults. The cut-off points used 
for adults from 18 years+ were those based on the WHO adult classification (WHO 
Global Database on Body Mass Index: underweight (< 18.5 kg/m
2
); normal weight 
(18.5 to 24.9 kg/m
2
); overweight (25.0 to 29.9 kg/m
2); and obese (≥ 30 kg/m2). For 
children aged 2-18, the International Obesity Task Force (IOTF) cut-offs were used 
to classify BMI into these four groups, the actual cut-offs depending on the child's 
age and sex, and were chosen to merge smoothly into the adults’ cut-offs. Children’s 
cut-off points were calculated by using the Microsoft Excel Add-in module 
lmsGrowth (www.healthforallchildren.co.uk (Pan H 2007, Cole TJ 2007) and 
established using survey data from six countries (Brazil, Great Britain, Hong Kong, 
the Netherlands, Singapore, and the United States) (Cole et al. 2000 and 2007).  
 
9.3.1.3 Smoking status 
Patients with no recorded smoking codes (recorded from 2004 up until the index RTI 
date) were categorized as unknown/not recorded. Patients with documented smoking 
data were categorized as current smoker, former smoker, never smoker, not a current 
smoker.  
 
9.3.1.4 Co-morbidity 
Following National Institute of Clinical Excellence (NICE) guidelines, which 
recommend that antibiotics should be given to patients who are systemically unwell, 
the following groups were examined: patients with significant heart, lung, renal, liver 
or neuromuscular disease, recent prescription for immunosuppressive drugs, and 
cystic fibrosis. We separately identified patients with diabetes and asthma from the 
GPRD tables provided. A co-morbidity was included if it was  diagnosed either on or 
before the patient’s index RTI date as we assumed that a GP was more likely to 
prescribe an antibiotic if the patient had any co-morbidity. The read codes used to 
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extract co-morbidities are listed in Appendix XIV. 
 
9.3.2 Predictors of antibiotic prescribing 
Predictors of same day antibiotic prescribing were examined using a multilevel 
logistic regression model using same day antibiotic prescribing as the binary 
outcome variable (antibiotic prescribed or not). Where numbers at each level 
allowed, variation in prescribing was accounted for at the level of the region (Wales, 
Scotland, North West England etc), general
 
practice, and individual, using the second 
order penalised
 
quasi-likelihood (2
nd
 order PQL) procedure.  Patients were 
considered to have been prescribed an antibiotic for an RTI if the prescription was 
issued on the day of the index RTI. Associations between certain factors and 
prescribing were examined firstly at the univariate level and significant predictors 
retained for the multilevel model. Odds ratios (ORs) were estimated together with 
95% confidence intervals (CIs).  
 
9.3.3 Association between antibiotics and complications 
Using the same multilevel modelling methods, the risk of developing serious 
complications in the 60 days after the index RTI was examined (binary outcome of a 
patient with an acute RTI developing a complication or not). The odds of developing 
a complication were compared using ORs and 95% CIs. They were compared firstly 
in those who were prescribed an antibiotic on the same day as the index RTI and 
those who were not, and secondly in those who were prescribed an antibiotic within 
60 days of the index RTI and those who were not, whilst adjusting for significant 
confounders discussed in section 9.3.1. Therefore, in the univariate model the 
significant confounders were identified, and in the multilevel model, the effect of 
antibiotic prescribing was adjusted for these significant confounders. 
 
Complications diagnosed only in primary care were initially examined. For a sub-set 
of practices linked to secondary care data, explained in section 9.2.4.2, complications 
diagnosed in either primary or secondary care were explored. For complications 
observed in both primary and secondary care, the majority of these had the same 
diagnosis. Where they differed, the earliest recorded complication was taken (and 
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any antibiotic prescribing taken up to this date).  
 
Sore throats and chest infections were examined separately (firstly for complications 
diagnosed in primary care and then for primary and secondary care diagnosed 
complications); these were the only infections which were sufficient in numbers to 
allow secondary analyses. 
 
9.3.4 Numbers needed to treat 
The numbers needed to be treated with antibiotics for one additional benefit (prevent 
a complication) (denoted by NNTB) were estimated from the reciprocal of the 
absolute risk reduction (ARR), alongside 95% confidence intervals (Cook and 
Sackett 1995). Confidence intervals for the NNTB were calculated by taking the 
reciprocals of the limits of 95% confidence intervals for the ARR. A negative 
absolute risk reduction indicated that the antibiotic had a harmful effect (causing a 
complication). Therefore a negative number needed to treat (NNT) was called the 
number needed to harm (and denoted by NNTH). 
 
Where a confidence interval for the positive absolute risk difference included zero, 
indicating no treatment effect (and NNT is infinite), the corresponding confidence 
interval for the NNT becomes less informative as it does not include the actual 
NNTB value. For example, an absolute risk difference of 10% with a wide 95% CI of 
-5% to 25%, showing a non-significant difference, gives a NNTB=10 (95% CI=-20 
to 4). In these cases the approach suggested by Altman (1998) is used with two 
separate intervals quoted. Altman (1998) suggests using the notation NNTB 4 to 
infinity () and NNTH 20 to  (or NNTH 20 to  to NNTB 4).  Figure 9.1 
illustrates the relationship between the ARR and the NNT and their confidence 
intervals. As a comparison to these NNTs based on crude risk differences, NNTs 
based on adjusted ORs (obtained from multivariate logistic regression) are also 
calculated (Bender and Blettner 2002). This adjustment is essential in light of the 
observational nature of GPRD data where confounding factors have to be taken into 
account to minimise bias.  
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Figure 9.1 Relationship between the absolute risk reduction and number needed to 
treat and their confidence intervals (NNTB=number needed to treat (benefit); 
NNTH=number needed to treat (harm)) 
 
Copyright ©1998 BMJ Publishing Group Ltd.
Altman, D. G BMJ 1998;317:1309-1312
 
 
9.3.5 Exclusions 
Patients who were either diagnosed with a complication on the same day as the index 
date or who died on the index date, were excluded as we could not infer that these 
patients developed the complication or died as a result of not being prescribed an 
antibiotic for the initial RTI (n=214). We additionally excluded patients who were 
diagnosed with an initial RTI of pneumonia (n=411) since only 54 (13.1%) were 
prescribed an antibiotic on the same day, with an additional 99 (24.1%) patients 
subsequently prescribed an antibiotic. This is low in comparison with the other RTI 
groups, especially as guidelines indicate that a diagnosis of pneumonia in the 
community should be treated with antibiotics (Lim et al. 2009). It is possible that 
these patients were sent straight to hospital as they were too sick to treat.   
 
All multilevel modelling was performed using MLwiN version 2.16 and all other 
analyses using SPSS version 16.0. 
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9.4 Results 
9.4.1 RTI cohort 
In 2005, 90,672 patient individual patients were diagnosed with an acute RTI (with 
no RTI in the prior 8 weeks) from 60 practices in 2005. Of these 60, 18 were from 
Wales, 3 from Scotland, 5, from Northern Ireland, 7 from London, 10 from South 
England, 8 from North West of England, 4 from the North East, and 5 from the East). 
Table 9.1 shows a summary of the characteristics of these patients. Deprivation was 
based on the practices’ deprivation as opposed to individual patients’ deprivation 
score, since a large proportion (69,416 (77%)) of the latter were missing. Due to the 
high proportion of missing BMI values, this factor was not included in any 
multivariate analyses as it may have led to bias in the results.   
 
The index RTI consisted of 151 individual Read code diagnoses, the most common 
of which were for ‘upper respiratory infection not otherwise specified (NOS)’ 
(H05z.00) and ‘upper respiratory tract infection NOS’ (H05z.11), with 8,901 and 
7,694 cases respectively (9.8% and 8.5% of all RTIs), and ‘sore throat symptom’ 
(1C9..00) with 8,300 (9.2%) cases (Appendix XI). ‘Chest infections/(NOS)’ 
(H06z000 and H06z011) accounted for 13,971 of RTIs (15.4%) and ‘acute tonsillitis’ 
(H03..00) for 6,701 (7.4%).  
 
When these individual Read codes were grouped, the majority of diagnoses that 
could be grouped were classed as sore throats and chest infections (N=23,016 
(25.4%) and 22,497 (24.8%) respectively) (Table 9.2). The RTIs that could not be 
grouped consisted of diagnoses such as upper respiratory (tract) infection NOS. 
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Table 9.1 Demographics of patients diagnosed with an RTI in 2005 (N(%) unless 
otherwise specified) 
 
Factors N (%) 
Age (years) 
0-4 
5-15 
16-64 
65 
 
6,318 (7.0) 
15,163 (16.7) 
53,532 (59.0) 
15,659 (17.3) 
Gender  
Male 
Female 
 
37,068 (40.9) 
53,604 (59.1) 
Practice deprivation
i
 
Least deprived 1 
2 
3 
4 
Most deprived 5 
 
14 (23.3) 
10 (40.0) 
14 (23.3) 
14 (23.3) 
8 (13.3) 
Diabetes diagnosed prior to RTI date  
% Yes 
 
6,609 (7.3) 
Asthma diagnosed prior to RTI date  
% Yes 
 
13,423 (14.8) 
Smoking status 
Current smoker 
Never smoked 
Former smoker 
Status unknown 
 
16,271 (17.9) 
37,387 (41.2) 
14,167 (15.6) 
22,847 (25.2) 
Co-morbidity
ii
 
% Yes 
 
18,470 (20.4) 
BMI (nearest to index date) 
Underweight 
Normal 
Overweight 
Obese 
Missing 
 
1,439 (2.6) 
22,409 (40.8) 
18,480 (33.6) 
12,662 (23.0) 
35,682 
Died within 60 day follow-up 407 (0.4) 
History (1 year prior to index RTI)  
Number of antibiotics  
median (range), mean (sd) 
None 
1-2 
3+ 
 
0 (0 to 41), 0.85 (1.58) 
53,141 (58.6) 
28,953 (31.9) 
8,578 (9.5) 
Complications (% Yes) 620 (0.7) 
Consultations 
Low (0-4 per annum) 
Med (5-10) 
High (>10) 
 
34,915 (38.5) 
28,926 (31.9) 
26,831 (29.6) 
i 
Practice deprivation based on Index of Multiple Deprivation score; 
ii 
Based on heart, lung, renal, 
liver, neuromuscular disease or ever had a prescription for immunosuppressive drugs 
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9.4.2 Antibiotic prescribing 
A total of 57,337 (63.2%) of the 90,672 patients were prescribed an antibiotic on the 
same day as the index RTI (Table 9.2); 409 (0.5%) were prescribed more than one 
antibiotic on the same day but the antibiotic prescribed last was assumed to be the 
one used, as described in section 9.2.3 above. The most commonly prescribed were 
broad-spectrum penicillins (N=33,515, 58.5%), benzylpenicillins and 
phenoxymethylpenicillin (N=10,588, 18.5%), and macrolides (6,710, 11.7%). 
Cephalosporins and tetracyclines accounted for 5.0% (N=2,863) and 4.4% (N=2,526) 
of prescribing respectively whilst quinolones, penicillin-resistant penicillins and 
trimethoprim made up only 2% (N=1,135). Of the patients who were excluded due to 
having a complication (N=59) or death (N=162) on the index RTI date, 26 (44%) and 
2 (1.2%) respectively received an antibiotic on the same day. 
 
Table 9.2 Number (%) of diagnoses by index RTI group alongside N (%) of 
antibiotic prescribed (no antibiotic prescribed, same day and subsequent) (sorted by 
% of same day prescribing) 
 
 
Total 
 diagnoses  
Antibiotic prescribed 
 Same day  
 
Subsequently
i
  No antibiotic 
prescribed 
Index RTI group N (%) N (% of total) 
Sinusitis 6,376 (7.0) 5,713 (89.6) 149 (2.3) 514 (8.1) 
Chest infection 22,497 (24.8) 18,954 (84.3) 906 (4.0) 2,637 (11.7) 
Ear infection 5,819 (6.4) 4,813 (82.7) 207 (3.6) 799 (13.7) 
Sore throat 23,016 (25.4) 14,625 (63.5) 1,421 (6.2) 6,970 (30.3) 
Laryngitis/ tracheitis 2,159 (2.4) 1,266 (58.6) 148 (6.9) 745 (34.5) 
Not grouped
ii
 30,805 (34.0) 11,966 (38.8) 3,113 (10.1) 15,726 (51.1) 
Total 90,672 (100.0) 57,337 (63.2) 5,944 (6.6) 27,391 (30.2) 
i 
1 to 60 days after the initial RTI 
ii
 Includes diagnoses that could not be grouped such as upper RTIs and bacterial infections
 
 
An additional 5,944 (6.6%) had an antibiotic subsequently prescribed, either between 
1 and 60 days of the index RTI or, if a complication did arise sooner than 60 days, up 
to the date of the complication. Therefore a total of 63,281 patients had an antibiotic 
prescribed within 60 days of the initial index RTI (69.8% of all RTI consultations). 
The median (25
th 
to 75
th
 percentiles) number of days between the index RTI and a 
subsequent antibiotic was 19 days (6 to 40 days). Table 9.2 shows that a high 
proportion of each RTI group were prescribed an antibiotic on the same day as the 
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RTI was diagnosed, ranging from 89.6% of patients diagnosed with sinusitis to 
38.8% for non-grouped diagnoses (e.g. URTI). Same day antibiotic prescribing 
varied substantially by practice, between 34% and 92%, and for subsequent 
prescribing between 2% and 10% (Figure 9.2). Subsequent prescribing was highest 
(10.1%) in the group including vague diagnoses such as Upper RTI not otherwise 
specified (NOS).     
 
Figure 9.2 Antibiotic prescribing in 60 GPRD practices 
 
 
 
Table 9.3 shows the results from the univariate and multivariate models examining 
the association between antibiotic prescribing on the same day as the index RTI and 
individual patient factors. In the univariate model, there was an increased odds of 
same day antibiotic prescribing for older patients, for those overweight or obese, 
those diagnosed with diabetes, asthma or another co-morbidity (heart, lung, liver 
disease etc), in smokers and ex-smokers, and for patients who were prescribed a 
higher number of antibiotics, consulted their GP more often and had at least one 
complication in the year prior to the RTI diagnosis. There was a decreased odds of 
same day antibiotic prescribing for patients who had an unknown smoking status.  
 
When these significant factors were included in a multivariate analysis, age, diabetes, 
asthma, co-morbidity, smoking, and prior antibiotic were all positively associated 
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with prescribing on the same day as the index RTI. Again patients with an unknown 
smoking status had lower odds of receiving an antibiotic on the same day as the RTI. 
Having a prior complication was no longer significant possibly due to correlation 
with other variables. There were significant differences between practices in same 
day antibiotic prescribing (σ2u0=0.245, (SE=0.049)) but no differences between 
regions. 
  
Table 9.3 Factors associated with same day antibiotic prescribing (as the index RTI) - univariate and multivariate analyses 
 
 Number of patients (%) Univariate Multivariate 
Factors No antibiotic 
prescribed 
N=33,335 
Antibiotic 
prescribed  
N=57,337 
Parameter 
estimate (SE) 
OR  
(95% CI) 
Parameter 
estimate (SE) 
OR  
(95% CI) 
Age (years) 
0-4 
5-15 
16-64 
65 
 
3,264 (51.7) 
7,051 (46.5) 
18,566 (34.7) 
4,454 (28.4) 
 
3,054 (48.3) 
8,112 (53.5) 
34,966 (65.3) 
11,205 (71.6) 
 
Ref 
0.204 (0.031) 
0.734 (0.028) 
0.996 (0.032) 
 
1 
1.23 (1.15 to 1.30) 
2.08 (1.97 to 2.20) 
2.71 (2.54 to 2.88) 
 
Ref 
0.190 (0.032) 
0.590 (0.041) 
0.801 (0.045) 
 
1 
1.21 (1.14 to 1.29) 
1.80 (1.66 to 1.95) 
2.23 (2.04 to 2.43)  
       
Gender 
Male 
Female 
 
13,739 (37.1) 
19,596 (36.6) 
 
23,329 (62.9) 
34,008 (63.4) 
 
Ref 
0.018 (0.014) 
 
1 
1.02 (0.99 to 1.05) 
 
- 
 
- 
       
Practice deprivation quintile 
Least deprived 1 
2 
3 
4 
Most deprived 5 
 
1,888 (30.8) 
1,393 (36.5) 
1,338 (41.5) 
1,861 (40.7) 
1,392 (39.6) 
 
4,240 (69.2) 
2,426 (63.5) 
1,885 (58.5) 
2,708 (59.3) 
2,125 (60.4) 
 
Ref 
-0.264 (0.210) 
-0.341 (0.194) 
-0.255 (0.198) 
0.027 (0.229) 
 
1 
0.77 (0.51 to 1.16) 
0.71 (0.49 to 1.04) 
0.77 (0.53 to 1.14) 
1.03 (0.66 to 1.61) 
 
- 
 
- 
       
BMI 
Underweight 
Normal 
Overweight 
Obese 
 
514 (35.7) 
7,683 (34.3) 
5,903 (31.9) 
3,868 (30.5) 
 
925 (64.3) 
14,726 (65.7) 
12,577 (68.1) 
8,794 (69.5) 
 
Ref 
0.045 (0.058) 
0.149 (0.059) 
0.230 (0.060) 
 
1 
1.05 (0.93 to 1.17) 
1.16 (1.03 to 1.30) 
1.26 (1.12 to 1.42) 
 
- 
 
- 
 
Diabetes 
 
 
2,131 (32.2) 
 
4,478 (67.8) 
 
0.303 (0.028) 
 
1.35 (1.28 to 1.43) 
 
0.082 (0.030) 
 
1.09 (1.02 to 1.15) 
Asthma 
 
4,320 (32.2) 9,103 (67.8) 0.240 (0.021) 1.27 (1.22 to 1.32) 0.063 (0.023) 1.07 (1.02 to 1.11) 
Co-morbidity 5,424 (29.4) 13,046 (70.6) 0.404 (0.019) 1.50 (1.44 to 1.55) 0.230 (0.021) 1.26 (1.21 to 1.31) 
       
2
8
3
 
  
Table 9.3 Factors associated with same day antibiotic prescribing (as the index RTI) - univariate and multivariate analyses 
 
 Number of patients (%) Univariate Multivariate 
Factors No antibiotic 
prescribed 
N=33,335 
Antibiotic 
prescribed  
N=57,337 
Parameter 
estimate (SE) 
OR  
(95% CI) 
Parameter 
estimate (SE) 
OR  
(95% CI) 
Smoking status 
Never smoked 
Current smoker  
Former smoker 
Status unknown 
 
13,364 (35.7) 
4,958 (30.5) 
4,305 (30.4) 
10,708 (46.9) 
 
24,023 (64.3) 
11,313 (69.5) 
9,862 (69.6) 
12,139 (53.1) 
 
Ref 
0.261 (0.021) 
0.259 (0.022) 
-0.483 (0.018) 
 
1 
1.30 (1.25 to 1.35) 
1.30 (1.24 to 1.35) 
0.62 (0.60 to 0.64) 
 
Ref 
0.256 (0.021) 
0.179 (0.022) 
-0.061 (0.032) 
 
1 
1.29 (1.24 to 1.35) 
1.20 (1.15 to 1.25) 
0.94 (0.88 to 1.00) 
History  
(1 year prior to index RTI): 
 
      
Antibiotics prescribed  
Low (0 per annum) 
Med (1-2) 
High (>3)  
 
20,797 (39.1) 
10,029 (34.6) 
2,509 (29.2) 
 
32,344 (60.9) 
18,924 (65.4) 
6,069 (70.8) 
 
Ref 
0.142 (0.016) 
0.344 (0.026) 
 
1 
1.15 (1.12 to 1.19) 
1.41 (1.34 to 1.48) 
 
Ref 
0.135 (0.017) 
0.270 (0.028) 
 
1 
1.14 (1.11 to 1.18) 
1.31 (1.24 to 1.38) 
 
Complications  
No 
Yes  
 
 
33,136 (36.8) 
199 (32.1) 
 
 
56,916 (63.2) 
421 (67.9) 
 
 
 
Ref 
0.221 (0.089)  
 
 
1 
1.25 (1.05 to 1.49) 
 
 
- 
 
 
- 
Consultations 
Low (0-4 per annum) 
Mid (5-10) 
High (>10) 
 
13,785 (39.5) 
10,593 (36.6) 
8,957 (33.4) 
 
21,130 (60.5) 
18,333 (63.4) 
17,874 (66.6) 
 
Ref 
0.121 (0.017) 
0.279 (0.018) 
 
1 
1.13 (1.09 to 1.17) 
1.32 (1.28 to 1.37) 
 
Ref 
-0.060 (0.018) 
-0.160 (0.022) 
 
1 
0.94 (0.91 to 0.98) 
0.85 (0.82 to 0.89) 
2
8
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9.4.3 Complications diagnosed in primary care 
9.4.3.1 All acute respiratory tract infections 
Of the 90,672 patients with an index RTI, 420 (46.32 per 10,000 patients) had a 
complication diagnosed by their GP within 60 days. The majority (62.7%) of these 
were lung complications (pneumonia, acute exacerbation of chronic obstructive 
pulmonary disease (AE COPD) and other lung complications) and throat 
complications such as quinsy, epiglottitis, and streptococcal throat/tonsillitis (Table 
9.4). The median number of days between the index RTI and the patient’s first 
complication varied by complication group; pneumonia, throat complications and 
scarlet fever all presented less than a median of 2 weeks after the initial RTI, with the 
other groups all presenting a median of 20 to 29 days later (Figure 9.3). The 
exception was meningitis with a median of 2 days (25
th
 to 75
th
 percentiles of 1 to 43 
days) but as this was based on only 3 cases, this length of time should be interpreted 
with caution. Patients that did not receive an antibiotic had a shorter duration to onset 
of complication (median 9 days (25
th 
to 75
th
 percentile =3 to 23 days). No differences 
were observed between the group that received an antibiotic on the same or 
subsequently (median 18 days (7 to 36 days) and 19.50 (9 to 34.50)). 
 
Table 9.4 Complications diagnosed in primary care within 60 days of the RTI    
  
Complication N (%) 
Median days  
after RTI  
(25th to 75th percentile)  
Pneumonia 188 (44.8) 12 (4 to 28) 
Other lung complications  
(AE COPD, consolidation, bronchiectasis) 
75 (17.9) 23 (13 to 39) 
Throat complications  
(quinsy, epiglottitis, strep throat) 
68 (16.2) 8 (3 to 18) 
Bacterial infection unspecified  
(Streptococcal, staphylococcal etc) 
26 (6.2) 23 (15 to 46) 
Septicaemia 21 (5.0) 20 (10 to 47) 
Pleural effusion 13 (3.1) 22 (11 to 46) 
Scarlet fever 12 (2.9) 8 (2 to 26) 
Other complications  (lymphadenitis, 
cellulitis, reactive arthropathy) 
11 (2.6) 22 (12 to 49) 
Meningitis 3 (0.7) 2 (1 to 43) 
Mastoiditis 3 (0.7) 29 (10 to 29) 
Total 420 (0.5%) 14 (5 to 32.75) 
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Figure 9.3 Box plot of the number of days between the index RTI and the first 
complication 
 
 
9.4.3.2 Risk of complications by antibiotic prescribing 
Patients prescribed an antibiotic on the same day as the index RTI were found to be 
at a lower risk of presenting with a complication in primary care in the 60 days after 
the index RTI (44.47 vs.49.50 per 10,000 patients) (Table 9.5). The absolute risk 
reduction (ARR) was 5.02 (95% CI=-1.96 to 14.63) although not significant, and the 
number of antibiotics needed to be prescribed to prevent one complication (NNTB) 
was 1991 (95% CI= NNTH 5100 to  to NNTB 684). An additional 5,944 patients 
were prescribed an antibiotic between 1 and 60 days after the index RTI (or until the 
first complication), of which 34 had a complication (57.20 per 10,000). The ARR for 
prescribing within any consultation (first or subsequent within 60 days of the initial 
RTI) was 2.16 (95% CI=-5.35 to 12.34), and the NNT=4637 (NNTH 1870 to  to 
NNTB 810). 
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Table 9.5 Risk of complications (diagnosed in primary care) within 60 days of the 
index RTI (per 10,000 patients) 
 
 Number of patients  
with a complication 
 (risk per 10,000 patients) 
Absolute risk 
reduction 
(ARR)  
(95% CI) 
Numbers needed to 
treat to prevent one 
complication 
(NNTB) (95% CI) 
Not prescribed 
an antibiotic 
Prescribed an 
antibiotic 
 
Same day 
prescribing  
165/33,335 
(49.50) 
255/57,337 
(44.47) 
5.02  
(-1.96 to 14.63) 
1991 (NNTH
i
 5100 to 
 to NNTB 684) 
     
Prescribing 
within 60 days  
131/27,391 
(47.83) 
289/63,281 
(45.67) 
2.16 
(-5.35 to 12.34) 
4637 (NNTH 1870 to 
 to NNTB 810) 
i  
NNTH=number needed to harm 
 
Table 9.6 shows the results from the univariate and multivariate models examining 
the association between the risk of complication in the 60 days after the index RTI 
diagnosis and individual patient factors. In the univariate model, there was an 
increased risk of a complication for older patients (aged 65), males, those diagnosed 
with diabetes, asthma or another co-morbidity, underweight patients, for patients 
whose status regarding smoking was unknown, who were prescribed a higher 
number of antibiotics (>3 per annum), who had a higher number of consultations (>5 
per annum) and had previously had a complication in the year prior to the RTI 
diagnosis.  
 
After adjusting for these significant confounders (excluding diabetes and asthma as 
they were no longer significant in the multivariate model), patients prescribed an 
antibiotic on the same day as the index RTI were found to be at a lower risk of 
developing a complication in primary care in the 60 days after the index RTI 
(adjusted OR=0.74, 95% CI =0.56 to 0.99) and the number needed to treat with 
antibiotics to prevent one complication based on the adjusted OR was 780. For 
prescribing within 60 days of the index RTI, the adjusted OR was 0.78 (95% CI=0.56 
to 1.07) and the NNTB=954.  
 
When comparing the number needed to treat between those based on the ARRs and 
the adjusted ORs, the NNTBs were smaller in the adjusted ORs. For example, for 
same day antibiotic prescribing the NNTBs were reduced from 1991 to 780 and for 
prescribing within 60 days of the index RTI, from 4637 to 954.  
  
Table 9.6 Factors associated with complications diagnosed in primary care within 60 days of the index RTI 
 
 Number of patients (%) Univariate Multivariate 
Factors No 
complication 
 
N=90,252 
Complication 
diagnosed
 
N=420 
Parameter 
estimate (SE) 
OR  
(95% Cl) 
Parameter 
estimate (SE) 
OR  
(95% Cl) 
Age (years) 
0-4 
5-15 
16-64 
65 
 
6,299 (99.7) 
15,135 (99.8) 
53,363 (99.7) 
15,455 (99.7) 
 
19 (0.3) 
28 (0.2) 
169 (0.3) 
204 (1.3) 
 
Ref 
-0.485 (0.303) 
0.056 (0.247) 
1.501 (0.245) 
 
1 
0.62 (0.34 to 1.12) 
1.06 (0.65 to 1.72) 
4.49 (2.78 to 7.25) 
 
Ref 
-0.343 (0.311) 
0.657 (0.334) 
1.807 (0.343) 
 
1 
0.71 (0.39 to 1.31) 
1.93 (1.00 to 3.71) 
6.09 (3.11 to 11.93) 
       
Gender 
Male 
Female 
 
36,872 (99.5) 
53,380 (99.6) 
 
196 (0.5) 
224 (0.4) 
 
Ref 
-0.234 (0.100)  
 
1 
0.79 (0.65 to 0.96) 
 
Ref 
-0.330 (0.105) 
 
1 
0.72 (0.59 to 0.88) 
       
Deprivation quintile 
Least deprived 1 
2 
3 
4 
Most deprived 5 
 
25,318 (99.6) 
14,632 (99.6) 
15,964 (99.4) 
22,543 (99.6) 
11,795 (99.4) 
 
104 (0.4) 
55 (0.4) 
89 (0.6) 
99 (0.4) 
73 (0.6) 
 
Ref 
-0.035 (0.237) 
0.322 (0.213) 
0.108 (0.209) 
0.448 (0.238) 
 
1 
0.97 (0.61 to 1.54) 
1.37 (0.91 to 2.09) 
1.11 (0.74 to 1.68) 
1.57 (0.98 to 2.50) 
 
- 
 
- 
       
BMI 
Underweight 
Normal 
Overweight 
Obese 
 
1,418 (98.5) 
22,288 (99.5) 
18,380 (99.5) 
12,606 (99.6) 
 
21 (1.5) 
121 (0.5) 
100 (0.5) 
56 (0.4) 
 
Ref 
-0.999 (0.243) 
-1.005 (0.247) 
-1.217 (0.263)  
 
1 
0.37 (0.23 to 0.59) 
0.37 (0.23 to 0.59) 
0.30 (0.18 to 0.50) 
 
- 
 
- 
 
Diabetes 
 
6,536 (98.9) 
 
73 (1.1) 
 
0.951 (0.133) 
 
2.59 (1.99 to 3.36) 
 
- 
 
- 
 
Asthma 
 
13,316 (99.2) 
 
107 (0.8) 
 
0.686 (0.115) 
 
1.99 (1.59 to 2.49) 
 
- 
 
- 
 
Co-morbidity 
 
 
2,745 (97.8) 
 
63 (2.2) 
 
1.037 (0.102) 
 
2.82 (2.31 to 3.44) 
 
0.409 (0.118) 
 
1.51 (1.19 to 1.90) 
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Table 9.6 Factors associated with complications diagnosed in primary care within 60 days of the index RTI 
 
 Number of patients (%) Univariate Multivariate 
Factors No 
complication 
 
N=90,252 
Complication 
diagnosed
 
N=420 
Parameter 
estimate (SE) 
OR  
(95% Cl) 
Parameter 
estimate (SE) 
OR  
(95% Cl) 
Smoking status 
Never smoked 
Current smoker  
Former smoker 
Status unknown 
 
37,199 (99.5) 
16,195 (99.5) 
14,074 (99.3) 
22,784 (99.7) 
 
188 (0.5) 
76 (0.5) 
93 (0.7) 
63 (0.3) 
 
Ref 
-0.091 (0.139) 
0.254 (0.130) 
-0.601 (0.148) 
 
1 
0.91 (0.70 to 1.20) 
1.29 (1.00 to 1.66) 
0.55 (0.41 to 0.73) 
 
Ref 
0.013 (0.144) 
-0.257 (0.137) 
0.617 (0.247) 
 
1 
1.01 (0.76 to 1.34) 
0.77 (0.59 to 1.01) 
1.85 (1.14 to 3.01) 
History  
(1 year prior to index RTI): 
      
 
Antibiotics prescribed  
Low (0 per annum) 
Med (1-2) 
High (>3)  
 
 
52,944 (99.6) 
28,838 (99.6) 
8,470 (98.7) 
 
 
197 (0.4) 
115 (0.4) 
108 (1.3) 
 
 
Ref 
0.087 (0.120) 
1.277 (0.123) 
 
 
1 
1.09 (0.86 to 1.38) 
3.59 (2.82 to 4.56) 
 
 
Ref 
-0.138 (0.127) 
0.589 (0.146) 
 
 
1 
0.87 (0.68 to 1.12) 
1.80 (1.35 to 2.40) 
       
Complications (Yes)  577 (93.1) 43 (6.9) 2.834 (0.169) 17.01 (12.22 to 23.69) 1.957 (0.189) 7.08 (4.89 to 10.25) 
       
Consultations 
Low (0-4 per annum) 
Mid (5-10) 
High (>10) 
 
34,826 (99.7) 
28,817 (99.6) 
26,609 (99.2) 
 
89 (0.3) 
109 (0.4) 
222 (0.8) 
 
Ref 
0.402 (0.146) 
1.208 (0.129)  
 
1 
1.49 (1.12 to 1.99) 
3.35 (2.60 to 4.31) 
 
Ref 
0.167 (0.157) 
0.365 (0.166) 
 
1 
1.18 (0.87 to 1.61) 
1.44 (1.04 to 1.99) 
 
Antibiotic prescribing 
      
Same day prescribing 
No antibiotic 
Antibiotic  
 
33,170 (99.5) 
57,082 (99.6) 
 
165 (0.5) 
255 (0.4) 
 
Ref 
-0.101 (0.144) 
 
1 
0.90 (0.68 to 1.20) 
 
Ref 
-0.297 (0.146) 
 
1 
0.74 (0.56 to 0.99) 
Prescribing within 60 days
i
 
No antibiotic 
Antibiotic 
 
27,260 (99.5) 
62,992 (99.5) 
 
131 (0.5) 
289 (0.5) 
Ref 
0.023 (0.159) 
1 
1.02 (0.75 to 1.40) 
Ref 
-0.254 (0.164) 
1 
0.78 (0.56 to 1.07) 
i
Adjusted for age, gender, co-morbidity, smoking status, and antibiotic prescribing, consultations, and complications in the year prior to the RTI
2
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9.4.3.3 Sore throat 
There were 23,016 consultations of sore throats in 2005, with 77 (33.45 per 10,000) 
complications being diagnosed in the 60 days after the initial RTI. Of these 
complications, 38 (49%) were for quinsy, 14 (18%) for various streptococcal 
infections (throat, tonsillitis), 9 (12%) for lung complications and the remainder for 
complications such as scarlet fever and septicaemia amongst others.  
 
The risk of developing a complication was higher in patients who were prescribed an 
antibiotic on the same day when compared to those not receiving an antibiotic (34.19  
vs. 32.18 per 10,000 patients) and the reduction in risk was negative although not 
significant (ARR=-2.01, 95% CI=-12.06 to 14.76) (Table 9.7). An additional 1,421 
patients were prescribed an antibiotic between 1 and 60 days after the index RTI (or 
until the first complication), of which 3 had a complication (21.11 per 10,000). By 
incorporating these patients, the risk of developing a complication was reversed 
(33.03 vs. 35.35 per 10,000 patients) but the reduction in risk was still not significant 
(p=0.783). The NNTBs based on absolute risk were -4973 (NNTH 829 to  to 
NNTB 678) and 4318 (NNTH 1079 to  to NNTB 472) for same day prescribing 
and prescribing within 60 days respectively. 
 
Only asthma and prior complications were associated with a complication arising 
from a sore throat diagnosis. After adjusting for these two factors, the OR for same 
day antibiotic prescribing was 1.07 (95% CI=0.67 to 1.70) and the NNTB was -4455 
(or NNTH=4455). For any prescribing within 60 days of the sore throat diagnosis, 
there was still no significant difference in risk between the two groups (adjusted 
OR=0.95, 95% CI=0.58 to 1.54) and the NNTB was 5677.  
 
9.4.3.4 Chest infection 
There were 22,497 patient consultations of chest infections in 2005, with 213 (94.68 
per 10,000) complications being diagnosed in the 60 days after the initial infection. 
Of these complications, 179 (84%) were for pneumonia and other lung complications 
such as AE COPD and bronchiectasis. 
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The risk of developing a complication was significantly lower in patients who were 
prescribed an antibiotic on the same day when compared to those not prescribed 
(77.56 vs. 186.28 per 10,000 patients) and the risk reduction was 108.73 (95% 
CI=69.14 to 160.05, p<0.001) (Table 9.7). The number of chest infections needed to 
treat with antibiotics to prevent one complication arising was 92 (95% CI=62 to 
145).  An additional 906 patients were prescribed an antibiotic within 60 days of the 
index RTI (or until the first complication), of whom 15 had a complication (165.56 
per 10,000). After incorporating these patients, the risk of developing a complication 
was still significantly lower in patients who were prescribed an antibiotic within 60 
days when compared to those not prescribed (81.57 vs. 193.40) per 10,000 patients) 
and the reduction in risk was slightly greater (ARR=111.83, 95% CI=65.83 to 
172.92, p<0.001). The number of chest infections needed to treat with antibiotics to 
prevent one complication arising was 89 (95% CI=58 to 152). After adjusting for 
age, co-morbidity, smoking status, prior complication, and antibiotic in the year prior 
to the chest infection, the adjusted OR for same day antibiotic prescribing was 0.42 
(95% CI=0.28 to 0.64, NNTB=93) and for prescribing within 60 days was 0.39 (95% 
CI=0.25 to 0.63, NNTB=85).  
 
Table 9.7 Risk of complications (diagnosed in primary care) within 60 days of the 
index sore throat/chest infection (per 10,000 patients) 
 
 Number of patients  
with a complication 
 (risk per 10,000 patients) 
ARR (95% CI) NNTB
i
 (95% CI) 
Not prescribed 
an antibiotic 
Prescribed an 
antibiotic 
Sore throats 
Same day 
prescribing  
27/8,391 
(32.18) 
50/14,625 
(34.19) 
-2.01 
(-12.06 to 14.76) 
-4973 (NNTH
ii
 829 
to  to NNTB 678) 
Prescribing within 
60 days  
24/6,790 
(35.35) 
53/16,046  
(33.03) 
2.32 
(-9.27 to 21.18) 
4318 (NNTH 1079 
to  to NNTB 472) 
     
Chest infections    
Same day 
prescribing  
66/3,543 
(186.28) 
147/18,954 
(77.56) 
108.73 
(69.14 to 160.05) 
92  
(62 to 145) 
Prescribing within 
60 days 
 
51/2,637 
(193.40) 
162/19,860 
(81.57) 
111.83 
(65.83 to 172.92) 
89  
(58 to 152) 
i 
NNTB = Number needed to benefit; 
ii 
NNTH = Number needed to harm 
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9.4.3.5 Ear infection, sinusitis, and non specific URTI codes 
There were 5,819 patient consultations of ear infections in 2005, with 10 
complications (17.19 per 10,000) being diagnosed in the 60 days after the initial 
infection. The risk of developing a complication was lower in patients who were 
prescribed an antibiotic on the same day when compared to those not prescribed 
(16.62  vs. 19.88 per 10,000 patients) and the number needed to treat with antibiotics 
to prevent one complication arising was 3068 (95% CI=-895 to 178 ).   
 
For sinusitis, there were 6,376 patient consultations with 7 developing into 
complications (10.98 per 10,000). Again the risk of developing a complication was 
lower in patients who were prescribed an antibiotic on the same day when compared 
to those not prescribed (10.50 vs. 15.08 per 10,000 patients) and the needed to treat 
with antibiotics to prevent one complication arising was 2183 (95% CI=-1276 to 
134). 
 
For general URTI, there were 30,805 patient consultations with 105 developing into 
complications (34.09 per 10,000). Again the risk of developing a complication was 
lower in patients who were prescribed an antibiotic on the same day when compared 
to those not prescribed (31.76 vs. 35.56 per 10,000 patients) and the needed to treat 
with antibiotics to prevent one complication arising was 2626 (95% CI=-2674 to 
599). 
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9.4.4 Complications diagnosed in primary and secondary care 
A total of 17 practices with 29,473 patients consented to being matched to Hospital 
Episode Statistics (HES) data (32.5% of the original dataset). Patients can only be 
matched if they have ever been hospitalised (as an inpatient, outpatient or attended 
A&E). The majority of patients (N=24,078, 81.7%) were a strong match (linked 
using NHS, DOB, & gender) and nine (0.03%) were a weak match. A small 
proportion of patients (N=5,196, 17.6%) could not be linked up to HES data, either 
because they had not ever been hospitalised or they did not have the required 
identifiers to allow linkage. Unfortunately, the GPRD data did not distinguish 
between these two reasons. This group who could not be linked was more likely to 
consist of young males, with less co-morbidity, non-smokers, of normal weight, with 
fewer antibiotic prescriptions, complications and consultations in the year prior to 
their RTI. They were also less likely to have received an antibiotic for the RTI and to 
have developed a complication. For these reasons it was believed that they were 
more likely to have not been hospitalised rather than not linked to HES data, and 
were included in the analysis. Lastly, 190 patients (0.6%) were missing a matching 
status and were excluded from analysis, leaving 29,283 patients to be analysed 
 
9.4.4.1 Representativeness of the linked practices 
Rates of complications diagnosed in primary care were slightly higher in linked 
practices than in non-linked (Table 9.8). Patients in the practices linked to secondary 
care data were on average younger, more likely to have had asthma, be a smoker or 
ex-smoker, and have had a complication in the year prior to the RTI. They were less 
likely to have diabetes, to have had an antibiotic prescribed or a consultation in the 
year before the RTI diagnosis, and to have been prescribed an antibiotic on the same 
day or subsequent to the index RTI. Patients were comparable on gender and co-
morbidities. Thus there were no indications that this subset of linked data was biased 
towards patients at a higher risk of complications, thus biasing the rate of 
complications in the dataset. It is safe to assume that results arising from this subset 
of data are reliable and any additional complications identified are accurate and not 
an artefact of the case-mix of patients included. While some comparisons are 
significant, differences are generally small as the numbers involved are large. 
Chapter 9 
295 
Table 9.8 Demographics of patients diagnosed with an RTI in 2005 (N(%) unless 
otherwise specified) – practices linked to HES data and those not linked 
 
Factors Non-linked 
practices  
Linked practices  Test 
statistic, p-
value 
Practices (patients) 43 (61,199) 17 (29,283)  
Complications in primary care 
N (rate per 10,000 patients) 
265(43.30) 155 (52.93) 2=3.976, 
p=0.046 
 
Gender  
Male 
Female 
 
24,943 (40.8) 
36,256 (59.2) 
 
12,048 (41.1) 
17,235 (58.9) 
 
2=1.222, 
p=0.269 
 
Age (years)  
median (25 to 75
th
 percentiles) 
 
38.0 (16 to 58) 
 
37.0 (16 to 56) 
MW, 
p<0.001 
 
Co-morbidity 
% Yes 
 
12,407 (20.3) 
 
6,032 (20.6) 
2=1.295, 
p=0.255 
 
Diabetes diagnosed prior to RTI  
% Yes 
 
4,785 (7.8) 
 
1,816 (6.2) 
2=76.591, 
 p<0.001 
 
Asthma diagnosed prior to RTI 
% Yes 
 
8,820 (14.4) 
 
4,576 (15.6) 
2=23.173, 
p<0.001 
 
Smoking status 
Never smoked 
Current smoker  
Former smoker 
Status unknown 
 
10808 (17.7) 
25597 (41.8) 
9419 (15.4) 
15375 (25.1) 
 
5414 (18.5) 
11704 (40.0) 
4735 (16.2) 
7430 (25.4) 
 
2=32.324, 
p<0.001 
History (1 year prior to index RTI) 
Number of antibiotics  
None 
1-2 
3+ 
 
35549 (58.1) 
19689 (32.5) 
5961 (9.7) 
 
17473 (59.7) 
9207 (31.4) 
2603 (8.9) 
 
2=26.932, 
p<0.001 
Complications 
% Yes 
 
388 (0.6) 
 
232 (0.8) 
 
2=7.291, 
p=0.007 
Consultations 
Low (0-4 per annum) 
Med (5-10) 
High (>10) 
 
22,823 (37.3) 
19,785 (32.3) 
18,591 (30.4) 
 
12,009 (41.0) 
9,084 (31.0) 
8,190 (28.0) 
 
2=120.548, 
p<0.001 
 
 
Antibiotic prescribed on same day 38,848 (63.5) 18,364 (62.7) 2=4.999, 
p=0.025 
 
Antibiotic prescribed within 60 
days 
42,837 (70.0) 20,302 (69.3) 2=4.165, 
p=0.041 
 
 
Chapter 9 
296 
9.4.4.2 All respiratory tract infections 
Of the 29,283 patients diagnosed with an RTI, 250 (85.37 per 10,000) had a 
complication diagnosed either in primary or secondary care within 60 days of the 
index RTI (Table 9.9). Of these, 155 (52.93 per 10,000 patients) presented, and were 
diagnosed with, a complication in primary care only (n=95) or in both primary and 
secondary care (n=60). An additional 95 complications (32.44 per 10,000 patients) 
were diagnosed in secondary care only but were not recorded in primary care during 
the 60 days after the index RTI.  Identifying these secondary care complications was 
especially significant in the area of lung complications (39% of pneumonia and 54% 
other lung complications identified), septicaemia where 33% of cases were 
identified, and pleural effusion where 69% of cases were identified. The 95 patients 
with complications diagnosed in secondary care only (when compared to patients 
with a complication presenting in primary care only or in both primary and 
secondary care) were more likely to be older, have a co-morbidity and a diagnosis of 
diabetes. They were also more likely to be a smoker or an ex smoker, be prescribed 
an antibiotic after the index RTI (and less likely to be prescribed an antibiotic on the 
same day as the index RTI). They had a high number of GP consultations prior to the 
index RTI but were less likely to have had a complication and a high number of 
antibiotics prescribed in the year prior to the index RTI. 
 
 
 
  
Table 9.9 Complications diagnosed in primary and secondary care within 60 days of the RTI (N(%) unless otherwise specified) 
 
 Complication presenting in: Median  
(25
th
 to 75
th
 
percentiles) days 
after index RTI 
Complication Primary care only 
or in both primary 
and secondary care 
Secondary  
care only 
Total 
Pneumonia 60 (39) 38 (40) 98 (39) 9 (3 to 23.50) 
Other lung complications (AE COPD, pleural 
empyema etc) 
33 (21) 38 (40) 71 (28) 23 (8 to 41) 
Throat complications (quinsy, epiglottitis, strep 
throat) 
34 (22) 1 (1) 35 (14) 6 (3 to 15) 
Bacterial infections  4 (3) 1 (1) 5 (2) 50 (31.50 to 52.00) 
Septicaemia 8 (5) 4 (4) 12 (5) 25 (4.50 to 39.75) 
Pleural effusion 4 (3) 9 (9) 13 (5) 25 (9.50 to 39.50) 
Scarlet fever 4 (3) 0 (0) 4 (2) 5 (1.25 to 39.50) 
Other complications (reactive arthropathy, 
cellulitis etc) 
6 (4) 4 (4) 10 (4) 33.50 (11 to 49.50) 
Meningitis 0 (0) 0 (0) 0 (0) - 
Mastoiditis 2 (1) 0 (0) 2 (1) - 
Total complications / Total patients  
(complication rate per 10,000 patients) 
155/29,283 
(52.93) 
95/29,283 
(32.44) 
250/29,283 
(85.37) 
- 
Median (25
th
 to 75
th
 percentiles)  
days after index RTI 
11  
( 4 to 27) 
22  
(7 to 43) 
14 
(4.75 to 31.25) 
- 
2
9
6
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Complications diagnosed in secondary care only had a significantly higher number of 
days between the index RTI and diagnosis (median= 22 days, 25
th
 to 75th 
percentiles= 7 to 43 days) than for complications diagnosed in primary care only, or 
primary and secondary care only (11, 4 to 27 days, p=0.002). As in the main dataset, 
the majority of complications affected the lung with 80% of those diagnosed only in 
secondary care had lung complications. The median number of days between the 
index RTI and the patients’ first complication were also comparable to the main 
datasets of primary care diagnosed complications (Table 9.10). Pneumonia and 
scarlet fever were diagnosed sooner in secondary care (9 vs. 12 days and 5 vs. 8 days 
respectively). Of the 60 complications diagnosed at both locations, 25 (42%) had the 
same dates (date of diagnosis in primary care was the same as the date of discharge 
from hospital), 27 (45%) had a complication diagnosed in primary care first (with a 
discharge date in secondary care between 1 and 23 days after), and 8 (13%) were 
discharged from hospital before the diagnosis had been recorded in primary care. 
 
Table 9.10 Median (25
th
 to 75
th
 percentiles) days after index RTI to first diagnosis of 
complication by health care setting  
 
 Diagnosed in: 
Complication Primary 
care 
Secondary care 
Pneumonia 12 (4 to 28) 9 (3 to 23.50) 
Other lung complications (AE COPD, 
pleural empyema etc) 
23 (13 to 39) 23 (8 to 41) 
Throat complications (quinsy, 
epiglottitis, strep throat) 
8 (3 to 18) 6 (3 to 15) 
Bacterial infections  23 (15 to 46) 50 (31.50 to 52.00) 
Septicaemia 20 (10 to 47) 25 (4.50 to 39.75) 
Pleural effusion 22 (11 to 46) 25 (9.50 to 39.50) 
Scarlet fever 8 (2 to 26) 5 (1.25 to 39.50) 
Other complications (reactive 
arthropathy, cellulitis etc) 
22 (12 to 49) 33.50 (11 to 49.50) 
Meningitis 2 (1 to 43) 0 
Mastoiditis 29 (10 to 29) 0 
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9.4.4.2.1 Risk of complications by antibiotic prescribing  
Patients prescribed an antibiotic on the same day as the index RTI were found to be 
at a significantly lower risk of presenting with a complication in primary care and/or 
secondary care in the 60 days after the index RTI (74.60 vs. 103.49 per 10,000 
patients) (Table 9.11). The ARR was 28.89 (95% CI=11.55 to 52.61, p=0.009) and 
the number of antibiotics needed to be prescribed to prevent one complication 
(NNTB) was 346 (95% CI=190 to 866). These effects were much higher than in table 
9.5. 
 
An additional 1,938 patients were prescribed an antibiotic between 1 and 60 days 
after the index RTI (or until the first complication), of which 32 had a complication 
(165.12 per 10,000). This subgroup of patients had a higher risk of complications 
than those prescribed an antibiotic on the same day. An exploration into this group 
found that they were more likely to be female, have asthma, diabetes, or a general 
co-morbidity, a higher number of antibiotics prescribed, higher number of 
consultations and more likely to have had a prior complication all in the year prior to 
the index RTI. For this subgroup of patients who were subsequently prescribed an 
antibiotic, the rates of complications were also higher in the main dataset for RTIs 
and for chest infections and the patient characteristics of this cohort were consistent 
with those found above. By including these patients, the ARR was 6.95 (95% CI= 
-10.61 to 31.61, not significant).  
 
Table 9.11 Risk of complications (diagnosed in primary and/or secondary care) 
within 60 days of the index RTI (per 10,000 patients) 
 
 Number of patients  
with a complication 
 (risk per 10,000 patients) 
ARR (95% CI) NNTB (95% CI) 
Not prescribed 
an antibiotic 
Prescribed an 
antibiotic 
 
Same day 
prescribing  
113/10,919 
(103.49) 
137/18,364 
(74.60) 
28.89  
(11.55 to 52.61) 
346  
(190 to 866) 
     
Prescribing within 
60 days  
81/8,981 
(90.19) 
169/20,302 
(83.24) 
6.95 
(-0.61 to 31.61) 
1439  
(NNTH
i
 942 to  
to NNTB 316) 
i 
NNTB = Number needed to benefit 
ii 
NNTH = Number needed to harm 
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Table 9.12 shows the results from the univariate and multivariate models examining 
the association between the risk of complication in the 60 days after the RTI 
diagnosis and individual patient factors. In the multivariate analysis, older patients 
(aged 65 years) were at an increased risk of a complication, as were males, patients 
previously diagnosed with a co-morbidity, previously prescribed a higher number of 
antibiotics (>3 per annum), with a higher number of consultations (>10 per annum) 
and with a previous complication in the year prior to the RTI diagnosis.  
 
After adjusting for these significant confounders, the OR for same day antibiotic 
prescribing was 0.55 (95% CI =0.39 to 0.77) and the number needed to treat with 
antibiotics to prevent one complication based on the OR was 216. For prescribing 
within 60 days of the index RTI, the adjusted OR was 0.65 (95% CI=0.46 to 0.93) 
indicating a significant risk reduction in developing a complication for those 
prescribed an antibiotic (NNTB=319).  
 
  
Table 9.12 Factors associated with complications diagnosed in primary and/or secondary care within 60 days of index date for the RTI - 
univariate and multivariate analyses 
 
 Number of patients (%) Univariate Multivariate 
Factors No 
complication 
 
N=29,033 
Complication 
diagnosed  
N=250 
Parameter 
estimate (SE) 
OR  
(95% Cl) 
Parameter 
estimate (SE) 
OR  
(95% Cl) 
Age (years) 
0-4 
5-15 
16-64 
65 
 
2,062 (99.5) 
4,824 (99.7) 
17,691 (99.5) 
4,456 (97.1) 
 
10 (0.5) 
15 (0.3) 
94 (0.5) 
131 (2.9) 
 
Ref 
-0.446 (0.412) 
0.093 (0.336) 
1.810 (0.332) 
 
1 
0.64 (0.29 to 1.44) 
1.10 (0.57 to 2.12) 
6.11 (3.19 to 11.71) 
 
Ref  
-0.317 (0.417) 
0.141 (0.342) 
1.386 (0.350) 
 
1 
0.73 (0.32 to 1.65) 
1.15 (0.59 to 2.25) 
4.00 (2.01 to 7.94) 
       
Gender 
Male 
Female 
 
11,924 (99.0) 
17,109 (99.3) 
 
124 (1.0) 
126 (0.7) 
 
Ref 
-0.346 (0.128) 
 
1 
0.71 (0.55 to 0.91) 
 
Ref 
-0.505 (0.132) 
 
1 
0.60 (0.47 to 0.78) 
       
Deprivation quintile 
Least deprived 1 
2 
3 
4 
Most deprived 5 
 
6053 (99.3) 
3766 (99.2) 
3172 (99.2) 
4499 (99.0) 
3443 (98.9) 
 
45 (0.7) 
31 (0.8) 
25 (0.8) 
47 (1.0) 
40 (1.1) 
 
Ref 
-0.103 (0.331) 
-0.002 (0.332) 
0.232 (0.261) 
0.298 (0.349) 
 
1 
0.90 (0.47 to 1.73) 
1.00 (0.52 to 1.91) 
1.26 (0.76 to 2.10) 
1.35 (0.68 to 2.67) 
 
 
 
       
BMI 
Underweight 
Normal 
Overweight 
Obese 
 
461 (96.0) 
7,611 (99.0) 
5,758 (99.1) 
3,803  (99.0) 
 
19 (4.0) 
75 (1.0) 
52 (0.9) 
38 (1.0) 
 
Ref 
-1.427 (0.264) 
-1.535 (0.276) 
-1.445 (0.289) 
 
1 
0.24 (0.14 to 0.40) 
0.22 (0.13 to 0.37) 
0.24 (0.13 to 0.42) 
  
       
Diabetes 1,774 (97.7) 42 (2.3) 1.115 (0.173) 3.05 (2.17 to 4.28) - - 
 
Asthma 
 
4,498 (98.3) 
 
78 (1.7) 
 
0.963 (0.142) 
 
2.62 (1.98 to 3.46) 
 
- 
 
- 
 
Co-morbidity 
 
5,910 (98.0) 
 
122 (2.0) 
 
1.314 (0.129) 
 
3.72 (2.89 to 4.79) 
 
0.582 (0.147) 
 
1.79 (1.34 to 2.39) 
3
0
0
 
  
Table 9.12 Factors associated with complications diagnosed in primary and/or secondary care within 60 days of index date for the RTI - 
univariate and multivariate analyses 
 
 Number of patients (%) Univariate Multivariate 
Factors No 
complication 
 
N=29,033 
Complication 
diagnosed  
N=250 
Parameter 
estimate (SE) 
OR  
(95% Cl) 
Parameter 
estimate (SE) 
OR  
(95% Cl) 
Smoking status 
Never smoked 
Current  smoker  
Former smoker 
Status unknown 
 
11,597 (99.1) 
5,364 (99.1) 
4,672 (98.7) 
7,400 (99.6) 
 
107 (0.9) 
50 (0.9) 
63 (1.3) 
30 (0.4) 
 
Ref 
-0.014 (0.174) 
0.373 (0.161) 
-0.826 (0.209) 
 
1 
0.99 (0.70 to 1.39) 
1.45 (1.06 to 1.99) 
0.44 (0.29 to 0.66) 
 
- 
 
- 
History 
 (1 year prior to index RTI): 
      
       
Antibiotics prescribed  
Low (0 per annum) 
Med (1-2) 
High (>3)  
 
 
17,370 (99.4) 
9,130 (99.2) 
2,533 (97.3) 
 
102 (0.6) 
77 (0.8) 
71 (2.7) 
 
Ref 
0.362 (0.153) 
1.567 (0.158) 
 
1 
1.44 (1.06 to 1.99) 
4.79 (3.52 to 6.53) 
 
Ref 
0.095 (0.160) 
0.795 (0.184) 
 
1 
1.10 (0.80 to 1.50) 
2.21 (1.54 to 3.18) 
Complications (Yes)  210 (90.5) 22 (9.5) 2.581 (0.236) 13.21 (8.32 to 20.98) 1.445 (0.259) 4.24 (2.55 to 7.05) 
       
Consultations 
Low (0-4 per annum) 
Mid (5-10)  
High (>10) 
 
11,964 (99.6) 
9,026 (99.4) 
8,043 (98.2) 
 
45 (0.4) 
58 (0.6) 
147 (1.8) 
 
Ref 
0.534 (0.200) 
1.583 (0.173) 
 
1 
1.71 (1.15 to 2.52) 
4.87 (3.47 to 6.84) 
 
Ref 
0.187 (0.211) 
0.514 (0.216) 
 
1 
1.21 (0.80 to 1.82) 
1.67 (1.09 to 2.55) 
       
Antibiotic prescribing       
Same day prescribing 
No antibiotic 
Antibiotic  
 
10,806 (99.0) 
18,227 (99.3) 
 
113 (1.0) 
137 (0.7) 
 
Ref 
-0.311 (0.158) 
 
1 
0.73 (0.54 to 1.00) 
 
Ref 
-0.606 (0.174) 
 
1 
0.55 (0.39 to 0.77) 
Prescribing within 60 days
i
 
No antibiotic 
Antibiotic 
 
8,900 (99.1) 
20,133 (99.2) 
 
81 (0.9) 
169 (0.8) 
 
Ref 
-0.037 (0.160) 
 
1 
0.96 (0.70 to 1.32) 
 
Ref 
-0.427 (0.179) 
 
1 
0.65 (0.46 to 0.93) 
i
Adjusted for age, gender, co-morbidity, and antibiotic prescribing, consultations, and complications in the year prior to the RTI
3
0
1
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9.4.4.3 Sore throats 
There were 7,131 episodes of sore throats with 38 (0.53%) complications being 
diagnosed in either primary or secondary care within 60 days of the initial infection.  
 
The risk of developing a complication was again higher in patients who received an 
antibiotic on the same day when compared to those not (60.51 vs. 39.94 per 10,000 
patients) but the risk reduction was greater but still not significantly different 
(ARR=20.58, 95% CI= -38.81 to 17.68) (Table 9.13). An additional 409 patients 
were prescribed an antibiotic between 1 and 60 days after the index RTI (or until the 
first complication), of which none developed a complication in the 60 days after the 
sore throat.  
 
The small numbers of complications involved did not allow the multilevel model to 
be fully fitted and no confounders could be included in the model. The unadjusted 
OR for same day prescribing was 1.52 (95% CI=0.73 to 3.16) and for prescribing 
within 60 days was 1.17 (95% CI=0.56 to 2.43). 
 
9.4.4.4 Chest infections 
There were 6,982 episodes of chest infection, with 134 (1.92%) complications being 
diagnosed in either primary or secondary care within 60 days of the initial infection. 
Of these complications, the majority (N=116, 87%) were pneumonia and lung 
complications.  
 
Once again the risk of developing a complication was significantly lower in patients 
who received an antibiotic on the same day as the index chest infection compared to 
those who did not receive an antibiotic (119.27 vs. 575.02, ARR=455.75 (95% 
CI=333.59 to 610.34, p<0.001) (Table 9.13). The number needed to be treated with 
antibiotics to prevent one complication was 22 (95% CI=16 to 30).  An additional 
301 patients were prescribed an antibiotic between 1 and 60 days after the index RTI 
(or until the first complication), of which 19 had a complication (631.23 per 10,000). 
By incorporating these patients, a similar reduction was seen for any antibiotic 
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prescribing within 60 days of the chest infection (ARR=409.94, 95% CI=272.49 to 
591.26, p<0.001, NNTB=24, 95% CI=17 to 37).  
 
After adjusting for significant confounders (age, co-morbidity and previous antibiotic 
and complications), the OR for same day prescribing as the chest infection was 0.19 
(95% CI=0.12 to 0.31, NNTB=22). For any prescribing within 60 days of the chest 
infection, the OR was 0.21 (95% CI=0.11 to 0.39, NNTB=23). 
 
Table 9.13 Risk of complications (diagnosed in primary and/or secondary care) 
within 60 days of the index sore throat/chest infection (per 10,000 patients)  
 
 Number of patients  
with a complication 
 (risk per 10,000 patients) 
ARR (95% CI) NNTB (95% CI) 
Not prescribed 
an antibiotic 
Prescribed an 
antibiotic 
Sore throats 
Same day 
prescribing  
10/2,504 
(39.94) 
28/4,627 
(60.51) 
-20.58  
(-38.81 to 17.68) 
-486 
(NNTH 28 to  
and NNTB 566) 
Prescribing 
within 60 days  
10/2,095  
(47.73) 
28/5,036 
(55.60) 
-7.87  
(-29.65 to 35.56) 
-1271 
(NNTH 337 to  
to NNTB 281) 
 
Chest infections 
Same day 
prescribing  
64/1,113 
(575.02) 
70/5,869 
(119.27) 
455.75  
(333.59 to 610.34) 
22 (16 to 30) 
Prescribing 
within 60 days  
45/812 
(554.19) 
89/6,170 
(144.25) 
409.94  
(272.49 to 591.26) 
24 (17 to 37) 
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9.4.5 Summary of results 
Table 9.14 summarises the results from this chapter examining the risk of 
complications arising from an acute RTI by antibiotic prescribing, firstly using the 
main set of GPRD patients (Table 9.14a) and then looking at the cohort of patients 
that were linked to hospital admissions data (Table 9.14b).  
 
Complications diagnosed in primary care were almost three times as likely to occur 
after a chest infection than they were after a sore throat (94.68 vs. 33.45 per 10,000). 
For all acute RTIs and chest infections, the risk of a complication arising was higher 
in patients that had not received an antibiotic when compared to those prescribed an 
antibiotic (either on the same day as the index RTI or within 60 days). In chest 
infections, the protective effect of antibiotic prescribing was most apparent with an 
absolute risk reduction of 108.73 per 10,000 for same day prescribing, resulting in 
low numbers needed to treat with antibiotics to benefit one patient avoiding a 
complication (NNTB=92). There was no evidence of a protective effect of antibiotic 
prescribing in diagnoses of sore throats. 
 
The risk of a complication was higher in patients subsequently prescribed an 
antibiotic (one to 60 days after the index RTI); for example in chest infections, 
patients subsequently prescribed an antibiotic had a rate of complication of 165.56 
per 10,000 compared to 77.56 per 10,000 in patients prescribed an antibiotic on the 
same day as the index RTI. These patients (subsequently prescribed an antibiotic) 
had more co-morbidities and were possible sicker than patients prescribed on the 
same day or not prescribed at all. Presumably these patients returned to the GP 
because they were still unwell and the complication may have been starting to 
develop when the antibiotic was subsequently prescribed.   
 
There was no evidence to suggest that the subset of patients linked to secondary care 
data were a biased sample of the whole set and no more likely to experience a 
complication (not a sicker cohort). The impact of including complications diagnosed 
in secondary care (not previously diagnosed in primary care) can be seen, with 
higher risks observed across all RTI groups. The impact of including secondary care 
diagnosed complications was most pronounced for all RTIs and chest infections, 
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where including secondary care complications increased the risk from 52.93 to 85.37 
per 10,000 patients, and from 88.80 to 191.92 per 10,000 patients respectively. 
Complications diagnosed in primary and/or secondary were again more frequently 
diagnosed in chest infections than in all RTIs (191.92 vs. 85.37 per 10,000) and 
lower in sore throats.  
 
Again for all acute RTIs and chest infections, the risk of complications identified in 
primary and secondary care was higher in patients that had not received an antibiotic 
when compared to those prescribed an antibiotic (either on the same day as the index 
RTI or within 60 days). In chest infections, the protective effect of antibiotics was 
most apparent with an absolute risk reduction of 455.75 per 10,000 for same day 
prescribing (an increase from when primary care complications were included), 
resulting in even lower numbers needed to treat (NNTB=22). Even when we 
considered secondary care complications, there was no evidence of a protective 
effect of antibiotic in diagnoses of sore throats, with only an additional 4 
complications identified in secondary care. 
 
In patients who had a complication diagnosed in secondary care, the rates of 
complications were high (32.44 per 10,000 for all RTIs and 103.12 per 10,000 in 
chest infections) compared to those diagnosed in primary care. In this cohort there 
were no differences between patients who were prescribed an antibiotic on the same 
day (n=42) compared to those who were not (n=53) with respect to their 
demographics. When we examined subsequent prescribing (n=65) vs. no prescribing 
(n=30) in the same cohort, then patients that were not prescribed an antibiotic were 
more likely to be older, less likely to have a co-morbidity, had a antibiotic prescribed 
in the year prior, had a complication in the year prior and less likely to have had a 
high number of consultations in the year prior. 
 
 
 
 
 
  
Table 9.14 Complication rates (per 10,000) by index RTI group and antibiotic prescribing status 
 
a. Complications diagnosed in primary care 
 
 
 Not prescribed 
an antibiotic 
Same day 
prescribing 
Subsequent 
prescribing 
 (1-60 days) 
Prescribing 
within 60 days 
Total  
All RTIs 131/27,391  
(47.83) 
255/57,337 
(44.47) 
34/5,944  
(57.20) 
289/63,281  
(45.67) 
420/90,972 
(46.32) 
 
 
Sore throat 24/6,790  
(35.35) 
50/14,625  
(34.19) 
3/1,421  
(21.11) 
53/16,046  
(33.03) 
77/23,016 
(33.45) 
 
 
Chest infection 51/2,637  
(193.40) 
147/18,954 
(77.56) 
15/906  
(165.56) 
162/19,860  
(81.57) 
213/22,497 
(94.68) 
 
 
  
b. Complications diagnosed in primary and/or secondary care Secondary  
care only 
 Not prescribed 
an antibiotic 
Same day 
prescribing 
Subsequent 
prescribing 
 (1-60 days) 
Prescribing 
within 60 days 
Total Total 
All RTIs 81/8,891  
(90.19) 
137/18,364 
(74.60) 
32/1,938  
(165.12) 
169/20,302  
(83.24) 
250/29,283 
(85.37) 
 
95 
Sore throat 10/2,095  
(47.73) 
28/4,627  
(60.51) 
0/409  
(0.00) 
28/5,036  
(55.60) 
38/7,131 
 (53.29) 
 
4 
Chest infection 45/812  
(554.19) 
70/5,869 
 (119.27) 
19/301  
(631.23) 
89/6,170 
 (144.25) 
134/6,982 
(191.92) 
72 
 
3
0
6
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9.5 Discussion 
9.5.1 Main findings 
The risk of developing a serious complication diagnosed in primary care after an 
acute RTI was higher in those not prescribed an antibiotic (either on the same day or 
in the 60 days subsequently) . However the absolute risk reduction (ARR) was non-
significant and the number of patients needing to be treated with an antibiotic to 
prevent one complication was high (1991). After adjusting for identified confounding 
factors, same day prescribing of antibiotics had a weak but significant protective 
effect against complications diagnosed in primary care, and although the numbers 
required to treat with antibiotics to prevent one complication had reduced, they 
remained high. In complications following a diagnosis of a sore throat, the risk of 
complication was lower for patients not prescribed an antibiotic and again the ARR 
was non-significant. In chest infections however, the risk of complications was 
higher in those not prescribed an antibiotic on the same day as the RTI with a 
significant decrease in risk with treatment of antibiotics. The number of patients with 
a chest infection needed to be prescribed an antibiotic to prevent one complication 
was much lower (92).  
 
Complications diagnosed in secondary care only (and not in primary care) were 
especially identified for lung complications, septicaemia and pleural effusion. When 
complications identified in primary and secondary care were taken into account, the 
risk of developing a complication was higher across all the RTI groups examined. 
The risk of complication was significantly higher for patients not being prescribed an 
antibiotic on the same day as the index RTI than for those prescribed an antibiotic. In 
chest infections, there was a substantial risk of complication, which was again 
significantly reduced in those prescribed an antibiotic (same day and at any time) and 
the number of patients with a chest infection needed to be prescribed an antibiotic to 
prevent one complication was 22.   
 
9.5.2 Strengths and weaknesses of the study 
Only a small number of studies have examined the effect of antibiotic prescribing on 
complications arising from acute RTIs at the individual patient level, whilst adjusting 
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for significant confounders. Although we were restricted in the size of our cohort (a 
maximum of 100,000 patient records), one of the main advantages was that we were 
able to obtain secondary care data for a sub-set of practices, thus identifying 
additional complications presenting in secondary care, not previously recorded in 
primary care and quantifying the number of these. Complications were identified by 
using Read codes and included all types of consultations such as surgery 
consultations and letter from outpatients. Thus we can be confident that the extra 
information derived from linking to HES is a very important finding as it indicates 
that the assumption of many researchers that most major diagnoses are recorded in 
primary care data, may be misleading.    
 
Not only did including secondary care complications increase the risk of 
complications, but it also increased the risk of complication in those not receiving an 
antibiotic on the same day as the index RTI. In RTIs, the risk of complications 
increased over two-fold (from 49.50 per 10,000 in the primary dataset to 103.49 in 
the dataset linked to secondary care data). The effect of linking to secondary care 
data was more evident in complications arising from chest infections where the risk 
increased from 186.28 to 575.02 per 10,000 patients in those not prescribed an 
antibiotic, and from 77.56 to 119.27 per 10,000 patients in those prescribed an 
antibiotic. Identifying secondary care complications increased the ARR which in turn 
reduced the NNTs (Table 9.15).  
 
Table 9.15 Numbers needed to treat (NNT) with antibiotics to prevent one 
complication by healthcare setting 
 
 Complication diagnosed in… 
 Primary care only Primary and/or 
secondary care 
All  RTIs   
Unadjusted model 1991 346 
Adjusted model 780 216 
Sore throat   
Unadjusted  -4973 -486 
Adjusted -4455 NA 
Chest   
Unadjusted  92 22 
Adjusted 93 22 
  NA = complications too rare to perform logistic regression modelling 
Chapter 9 
310 
 The increases in complications rates found by incorporating secondary care 
complications could not be attributed to any differences in the case-mix of patients 
between the two datasets, suggesting that the increase in complications was a true 
reflection of the incidence of complications in the population. 
The under-recording that can occur by only assessing GP records for complications 
was minimised, and the population of complications more accurately estimated. The 
entire population of complications, however, is still under-recorded as it excludes 
patients who are seen in out of hours clinics and not recorded in the GP notes, and 
also patients presenting to emergency departments and sent home without being 
admitted to hospital.  
 
This study was also able to assess the impact of prescribing an antibiotic after the 
initial RTI was diagnosed (between 1 and 60 days). This could be interpreted as 
delayed prescribing but it was impossible to know if the delay was due to the GP or 
due to the patient re-consulting independently. This group of patients had higher 
complication rates (identified in primary and/or secondary care) for patients 
diagnosed with any RTIs and also chest infections. In fact these rates were higher 
than those not prescribed antibiotics.  
 
This was an observational study using routinely collected data, and therefore possible 
confounders may be unequally distributed between those prescribed an antibiotic and 
those not. In this study, however, we fitted models to assess patient characteristics 
which appeared to influence the decisions of GPs to prescribe an antibiotic or not, for 
example to sicker patients and to those who were at a higher risk of complications 
though. Data on individuals’ resistance levels was not available. We then adjusted 
for these confounders in the main analysis, estimating the effect of prescribing 
antibiotics on the risk of complications. Sufficient data were not available to examine 
the risk of complications by antibiotic type and dose as planned, nor were there 
enough to examine the interaction between age and antibiotic prescribing as seen in 
other studies (Petersen et al. 2007). Although we were able to identify the 
characteristics of patients more likely to receive an antibiotic prescription, we were 
not able to adjust for severity of the presenting infections; patients with more severe 
disease would have been more likely to receive a prescription for an antibiotic.   
 
Chapter 9 
311 
There was also insufficient outcome data to examine complications presenting in 30 
days as planned, in addition to 60 days. A variety of follow-up times have been used 
in other studies, varying from 30 days to 3 months (Dunn et al. 2007 and Winchester 
et al. 2009 respectively). However, whilst the average time between an RTI and a 
complication for all complications was 14 (25
th
 to 75
th
 percentiles 5 to 32.75) days, 
they varied greatly by type of complication. For example, the average time between 
an RTI and pneumonia was 12 (4 to 28) days while for septicaemia the average was 
20 (10 to 47) days. This variation was also found in the study by Thompson et al. 
(2009a) where the average time between an episode of otitis media and mastoiditis 
was 21.5 (6.0 to 51.5) days.  
 
Whilst GPRD data is a very useful data source into gaining an insight into primary 
care observational data, it has some limitations. Firstly, patients who choose to 
present with RTI symptoms to their GP may be unrepresentative in respect of clinical 
factors such as age, duration of symptoms, and co morbidity (McKinlay 1972; Van 
Duijn et al. 2007). It has been estimated that between 10% and 30% of patients with 
an episode of respiratory tract symptoms consult a GP (Bruijnzeels et al. 1998; Van 
Duijn et al. 2007). The outcomes for those patients who do not present are either that 
the RTI would be self-limiting, and resolve without antibiotics, or else the patient 
would deteriorate and present to primary or secondary care with a complication. 
Therefore assessing the impact of this bias is difficult. For patients who do present to 
their GP it has been suggested that a potential limitation is that not all consultations 
for such minor infections are recorded in GP records (Hayward et al. 2007), leading 
to a possible underestimation in the number of patients not receiving an antibiotic. 
Diagnoses recorded by GPs may be influenced by their prescribing decisions (also 
referred to as diagnostic drift) but hard evidence of this is limited. Indeed, several 
studies have claimed that no evidence exists to support a shift in diagnostic 
preference (Fleming et al. 2003; Ashworth et al. 2005a).
 
Nonetheless this bias would 
lead to an overestimation of the proportion of patients who received an antibiotic.  
 
We acknowledge that antibiotic prescribing is an imperfect proxy for antibiotic 
consumption. However, evidence suggests that only 6-8% of prescriptions are not 
dispensed
 
(personal communication, Dr Efrosini Setakis, GPRD) and that the 
majority of adults in the UK (90%) claim to finish their course of antibiotics 
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(Pecherer 2001). This would therefore lead to only a small bias in prescribing data 
although this bias may vary by the type of acute RTI (the more serious the infection, 
the higher the likelihood of dispensing the prescription and adhering to the 
antibiotic). Adjusting for the possible bias found in the group prescribed antibiotics is 
likely to increase any effect found between the two groups and so any conclusions 
made are likely to be conservative. Lastly, we are not able to demonstrate causality 
as we cannot assert that the patients who did not have an antibiotic but then went on 
to have a complication could have avoided the complication if they had in fact 
received the antibiotic. 
 
We excluded pneumonia as an RTI since the percentage of patients receiving an 
antibiotic was low; 13.1% on the same day as pneumonia was diagnosed. This low 
percentage could be attributed not to inadequate care by the GP but as a result of a 
referral to hospital for additional treatment (such as a chest x-ray alongside 
antibiotics).  
 
9.5.3 Comparisons with existing literature 
Before comparing our results with other literature we first assess whether our cohort 
is comparable to the whole GPRD database, and therefore representative of GP 
consultations and prescribing in the UK, (with respect to the proportion of RTIs seen 
and the proportion prescribed an antibiotic). A comparison will then be made with 
the literature examining the relationship between antibiotics and complications.  
 
9.5.3.1 External validity of the GPRD RTI cohort 
Comparing our cohort of patients with an RTI to the general population with an RTI 
is difficult as little comparative data exists. However, output from a study funded by 
the Department of Health for a collaboration between the University College London 
Centre for Infectious Disease Epidemiology and the Health Protection Agency 
(http://www.idrn.org/antimicrobial_prescribing) showed that in data from 179 
practices in the GPRD (for 2000/01) (with an age sex structure similar to the UK 
population),  the proportions of consultations for sore throats, ear infections, 
sinusitis, URTIs and LRTIs were similar to those found in our cohort of patients. For 
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example, in our study, 25.4% and 7.0% of RTIs were for consultations of sore throats 
and sinusitis respectively (compared to 20.9% and 7.6% respectively in the larger 
dataset).  
 
The proportion of antibiotics prescribed to RTIs in our study was similar to that 
found in GPRD based studies which included a larger population of GPs. Table 9.16 
shows comparative figures from this and two other studies and the differences are 
minimal.  
 
Table 9.16 Proportion of antibiotics prescribed by type of RTI  
 
 Petersen and 
Hayward (2007) 
Ashworth et al. 
(2004) 
Cannings-John 
(2012) 
Study period 1991 to 2001 1994 to 2000 2005 
N practices (patients)  108 (642,685) 162 (not stated) 60 (90,672) 
Chest infection 82.2% 89% 84.3% 
Ear infection 82.5% 81% 82.7% 
Sore throat 64.3% 60% 63.5% 
Upper RTI 44.2% 47% 34.0% 
 
9.5.3.2 Predictors of complications 
Until recently the role of antibiotics in the development of complications arising 
from RTIs had been examined only by ecological studies or meta-analyses of trials in 
which complications were not the primary outcome. Randomised controlled trials are 
the gold standard but the large numbers required to power studies to examine the rare 
events of complications mean they have not been carried out. Additionally the study 
populations of these RCTs have generally been selective (e.g. patients with 
streptococcal sore throat). Lately, observational studies, mainly using the general 
practice research database (GPRD), have been used to examine this association.  
 
We were able to show that in patients with a diagnosis of any RTI in primary care, 
whilst antibiotics had a protective effect,
 
the number needed to treat to prevent 
complications was high. However, the relatively small sample size did not allow us 
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to explore the protective effect of antibiotics in all RTI groups especially by age 
groups, apart from in sore throats and chest infections (followed by any 
complication). In sore throats, a meta-analysis has shown that antibiotics had a 
protective effect against acute rheumatic fever and quinsy (Spinks et al. 2006) but 
these were based on studies in the 1950s-60s, a period where the background 
incidences of these infections were much higher in Western society. A large 
observational study in primary care by Petersen et al. (2007) showed that same day 
antibiotic prescribing did reduce the risk of quinsy diagnosed in primary care (after 
adjusting for age, gender, deprivation),
 
but the number needed to treat to prevent one 
serious complication
 
was high. Conversely, a case-control study by Dunn et al. 
(2006) showed that antibiotic exposure had no effect on the occurrence of quinsy 
arising from sore throats. However, there was some evidence to suggest that 
antibiotics may reduce the risk of quinsy in patients with a diagnosis of tonsillitis.  
 
The study by Petersen et al. (2007) also showed that antibiotics reduced the risk of 
pneumonia (following a chest infection) across all ages, and the risk of pneumonia 
was particularly high in the 65 plus age group. The number of patients needed to 
treat with antibiotics to prevent one complication of pneumonia following a chest 
infection was smaller than in other RTI groups and also reduced with age. 
Winchester et al. (2009) additionally examined patients diagnosed with LRTIs and 
found that an antibiotic prescription on the same day was less likely to result in 
hospitalisations and death from pneumonia. We also found that exposure to 
antibiotics reduced the risk of developing any complication (diagnosed in primary 
care) arising from chest infections, with relatively small numbers needed to treat. 
Additionally we found that when complications recorded in secondary care were 
considered, the number of patients needed to be treated with antibiotics was reduced 
drastically. 
 
9.5.4 Implications of findings for clinical practice and future research 
These observational studies concluded that antibiotic prescribing could be reduced in 
primary care, especially for sore throats, ear infections and URTI, since the numbers 
needed to treat were so high that few complications would be likely to arise. 
Research should also focus on developing
 
clinical algorithms to identify which 
Chapter 9 
315 
symptoms and signs patients present with at the diagnosis of an RTI are more likely 
to predict if a complication will occur, so that prescribing can be targeted more 
precisely at high-risk patients. This is especially relevant in chest infections where 
the numbers needed to treat were much lower, especially in older patients. Targetting 
a more specific group of patients based on their symptoms or bacterial infections has 
been shown to reduce complications, when a subset of patients with higher clinical 
likelihood of group A β-hemolytic streptococcus (GABHS) showed more benefit 
from antibiotics in prevention of quinsy (Dagnelie et al. 1996; Zwart et al. 2000).  
We suggest that before further reductions are made in antibiotic prescribing for 
URTIs, sore throats and otitis media, a large scale observational study (using the 
GPRD or equivalent) should be carried out to examine the risk associated with 
withholding antibiotics on complications diagnosed in primary and secondary care. 
Ideally it would be useful to examine this association over a longer time period to see 
if, as antibiotic prescribing in RTIs decreased in primary care (albeit the proportion 
of prescribing being high), the numbers required to treat with antibiotics to prevent 
one complication changed over time. The sample size would have to be sufficiently 
large to permit examination of risk by certain RTI groups (sore throats, otitis media, 
sinusitis, URTI, chest infection) and by age group. It would also be of interest to see 
whether risk varies by type and dose of antibiotic. 
 
9.6 Introduction to Chapter 10 
The current chapter concludes the research into the possible risks associated with 
antibiotic prescribing with respects to complications. Within each chapter, results 
and discussion have been presented enabling each to be read independently (albeit 
that the research theme connects each chapter). The final chapter synthesises the 
research presented in each chapter and provides a summary of the thesis, reflects on 
the main strengths and weaknesses and implications of the results to clinical practice 
and suggests future areas of research. 
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Chapter 10 Discussion 
The aim of this thesis was to investigate the relationship between antibiotic 
prescribing, resistance and complications arising from acute RTIs and objectives 
were set out in Chapter 1. Rather than address each individual objective and repeat 
the results in respective chapters, this chapter will summarise the results, highlight 
the study strengths and weaknesses, and discuss the implications of the results to 
both clinical practice and future research. 
 
10.1 Main findings 
10.1.1 Antibiotic dispensing  
This study covers an era where UK general practitioners were advised that a strategy 
of no or delayed antibiotic prescribing should generally apply to patients presenting 
with certain acute RTIs (acute otitis media, sore throat/pharyngitis/tonsillitis, 
common cold, acute rhinosinusitis, acute cough/bronchitis) (SMAC 1998, NICE 
Clinical Guidelines 69, 2008). This resulted in a decline in antibiotic dispensing 
which is replicated in this research for the Welsh population between 1996 and 2006. 
Reductions were seen in overall dispensing for antibiotics used in the treatment of 
RTIs and for the majority of antibiotic classes, for all ages and children (using liquid 
oral antibiotics). The exception to this was flucloxacillin which significantly 
increased over the period. Dispensing rates and trends vary widely amongst Welsh 
practices; practices with the highest initial rates decreased their dispensing the most. 
Worryingly the trend in dispensing rates had slowed down by 2004/05 and in 
2005/06 had started to turn.  
 
10.1.2 The benefits of reducing antibiotic dispensing 
The main benefit of the reduction in dispensing is the belief that antimicrobial 
resistance will be contained. This study showed significant reductions in resistance to 
amoxicillin and tetracycline in H. influenzae isolates for all samples (including 
wound and urine) submitted by GPs over the same time period. Resistance to 
erythromycin in S. pneumoniae isolates increased over time. Similar trends to these 
are seen in samples taken from the respiratory tract (ear, nose and throat and sputum 
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samples). Evidence suggests a positive association between lagged antibiotic 
dispensing and resistance, even after adjusting for confounders indicating that 
resistance was more likely to occur in patients from a practice dispensing at a higher 
rate. However, reducing total antibiotic dispensing at a practice level did not impact 
favourably on resistance in RTI samples. No clear pattern was found between change 
in dispensing and change in resistance for any of the organism/ antibiotic 
combinations that were examined although the study lacked power.  
 
10.1.3 The risks of reducing antibiotic dispensing 
With little evidence of a relationship between reductions in dispensing and resistance 
at a practice level, the research addressed the possible disadvantages of reductions in 
primary care dispensing; namely a possible increased risk of developing a serious 
infection or complication. Trends from all-Wales data suggest that overall, 
complications presenting in secondary care and outcomes such as pneumonia, 
septicaemia, and pleural empyema increased. Albeit from a small number of 
practices, primary care diagnosed pneumonia and empyema demonstrated a 
conflicting trend and decreased between 1996 and 2000.  
 
The reasons for these increases in complications are unknown but one possible 
contributing factor is the reduction in antibiotics dispensing in RTIs, that is, a blanket 
reduction of antibiotics occurred instead of targeting antibiotics to those that they 
should be offered to (for example in patients that were systemically unwell or had a 
pre-existing co-morbidity). Trends in complications appear to have coincided with 
reductions in dispensing. Initial results showed a negative relationship between 
hospitalised complications and dispensing in the community even after adjusting for 
practice characteristics. However, this relationship disappeared after adjusting for 
study year, suggesting it was acting as a confounder representing unknown factors 
causing dispensing to fall and complications to rise. The relationship also 
disappeared after excluding the early period (1996 and 1997) where the greatest 
reduction in antibiotic dispensing was observed. There was also a lack of association 
found between changes in dispensing and changes in complications, reinforcing this 
finding. There was insufficient resistance data at general practice level to examine 
the possible modifying effect on the relationship between complications and 
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dispensing.  
 
We cannot conclude a cause-effect relationship between antibiotic dispensing and 
adverse outcomes of acute RTIs, but this may be due to the aggregate level of the 
data. It does lead however to testing the hypothesis further, to an assessment at the 
individual patient level. For patients presenting to primary care with an acute RTI, 
same day antibiotics were more likely to be prescribed to older patients, patients with 
a co-morbidity, diabetes, or asthma, current and ex-smokers, and patients who had 
been previously prescribed antibiotics. Same day antibiotics were less likely to have 
been prescribed to patients frequently consulting for any illness in the prior year. 
 
Same day prescribing of antibiotics had a weak but significant protective effect 
against complications diagnosed in primary care, although the numbers required to 
treat (NNT) with antibiotics to prevent one complication were very large. The 
absolute risk of a complication was small (49.50 per 10,000 patients). When 
secondary care complications were considered in a subset of patients and practices, 
the risk of developing a complication was significantly higher for patients not 
prescribed an antibiotic on the same day as the index RTI than for those prescribed 
an antibiotic and the NNT reduced from 780 to 216. Following a diagnosis of a sore 
throat, the risk of complication was lower for patients not prescribed an antibiotic 
and the reduction in risk was non-significant. In chest infections, the risk of primary 
care recorded complication was higher in those not prescribed an antibiotic on the 
same day as the RTI with a significant decrease in risk with treatment of antibiotics. 
When secondary care complications were included the NNT reduced from 92 to 22. 
 
10.2 Study strengths and limitations 
The strengths and weaknesses of the datasets used as well as the methods and 
analyses used have previously been discussed at length, and hence will be 
summarised here. 
 
10.2.1 Strengths - Practice level 
Three national high quality datasets were successfully obtained and linked, 
Chapter 10 
319 
something that can be achieved in a country such as Wales where good links exist 
between the NHS and academia. Relatively few people are responsible for the 
datasets and this makes it easier to obtain sharing agreements. There does not appear 
to be anything unique about Welsh general practices that would limit the 
applicability of these findings to other settings. To date this is one of only a few 
studies to examine the variation in trends of the three outcomes amongst general 
practices and on such a large scale, over a large period of time, and using detailed 
data. In addition we were able to look at liquid oral antibiotic dispensing, a proxy for 
dispensing in children and only once previously examined. A comprehensive list of 
ICD10 codes for acute RTIs and their complications was produced which enabled an 
examination of a wide set of complications which had not previously been carried 
out. This level of detail made each dataset very rich and resulted in multiple outputs. 
It also allowed an exploration of the trends in the proportion of submitted isolate 
samples tested for resistance in H. influenzae, S. pyogenes and S. pneumoniae 
isolates. It is very rare to obtain sampling data and to assess the sampling rate per 
practice and the association with resistance rates. 
 
This study allowed not only an exploration of the relationship between individual 
resistance data and practice based antibiotic dispensing data but also to examine the 
link between reduced dispensing and reductions in resistance at a practice level. This 
has not previously been examined in these particular isolates relating to RTIs. This is 
also the first time an ecological level study has examined the relationship between 
dispensing, resistance and complications in a large population. Including resistance 
data was important and strengthened the analysis as it allowed an exploration of how 
resistance modified any relationship between complications and dispensing. This is 
also the first observational study to examine the association between change in the 
rate of antibiotic dispensing and change in complication rates over time.  
 
10.2.2 Strengths - Individual patient level 
To date, this is one of only a small number of observational studies to examine the 
effect of antibiotic prescribing on complications arising from acute RTIs at the 
individual patient level, whilst adjusting for significant confounders. Although the 
size of the cohort was restricted, one of the main strengths of this study was that 
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secondary care data was obtained for a sub-set of practices, thus identifying 
additional complications presenting in secondary care and not previously recorded in 
primary care. This, to our knowledge, has not been done before in this research area. 
Therefore the under-recording that can occur by only assessing GP records for 
complications was minimised, and the population of complications more accurately 
estimated. This translated into reduced NNTs in this subgroup as more complications 
were identified, especially in lung infections. We were able to examine the difference 
in risk associated with being prescribed an antibiotic and the number of antibiotic 
prescriptions needed to prevent one complication.  
 
Identified patients from primary care and linking to secondary care data enabled a 
patient journey to be built, through primary care and, for a proportion, secondary 
care. Thus each patient could be flagged as being prescribed an antibiotic (either on 
the same day as the acute RTI or subsequently) or not, as were any complications 
diagnosed and recorded in primary care and/or secondary care. This study is the also 
the first to assess the risk of complications on prescribing an antibiotic after the 
initial RTI was diagnosed. In addition to all acute RTIs, the protective effect of 
antibiotics against overall complications was examined in patients presenting with 
sore throats and chest infections.  
 
10.2.3 Limitations - Practice level 
There are also limitations to each of these datasets. The largest was that dispensing 
data was only available at a practice level and thus individual dispensing data could 
not be linked to resistance and hospital data which was available at an individual 
patient level. For dispensing data, antibiotics given for all types of indications were 
used and not just for RTIs, thus overestimating the antibiotics prescribed for RTIs. 
There is also a risk of an underestimation in dispensing due to out of hours (OOH) 
data not being captured. Dispensing of antibiotics is an imperfect proxy for antibiotic 
consumption but is an improvement of those prescribed. This would lead to a very 
small bias in dispensing data although this bias may vary by the type of acute RTI. 
Dispensing in children could be overestimated since liquid oral antibiotics are also 
dispensed in the elderly. These biases are bound to reduce associations compared to 
examining individual data as Donnan et al. (2004) showed. 
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Patient Episode Dataset for Wales (PEDW) data is based on episodes of consultant 
care which are usually combined to create hospital admissions (or spells) to ensure 
that double counting of diagnoses is kept to a minimum. The use of a 91 day cut-off 
(linking episodes within 91 days of the initial infection) to create an event of 
infection may mean that we have under-estimated the number of complications. Our 
measure of infection is therefore likely to be conservative. The study was also 
limited in that it does not capture the true incidence rate of complications in the 
population since those presenting to primary care only or A&E are not captured.  
This data was also limited in the rarity of some of the complications such as quinsy 
which restricted modelling at a practice level.  
 
Resistance data was more limited than dispensing and complications data; data could 
only be obtained from 11 of the 18 laboratories which serve Welsh general practices 
although the practices were broadly similar to the remaining Welsh practices. 
Routinely collected data using samples submitted by GPs may not necessarily be 
typical of all infections presenting to primary care but little is known about how 
representative reported levels of resistance are as samples submitted to microbiology 
by general practices vary widely. To limit the bias, laboratories demonstrating 
selectivity in the samples that were tested were excluded from all analyses. Practices 
submitting a small number of samples were not more likely to have higher resistance 
rates. Following this, the largest weakness of the resistance data was the small 
number of samples (with H. influenzae, S. pneumoniae and S. pyogenes identified) 
and resistance rates per annum for a large proportion of practices. This made 
examining resistance rates at a practice level very restrictive, especially in samples 
taken from the respiratory tract (Sputum and ENT). Aggregating at the LHB level is 
a large level and thus not informative as we would not especially expect differences 
in rates at this level. 
 
The main weakness in all these analyses is that results are offered at the level of 
general practice and suffer from the ‘ecological fallacy’ in which erroneous 
inferences regarding individuals within the same area are made from ecological 
models based on aggregate data. However, it is probably the lowest and most 
relevant level to use with this type of data. 
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10.2.4 Limitations - Individual patient level 
Whilst GPRD data is a very useful data source into gaining an insight into primary 
care observational data, it has some limitations. This was a relatively limited cohort 
of patients with an acute RTI with a small number of complications identified (at 
most only 0.85% of all RTIs). Thus sufficient data were not available to examine the 
risk of complications by severity of the acute RTI, antibiotic type and dose as 
planned, nor were there enough to examine the interaction between age and antibiotic 
prescribing. There was also insufficient outcome data to examine complications 
presenting in 30 days as planned, in addition to 60 days. Also, due to the rarity of 
some complications, specific complications after an acute RTI such as quinsy after a 
sore throat or mastoiditis after acute otitis media could not be examined. Although 
primary and secondary care complications were obtained for 32.5% of the original 
cohort, the entire population of complications is still under-recorded. It excludes 
patients who are seen in OOH clinics and not recorded in the GP notes, and also 
patients presenting to emergency departments and sent home without being admitted 
to hospital.   
 
Some biases are not confined to this research and would be difficult to remove in any 
epidemiological study using routine primary care data. Patients who choose to 
present with an RTI symptom to their GP may be unrepresentative in respect of 
clinical factors such as age, duration and severity of symptoms, and co morbidity. 
For those patients who do not present, the RTI will either be self-limiting and resolve 
without antibiotics or else deteriorate and present eventually to primary or secondary 
care in the form of a complication (without a prior acute RTI) but we have no data on 
the chances of these outcomes. Assessing the impact of this bias is difficult but as 
Fleming (2007) stated “The surveillance of persons presenting for healthcare is as 
close to complete population-based surveillance as is realistically achievable”. For 
patients who do present to their GP, it has been suggested that a potential limitation 
is that not all consultations for such minor infections are recorded in GP records 
(Hayward et al. 2007), leading to a possible underestimate of the number of patients 
not receiving an antibiotic, although this is increasingly unlikely with record 
computerisation. Diagnoses recorded by GPs may be influenced by their prescribing 
decisions (also referred to as diagnostic drift) but without examining trends to 
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identify any evidence of a change in diagnostic behaviour, it is difficult to speculate 
whether this happens. Missing data was also a potential weakness as some factors, 
especially lifestyle factors such as BMI and smoking, may not be up-to-date, only 
being measured at registration at the practice. These data are not strictly missing but 
rather not measured, since there was no cause for concern. Patients with more 
regularly measured BMI are more closely monitored due to a health problem. 
Therefore including BMI would potentially be a misleading factor and a proxy for a 
comorbidity or ill health. 
 
As already acknowledged in previous sections, antibiotic prescribing is an imperfect 
proxy for antibiotic consumption. This would lead to only a small bias in estimating 
consumption although this bias may vary by the type of acute RTI (the more serious 
the infection, the higher the likelihood of dispensing the prescription and adhering to 
the antibiotic). Lastly, we are not able to demonstrate causality as there is no 
evidence to suggest that the patients who did not have an antibiotic but then went on 
to have a complication could have avoided the complication if they had in fact 
received the antibiotic.  
 
10.3 Implications of main findings for clinical practice  
10.3.1 Should ecological level data be used to inform clinical decision? 
We cannot conclude that at a practice level antibiotic dispensing is the main driver in 
the rise in complications. This may be due to the aggregate nature of the data and 
analysis by ‘concealing’ information, which made it difficult to come to a firm 
conclusion regarding associations. Making recommendations that might be 
implemented in practice is then impossible especially since it has been shown here 
and in other studies that group level data may hide associations found at individual 
level (Donnan et al. 2004). The discrepancy in results between Chapters 8 and 9 
meant that using aggregate data has great dangers. The natural path for future work is 
then to obtain individual patient level data to assess the true protective effect of 
antibiotics on complications.  
 
Despite a number of limitations, using these datasets is the only way to reliably 
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estimate antibiotic dispensing, resistance and complications in primary care at a 
macro and micro level for the whole population of Wales and practice level 
respectively. We can be reasonably confident that our findings are reliable and 
generalisable as they are based on an entire population and results are in agreement 
with the majority of the body of published evidence. 
 
10.3.2 Should antibiotics be prescribed to prevent complications? 
The results from the individual patient level data show that in the 60 days after an 
RTI diagnosis, complications are rare (46 per10,000 patients). Prescribing antibiotics 
for acute RTIs was seen to have a protective effect over suppurative and non-
suppurative complications diagnosed in primary care but the absolute risk reduction 
(ARR) was small. This was after adjusting for confounding variables, in other words 
patients with a higher likelihood to be prescribed an antibiotic such as age and 
comorbidity. Similarly, for any complication following a sore throat diagnosis, the 
risk reduction was small.  
 
In contrast, the reduction in risk of complications following a chest infection was 
larger with an NNT was 92. These findings are supported by other studies, three of 
which were retrospective cohort studies using the GPRD (Dunn et al. (2006), 
Petersen et al. (2007), and Winchester et al. (2009)) and a case-control study in 
children (Crocker et al. 2012). These studies concluded that antibiotic prescribing 
could be reduced in primary care, especially for sore throats, ear infections and 
URTI, since the NNT were so high that few complications would be likely to arise. 
The results from this work support this recommendation.   
 
However, in a sub-group of the original sample of nearly 30,000 patients, when 
secondary care complications are also included to give a more accurate reflection of 
complications in the population, the NNTs in all RTIs are reduced. This is due to 
39% of total pneumonia cases, 54% of other lung complications, 33% of septicaemia 
cases, and 69% of pleural effusion cases being identified only in secondary care. 
Even so, for complications following all RTIs and sore throat, the NNTs are still 
large. This is most probably due to few quinsy cases being identified in secondary 
care within this year. The NNT in chest infection however is considerably reduced 
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from 92 to 22. Primary and secondary care complications have not been examined in 
previous studies; this component of the study is therefore a valuable addition and 
greatly improves the evidence base.   
 
10.4 Key messages for general practitioners  
 Antibiotic prescribing for nonspecific coding in URTIs is low and 
complications in this subgroup are rare. GPs can be confident that not 
prescribing an antibiotic for a patient presenting with vague RTI symptoms 
will not result in an adverse outcome. 
 Antibiotics should not be considered for sore throat as the risk of developing 
a complication is low unless presenting in patients with asthma or who have 
previously developed a complication in the year prior to the new throat 
infection.  
 Complications occurring in ears and sinuses were also rare but over 80% of 
those presenting with these symptoms were prescribed antibiotics.  
 GPs cannot be confident about withholding antibiotics for patients presenting 
with chest infections and should be especially considered in the elderly (65 
plus years), those with a comorbidity, and those with a prior complication in 
the previous year.  
 
10.5 Implications of main findings for future research 
10.5.1 Study design 
Routinely collected data analysed at an aggregate level is particularly useful in the 
monitoring of trends at a macro level. At a micro level, using aggregate data can be a 
stepping stone to using individual data as it can be used to generate hypotheses, 
especially as routinely collected data is more readily available than individual patient 
level data. However, as we have shown, there is strong evidence to demonstrate that 
aggregate level data can obscure important associations occurring at an individual 
level.  
 
RCTs are the gold standard when it comes to study design as through randomisation 
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they reduce the problem of confounding, an important limitation of observational 
studies. In this clinical area RCTs would need to be very large to be adequately 
powered to examine differences in rare complications. Also patients recruited would 
not be representative of routine practice as trials would exclude the most sick or 
those at a higher risk for ethical reasons. Therefore using datasets containing 
individual patient data are most appropriate. Can we use them to evaluate the 
efficacy of treatment in real life to bridge results from RCTs to clinical practice using 
cohort data? Is it possible that results of a cohort study could change clinical 
practice? 
 
10.5.2 Blanket reductions in dispensing or in inappropriate dispensing? 
We were restricted to examining dispensing at a general practice level and found a 
decrease in most antibiotics over the period. For mainstream patients this reduction 
in antibiotics would pose no risk but for patients at risk it might. It would therefore 
be worth exploring the reasons for the variations and reductions found in antibiotic 
dispensing by GPs and practices. There is a need to clarify whether GPs are 
following national guidelines, whether appropriate dispensing is being achieved by 
GPs by reducing inappropriate dispensing or whether a blanket reduction is being 
practiced over time. Analysing changes in inappropriate prescribing would be more 
powerful than overall antibiotic dispensing. Defining what is appropriate dispensing 
will depend on patient symptoms and diagnoses as well as characteristics and thus 
individual patient data and medical history would be required in those presenting 
with a suspected infection. 
  
10.5.3 Identifying those that will benefit from antibiotics 
Before further reductions are made in antibiotic prescribing for ear infections, chest 
infections, sore throats and sinusitis, a large scale observational study should be 
carried out to examine the risk associated with withholding antibiotics on 
complications diagnosed in primary and secondary care (including A&E and Out of 
Hours). Ideally it would be useful to examine this association over a longer time 
period to see if, as antibiotic prescribing in RTIs decreased in primary care (albeit the 
proportion of prescribing remaining high), the numbers required to treat with 
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antibiotics to prevent one complication changed over time. The sample size would 
have to be sufficiently large to permit examination of risk by certain RTI groups 
(sore throats, otitis media, sinusitis, URTI, chest infection) and severity (using signs 
and symptoms or evidence of a bacterial infection) and by age group. This would 
help to identify, at the diagnosis of an RTI, which patient characteristics and signs 
and symptoms are more likely to predict if a complication will occur, so that 
prescribing can be targeted more precisely at high-risk patients. This is especially 
relevant in chest infections where the numbers needed to treat were much lower. It 
would also be of interest to see whether risk varies by type, dose and duration of the 
antibiotic. Shorter higher dose courses can achieve the same outcomes but with less 
impact on resistance selection, but at what cost to complications (Wise et al. 2011)? 
This would then determine how short treatment can be before an impact is seen on 
adverse outcomes.  
 
It would be important to examine the difference between patients who do receive an 
antibiotic, but still go on to develop a complication, and those who did receive the 
antibiotic and did not develop a complication. What makes this subgroup different?  
In addition, a proportion of patients do not present to primary care with an acute RTI 
but subsequently end up in A&E or are hospitalised with a complication. We 
hypothesise that these patients are different to patients who do consult with an acute 
RTI (and subsequently present with a serious or complicated infection in hospital). 
 
All of this work could be achieved by using routinely collected data from Wales 
from the Secure Anonymised Information Linkage (SAIL) Databank established by 
the Health Information Research Unit (HIRU) in Swansea and the newly established 
Clinical Practice Research Datalink (CPRD) which links GRPD data to HES. The 
main aim of SAIL is to link together the widest possible range of anonymised, 
electronically-held, person-based, routinely-collected data for the purpose of 
conducting and supporting health-related research. Datasets that have been linked in 
SAIL include primary care data from GPs in Wales, secondary care data on hospital 
in-patients from the Patient Episode Database for Wales (PEDW), accident and 
emergency data, and local authority social services data. These data allow a patient to 
be followed-up over time utilising several datasets and thus creating a patient’s 
clinical pathway. Similar conclusions were found in a review of the evidence of the 
Chapter 10 
328 
role of antibiotics in preventing serious complications of URTIs in children (Keith et 
al. 2010). In their conclusions for further research, the only feasible option to 
examine risk factors of patients who develop complications would be through 
linkage of large national datasets such as these. Although routinely collected data 
sets are, by their nature, restricted to data that have been recorded for a reason (such 
as in the case with BMI recording), there are great benefits from obtaining a very 
large sample size with resulting high power. The possibility of using these linked 
datasets in Wales must be a natural step forward in this research area. This would 
improve the evidence base, allowing clinicians to make better informed decisions in 
the prescribing of antibiotics when faced with an acute RTI and helping to identify 
which patient groups antibiotics should be targeted to protect individuals from harm. 
 
10.6 Conclusions 
This thesis has contributed to the important debate of the relationship between 
antibiotic use in primary care and complications arising from acute RTIs. As in other 
countries, Wales’ general practitioners have followed national guidelines and, over 
the study period, reduced their dispensing of antibiotics most commonly used in the 
treatment of acute RTIs. This trend appears to have changed in the later study years. 
Although variations in dispensing rates and trends were observed between practices, 
the majority changed their antibiotic dispensing behaviour. What is unknown is 
whether the reduction was restricted to those who need them the most or whether a 
blanket reduction was implemented. One rationale for limiting antibiotic 
consumption is to contain or reduce antibiotic resistance. Whilst certain resistance 
rates, such as amoxicillin resistance in H.influenzae isolates, have decreased, trends 
in others (erythromycin resistance in S. pneumoniae isolates) are upwards. We have 
shown that, at a general practice level, a relationship exists between lagged 
dispensing and resistance but no clear patterns were found between a change in 
dispensing and resistance. The possible benefit of reducing antibiotic consumption in 
the community is counter balanced by the risk of developing a serious infection or 
complication. At an all-Wales level, trends in certain complications diagnosed in 
secondary care are increasing whilst the opposite trends are seen for the same 
complications diagnosed in primary care (albeit in a small sample of practices), 
possibly an indication of a change of where patients present. Again no clear 
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relationship was evident between dispensing and complications at the general 
practice level. It is clear that ecological level evidence will not change clinical 
practice and that individual level evidence is required from large observational 
studies. This thesis showed that, from a large cohort diagnosed with an acute RTI, 
the absolute risk of developing any complication was small. Antibiotics are not 
justified to reduce the risk of a complication in those diagnosed with an acute RTI or 
sore throat. However, for patients presenting with a chest infection, the risk of 
developing a complication is high and antibiotics appears to reduce the risk of a 
complication. Further research is required to identify subgroups of patients or certain 
risk factors for these complications to assist GPs to prescribe antibiotics 
appropriately, ensuring that those needing antibiotics the most receive them and do 
not come to unnecessary harm. 
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Appendix I Literature search terms by databases 
 
1. Relationship between antibiotic prescribing and resistance.  
MEDLINE 
# Search History Results 
1 exp anti-bacterial agents/ 344750  
2 anti?biot$.mp. 151921  
3 anti?microb$.mp. 43527  
4 or/1-3 425041  
5 prescri$.mp. 67453  
6 Dispens$.mp. 12631  
7 Prescriptions, Drug/ 14246  
8 exp Drug Utilization/ 12312  
9 or/5-8 84736  
10 4 and 9 8591  
11 
drug resistance, microbial/ or drug resistance, bacterial/ or drug 
resistance, multiple/ or drug resistance, multiple, bacterial/ 
65011  
12 resistan$.mp. 424233  
13 susceptib$.mp. 158821  
14 or/11-13 540820  
15 10 and 14 2639  
16 limit 15 to humans 2482  
17 Limit 16 to English language 1991 
 
EMBASE 
# Search History Results 
1 exp Antibiotic Agent/ 444426  
2 anti?biot$.mp. 216454  
3 anti?microb$.mp. 47854  
4 or/1-3 502601  
5 drug utilization/ or "utilization review"/ 5969  
6 prescri$.mp. 75155  
7 dispens$.mp. 9558  
8 "drug use"/ or prescription/ 63559  
9 or/5-8 111879  
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10 4 and 9 15667  
11 antibiotic sensitivity/ or antibiotic resistance/ or penicillin resistance/ 57582  
12 exp drug resistance/ 83599  
13 susceptib$.mp. 139533  
14 resistan$.mp. 357922  
15 or/11-14 467563  
16 10 and 15 4410  
17 limit 16 to human 3719  
18 Limit 17 to English language  3058 
 
EBM Review 
# Search History Results 
1 anti?biotic$.mp.  11526  
2 anti?microbi$.mp.  2552  
3 anti?bacteri$.mp.  4983  
4 or/1-3  15432  
5 prescri$.mp.  6823  
6 dispens$.mp.  543  
7 utili$.mp.  9715  
8 or/5-7  16095  
9 4 and 8  1200  
10 resistan$.mp.  17274  
11 susceptib$.mp.  3505  
12 or/10-11  19919  
13 9 and 12  305  
14 remove duplicates from 13  302 
2. Relationship between antibiotic prescribing and infections 
 
MEDLINE 
1966 to February Week 3 2006 
# Search History Results 
1 Acute Disease/ 10733  
2 exp Bacterial Infections/ 248645  
3 exp Community-Acquired Infections/ 1908  
4 Communicable Diseases/ 1908  
5 exp Respiratory Tract Infections/ 75860  
6 exp Pneumonia/ 58991  
7 suppuration/ or brain abscess/ or lung abscess/ or peritonsillar 11889  
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abscess/ 
8 exp Otitis Media/ 13091  
9 
exp bronchitis/ or exp laryngitis/ or pleural diseases/ or exp 
empyema, pleural/ 
20447  
10 exp Urinary Tract Infections/ 25328  
11 exp Sepsis/ 30775  
12 exp skin diseases, infectious/ or exp soft tissue infections/ 51719  
13 exp Impetigo/ 1068  
14 exp Nephritis/ 29918  
15 exp Lymphangitis/ 472  
16 Wound Infection/ 11566  
17 exp Pharyngeal Diseases/ 18322  
18 exp aspergillosis/ 4691  
19 quinsy.mp. 63  
20 infection$.mp. 631203  
21 sore throat$.mp. 3397  
22 Staphylococcal Infections/ or exp Streptococcal Infections/ 10841  
23 Cough/ 17496  
24 acute disease$.mp. 11854  
25 communicable disease$.mp. 2684  
26 pneumonia.mp. 65565  
27 (suppuration or abscess$).mp. 34297  
28 
(otitis media or bronchitis or laryngitis or pleural disease$ or 
empyema or pleural).mp. 
51376  
29 UTI.mp. 2652  
30 RTI.mp. 778  
31 cough.mp. 13706  
32 
(sepsis or impetigo or nephritis or lymphangitis or pharyngeal 
disease$ or aspergillosis).mp. 
66865  
33 (skin disease$ or soft tissue$).mp. 76763  
34 or/1-33 986810  
35 exp anti-bacterial agents/ 881475  
36 anti?biot$.mp. 216454  
37 anti?microb$.mp. 47854  
38 anti?bacter$.mp. 28737  
39 or/35-38 923724  
40 Prescriptions, Drug/ 36645  
Appendix I 
352 
41 exp drug utilization/ 4562  
42 drug util$.mp. 5241  
43 prescri$.mp. 75155  
44 dispens$.mp. 9558  
45 or/40-44 85815  
46 39 and 45 16476  
47 34 and 46 8379  
48 limit 47 to humans 7798  
49 limit 48 to english language 6142  
 
EMBASE 
1980 to 2006 Week 07 
# Search History Results 
1 exp Respiratory Tract Infection/ 75860  
2 exp Urinary Tract Infection/ 25328  
3 exp ear infection/ or exp otitis media/ 14411  
4 skin infection/ or exp bacterial skin disease/ 26340  
5 exp Soft Tissue Infection/ 2459  
6 exp Bacterial Infection/ 248645  
7 exp Abscess/ 23560  
8 Communicable Disease/ 1908  
9 
exp dermatitis/ or exp respiratory tract inflammation/ or exp urinary 
tract inflammation/ 
191116  
10 exp Pharyngitis/ 6379  
11 exp Sinusitis/ 10981  
12 Lymphangitis/ 472  
13 exp Aspergillosis/ 4691  
14 quinsy/ 7  
15 cough.mp. 13706  
16 infection$.mp. 631203  
17 sore throat$.mp. or Sore Throat/ 3397  
18 quinsy.mp. 63  
19 (Aspergillosis or lymphangitis or sinusitis or pharyngitis).mp. 23951  
20 (RTI or UTI).mp. 3393  
21 otitis media.mp. 13749  
22 skin diseas$.mp. 26230  
23 abscess.mp. 31078  
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24 communicable disease.mp. 2248  
25 
(dermatitis or respiratory tract inflammmation or urinary tract 
inflammation).mp. 
33919  
26 or/1-25 941139  
27 exp antibiotic agent/ 444426  
28 anti?biot$.mp. 216454  
29 anti?microb$.mp. 47854  
30 anti?bacter$.mp. 28737  
31 or/27-30 511487  
32 drug utilization/ or "utilization review"/ 5969  
33 prescri$.mp. 75155  
34 dispens$.mp. 9558  
35 "drug use"/ or prescription/ 63559  
36 or/32-35 111879  
37 31 and 36 15765  
38 37 and 26 8843  
39 limit 38 to human 8197  
40 limit 39 to english language 6456  
 
 
EBM Review 
 
# Search History Results 
1 exp Respiratory Tract Infection/ 5769  
2 exp Urinary Tract Infection/ 1545  
3 exp ear infection/ or exp otitis media/ 744  
4 skin infection/ or exp bacterial skin disease/ 195  
5 exp Soft Tissue Infection/ 28  
6 exp Bacterial Infection/ 9151  
7 exp Abscess/ 337  
8 
exp dermatitis/ or exp respiratory tract inflammation/ or exp 
urinary tract inflammation/ 
1718  
9 exp Pharyngitis/ 464  
10 exp Sinusitis/ 354  
11 Lymphangitis/ 9  
12 exp Aspergillosis/ 48  
13 cough.mp. 2507  
14 infection$.mp. 30624  
15 sore throat$.mp. or Sore Throat/ 800  
16 quinsy.mp. 13  
17 (Aspergillosis or lymphangitis or sinusitis or pharyngitis).mp. 1833  
18 (RTI or UTI).mp. 428  
19 otitis media.mp. 1452  
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20 skin diseas$.mp. 1024  
21 abscess.mp. 856  
22 communicable disease.mp. 54  
23 
(dermatitis or respiratory tract inflammmation or urinary tract 
inflammation).mp. 
2428  
24 anti?biot$.mp. 11576  
25 anti?microb$.mp. 2562  
26 anti?bacter$.mp. 4985  
27 drug utilization/ or "utilization review"/ 201  
28 prescri$.mp. 6823  
29 dispens$.mp. 543  
30 "drug use"/ or prescription/ 0  
31 or/1-23 42402  
32 or/24-26 15478  
33 or/27-30 7311  
34 32 and 33 840  
35 31 and 34 646  
36 remove duplicates from 35 631  
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Appendix II Antibiotics used in the treatment of respiratory tract infections 
 
  Dataset 
BNF Sub-Section BNF Chemical 1996-
2003           
2000-
2006 
5.1.1 Penicillins 
5.1.1.1 Benzylpenicillin and 
phenoxymethylpenicillin 
    
 Benzylpenicillin 
Phenoxymethylpenicillin Benzathine 
Penicillin 
Procaine 
Benzylpenicillin 
 
 
 
 
 
 
 
5.1.1.2 Penicillinase-resistant 
penicillins        
   
 Flucloxacillin Sodium 
Flucloxacillin Magnesium 
  
 
5.1.1.3 Broad-spectrum penicillins     
 Amoxicillin 
Amoxicillin Sodium 
Ampicillin  
Co-Amoxiclav 
Co-Fluampicil 
  
 
 
 
 
 
 
 
 
 
5.1.2 Cephalosporins and other  beta-
lactams 
   
 Meropenem 
Cefpirome Sulphate 
Aztreonam  
Cefprozil  
Cefuroxime Axetil 
Cefamandole 
Cefazolin Sodium 
Imipenem with cilastatin Cefadroxil 
(1
st
 generation)  
Cefalexin (1
st
) 
Cefradine (1
st
)  
Cefaclor (2
nd
) 
Cefuroxime Sodium (2
nd
) 
Cefixime (3
rd
)  
Cefotaxime Sodium (3
rd
)  
Cefpodoxime (3
rd
) 
Ceftriaxone Sodium (3
rd
) 
Ceftazidime Pentahydrate (3
rd
) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1.3 Tetracyclines    
 Demeclocycline Hydrochloride 
Doxycycline Hyclate 
Lymecycline 
Minocycline Hydrochloride 
Oxytetracycline 
Tetracycline 
Tetracycline combined preps 
 
 
 
 
 
 
 
 
 
5.1.5 Macrolides    
 Erythromycin 
Erythromycin Estolate 
Erythromycin Ethylsuccinate 
Erythromycin Lactobionate 
Erythromycin Stearate  
Azithromycin 
 
 
 
 
 
 
 
 
 
 
 
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  Dataset 
BNF Sub-Section BNF Chemical 1996-
2003           
2000-
2006 
Clarithromycin          
Telithromycin 
 
5.1.8 Sulphonamides and trimethoprim     
 Trimethoprim   
5.1.12 Quinolones    
 Ciprofloxacin 
Levofloxacin 
Moxifloxacin  
Ofloxacin  
Nalidixic acid  
Norfloxacin 
  
 
 
 
 
 
Appendix III 
357 
Appendix III Liquid oral antibiotic preparations 
 
BNF Sub Section Chemical Preparation 
Aminoglycosides Gentamicin Sulphate Gentamicin Sulph_Pdr 
 Tobramycin With Sodium 
Chloride 
Tobramycin/sod 
Chlor_Inf 80mg/20ml 
 Tobramycin Tobramycin_Liq Spec 
40mg/5ml 
 Gentamicin Sulphate Cidomycin_Ster Pdr 
Benzylpenicillin & 
Phenoxymethylpenicill
in 
Phenoxymethylpenicillin 
(Penicillin V) 
Phenoxymethylpenicilli
n_Soln 250mg/5mlSF 
  Apsin Vk_Gran For Syr 
250mg/5ml 
  Phenoxymethylpenicilli
n_Soln 125mg/5ml 
  Phenoxymethylpenicilli
n_Soln 250mg/5ml 
  Tenkicin_Pdr For Elix 
125mg/5ml 
  Tenkicin_Pdr For Elix 
250mg/5ml 
  Phenoxymethylpenicilli
n_Soln 125mg/5mlSF 
Broad-Spectrum 
Penicillins 
Ampicillin Penbritin_Pdr For Syr 
Fte 250mg/5ml 
 Ampicillin Ampicillin_Oral Susp 
125mg/5ml 
 Amoxicillin Respillin_Pdr For Syr 
250mg/5ml S/f 
 Ampicillin Ampicillin_Oral Susp 
125mg/5ml S/f 
 Ampicillin Ampicillin_Oral Susp 
250mg/5ml 
 Ampicillin Penbritin_Pdr For Paed 
Susp 125mg/1.25ml 
 Amoxicillin Respillin_Pdr For Syr 
250mg/5ml 
 Ampicillin Penbritin_Pdr For Syr 
125mg/5ml 
 Co-Amoxiclav 
(Amoxicillin/Clavul Acid) 
Augmentin_Pdr For 
Susp 125/31mg/5ml S/f 
 Co-Amoxiclav 
(Amoxicillin/Clavul Acid) 
Augmentin_Pdr For 
Susp 250/62mg/5ml S/f 
 Co-Amoxiclav 
(Amoxicillin/Clavul Acid) 
Augmentin_Tab Disper 
375mg 
 Amoxicillin Respillin_Pdr For Syr 
125mg/5ml S/f 
 Co-Amoxiclav 
(Amoxicillin/Clavul Acid) 
Co-Amoxiclav_Susp 
125mg/31mg/5ml S/f 
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BNF Sub Section Chemical Preparation 
Broad Spectrum 
Penicillins 
Amoxicillin Amoxil Sf_Pdr For Syr 
250mg/5ml 
 Co-Amoxiclav 
(Amoxicillin/Clavul Acid) 
Co-Amoxiclav_Tab 
Disper 250mg/125mg 
 Amoxicillin Almodan_Syr 
125mg/5ml 
 Co-Amoxiclav 
(Amoxicillin/Clavul Acid) 
Ranclav_Pdr For Susp 
250mg/62mg/5ml S/f 
 Co-Amoxiclav 
(Amoxicillin/Clavul Acid) 
Augmentin-Duo 
400/57_Pdr For Susp 
S/f 
 Amoxicillin Amoxicillin_Oral Susp 
250mg/5ml S/f 
 Amoxicillin Almodan_Syr 
125mg/5ml S/f 
 Amoxicillin Almodan_Syr 
250mg/5ml 
 Amoxicillin Almodan_Syr 
250mg/5ml S/f 
 Amoxicillin Amix 125_Pdr For Susp 
125mg/5ml S/f 
 Amoxicillin Amix 250_Pdr For Susp 
250mg/5ml S/f 
 Amoxicillin Amoxicillin_Gran Sach 
125mg S/f 
 Amoxicillin Amoxicillin_Oral Pdr 
Sach 3g S/f 
 Amoxicillin Amoxicillin_Oral Susp 
125mg/5ml 
 Amoxicillin Amoxil_Pdr For Paed 
Susp 125mg/1.25ml 
 Amoxicillin Amoxicillin_Oral Susp 
250mg/5ml 
 Amoxicillin Respillin_Pdr For Syr 
125mg/5ml 
 Amoxicillin Amoxicillin_Oral Susp 
Paed 125mg/1.25ml 
 Amoxicillin Amoxicillin_Tab Disper 
500mg 
 Amoxicillin Amoxil Sf_Pdr For Syr 
125mg/5ml 
 Co-
Fluampicil(Flucloxacillin/Ampi
cillin) 
Co-Fluampicil_Syr 
125mg/125mg/5ml 
 Amoxicillin Amoxil Sf_Sach 3g 
 Co-
Fluampicil(Flucloxacillin/Ampi
cillin) 
Magnapen_Pdr For Syr 
250mg/5ml 
 Amoxicillin Galenamox_Susp 
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BNF Sub Section Chemical Preparation 
125mg/5ml S/f 
Broad Spectrum 
Penicillins 
Amoxicillin Galenamox_Susp 
250mg/5ml S/f 
 Amoxicillin Amoxicillin_Oral Susp 
125mg/5ml S/f 
 Co-Amoxiclav 
(Amoxicillin/Clavul Acid) 
Ranclav_Pdr For Susp 
125mg/31mg/5ml S/f 
Cephalosporins,Cepha
mycins & Betalactams 
Cefpodoxime Cefpodoxime_Susp 
40mg/5ml 
 Cefuroxime Axetil Zinnat_Gran For Susp 
125mg/5ml 
 Cefalexin Ceporex_Gran For Syr 
250mg/5ml 
 Cefalexin Ceporex_Gran For Syr 
500mg/5ml 
 Cefalexin Keflex_Gran For Paed 
Susp 125mg/5ml 
 Cefalexin Keflex_Gran For Susp 
250mg/5ml 
 Cefalexin Tenkorex_Pdr For Susp 
125mg/5ml 
 Cefalexin Tenkorex_Pdr For Susp 
250mg/5ml 
 Cefalexin Cefalexin_Oral Susp 
500mg/5ml 
 Cefixime Suprax_Pdr For Oral 
Susp Paed 100mg/5ml 
 Cefalexin Cefalexin_Oral Susp 
250mg/5ml S/f 
 Cefpodoxime Orelox Paed_Gran For 
Susp 40mg/5ml 
 Cefprozil Cefzil_Gran For Susp 
250mg/5ml 
 Cefradine Cefradine_Oral Soln 
250mg/5ml 
 Cefradine Velosef_Pdr For Syr 
250mg/5ml 
 Cefuroxime Axetil Cefuroxime 
Axetil_Gran Sach 
125mg 
 Cefuroxime Axetil Cefuroxime 
Axetil_Susp 125mg/5ml 
 Cefixime Cefixime_Oral Susp 
100mg/5ml 
 Cefadroxil Baxan_Pdr For Susp 
250mg/5ml 
 Cefaclor Cefaclor_Oral Susp 
125mg/5ml 
 Cefaclor Cefaclor_Oral Susp 
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BNF Sub Section Chemical Preparation 
125mg/5ml S/f 
Cephalosporins,Cepha
mycins & Betalactams 
Cefaclor Cefaclor_Oral Susp 
250mg/5ml 
 Cefaclor Cefaclor_Oral Susp 
250mg/5ml S/f 
 Cefaclor Distaclor_Gran For 
Susp 125mg/5ml 
 Cefaclor Distaclor_Gran For 
Susp 250mg/5ml 
 Cefaclor Keftid_Pdr For Susp 
125mg/5ml S/f 
 Cefalexin Ceporex_Gran For Syr 
125mg/5ml 
 Cefadroxil Baxan_Pdr For Susp 
125mg/5ml 
 Cefuroxime Axetil Zinnat_Gran Sach 
125mg 
 Cefadroxil Baxan_Pdr For Susp 
500mg/5ml 
 Cefadroxil Cefadroxil_Susp 
125mg/5ml 
 Cefadroxil Cefadroxil_Susp 
250mg/5ml 
 Cefadroxil Cefadroxil_Susp 
500mg/5ml 
 Cefalexin Cefalexin_Oral Susp 
125mg/5ml 
 Cefalexin Cefalexin_Oral Susp 
125mg/5ml S/f 
 Cefalexin Cefalexin_Oral Susp 
250mg/5ml 
 Cefaclor Keftid_Pdr For Susp 
250mg/5ml S/f 
Clindamycin and 
Lincomycin 
Clindamycin Hydrochloride Clindamycin Hcl_Liq 
Spec 75mg/5ml 
Macrolides Erythromycin Estolate Erythromycin 
Estolate_Mix 
250mg/5ml 
 Erythromycin Estolate Ilosone_Susp Fte 
250mg/5ml 
 Erythromycin Ethylsuccinate Arpimycin_Gran For 
Susp 125mg/5ml 
 Erythromycin Ethylsuccinate Arpimycin_Gran For 
Susp 125mg/5ml S/f 
 Erythromycin Ethylsuccinate Arpimycin_Gran For 
Susp 250mg/5ml 
 Erythromycin Ethylsuccinate Arpimycin_Gran For 
Susp 250mg/5ml S/f 
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BNF Sub Section Chemical Preparation 
 
Macrolides Erythromycin Ethylsuccinate Erycen_Susp 
250mg/5ml 
 Erythromycin Ethylsuccinate Erythroden_Gran For 
Susp 125mg/5ml 
 Erythromycin Ethylsuccinate Erythroden_Gran For 
Susp 250mg/5ml 
 Erythromycin Ethylsuccinate Erythromycin_Ethylsuc 
Sach 250mg 
 Erythromycin Ethylsuccinate Erythromycin_Ethylsuc 
Susp 125mg/5ml S/f 
 Erythromycin Estolate Erythromycin 
Estolate_Mix 
125mg/5ml 
 Erythromycin Ethylsuccinate Erythromycin_Ethylsuc 
Susp 500mg/5ml 
 Erythromycin Ethylsuccinate Erythromycin_Ethylsuc 
Susp 125mg/5ml 
 Erythromycin Ethylsuccinate Erythromycin_Ethylsuc 
Susp 500mg/5ml S/f 
 Erythromycin Ethylsuccinate Erythroped Fte Sf_Gran 
For Susp 500mg/5m 
 Erythromycin Ethylsuccinate Erythroped Fte_Gran 
For Susp 500mg/5ml 
 Erythromycin Ethylsuccinate Erythroped Pi Sf_Susp 
125mg/5ml 
 Erythromycin Ethylsuccinate Erythroped Pi_Susp 
125mg/5ml 
 Erythromycin Ethylsuccinate Erythroped Sf_Gran For 
Susp 250mg/5ml 
 Erythromycin Ethylsuccinate Erythroped_Gran For 
Susp 250mg/5ml 
 Erythromycin Ethylsuccinate Primacine_Gran For 
Susp 125mg/5ml S/f 
 Erythromycin Ethylsuccinate Rommix 125_Susp 
125mg/5ml 
 Azithromycin Zithromax_Pdr For Oral 
Susp 200mg/5ml 
 Azithromycin Azithromycin_Oral 
Susp 200mg/5ml 
 Erythromycin Ethylsuccinate Erythromycin_Ethylsuc 
Susp 250mg/5ml S/f 
 Clarithromycin Klaricid_Pdr Sach 
250mg 
 Clarithromycin Klaricid_Gran For Paed 
Susp 125mg/5ml 
 Clarithromycin Clarosip_Gran Straw 
250mg 
 Clarithromycin Clarosip_Gran Straw 
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BNF Sub Section Chemical Preparation 
125mg 
Macrolides Clarithromycin Clarithromycin_Pdr 
Sach 250mg 
 Clarithromycin Clarithromycin_Oral 
Susp 250mg/5ml 
 Clarithromycin Clarithromycin_Oral 
Susp 125mg/5ml 
 Clarithromycin Clarithromycin_Gran 
Straw 250mg 
 Clarithromycin Clarithromycin_Gran 
Straw 187.5mg 
 Clarithromycin Klaricid_Gran For Paed 
Susp 250mg/5ml 
 Clarithromycin Clarithromycin_Gran 
Straw 125mg 
 Erythromycin Ethylsuccinate Erythromycin_Ethylsuc 
Susp 250mg/5ml 
Metronidazole, 
Tinidazole & 
Ornidazole 
Metronidazole Metronidazole_Oral 
Susp 200mg/5ml 
 Metronidazole Flagyl-S_Susp 
200mg/5ml 
 Metronidazole Norzol_Susp 
200mg/5ml 
Penicillinase-Resistant 
Penicillins 
Flucloxacillin Magnesium Floxapen_Pdr For Syr 
125mg/5ml 
 Flucloxacillin Sodium Flucloxin_Pdr For Syr 
125mg/5ml 
 Flucloxacillin Sodium Fluclox Sod_Oral Soln 
250mg/5ml 
 Flucloxacillin Magnesium Floxapen_Pdr For Syr 
250mg/5ml 
 Flucloxacillin Magnesium Fluclox Mag_Oral Susp 
125mg/5ml 
 Flucloxacillin Magnesium Fluclox Mag_Oral Susp 
250mg/5ml 
 Flucloxacillin Sodium Fluclox Sod_Oral Soln 
125mg/5ml 
 Flucloxacillin Sodium Fluclox Sod_Oral Soln 
125mg/5ml S/f 
Quinolones Nalidixic Acid Nalidixic Acid_Oral 
Susp 300mg/5ml S/f 
 Nalidixic Acid Negram_Susp 
300mg/5ml S/f 
 Nalidixic Acid Nalidixic Acid_Oral 
Susp 300mg/5ml 
 Nalidixic Acid Mictral_Gran Sach 7g 
 Nalidixic Acid Gppe Gran 
Sach_Mictral 7g 
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BNF Sub Section Chemical Preparation 
 Ciprofloxacin Ciprofloxacin_Gran For 
Susp 250mg/5ml 
Quinolones Nalidixic Acid Uriben_Susp 
300mg/5ml 
 Ciprofloxacin Ciproxin_Gran For 
Susp 250mg/5ml 
Some Other 
Antibiotics 
Chloramphenicol Chloramphen Palm_Liq 
Spec 125mg/5ml 
 Colistin Sulphate Colistin Sulph_Elix 
250,000u/5ml 
 Fusidic Acid Fucidin_Paed Susp 
250mg/5ml 
 Fusidic Acid Fusidic Acid_Mix 
250mg/5ml 
 Colistin Sulphate Colomycin_Pdr For Syr 
250,000u/5ml 
Sulphonamides And 
Trimethoprim 
Co-
Trimoxazole(Trimethoprim/Sulf
amethox 
Chemotrim_Susp Paed 
240mg/5ml 
 Co-
Trimoxazole(Trimethoprim/Sulf
amethox 
Co-Trimoxazole_Oral 
Susp 480mg/5ml 
 Co-
Trimoxazole(Trimethoprim/Sulf
amethox 
Co-Trimoxazole_Oral 
Susp 480mg/5ml @gn 
 Co-Trimoxazole 
(Trimethoprim/Sulfamethox 
Co-Trimoxazole_Oral 
Susp Paed 240mg/5ml 
 Co-
Trimoxazole(Trimethoprim/Sulf
amethox 
Co-Trimoxazole_Susp 
Paed 240mg/5ml S/f 
 Trimethoprim Trimopan_Susp 
50mg/5ml S/f 
 Co-
Trimoxazole(Trimethoprim/Sulf
amethox 
Laratrim_Paed Susp 
240mg/5ml 
 Trimethoprim Monotrim_Susp 
50mg/5ml S/f 
 Trimethoprim Trimethoprim_Oral 
Susp 50mg/5ml S/f 
 Co-Trimoxazole 
(Trimethoprim/Sulfamethox 
Septrin_Paed Susp 
240mg/5ml S/f 
Tetracyclines Oxytetracycline Oxytetracycline_Susp 
250mg/5ml 
 Oxytetracycline Oxytetracycline_Oral 
Liq @spec 
 Oxytetracycline Oxytetracycline_Liq 
Spec 250mg/5ml 
 Oxytetracycline Oxytetracycline_Liq 
Spec 100mg/5ml 
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BNF Sub Section Chemical Preparation 
 Oxytetracycline Oxytetracycline_Liq 
Spec 125mg/5ml 
Tetracyclines Tetracycline Tetracycline_Liq Spec 
125mg/5ml 
 Doxycycline Hyclate Doxycycline 
Hyclate_Tab Disper 
100mg 
 Chlortetracycline Hydrochloride Chlortet Hcl_Pdr @gn 
 Chlortetracycline Hydrochloride Aureomycin_Pdr 
 Doxycycline Hyclate Vibramycin-D_Tab 
Disper 100mg 
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Appendix IV Broad- and narrow-spectrum classifications 
 
BNF Chemical BNF sub-section 
Broad (B)/ 
Narrow (N)- 
spectrum 
Co-Amoxiclav Broad-spectrum penicillins B 
Amoxicillin Broad-spectrum penicillins B 
Amoxicillin Sodium Broad-spectrum penicillins B 
Ampicillin Broad-spectrum penicillins B 
Co-Fluampicil Broad-spectrum penicillins B 
Cefaclor Cephalosporins B 
Cefamandole Cephalosporins B 
Cefixime Cephalosporins B 
Cefotaxime Sodium Cephalosporins B 
Cefpodoxime Cephalosporins B 
Cefprozil Cephalosporins B 
Ceftazidime Pentahydrate Cephalosporins B 
Ceftriaxone Sodium Cephalosporins B 
Cefuroxime Axetil Cephalosporins B 
Cefuroxime Sodium Cephalosporins B 
Aztreonam Cephalosporins B 
Cefadroxil Cephalosporins B 
Cefalexin Cephalosporins B 
Cefazolin Sodium Cephalosporins B 
Cefpirome Sulphate Cephalosporins B 
Cefradine Cephalosporins B 
Imipenem With Cilastatin Cephalosporins B 
Meropenem Cephalosporins B 
Azithromycin Macrolides B 
Clarithromycin Macrolides B 
Cinoxacin Quinolones B 
Ciprofloxacin Quinolones B 
Levofloxacin Quinolones B 
Moxifloxacin Quinolones B 
Nalidixic Acid Quinolones B 
Norfloxacin Quinolones B 
Ofloxacin Quinolones B 
Chlortetracycline Hydrochloride Tetracyclines B 
Demeclocycline Hydrochloride Tetracyclines B 
Doxycycline Hyclate Tetracyclines B 
Lymecycline Tetracyclines B 
Minocycline Hydrochloride Tetracyclines B 
Oxytetracycline Tetracyclines B 
Tetracycline Tetracyclines B 
Tetracycline Combined Preparations Tetracyclines B 
Flucloxacillin Magnesium Flucloxacillin N 
Flucloxacillin Sodium Flucloxacillin N 
Erythromycin Macrolides N 
Erythromycin Estolate Macrolides N 
Erythromycin Ethylsuccinate Macrolides N 
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BNF Chemical BNF sub-section 
Broad (B)/ 
Narrow (N)- 
spectrum 
Erythromycin Lactobionate Macrolides N 
Erythromycin Stearate Macrolides N 
Telithromycin Macrolides N 
Benzathine Penicillin Phenoxymethylpenicillin N 
Benzylpenicillin Sodium (Pen G) Phenoxymethylpenicillin N 
Phenoxymethylpenicillin (Pen V) Phenoxymethylpenicillin N 
Procaine Benzylpenicillin Phenoxymethylpenicillin N 
Trimethoprim Trimethoprim N 
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Appendix V Modelling for antibiotic resistance and lagged dispensing in H. influenzae, S. pneumoniae and S. pyogenes in 
sputum/ENT isolates.  
Organism Antibiotic 
resistance 
Lagged 
antibiotic 
dispensing 
Parameter 
estimate 
Standard 
error 
Dispensing 
rate IQR
i
 
OR (IQR)
ii
  
(95% CI) 
Adjusted OR  
(95% CI) 
H. influenzae Amoxicillin BSPs 0.58 0.20 0.12 1.07 (1.02 to 1.13) 1.06 (1.01 to 1.12) 
  Tetracyclines 1.15 1.30 0.02 1.03 (0.97 to 1.08) - 
  Macrolides 1.20 0.57 0.05 1.06 (1.00 to 1.12) 1.04 (0.98 to 1.10) 
  Beta-lactams 0.35 0.16 0.18 1.07 (1.01 to 1.13) 1.05 (0.98 to 1.12) 
H. influenzae Tetracycline BSPs 1.24 0.84 0.12 1.17 (0.96 to 1.43) - 
  Tetracyclines 8.25 5.04 0.02 1.19 (0.97 to 1.48) - 
  Macrolides 1.44 2.29 0.05 1.07 (0.87 to 1.32) - 
  Beta-lactams 0.52 0.63 0.18 1.10 (0.88 to 1.38) - 
S. pneumoniae Erythromycin BSPs -0.69 0.48 0.12 0.92 (0.82 to 1.03) - 
  Tetracyclines 0.93 2.91 0.02 1.02 (0.90 to 1.15) - 
  Macrolides -1.17 1.27 0.05 0.95 (0.84 to 1.06) - 
  Beta-lactams -0.62 0.35 0.18 0.89 (0.78 to 1.01) - 
S. pneumoniae Penicillin BSPs 0.71 0.64 0.12 1.09 (0.94 to 1.27) - 
  Tetracyclines 6.73 4.01 0.02 1.16 (0.98 to 1.37) - 
  Macrolides 1.82 1.74 0.05 1.09 (0.93 to 1.28) - 
  Beta-lactams 0.15 0.50 0.18 1.03 (0.86 to 1.23) - 
S. pyogenes Erythromycin BSPs 0.49 0.61 0.12 1.06 (0.92 to 1.23) - 
  Tetracyclines 5.71 3.50 0.02 1.13 (0.98 to 1.31) - 
  Macrolides 3.67 1.35 0.05 1.19 (1.05 to 1.35) 1.29 (1.12 to 1.48) 
  Beta-lactams 0.72 0.42 0.18 1.14 (0.98 to 1.33) - 
i
 Inter quartile range (IQR) is the difference between the 75
th
 and 25
th
 percentile of the dispensing rate distribution 
ii
 Odds Ratio (OR) is the odds of resistance at 75
th
 percentile of dispensing distribution compared to the 25
th
 percentile   
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Appendix VI Changes (%) in resistance to amoxicillin and tetracycline over an 8-year period, in Sputum and ENT H. influenzae 
isolates, by quartile of reductions in: 
 
(a) Total antibiotic dispensing 
 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Amoxicillin resistance 
1998, % 20.1  22.2 18.7 18.0 19.7 
2005, %  19.3 16.7 15.4 15.5 16.7 
Change, % (95% CI)  0.8 (-4.9 to 6.5) 5.5 (0.2 to 10.6) 3.3 (-2.1 to 8.6) 2.5 (-2.3 to 7.2) 3.0 (0.4 to 5.6) 
      
Tetracycline resistance 
1998, % 2.5 3.2 3.5 3.1 3.2 
2005, % 2.8 0.4 2.7 0.41 1.6 
Change, % (95% CI)   0.3 (-2.6 to 3.5) 2.8 (0.4 to 5.4) 0.8 (-3.0 to 4.0) 2.7 (0.4 to 5.1) 1.5 (0.2 to 2.8) 
      
 
(b) Broad Spectrum Penicillin dispensing 
 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Amoxicillin resistance 
1998, % 21.7 19.8 19.0 18.9 19.7 
2005, % 19.5 15.3 18.5 14.1 16.7 
Change, % (95% CI)   2.2 (-3.8 to 8.1) 4.5 (-0.4 to 9.4) 0.5 (-4.7 to 5.7) 4.8 (-0.2 to 9.7) 3.0 (0.4 to 5.6) 
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(c) Tetracycline dispensing 
 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Tetracycline resistance 
1998, % 2.2 2.6 3.5 4.3 3.1 
2005, % 1.5 2.1 1.5 1.5 1.6 
Change, % (95% CI)   0.7 (-1.5 to 2.9) 0.5 (3.7 to 4.1) 2.0 (-0.8 to 4.6) 2.9 (-0.5 to 6.2) 1.5 (0.2 to 2.8) 
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Appendix VII Changes (%) in resistance to erythromycin and penicillin over an 8-year period, in Sputum and ENT S. pneumoniae 
isolates, by quartile of reductions in: 
 
(a) Total antibiotic dispensing 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Erythromycin resistance  
1998, %             8.9         7.4         4.0              10.6         7.9  
2005, %           10.6       13.3         7.2              10.6       10.6  
Change, % (95% CI)   1.7 (-5.1 to 8.9)  6.0 (-0.4 to 12.7)  3.2 (-2.2 to 8.2)  =0.0 (-6.4 to 6.0)  2.7 (-0.4 to 5.7)  
 
Penicillin resistance 
1998, %             5.6         3.3        7.2            5.2         5.4  
2005, %             3.7         6.7         3.6            3.2         4.4  
Change, % (95% CI)   1.9 (-3.1 to 7.3)  3.4 (-1.4 to 8.4)  3.6 (-1.4 to 8.7)  1.9 (-2.3 to 6.0) 1.0 (-1.3 to 3.3)  
      
 
 (b) Macrolide dispensing 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Erythromycin resistance   
1998, % 10.3 6.0 8.7 6.1 7.9 
2005, % 10.7 9.4 9.7 13.2 10.6 
Change, % (95% CI)   0.5 (-6.6 to 7.5) 3.5 (-1.9 to 9.2) 1.0 (-4.8 to 6.5) 7.1 (0.0 to 14.3) 2.7 (-0.4 to 5.7) 
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(c) BSP dispensing 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Penicillin resistance   
1998, % 6.6 3.4 5.3 6.4 5.4 
2005, % 5.5 4.6 4.1 3.6 4.4 
Change, % (95% CI)   1.0 (-4.9 to 7.5) 1.2 (-5.5 to 3.1) 1.2 (-3.6 to 6.1) 2.8 (-1.6 to 7.1) 1.0 (-1.3 to 3.3) 
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Appendix VIII Changes (%) in resistance to erythromycin over an 8-year period, in Sputum and ENT S. pyogenes isolates, by quartile 
of reductions in: 
 
(a) Total antibiotic dispensing 
 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
Erythromycin resistance 
1998, % 4.3 1.7 1.6 4.3 3.2 
2005, % 6.7 4.5 4.4 0.6 4.1 
Change, % (95% CI)   2.4 (-2.1 to 7.4) 2.8 (-1.3 to 7.8) 2.8 (-0.9 to 7.9) 3.7 (0.4 to 6.8) 0.9 (-1.0 to 3.0) 
      
 
(b) Macrolide dispensing  
 
 Reduced dispensing most Reduced dispensing least  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Overall 
  Erythromycin resistance 
1998, % 4.0 2.6 2.9 2.9 3.2 
2005, % 4.7 4.4 5.2 1.6 4.1  
Change, % (95% CI)   0.6 (-3.1 to 5.0) 1.8 (-2.3 to 6.4) 2.3 (-1.7 to 7.6) 1.3 (-3.1 to 5.2) 0.9 (-1.0 to 3.0) 
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Appendix IX List of respiratory infections seen in hospital (ICD10 codes) 
 
ICD10  ICD10 DESCRIPTION 
J00 Acute nasopharyngitis [common cold] 
J01 Acute sinusitis   
J02 Acute pharyngitis 
J03 Acute tonsillitis 
J04 Acute tracheitis 
J06 Acute upper respiratory infections of multiple and 
unspecified sites 
J22 Unspecified acute lower respiratory infection  
H650 Acute serous otitis media 
H651 Other acute nonsuppurative otitis media 
H660 Acute suppurative otitis media 
H659 Nonsuppurative otitis media, unspecified (acute or 
chronic) 
H664 Suppurative otitis media, unspecified (acute or 
chronic) 
H669 Otitis media, unspecified (NOS, acute, chronic) 
J20 (exc J203, J204, J205, 
J206, J207) 
Acute bronchitis exc viruses 
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Appendix X Complications arising from RTIs (ICD10 codes) 
 
ICD10  ICD10 DESCRIPTION 
A36 Diptheria 
A38 Scarlet fever 
A39 Meningococcal infection 
A40  Streptococcal septicaemia 
A41 Other septicaemia 
A481 Legionnaires disease 
A491 Streptococcal infection, unspecified 
A492 Haemophilus influenzae infection, unspecified 
A493 Mycoplasma infection, unspecified 
A70 Chlamydia psittaci infection 
B960 Mycoplasma pneumoniae as the cause of diseases classified to 
other chapters 
B961 Klebsiella pneumoniae as the cause of diseases classified to 
other chapters 
G00 Bacterial meningitis, not elsewhere classified 
G01* Meningitis in bacterial diseases classified elsewhere 
G042 Bacterial meningoencephalitis and meningomyelitis, not 
elsewhere classified 
G048 Other encephalitis, myelitis and encephalomyelitis 
G050* Encephalitis, myelitis and encephalomyelitis in diseases 
classified elsewhere 
G06 Intracranial and intraspinal abscess and granuloma 
G08 Intracranial and intraspinal phlebitis and thrombophlebitis 
H67* Otitis media in diseases classified elsewhere 
H70 Mastoiditis and related conditions 
H75* Other disorders of middle ear and mastoid in diseases classified 
elsewhere 
I00 Rheumatic fever without heart involvement  
I01 Rheumatic fever with heart involvement 
I02 Rheumatic chorea 
I301 Infective pericarditis 
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ICD10  ICD10 DESCRIPTION 
I33 Acute and subacute endocarditis 
I38 Endocarditis, valve unspecified 
J051 Acute epiglottitis 
J13 Pneumonia due to Strep p 
J14 Pneumonia due to H influenzae 
J15 Bacterial pneumonia, not elsewhere classified 
J16 Pneumonia due to other infectious organisms (not elsewhere 
classified) 
J170* Pneumonia in bacterial diseases classified elsewhere 
J178* Pneumonia in other diseases classified elsewhere 
J18 Pneumonia, organism unspecified 
J340 Abscess, furuncle and carbuncle of nose 
J36 Abscess of peritonsillar 
J390 Retropharyngeal and parapharyngeal abscess 
J391 Other abscess of pharynx 
J398 Other specified diseases of upper respiratory tract 
J399 Disease of upper respiratory tract, unspecified  
J40 Bronchitis (not acute or chronic) 
J440 COPD with acute lower respiratory infection 
J441 COPD with acute exacerbation, unspecified 
J47 Bronchiectasis 
J85 Abscess of lung and mediastinum 
J86 Pyothorax 
J90 Pleural effusion, not elsewhere classified 
J91* Pleural effusion in conditions classified elsewhere 
L040 Acute lymphadenitis of face, head and neck 
L048 Acute lymphadenitis of other sites 
L049  Acute lymphadenitis, unspecified 
L540* Erythema marginatum in acute rheumatic fever 
M001 Pneumococcal arthritis and polyarthritis 
M002 Other streptococcal arthritis and polyarthritis 
M008 Arthritis and polyarthritis due to other specified bacterial agents 
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ICD10  ICD10 DESCRIPTION 
M009 Pyogenic arthritis, unspecified (infective arthritis) 
M010* Meningococcal arthritis  
M013* Arthritis in other bacterial diseases classified elsewhere 
M028 Other reactive arthropathies 
M029 Reactive arthropathy, unspecified 
M03* Post infective and reactive arthropathies in disease classified 
elsewhere  
N00 Acute nephritic syndrome (glomerulonephritis) 
N01 Rapidly progressive nephritic syndrome 
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Appendix XI List of respiratory tract infections (Read codes) by type and the 
number of patients identified with each code 
 
 (a) Sore throats   
Read code Description  N % 
1C9..00 Sore throat symptom 8,300 9.2 
1C9..11 Throat soreness 2,706 3.0 
1C92.00 Has a sore throat 49 0.1 
1C93.00 Persistent sore throat 0 0.0 
1C9Z.00 Sore throat symptom NOS 2 0.0 
1CA..00 Hoarseness symptoms 135 0.1 
1CA..11 Hoarseness - throat symptoms 6 0.0 
1CB3.00 Throat pain 191 0.2 
1CB3.11 Pain in throat 23 0.0 
2DB6.00 O/E - follicular tonsillitis 5 0.0 
2DC1.00 O/E - pharynx hyperaemic 21 0.0 
2DC1.11 O/E - fauces injected 27 0.0 
2DC2.00 O/E - granular pharyngitis 0 0.0 
2DC3.00 Inflamed throat 135 0.1 
A340.00 Streptococcal sore throat 16 0.0 
A340200 Streptococcal pharyngitis 1 0.0 
A340300 Streptococcal tonsillitis 26 0.0 
H00..00 Acute nasopharyngitis 7 0.0 
H02..00 Acute pharyngitis 2,168 2.4 
H02..11 Sore throat NOS 477 0.5 
H02..12 Viral sore throat NOS 114 0.1 
H02..13 Throat infection - pharyngitis 784 0.9 
H020.00 Acute gangrenous pharyngitis 0 0.0 
H021.00 Acute phlegmonous pharyngitis 3 0.0 
H022.00 Acute ulcerative pharyngitis 0 0.0 
H023.00 Acute bacterial pharyngitis 0 0.0 
H023000 Acute pneumococcal pharyngitis 0 0.0 
H023100 Acute staphylococcal pharyngitis 0 0.0 
H023z00 Acute bacterial pharyngitis NOS 0 0.0 
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Read code Description  N % 
H024.00 Acute viral pharyngitis 78 0.1 
H02z.00 Acute pharyngitis NOS 172 0.2 
H03..00 Acute tonsillitis 6,701 7.4 
H03..11 Throat infection - tonsillitis 66 0.1 
H03..12 Tonsillitis 542 0.6 
H030.00 Acute erythematous tonsillitis 1 0.0 
H031.00 Acute follicular tonsillitis 45 0.0 
H032.00 Acute ulcerative tonsillitis 0 0.0 
H033.00 Acute catarrhal tonsillitis 0 0.0 
H034.00 Acute gangrenous tonsillitis 0 0.0 
H035.00 Acute bacterial tonsillitis 12 0.0 
H035000 Acute pneumococcal tonsillitis 0 0.0 
H035100 Acute staphylococcal tonsillitis 0 0.0 
H035z00 Acute bacterial tonsillitis NOS 0 0.0 
H036.00 Acute viral tonsillitis 24 0.0 
H037.00 Recurrent acute tonsillitis 31 0.0 
H03z.00 Acute tonsillitis NOS 140 0.2 
H050.00 Acute laryngopharyngitis 2 0.0 
H052.00 Pharyngotracheitis 4 0.0 
H053.00 Tracheopharyngitis 0 0.0 
H055.00 Pharyngolaryngitis 2 0.0 
H121100 Atrophic pharyngitis 0 0.0 
H121200 Granular pharyngitis 0 0.0 
H121300 Hypertrophic pharyngitis 0 0.0 
H14y600 Lingular tonsillitis 0 0.0 
H271100 Influenza with pharyngitis 0 0.0 
Hyu0100 [X]Acute pharyngitis due to other specified 
organisms 
0 0.0 
Hyu0200 [X]Acute tonsillitis due to other specified 
organisms 
0 0.0 
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(b) Sinusitis 
Read code Description  N % 
1BA5.11 Pain in sinuses 624 0.7 
1CC..00 Blocked sinuses 35 0.0 
2DA2.00 O/E - maxillary sinus tenderness 6 0.0 
2DA3.00 O/E - frontal sinus tenderness 5 0.0 
H01..00 Acute sinusitis 4,422 4.9 
H01..11 Sinusitis 1,154 1.3 
H010.00 Acute maxillary sinusitis 56 0.1 
H010.11 Antritis - acute 1 0.0 
H011.00 Acute frontal sinusitis 17 0.0 
H012.00 Acute ethmoidal sinusitis 1 0.0 
H013.00 Acute sphenoidal sinusitis 1 0.0 
H01y.00 Other acute sinusitis 0 0.0 
H01y000 Acute pansinusitis 1 0.0 
H01yz00 Other acute sinusitis NOS 0 0.0 
H01z.00 Acute sinusitis NOS 0 0.0 
H130.12 Maxillary sinusitis 35 0.0 
H131.11 Frontal sinusitis 11 0.0 
H135.00 Recurrent sinusitis 7 0.0 
H13y.00 Other chronic sinusitis 0 0.0 
H13y100 Pansinusitis 0 0.0 
Hyu0000 [X]Other acute sinusitis 0 0.0 
Hyu2200 [X]Other chronic sinusitis 0 0.0 
SN31.11 Aerosinusitis 0 0.0 
 
(c) Laryngitis/ tracheitis 
Read code Description  N % 
H04..00 Acute laryngitis and tracheitis 7 0.0 
H040.00 Acute laryngitis 983 1.1 
H040000 Acute oedematous laryngitis 0 0.0 
H040100 Acute ulcerative laryngitis 0 0.0 
H040200 Acute catarrhal laryngitis 1 0.0 
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Read code Description  N % 
H040300 Acute phlegmonous laryngitis 1 0.0 
H040400 Acute haemophilus influenzae laryngitis 0 0.0 
H040500 Acute pneumococcal laryngitis 0 0.0 
H040600 Acute suppurative laryngitis 0 0.0 
H040w00 Acute viral laryngitis unspecified 30 0.0 
H040x00 Acute bacterial laryngitis unspecified 0 0.0 
H040z00 Acute laryngitis NOS 0 0.0 
H041.00 Acute tracheitis 782 0.9 
H041000 Acute tracheitis without obstruction 0 0.0 
H041100 Acute tracheitis with obstruction 0 0.0 
H041z00 Acute tracheitis NOS 0 0.0 
H042.00 Acute laryngotracheitis 60 0.1 
H042.11 Laryngotracheitis 23 0.0 
H042000 Acute laryngotracheitis without obstruction 0 0.0 
H042100 Acute laryngotracheitis with obstruction 0 0.0 
H042z00 Acute laryngotracheitis NOS 0 0.0 
H044.00 Croup 271 0.3 
H04z.00 Acute laryngitis and tracheitis NOS 1 0.0 
H271000 Influenza with laryngitis 0 0.0 
 
(d) Ear infections 
Read code Description  N % 
F51..00 Nonsuppurative otitis media + eustachian tube 
disorders 
1,314 1.4 
F510.00 Acute non suppurative otitis media 280 0.3 
F510000 Acute otitis media with effusion 4 0.0 
F510011 Acute secretory otitis media 55 0.1 
F510100 Acute serous otitis media 146 0.2 
F510200 Acute mucoid otitis media 1 0.0 
F510300 Acute sanguinous otitis media 0 0.0 
F510z00 Acute nonsuppurative otitis media NOS 4 0.0 
F514.00 Unspecified nonsuppurative otitis media 3 0.0 
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Read code Description  N % 
F514100 Serous otitis media NOS 6 0.0 
F514200 Catarrhal otitis media NOS 55 0.1 
F514300 Mucoid otitis media NOS 0 0.0 
F514z00 Nonsuppurative otitis media NOS 1 0.0 
F52..00 Suppurative and unspecified otitis media 671 0.7 
F520.00 Acute suppurative otitis media 276 0.3 
F520000 Acute suppurative otitis media tympanic 
membrane intact 
4 
0.0 
F520100 Acute suppurative otitis media tympanic 
membrane ruptured 
0 0.0 
F520300 Acute suppurative otitis media due to disease 
EC 
0 0.0 
F520z00 Acute suppurative otitis media NOS 0 0.0 
F524.00 Purulent otitis media NOS 0 0.0 
F524000 Bilateral suppurative otitis media 2 0.0 
F525.00 Recurrent acute otitis media 6 0.0 
F526.00 Acute left otitis media 308 0.3 
F527.00 Acute right otitis media 357 0.4 
F528.00 Acute bilateral otitis media 84 0.1 
F52z.00 Otitis media NOS 1,839 2.0 
F52z.11 Infection ear 401 0.4 
F540.00 Acute myringitis without otitis media 2 0.0 
FyuP000 [X]Other acute nonsuppurative otitis media 0 0.0 
FyuP300 [X]Otitis media in bacterial diseases classified 
elsewhere 
0 0.0 
FyuP400 [X]Otitis media in viral diseases classified 
elsewhere 
0 0.0 
FyuP500 [X]Otitis media in other diseases classified 
elsewhere 
0 0.0 
SN30.11 Aero-otitis media 0 0.0 
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(e) Chest infection 
Read code Description  N % 
1712 Dry cough 767 0.8 
1713 Productive cough - clear sputum 122 0.1 
1714 Productive cough - green sputum 418 0.5 
1715 Productive cough - yellow sputum 269 0.3 
1716 Productive cough – NOS 176 0.2 
1719 Chesty cough 2,091 2.3 
171E Unexplained cough 0 0.0 
171F Cough with fever 3 0.0 
171Z Cough symptoms NOS 66 0.1 
A79A.00 Respiratory syncytial virus infection 3 0.0 
H06..00 Acute bronchitis and bronchiolitis 0 0.0 
H060.00 Acute bronchitis 2,384 2.6 
H060.11 Acute wheezy bronchitis 298 0.3 
H060000 Acute fibrinous bronchitis 0 0.0 
H060100 Acute membranous bronchitis 0 0.0 
H060200 Acute pseudomembranous bronchitis 0 0.0 
H060300 Acute purulent bronchitis 0 0.0 
H060400 Acute croupous bronchitis 3 0.0 
H060500 Acute tracheobronchitis 90 0.1 
H060600 Acute pneumococcal bronchitis 0 0.0 
H060700 Acute streptococcal bronchitis 0 0.0 
H060800 Acute haemophilus influenzae bronchitis 0 0.0 
H060A00 Acute bronchitis due to mycoplasma 
pneumoniae 
0 0.0 
H060B00 Acute bronchitis due to coxsackievirus 0 0.0 
H060C00 Acute bronchitis due to parainfluenza virus 0 0.0 
H060D00 Acute bronchitis due to respiratory syncytial 
virus 
0 0.0 
H060E00 Acute bronchitis due to rhinovirus 0 0.0 
H060F00 Acute bronchitis due to echovirus 0 0.0 
H060w00 Acute viral bronchitis unspecified 9 0.0 
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Read code Description  N % 
H060x00 Acute bacterial bronchitis unspecified 1 0.0 
H060z00 Acute bronchitis NOS 0 0.0 
H062.00 Acute lower respiratory tract infection 395 0.4 
H06z.00 Acute bronchitis or bronchiolitis NOS 0 0.0 
H06z000 Chest infection NOS 6,940 7.7 
H06z011 Chest infection 7,031 7.8 
H06z100 Lower resp tract infection 506 0.6 
H06z112 Acute lower respiratory tract infection 0 0.0 
H06z200 Recurrent chest infection 17 0.0 
H07..00 Chest cold 128 0.1 
H24..11 Chest infection with infectious disease EC 0 0.0 
H260000 Lung consolidation 11 0.0 
H30..00 Bronchitis unspecified 293 0.3 
H30..11 Chest infection - unspecified bronchitis 1 0.0 
H30..12 Recurrent wheezy bronchitis 8 0.0 
H300.00 Tracheobronchitis NOS 5 0.0 
H301.00 Laryngotracheobronchitis 3 0.0 
H302.00 Wheezy bronchitis 94 0.1 
H30z.00 Bronchitis NOS 1 0.0 
H312200 Acute exacerbation of chronic obstructive 
airways disease 
361 0.4 
H3y0.00 Chronic obstruct pulmonary disease with acute 
lower respiratory infection 
3 
0.0 
Hyu1000 [X]Acute bronchitis due to other specified 
organisms 
0 0.0 
 
(f) Not grouped – Lower RTIs 
Read code Description  N % 
A3A4.00 Legionella 0 0.0 
Hyu1.00 [X]Other acute lower respiratory infections 0 0.0 
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(g) Not grouped –Upper RTIs 
Read code Description  N % 
Hyu0400 [X]Flu+oth respiratory manifestations,'flu virus 
identified 
0 0.0 
Hyu0600 [X]Influenza+oth respiratory manifestatns,virus 
not identifd 
0 0.0 
Hyu0500 [X]Influenza+other manifestations,influenza 
virus identified 
0 0.0 
Hyu0300 [X]Other acute upper respiratory 
infections/multiple sites 
0 0.0 
AyuD.00 [X]Other viral diseases 0 0.0 
H051.00 Acute upper respiratory tract infection 2,631 2.9 
A790.00 Adenovirus 1 0.0 
1C86 Blocked nose 160 0.2 
H00..11 Common cold 286 0.3 
H00..12 Coryza - acute 292 0.3 
H00..13 Febrile cold 2 0.0 
1652 Feels hot/ feverish 239 0.3 
165..11 Fever symptoms 588 0.6 
1653 Fever with sweating 0 0.0 
1656 Feverish cold 55 0.1 
H27z.11 Flu like illness 1,806 2.0 
H27..00 Influenza 205 0.2 
H27z.12 Influenza like illness 13 0.0 
H27z.00 Influenza NOS 3 0.0 
H271.00 Influenza with other respiratory manifestation 0 0.0 
H271z00 Influenza with respiratory manifestations NOS 0 0.0 
1C83 Nasal discharge present 44 0.0 
H1y1z14 Nasal infection 163 0.2 
2D2..00 O/E - nasal discharge 30 0.0 
2D2Z.00 O/E - nasal discharge - NOS 0 0.0 
2D2..11 O/E - nose discharge 2 0.0 
2E34.00 O/E - temperature elevated 1 0.0 
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2D24.00 O/E - nasal discharge - mucopurulent 3 0.0 
H05..00 Other acute upper respiratory infections 1 0.0 
H05y.00 Other upper respiratory infections of multiple 
sites 
0 0.0 
2D26.00 Postnasal discharge 70 0.1 
H00..15 Pyrexial cold 17 0.0 
H054.00 Recurrent upper respiratory tract infection 11 0.0 
H00..16 Rhinitis - acute 218 0.2 
A793.00 Rhinovirus 0 0.0 
165Z.00 Temperature symptom NOS 7 0.0 
165..00 Temperature symptoms 407 0.4 
H05z.00 Upper respiratory infection NOS 8,901 9.8 
H05z.11 Upper respiratory tract infection NOS 7,694 8.5 
A79z.11 Viral illness 960 1.1 
A79z.00 Viral infection NOS 2,374 2.6 
H05z.12 Viral upper respiratory tract infection NOS 305 0.3 
Hyu0.00 [X]Acute upper respiratory infections 0 0.0 
2D22.00 O/E - rhinorrhoea 2 0.0 
2D23.00 O/E - nasal discharge - foul smell 1 0.0 
 
(h) Not grouped – RTIs 
Read code Description N % 
A3Bz.00 Bacterial infection NOS 0 0.0 
A3y..00 Other specified bacterial diseases 0 0.0 
A3z..00 Other bacterial disease NOS 0 0.0 
H0...00 Acute respiratory infections 1,051 1.2 
H06z111 Respiratory tract infection 2,180 2.4 
H0y..00 Other specified acute respiratory infections 1 0.0 
H0z..00 Acute respiratory infection NOS 61 0.1 
H5yy.11 Respiratory infection NOS 20 0.0 
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(i) Pneumonia 
Read code Description  N % 
A3BXB00 Klebsiella pneumoniae/cause/disease 
classified/other chapters 
2 0.0 
A3By400 Pleuropneumonia-like organism (PPLO) 
infection 
0 0.0 
AyuK900 [X]Mycoplasma pneumoniae [PPLO] 
/cause/disease classified/other chapters 
0 0.0 
AyuKA00 [X]Klebsiella pneumoniae/cause/disease 
classified/other chapters 
0 0.0 
H2...00 Pneumonia and influenza 13 0.0 
H20..00 Viral pneumonia 6 0.0 
H20..11 Chest infection - viral pneumonia 1 0.0 
H200.00 Pneumonia due to adenovirus 0 0.0 
H201.00 Pneumonia due to respiratory syncytial virus 0 0.0 
H202.00 Pneumonia due to parainfluenza virus 0 0.0 
H20y.00 Viral pneumonia NEC 0 0.0 
H20z.00 Viral pneumonia NOS 2 0.0 
H21..00 Lobar (pneumococcal) pneumonia 58 0.1 
H21..11 Chest infection - pneumococcal pneumonia 0 0.0 
H22..00 Other bacterial pneumonia 8 0.0 
H22..11 Chest infection - other bacterial pneumonia 1 0.0 
H220.00 Pneumonia due to klebsiella pneumoniae 0 0.0 
H221.00 Pneumonia due to pseudomonas 0 0.0 
H222.11 Pneumonia due to haemophilus influenzae 0 0.0 
H223.00 Pneumonia due to streptococcus 1 0.0 
H223000 Pneumonia due to streptococcus, group B 0 0.0 
H224.00 Pneumonia due to staphylococcus 0 0.0 
H22y.00 Pneumonia due to other specified bacteria 1 0.0 
H22y000 Pneumonia due to escherichia coli 0 0.0 
H22y011 E.coli pneumonia 0 0.0 
H22y100 Pneumonia due to proteus 0 0.0 
H22y200 Pneumonia - Legionella 1 0.0 
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H22yX00 Pneumonia due to other aerobic gram-negative 
bacteria 
0 0.0 
H22yz00 Pneumonia due to bacteria NOS 0 0.0 
H22z.00 Bacterial pneumonia NOS 0 0.0 
H23..00 Pneumonia due to other specified organisms 7 0.0 
H23..11 Chest infection - pneumonia organism OS 0 0.0 
H230.00 Pneumonia due to Eaton's agent 0 0.0 
H231.00 Pneumonia due to mycoplasma pneumoniae 0 0.0 
H232.00 Pneumonia due to pleuropneumonia like 
organisms 
0 0.0 
H233.00 Chlamydial pneumonia 0 0.0 
H23z.00 Pneumonia due to specified organism NOS 0 0.0 
H24..00 Pneumonia with infectious diseases EC 0 0.0 
H240.00 Pneumonia with measles 0 0.0 
H241.00 Pneumonia with cytomegalic inclusion disease 0 0.0 
H243.00 Pneumonia with whooping cough 0 0.0 
H243.11 Pneumonia with pertussis 0 0.0 
H24y400 Pneumonia with salmonellosis 0 0.0 
H24y700 Pneumonia with varicella 0 0.0 
H24z.00 Pneumonia with infectious diseases EC NOS 0 0.0 
H25..00 Bronchopneumonia due to unspecified 
organism 
128 
0.1 
H25..11 Chest infection - unspecified 
bronchopneumonia 
0 0.0 
H26..00 Pneumonia due to unspecified organism 202 0.2 
H26..11 Chest infection - pnemonia due to unspecified 
organism 
0 0.0 
H260.00 Lobar pneumonia due to unspecified organism 14 0.0 
H261.00 Basal pneumonia due to unspecified organism 26 0.0 
H262.00 Postoperative pneumonia 0 0.0 
H270.00 Influenza with pneumonia 0 0.0 
H270.11 Chest infection - influenza with pneumonia 0 0.0 
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H270000 Influenza with bronchopneumonia 1 0.0 
H270100 Influenza with pneumonia, influenza virus 
identified 
0 0.0 
H270z00 Influenza with pneumonia NOS 0 0.0 
H28..00 Atypical pneumonia 6 0.0 
H2y..00 Other specified pneumonia or influenza 0 0.0 
H2z..00 Pneumonia or influenza NOS 46 0.1 
H530200 Gangrenous pneumonia 0 0.0 
H540000 Hypostatic pneumonia 0 0.0 
H540100 Hypostatic bronchopneumonia 0 0.0 
H56y100 Interstitial pneumonia 2 0.0 
H571.00 Rheumatic pneumonia 0 0.0 
Hyu0800 [X]Other viral pneumonia 0 0.0 
Hyu0900 [X]Pneumonia due to other aerobic gram-
negative bacteria 
0 0.0 
Hyu0A00 [X]Other bacterial pneumonia 0 0.0 
Hyu0B00 [X]Pneumonia due to other specified infectious 
organisms 
0 0.0 
Hyu0C00 [X]Pneumonia in bacterial diseases classified 
elsewhere 
0 0.0 
Hyu0D00 [X]Pneumonia in viral diseases classified 
elsewhere 
0 0.0 
Hyu0G00 [X]Pneumonia in other diseases classified 
elsewhere 
0 0.0 
Hyu0H00 [X]Other pneumonia, organism unspecified 0 0.0 
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Read code Description 
A32.. Diphtheria 
A320. Faucial 
A321. Nasopharyngeal 
A322. Anterior nasal 
A323. Laryngeal 
A32y. Other specific diphtheria 
A32z. Diphtheria NOS 
A34.. Streptococcal sore throat and scarlatina 
A340. Streptococcal sore throat 
A341. Scarlet fever 
A342. Streptococcal sore throat with scarlatina NOS 
A36.. Meningococcal infection 
A360. Meningococcal meningitis 
A361. Meningococcal encephalitis 
A362. Meningococcal septicaemia 
A363. Waterhouse-Friderichsen syndrome ( E35.1* ) 
A364. Meningococcal carditis 
A365. Meningococcal meningitis with acute meningococcal septicaemia 
A366. Meningococcal meningitis with  meningococcal septicaemia 
A36y. Other specified meningococcal infection 
A36z. Meningococcal infection NOS 
A38.. Septicaemia 
A380. Streptococcal septicaemia 
A3800 Septicaemia due to streptococcus, group A 
A3801 Septicaemia due to streptococcus, group B 
A3802 Septicaemia due to streptococcus, group D 
A3803 Septicaemia due to streptococcus pneumoniae 
A3804 Septicaemia due to enterococcus 
A3805 Vancomycin resistant enterococcal septicaemia 
A381. Staphylococcal septicaemia 
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A382. Pneumococcal septicaemia 
A383. Septicaemia due to anaerobes (includes Lemierre's disease) 
A384. Septicaemia due to other gram negative organisms 
A38y. Other specified septicaemia 
A38z. Septicaemia NOS 
A3B.. Bacterial infections - causative organisms 
A3B0. Streptococcal infection 
A3B1. Staphylococcal infection 
A3B2 Pneumococcal infection 
A3B5. Haemophilus influenzae infection 
A3B7. Pseudomonas infection 
A3BX. Bacterial causes of diseases classified elsewhere 
A3Bx. Bacteria causing diseases classified elsewhere 
A3By. Other specified bacterial infection 
A3Bz. Bacterial infection NOS 
A73.. Ornithosis - psittacosis 
A730. Ornithosis with pneumonia 
A73x. Ornithosis with other specified complications 
A73y. Ornithosis with unspecified complications 
A73z. Unspecified Ornithosis 
F00.. Bacterial meningitis 
F000. Haemophilus meningitis 
F001. Pneumococcal meningitis  
F002. Streptococcal meningitis 
F003. Staphylococcal meningitis  
F005. Meningitis - meningococcal 
F007. Meningitis in other bacterial disease classified elsewhere 
F00y. Other specified bacterial meningitis 
F00z. Bacterial meningitis NOS 
F0330 Encephalitis due to meningococcus 
F033z Unspecified encephalitis due to other infection EC 
F03X. Bacterial meningoencephalitis and meningomyelitis, not 
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elsewhere classified 
F03z. Encephalitis NOS 
F04.. Intracranial and intraspinal abscesses 
F040. Intracranial abscess 
F041. Intraspinal abscess 
F04X. Extradural and subdural abscess, unspecified 
F04z. Intracranial or intraspinal abscess NOS (epidural abscess) 
F53..  Mastoiditis 
F530. Acute mastoiditis 
F531. Chronic mastoiditis 
F532. Petrositis 
F53z. Mastoiditis NOS 
F551. Adhesive middle ear disease 
F552. Other acquired abnormality of ear ossicles 
F55y. Other middle ear and mastoid disorders OS 
F55z. Middle ear or mastoid disorder NOS 
Fyu00 [X]Other bacterial meningitis 
Fyu05 [X]Bacterial meningoencephalitis and meningomyelitis, not 
elsewhere classified 
Fyu06 [X]Other encephalitis, myelitis and encephalomyelitis 
Fyu07 [X]Encephalitis, myelitis and encephalomyelitis in bacterial 
diseases classified elsewhere 
Fyu0B [X]Intracranial and intraspinal abscess and granuloma in 
diseases classified elsewhere 
G0... Acute rheumatic fever 
G00.. Rheumatic fever without heart involvement 
G01.. Rheumatic fever with heart involvement 
G02.. Rheumatic chorea 
G0y.. Other specified acute rheumatic fever 
G0z.. Acute rheumatic fever NOS 
G50z2 Acute pericarditis - pneumococcal 
G50z3 Acute pericarditis - staphylococcal 
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G50z4 Acute pericarditis - streptococcal 
G50z5 Acute purulent pericarditis unspecified 
G51.. Acute and subacute endocarditis 
G510. Acute and subacute bacterial endocarditis 
G511. Acute and subacute infective endocarditis in diseases EC 
G51z. Acute and subacute endocarditis unspecified 
H043. Acute epiglottitis (non strep) 
H0430 Acute epiglottitis without obstruction 
H0431 Acute epiglottitis with obstruction 
H043z Acute epiglottitis NOS 
H14.. Chronic tonsil and adenoid disease 
H140. Chronic tonsillitis/adenoiditis 
H141. Tonsil and/or adenoid hypertrophy 
H142. Adenoid vegetations 
H143. Chronic adenotonsillitis 
H14y. Other chronic diseases of tonsils and adenoids 
H14z. Chronic tonsil and adenoid disease NOS 
H15.. Peritonsillar abscess - quinsy 
H1y21 Pharynx or nasopharynx cellulitis 
H1y22 Parapharyngeal abscess 
H1y23 Retropharyngeal abscess 
H1y26 Pharynx or nasopharynx abscess 
H1y8. Upper respiratory tract hypersensitivity reaction NOS 
2DB5. O/E – quinsy present 
H21.. Lobar (pneumococcal) pneumonia 
H22.. Other bacterial pneumonia 
H23.. Pneumonia due to other specified organisms 
H24.. Pneumonia with infectious diseases EC 
H25.. Bronchopneumonia due to unspecified organism 
H26.. Pneumonia due to unspecified organism 
H28.. Atypical pneumonia 
H313. Mixed simple and mucopurulent chronic bronchitis 
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H34.. Bronchiectasis 
H3y1. Chronic obstructive pulmonary disease with acute exacerbation, 
unspecified 
H5016 Pyothorax 
H510B Streptococcal pleurisy 
H511. Bacterial pleurisy with effusion 
H51y. Other pleural effusion excluding mention of tuberculosis 
H51z. Pleural effusion NOS 
H51zz Pleural effusion NOS 
H53.. Abscess of lung and mediastinum 
H530. Abscess of lung 
H531. Abscess of mediastinum 
H53z. Abscess of lung and mediastinum NOS 
K0A0. Acute nephritic syndrome 
K0A1. Rapidly progressive nephritic syndrome 
M0002 Carbuncle of nasal septum 
M0102 Boil of nasal septum 
M0301 Cellulitis and abscess of nose 
M043. Acute lymphadenitis of face, head and neck 
M15y6 Erythema marginatum in acute rheumatic fever 
N0108 Staphylococcal arthritis and polyarthritis 
N0109 Pneumococcal arthritis and polyarthritis 
N010z Pyogenic arthritis NOS 
N014. Arthropathy associated with other bacterial diseases 
N01w. Reactive arthropathy, unspecified 
N0380 Postmeningococcal arthritis 
N0381 Postinfective arthropathy in syphilis 
N0420 Rheumatic carditis 
Nyu00 [X]Other streptococcal arthritis and polyarthritis 
R0555 [D] septic shock 
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ICD10 Code Description 
A36 Diptheria 
A38 Scarlet fever 
A39  Meningococcal infection  
A39.0+  Meningococcal meningitis ( G01* ) 
A39.1+  Waterhouse-Friderichsen syndrome ( E35.1* ) 
A39.2  Acute meningococcaemia  
A39.3  Chronic meningococcaemia  
A39.4  Meningococcaemia, unspecified  
A39.5+  Meningococcal heart disease  
A39.8  Other meningococcal infections  
A39.9  Meningococcal infection, unspecified  
A40  Streptococcal septicaemia  
A40.0  Septicaemia due to streptococcus, group A  
A40.1  Septicaemia due to streptococcus, group B  
A40.2  Septicaemia due to streptococcus, group D  
A40.3  Septicaemia due to Streptococcus pneumoniae. Pneumococcal 
septicaemia  
A40.8  Other streptococcal septicaemia  
A40.9  Streptococcal septicaemia, unspecified  
A41  Other septicaemia  
A41.0  Septicaemia due to Staphylococcus aureus  
A41.1  Septicaemia due to other specified staphylococcus  
A41.2  Septicaemia due to unspecified staphylococcus  
A41.3  Septicaemia due to Haemophilus influenzae  
A41.4  Septicaemia due to anaerobes  
A41.5  Septicaemia due to other Gram-negative organisms  
A41.8  Other specified septicaemia  
A41.9  Septicaemia, unspecified  inc septic shock 
A48.1  Legionnaires disease 
A49.1  Streptococcal infection, unspecified  
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A49.2 Haemophilus influenzae infection, unspecified  
A49.3 Mycoplasma infection, unspecified 
A70 Chlamydia psittaci infection 
B96.0 Mycoplasma pneumoniae [M. pneumoniae] as the cause of 
diseases classified to other chapters 
B96.1 Klebsiella pneumoniae [K. pneumoniae] as the cause of diseases 
classified to other chapters 
G00  Bacterial meningitis, not elsewhere classified  
G00.0  Haemophilus meningitis: Meningitis due to Haemophilus influenzae 
G00.1  Pneumococcal meningitis  
G00.2  Streptococcal meningitis  
G00.3  Staphylococcal meningitis  
G00.8  Other bacterial meningitis: Meningitis due to escherichia coli, 
Friedländer bacillus, Klebsiella 
G00.9  Bacterial meningitis, unspecified:  Meningitis purulent NOS, 
pyogenic NOS, suppurative NOS 
G01*  Meningitis in bacterial diseases classified elsewhere  
G04.2  Bacterial meningoencephalitis and meningomyelitis, not 
elsewhere classified  
G04.8  Other encephalitis, myelitis and encephalomyelitis 
(Postinfectious encephalitis and encephalomyelitis NOS) 
G05.0*  Encephalitis, myelitis and encephalomyelitis in bacterial diseases 
classified elsewhere  
G06  Intracranial and intraspinal abscess and granuloma  
G06.0  Intracranial abscess and granuloma  
G06.1  Intraspinal abscess and granuloma  
G06.2  Extradural and subdural abscess, unspecified  
G08  Intracranial and intraspinal phlebitis and thrombophlebitis  
H67*  Otitis media in diseases classified elsewhere  
H70  Mastoiditis and related conditions  
H70.0  Acute mastoiditis (Abscess, Empyema) 
H70.1  Chronic mastoiditis (Caries, Fistula) 
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H70.2  Petrositis (inflammation of petrous bone (acute)(chronic)) 
H70.8  Other mastoiditis and related conditions  
H70.9  Mastoiditis, unspecified  
H75*  Other disorders of middle ear and mastoid in diseases classified 
elsewhere 
H75.0*  Mastoiditis in infectious and parasitic diseases classified elsewhere  
H75.8*  
Other specified disorders of middle ear and mastoid in diseases 
classified elsewhere  
I00  Rheumatic fever without mention of heart involvement 
(Arthritis, rheumatic, acute or subacute) 
I01  Rheumatic fever with heart involvement  
I01.0  Acute rheumatic pericarditis (Any condition in I00 with pericarditis) 
I01.1  Acute rheumatic endocarditis (Any condition in I00 with 
endocarditis or valvulitis) 
I01.2  Acute rheumatic myocarditis (Any condition in I00 with 
myocarditis) 
I01.8  Other acute rheumatic heart disease (Any condition in I00 with other 
or multiple types of heart involvement) 
I01.9  Acute rheumatic heart disease, unspecified (Any condition in I00 
with unspecified type of heart involvement) 
I02  Rheumatic chorea  
I02.0  Rheumatic chorea with heart involvement  
I02.9  Rheumatic chorea without heart involvement  
I30.1 Infective pericarditis 
I33  Acute and subacute endocarditis  
I33.0  Acute and subacute infective endocarditis  
I33.9  Acute endocarditis, unspecified  
I38  Endocarditis, valve unspecified  
J05.1  Acute epiglottitis  
J13  Pneumonia due to Streptococcus pneumoniae  
J14  Pneumonia due to Haemophilus influenzae  
J15  Bacterial pneumonia, not elsewhere classified  
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J15.0  Pneumonia due to Klebsiella pneumoniae  
J15.1  Pneumonia due to Pseudomonas  
J15.2  Pneumonia due to staphylococcus  
J15.3  Pneumonia due to streptococcus, group B  
J15.4  Pneumonia due to other streptococci  
J15.5  Pneumonia due to Escherichia coli  
J15.6  Pneumonia due to other aerobic Gram-negative bacteria  
J15.7  Pneumonia due to Mycoplasma pneumoniae  
J15.8  Other bacterial pneumonia  
J15.9  Bacterial pneumonia, unspecified  
J16  Pneumonia due to other infectious organisms, not elsewhere 
classified  
J16.0  Chlamydial pneumonia  
J16.8  Pneumonia due to other specified infectious organisms  
J17.0*  Pneumonia in bacterial diseases classified elsewhere  
J17.8*  Pneumonia in other diseases classified elsewhere  
J18  Pneumonia, organism unspecified  
J18.0  Bronchopneumonia, unspecified  
J18.1  Lobar pneumonia, unspecified  
J18.2  Hypostatic pneumonia, unspecified  
J18.8  Other pneumonia, organism unspecified  
J18.9  Pneumonia, unspecified  
J34.0  Abscess, furuncle and carbuncle of nose  
J36  Peritonsillar abscess  
J39 Other diseases of upper respiratory tract 
J39.0  Retropharyngeal and parapharyngeal abscess  
J39.1  Other abscess of pharynx  
J39.8 Other specified diseases of upper respiratory tract 
J39.9 Disease of upper respiratory tract, unspecified 
J40 Bronchitis, not specified as acute or chronic  
J44.0  Chronic obstructive pulmonary disease with acute lower 
respiratory infection  
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J44.1  Chronic obstructive pulmonary disease with acute exacerbation, 
unspecified  
J47  Bronchiectasis  
J85  Abscess of lung and mediastinum  
J86  Pyothorax  
J86.0  Pyothorax with fistula  
J86.9  Pyothorax without fistula  
J90  Pleural effusion, not elsewhere classified  
J91*  Pleural effusion in conditions classified elsewhere  
L04.0  Acute lymphadenitis of face, head and neck  
L04.8  Acute lymphadenitis of other sites  
L04.9  Acute lymphadenitis, unspecified  
L54.0*  Erythema marginatum in acute rheumatic fever ( I00+ ) 
M00.1  Pneumococcal arthritis and polyarthritis  
M00.2  Other streptococcal arthritis and polyarthritis  
M00.8  Arthritis and polyarthritis due to other specified bacterial 
agents  
M00.9  Pyogenic arthritis, unspecified 
M01.0*  Meningococcal arthritis ( A39.8+ ) 
M01.3*  Arthritis in other bacterial diseases classified elsewhere  
M02.8  Other reactive arthropathies  
M02.9  Reactive arthropathy, unspecified  
M03*  Postinfective and reactive arthropathies in diseases classified 
elsewhere  
M03.0* Postmeningococcal arthritis 
M03.1* Postmeningococcal arthritis 
M03.2* Other postinfectious arthropathies in diseases classified elsewhere 
M03.6* Reactive arthropathy in other diseases classified elsewhere 
N00  Acute nephritic syndrome (glomerulonephritis)  
N01  Rapidly progressive nephritic syndrome  
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(a) Lung Disease 
Read Code Description 
C370% Cystic fibrosis 
H31% Chronic bronchitis  
H32% Emphysema  
H34% Bronchiectasis  
H35% Extrinsic allergic alveolitis  
H36% Mild chronic obstructive pulmonary disease 
H37% Mod chronic obstructive pulmonary disease  
H38% Severe chronic obstructive pulmonary disease  
H3y% Chronic obstructive airway disease.OS  
H3z% Chronic obstructive airway disease NOS  
H40-H46 Lung disease due to external agents  
H47y0 Detergent asthma 
H48-H4z Lung disease due to external agents 
H5410 Chronic pulmonary oedema  
H55 Postinflammatory pulmonary.fibrosis  
H563% Idiopath.fibrosing alveolitis  
H57% Lung involvement in disease  
H583 Pulmonary eosinophilia 
H591 Chronic respiratory failure  
Hyu3% [X]Chronic lower respiratory disease  
Hyu4000 [X]Pneumoconiosis due to other dust containing silica        
Hyu4100 [X]Pneumoconiosis due to other specified inorganic dusts     
Hyu5% [X]Oth resp dis aff interstit  
Q3170 Chronic lung disease of prematurity  
 
(b) Renal Disease 
Read code Description  
7B00% Transplantation of kidney  
7B012 Bilateral nephrectomy  
7B015 Transplant nephrectomy  
7B063 Exploration of renal transplant  
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8L50 Renal transplant planned  
G220.00 Malignant hypertensive renal disease                         
G222.00 Hypertensive renal disease with renal failure                
G23..00 Hypertensive heart and renal disease                         
K01% Nephrotic syndrome 
K02% Chronic glomerulonephritis  
K05% Chronic renal failure  
K0A3% Chronic nephritic syndrome 
K0D End-stage renal disease  
Kyu21 [X]Other chronic renal failure  
SP083 Kidney transplant failure and rejection  
TB001 Kidney transplant with complication, without blame  
ZV420 [V]Kidney transplanted CTV3  
 
(c) Neuromuscular Disease 
Read code Description  
C370.00 Cystic fibrosis                                              
C370.11 Fibrocystic disease                                          
C370.12 Mucoviscidosis                                               
F12% Parkinson's disease                                          
F134% Huntington's chorea                                          
F150.00 Werdnig - Hoffmann disease                                   
F150.11 Infantile spinal muscular atrophy                            
F151% Spinal muscular atrophy                                      
F152000 Amyotrophic lateral sclerosis                                
F20..00 Multiple sclerosis                                           
F380.00 Myasthenia gravis                                            
F39..00 Muscular dystrophies and other myopathies                    
G61..12 Stroke due to intracerebral haemorrhage                      
G64..13 Stroke due to cerebral arterial occlusion                    
G66..00 Stroke and cerebrovascular accident unspecified              
G66..12 Stroke unspecified                                           
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(d) Liver Disease  
Read code Description  
J6% Liver, biliary, pancreas + gastrointestinal diseases NEC     
J61% Cirrhosis and chronic liver disease  
J62% Liver abscess and sequelae of chronic liver disease          
J62..% Liver abscess and sequelae of chronic liver dis  
J6353 Toxic liver dis with chronic persist.hepatitis  
J6353 Toxic liver disease with chronic persistent hepatitis        
J6354 Toxic liver dis with chronic lobular hepatitis  
J6354 Toxic liver disease with chronic lobular hepatitis  
J6355 Toxic liver dis with chronic active hepatitis  
J6355 Toxic liver disease with chronic active hepatitis 
J6356 Toxic liver dis with fibrosis & cirrhosis of liver 
J6356 Toxic liver disease with fibrosis & cirrhosis of liver  
J63B Autoimmune hepatitis  
PB61% Biliary atresia  
PB63% Congenital absence of liver & gallbladder  
PB6yl Congenital hepatomegaly CTV3  
 
(e) Heart Disease 
Read code Description  
7919600 Percutaneous transluminal pulmonary valve replacement            
G1% Chronic rheumatic heart disease  
G21% Hypertensive heart disease  
G220 Malignant hypertensive renal disease  
G222 Hypertensive renal disease with renal failure  
G23% Hypertensive heart+renal dis.  
G3% Ischaemic heart disease  
G41% Chronic pulmonary heart diseas  
G55% Cardiomyopathy 
G58% Heart failure  
G5yy9 Left ventricul systol dysfunc  
G5yyA Left ventric diastolic dysfunc  
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P5% Bulb.cordis/cardiac sept.anom.  
P60-P6X Other congenital heart anomal.  
P6y Other congenital heart anomal.  
P6y0-P6y3 Other congenital heart anomal.  
P6y63-P6y6z Other congenital heart anomal.  
P6yy-P6zz Other congenital heart anomal.  
P6z% Congenital heart anomaly NOS                                 
SP08400 Heart transplant failure and rejection                       
TB00000 Heart transplant with complication, without blame            
ZV42100 [V]Heart transplanted                                        
ZVu6e00 [X]Presence of other heart valve replacement                 
 
(f) Immunosuppressant drugs 
BNF chapter Description 
6.3.1 Replacement corticosteroids for endocrine conditions 
6.3.2 Glucocorticoid therapy  
8.1.1 Alkylating Drugs 
8.1.2 Cytotoxic Antibiotics 
8.1.3 Anti metabolites  
8.1.4 Vinca Alkaloids etc  
8.1.5 Other anti neoplastic drugs  
8.1.6 Chemotherapy induced mucositis and myelosuppression 
8.2.1 Anti proliferative immunosuppressants  
8.2.2 Cortico-steroids and other immunosuppressants 
8.2.3 Rituximab 
8.2.4 Interferons  
 
